



(12)

Oversættelse af europæisk patent

Patent- og
Varemærkestyrelsen

(51) Int.Cl.: **A 61 K 39/395 (2006.01)** **A 61 P 35/00 (2006.01)** **A 61 K 39/00 (2006.01)** **C 07 K 16/00 (2006.01)** **A 61 K 45/06 (2006.01)** **C 07 K 16/28 (2006.01)**

(45) Oversættelsen bekendtgjort den: **2016-11-07**

(80) Dato for Den Europæiske Patentmyndigheds
bekendtgørelse om meddelelse af patentet: **2016-07-20**

(86) Europæisk ansøgning nr.: **07812341.1**

(86) Europæisk indleveringsdag: **2007-06-26**

(87) Den europæiske ansøgnings publiceringsdag: **2009-03-04**

(86) International ansøgning nr.: **US2007072153**

(87) Internationalt publikationsnr.: **WO2008019199**

(30) Prioritet: **2006-06-26 US 816688 P**

(84) Designerede stater: **AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR**

(73) Patenthaver: **MacroGenics, Inc., 9704 Medical Center Drive, Rockville, MD 20850, USA**

(72) Opfinder: **JOHNSON, Leslie, S., 14411 Poplar Hill Road, Darnestown, MD 20874, USA**
HUANG, Ling, 8210 Moorland Lane, Bethesda, MD 20817, USA
GERENA, Robyn, 5008 Kelly Jane Ct, Sandston, VA 23510, USA

(74) Fuldmægtig i Danmark: **JESPER LEVIN A/S, P.O. Box 40, 2900 Hellerup, Danmark**

(54) Benævnelse: **FC-RIIB-SPECIFIKKE ANTISTOFFER OG FREMGANGSMÅDER TIL ANVENDELSE DERAF**

(56) Fremdragne publikationer:
WO-A2-2004/065423
WO-A2-2005/115452
WO-A2-2007/021841
US-A1- 2005 260 213
US-A1- 2007 036 799
TRIDANDAPANI ET AL.: 'Regulated Expression and Inhibitory Function of FcγRIIb in Human Monocytic Cells'
JOURNAL OF BIOLOGICAL CHEMISTRY vol. 277, no. 7, February 2002, pages 5082 - 5089, XP002904892
OSBOURN J ET AL: "From rodent reagents to human therapeutics using antibody guided selection",
METHODS, ACADEMIC PRESS, vol. 36, no. 1, 1 May 2005 (2005-05-01), pages 61-68, XP004852553, ISSN: 1046-2023, DOI: 10.1016/J.YMETH.2005.01.006
DE LA LASTRA J M PEREZ ET AL: "Epitope mapping of 10 monoclonal antibodies against the pig analogue of
human membrane cofactor protein (MCP)", IMMUNOLOGY, vol. 96, no. 4, April 1999 (1999-04), pages 663-670,
ISSN: 0019-2805
GARAMBOIS VÉRONIQUE ET AL: 'Fully human IgG and IgM antibodies directed against the carcinoembryonic
antigen (CEA) Gold 4 epitope and designed for radioimmunotherapy (RIT) of colorectal cancers' BMC CANCER,
BIOMED CENTRAL, LONDON, GB vol. 4, no. 1, 75, 15 October 2004, pages 1 - 11, XP021004678 DOI:

Fortsættes ...

10.1186/1471-2407-4-75 ISSN: 1471-2407

VERI MARIA-CONCETTA ET AL: "Monoclonal antibodies capable of discriminating the human inhibitory Fc gamma-receptor IIB (CD32B) from the activating Fc gamma-receptor IIA (CD32A): biochemical, biological and functional characterization", IMMUNOLOGY, BLACKWELL PUBLISHING, OXFORD, GB, vol. 121, no. 3, 1 July 2007 (2007-07-01), pages 392-404, XP002498115, ISSN: 0019-2805, DOI: 10.1111/J.1365-2567.2007.02588.X

VERI MARIA-CONCETTA ET AL: "Therapeutic control of B cell activation via recruitment of Fc gamma receptor IIb (CD32B) inhibitory function with a novel bispecific antibody scaffold", ARTHRITIS & RHEUMATISM, WILEY, US, vol. 62, no. 7, 1 July 2010 (2010-07-01), pages 1933-1943, XP002605114, ISSN: 0004-3591, DOI: 10.1002/ART.27477

DESCRIPTION

1. FIELD OF THE INVENTION

[0001] The present invention relates, as specified by the claims, to antibodies or fragments thereof that specifically bind Fc γ RIIB, particularly human Fc γ RIIB, with greater affinity than said antibodies or fragments thereof bind Fc γ RIIA, particularly human Fc γ RIIA. The present specification also encompasses the use of an anti-Fc γ RIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. Such use may also include combination with other cancer therapies. The present specification provides pharmaceutical compositions comprising an anti-Fc γ RIIB antibody or an antigen-binding fragment thereof, in amounts effective to prevent, treat, manage, or ameliorate a cancer, such as a B-cell malignancy, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. Preferred embodiments of the invention are set forth in the dependent claims. Also described are methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. In addition also described are methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention with a vaccine composition.

2. BACKGROUND OF THE INVENTION

2.1 Fc RECEPTEORS AND THEIR ROLES IN THE IMMUNE SYSTEM

[0002] The interaction of antibody-antigen complexes with cells of the immune system results in a wide array of responses, ranging from effector functions such as antibody-dependent cell-mediated cytotoxicity, mast cell degranulation, and phagocytosis to immunomodulatory signals such as regulating lymphocyte proliferation and antibody secretion. All these interactions are initiated through the binding of the Fc domain of antibodies or immune complexes to specialized cell surface receptors on hematopoietic cells. The diversity of cellular responses triggered by antibodies and immune complexes results from the structural heterogeneity of Fc receptors. Fc receptors share structurally related ligand binding domains which presumably mediate intracellular signaling.

[0003] The Fc receptors, members of the immunoglobulin gene superfamily of proteins, are surface glycoproteins that can bind the Fc portion of immunoglobulin molecules. Each member of the family recognizes immunoglobulins of one or more isotypes through a recognition domain on the a chain of the Fc receptor. Fc receptors are defined by their specificity for immunoglobulin subtypes. Fc receptors for IgG are referred to as Fc γ R, for IgE as Fc ϵ R, and for IgA as Fc α R. Different accessory cells bear Fc receptors for antibodies of different isotype, and the isotype of the antibody determines which accessory cells will be engaged in a given response (reviewed by Ravetch J.V. et al. 1991, Annu. Rev. Immunol. 9: 457-92; Gerber J.S. et. al. 2001 Microbes and Infection, 3: 131-139; Billadeau D.D. et al. 2002, The Journal of Clinical Investigation, 2(109): 161-1681; Ravetch J.V. et al. 2000, Science, 290: 84-89; Ravetch J.V. et al., 2001 Annu. Rev. Immunol. 19:275-90 ; Ravetch J.V. 1994, Cell, 78(4): 553-60). The different Fc receptors, the cells that express them, and their isotype specificity is summarized in Table 1 (adapted from Immunobiology: The Immune System in Health and Disease, 4th ed. 1999, Elsevier Science Ltd/Garland Publishing, New York). Other prior art includes WO 2005115452 which relates to antibodies or fragments thereof that specifically bind Fc γ RIIB, particularly human Fc γ RIIB, with greater affinity than said antibodies or fragments thereof bind Fc γ RIIA, particularly human Fc γ RIIA. It also discloses use of an anti-Fc γ RIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. Also described are methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies described therein to enhance the effector function of the therapeutic antibodies, and methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.

[0004] WO 2007021841 relates to molecules, particularly polypeptides, more particularly immunoglobulins (e.g. antibodies), comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds Fc γ RIIA and/or Fc γ RIIA with a greater affinity, relative to a comparable molecule comprising the wild-type Fc region. The molecules are described as particularly useful in preventing, treating, or ameliorating one

or more symptoms associated with a disease, disorder, or infection; for the treatment or prevention of a disease or disorder where an enhanced efficacy of effector cell function (e.g. ADCC) mediated by Fc γ R is desired, e.g. cancer, infectious disease; and in enhancing the therapeutic efficacy of therapeutic antibodies the effect of which is mediated by ADCC.

Fc γ Receptors

[0005] Each member of this family is an integral membrane glycoprotein, possessing extracellular domains related to a C2-set of immunoglobulin-related domains, a single membrane spanning domain and an intracytoplasmic domain of variable length. There are three known Fc γ Rs, designated Fc γ RI(CD64), Fc γ RII(CD32), and Fc γ RIII(CD16). The three receptors are encoded by distinct genes; however, the extensive homology between the three family members suggest they arose from a common progenitor perhaps by gene duplication. This invention specifically focuses on Fc γ RII(CD32).

Fc γ RII(CD32)

[0006] Fc γ RII proteins are 40 KDa integral membrane glycoproteins which bind only the complexed IgG due to a low affinity for monomeric Ig ($10^6 M^{-1}$). This receptor is the most widely expressed Fc γ R, present on all hematopoietic cells, including monocytes, macrophages, B cells, NK cells, neutrophils, mast cells, and platelets. Fc γ RII has only two immunoglobulin-like regions in its immunoglobulin binding chain and hence a much lower affinity for IgG than Fc γ RI. There are three human Fc γ RII genes (Fc γ RII-A, Fc γ RII-B, Fc γ RII-C), all of which bind IgG in aggregates or immune complexes.

[0007] Distinct differences within the cytoplasmic domains of Fc γ RII-A (CD32A) and Fc γ RII-B (CD32B) create two functionally heterogeneous responses to receptor ligation. The fundamental difference is that the A isoform initiates intracellular signaling leading to cell activation such as phagocytosis and respiratory burst, whereas the B isoform initiates inhibitory signals, e.g., inhibiting B-cell activation.

Signaling through Fc γ Rs

[0008] Both activating and inhibitory signals are transduced through the Fc γ Rs following ligation. These diametrically opposing functions result from structural differences among the different receptor isoforms. Two distinct domains within the cytoplasmic signaling domains of the receptor called immunoreceptor tyrosine based activation motifs (ITAMs) or immunoreceptor tyrosine based inhibitory motifs (ITIMs) account for the different responses. The recruitment of different cytoplasmic enzymes to these structures dictates the outcome of the Fc γ R-mediated cellular responses. ITAM-containing Fc γ R complexes include Fc γ RI, Fc γ RIIA, Fc γ RIIA, whereas ITIM-containing complexes only include Fc γ RIIB.

[0009] Human neutrophils express the Fc γ RIIA gene. Fc γ RIIA clustering via immune complexes or specific antibody cross-linking serves to aggregate ITAMs along with receptor-associated kinases which facilitate ITAM phosphorylation. ITAM phosphorylation serves as a docking site for Syk kinase, activation of which results in activation of downstream substrates (e.g., PI3K). Cellular activation leads to release of proinflammatory mediators.

[0010] The Fc γ RIIB gene is expressed on B lymphocytes; its extracellular domain is 96% identical to Fc γ RIIA and binds IgG complexes in an indistinguishable manner. The presence of an ITIM in the cytoplasmic domain of Fc γ RIIB defines this inhibitory subclass of Fc γ R. Recently the molecular basis of this inhibition was established. When colligated along with an activating Fc γ R, the ITIM in Fc γ RIIB becomes phosphorylated and attracts the SH2 domain of the inositol polyphosphate 5'-phosphatase (SHIP), which hydrolyzes phosphoinositol messengers released as a consequence of ITAM-containing Fc γ R-mediated tyrosine kinase activation, consequently preventing the influx of intracellular Ca⁺⁺. Thus, crosslinking of Fc γ RIIB dampens the activating response to Fc γ R ligation and inhibits cellular responsiveness. B cell activation, B cell proliferation and antibody secretion is thus aborted.

TABLE 1. Receptors for the Fc Regions of Immunoglobulin Isotypes

Receptor	Fc γ RI (CD64)	Fc γ RII-A (CD32)	Fc γ RII-B2 (CD32)	Fc γ RII-B1 (CD32)	Fc γ RIII (CD16)	Fc ϵ RI	Fc α RI (CD89)
Binding	IgG1 108 M-1	IgG1 2 x 106 M-1	IgG1 2 x 106 M-1	IgG1 2 x 106 M-1	IgG1 5 x 105 M-1	IgG1 1010 M-1	IgG1, IgA2 107 M-1

Receptor	Fc γ RI (CD64)	Fc γ RII-A (CD32)	Fc γ RII-B2 (CD32)	Fc γ RII-B1 (CD32)	Fc γ RIII (CD16)	Fc ϵ RI	Fc α RI (CD89)
Cell Type	Macrophages Neutrophils Eosinophils Dendritic cells	Macrophages Neutrophils Eosinophils Dendritic cells Platelets Langerhan cells	Macrophages Neutrophils Eosinophils	B cells Mast cells	NK cells Eosinophil macrophages, Neutrophils Mast Cells	Mast cells Eosinophil Basophils	Macrophages Neutrophils Eosinophils
Effect of Ligation	Uptake Stimulation Activation of respiratory burst Induction of killing	Uptake Granule release	Uptake Inhibition of Stimulation	No uptake Inhibition of Stimulation	Induction of Killing	Secretion of granules	Uptake Induction of killing

2.2 DISEASES OF RELEVANCE

2.2.1 CANCER

[0011] A neoplasm, or tumor, is a neoplastic mass resulting from abnormal uncontrolled cell growth which can be benign or malignant. Benign tumors generally remain localized. Malignant tumors are collectively termed cancers. The term "malignant" generally means that the tumor can invade and destroy neighboring body structures and spread to distant sites to cause death (for review, see Robbins and Angell, 1976, Basic Pathology, 2d Ed., W.B. Saunders Co., Philadelphia, pp. 68-122). Cancer can arise in many sites of the body and behave differently depending upon its origin. Cancerous cells destroy the part of the body in which they originate and then spread to other part(s) of the body where they start new growth and cause more destruction.

[0012] More than 1.2 million Americans develop cancer each year. Cancer is the second leading cause of death in the United States and if current trends continue, cancer is expected to be the leading cause of the death by the year 2010. Lung and prostate cancer are the top cancer killers for men in the United States. Lung and breast cancer are the top cancer killers for women in the United States. One in two men in the United States will be diagnosed with cancer at some time during his lifetime. One in three women in the United States will be diagnosed with cancer at some time during her lifetime. A cure for cancer has yet to be found. Current treatment options, such as surgery, chemotherapy and radiation treatment, are often times either ineffective or present serious side effects.

2.2.1.1 B-CELL MALIGNANCIES

[0013] B cell malignancies, including, but not limited to, B-cell lymphomas and leukemias, are neoplastic diseases with significant incidence in the United States. There are approximately 55,000 new lymphoma cases per year in the U.S. (1998 data), with an estimated 25,000 deaths per year. This represents 4% of cancer incidence and 4% of all cancer-related deaths in the U.S. population. The revised European-American classification of lymphoid neoplasms (1994 REAL classification, modified 1999) grouped lymphomas based on their origin as either B cell lineage lymphoma, T cell lineage lymphoma, or Hodgkin's lymphoma. Lymphoma of the B cell lineage is the most common type of non-Hodgkin's lymphoma (NHL) diagnosed in the U.S. (Williams, Hematology 6th ed. (Beutler et al. Ed.), McGraw Hill 2001).

Chronic lymphocytic leukemia (CLL) is a neoplastic disease characterized by the accumulation of small, mature-appearing lymphocytes in the blood, marrow, and lymphoid tissues. CLL has an incidence of 2.7 cases per 100,000 in the U.S. The risk increases progressively with age, particularly in men. It accounts for 0.8% of all cancers and is the most common adult leukemia, responsible for 30% of all leukemias. In nearly all cases (>98%) the diseased cells belong to the B lymphocyte lineage. A non-leukemic variant, small lymphocytic lymphoma, constitutes 5-10% of all lymphomas, has histological, morphological and immunological features indistinguishable from that of involved lymph nodes in patients with B-CLL (Williams, 2001).

[0014] The natural history of chronic lymphocytic leukemia falls into several phases. In the early phase, chronic lymphocytic leukemia is an indolent disease, characterized by the accumulation of small, mature, functionally-incompetent malignant B-cells having a lengthened life span. Eventually, the doubling time of the malignant B-cells decreases and patients become increasingly

symptomatic. While treatment with chemotherapeutic agents can provide symptomatic relief, the overall survival of the patients is only minimally extended. The late stages of chronic lymphocytic leukemia are characterized by significant anemia and/or thrombocytopenia. At this point, the median survival is less than two years (Foon et al., 1990, Annals Int. Medicine 113:525). Due to the very low rate of cellular proliferation, chronic lymphocytic leukemia is resistant to treatment with chemotherapeutic agents.

[0015] Recently, gene expression studies have identified several genes that may be up regulated in lymphoproliferative disorders. One molecule thought to be over-expressed in patients with B-cell chronic lymphocytic leukemia (B-CLL) and in a large fraction of non-Hodgkin lymphoma patients is CD32B (Alizadeh et al., 2000, Nature 403:503-511; Rosenwald et al., 2001, J. Exp. Med. 184:1639-1647). However, the role of CD32B in B-CLL is unclear since one report demonstrates that CD32B was expressed on a low percentage of B-CLL cells and at a low density (Damle et al., 2002, Blood 99:4087-4093). CD32B is a B cell lineage surface antigen, whose over-expression in B cell neoplasia makes it a suitable target for therapeutic antibodies. In addition, CD32B belongs to the category of inhibitory receptors, whose ligation delivers a negative signal. Therefore, antibodies directed against CD32B could function to eliminate tumor cells by mechanisms that include complement dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), but also triggering an apoptotic signal. The high homology of CD32B with its counterpart, CD32A, an activating Fc γ receptor, has thus far hampered the generation of antibodies that selectively recognize one but not the other form of the molecule.

2.2.1.2 Cancer Therapy

[0016] Currently, cancer therapy may involve surgery, chemotherapy, hormonal therapy and/or radiation treatment to eradicate neoplastic cells in a patient (See, for example, Stockdale, 1998, "Principles of Cancer Patient Management", in *Scientific American: Medicine*, vol. 3, Rubenstein and Federman, eds., Chapter 12, Section IV). Recently, cancer therapy could also involve biological therapy or immunotherapy. All of these approaches pose significant drawbacks for the patient. Surgery, for example, may be contraindicated due to the health of the patient or may be unacceptable to the patient. Additionally, surgery may not completely remove the neoplastic tissue. Radiation therapy is only effective when the neoplastic tissue exhibits a higher sensitivity to radiation than normal tissue, and radiation therapy can also often elicit serious side effects. Hormonal therapy is rarely given as a single agent and although can be effective, is often used to prevent or delay recurrence of cancer after other treatments have removed the majority of the cancer cells. Biological therapies/immunotherapies are limited in number and may produce side effects such as rashes or swellings, flu-like symptoms, including fever, chills and fatigue, digestive tract problems or allergic reactions.

[0017] With respect to chemotherapy, there are a variety of chemotherapeutic agents available for treatment of cancer. A significant majority of cancer chemotherapeutics act by inhibiting DNA synthesis, either directly, or indirectly by inhibiting the biosynthesis of the deoxyribonucleotide triphosphate precursors, to prevent DNA replication and concomitant cell division (See, for example, Gilman et al., Goodman and Gilman's: *The Pharmacological Basis of Therapeutics*, Eighth Ed. (Pergamon Press, New York, 1990)). These agents, which include alkylating agents, such as nitrosourea, anti-metabolites, such as methotrexate and hydroxyurea, and other agents, such as etoposides, camptothecins, bleomycin, doxorubicin, daunorubicin, etc., although not necessarily cell cycle specific, kill cells during S phase because of their effect on DNA replication. Other agents, specifically colchicine and the vinca alkaloids, such as vinblastine and vincristine, interfere with microtubule assembly resulting in mitotic arrest. Chemotherapy protocols generally involve administration of a combination of chemotherapeutic agents to increase the efficacy of treatment.

[0018] Despite the availability of a variety of chemotherapeutic agents, chemotherapy has many drawbacks (See, for example, Stockdale, 1998, "Principles Of Cancer Patient Management" in *Scientific American Medicine*, vol. 3, Rubenstein and Federman, eds., ch. 12, sect. 10). Almost all chemotherapeutic agents are toxic, and chemotherapy causes significant, and often dangerous, side effects, including severe nausea, bone marrow depression, immunosuppression, etc. Additionally, even with administration of combinations of chemotherapeutic agents, many tumor cells are resistant or develop resistance to the chemotherapeutic agents. In fact, those cells resistant to the particular chemotherapeutic agents used in the treatment protocol often prove to be resistant to other drugs, even those agents that act by mechanisms different from the mechanisms of action of the drugs used in the specific treatment; this phenomenon is termed pleiotropic drug or multidrug resistance. Thus, because of drug resistance, many cancers prove refractory to standard chemotherapeutic treatment protocols.

[0019] B cell malignancy is generally treated with single agent chemotherapy, combination chemotherapy and/or radiation therapy. These treatments can reduce morbidity and/or improve survival, albeit they carry significant side effects. The response of B-cell malignancies to various forms of treatment is mixed. For example, in cases in which adequate clinical staging of non-Hodgkin's lymphoma is possible, field radiation therapy can provide satisfactory treatment. Certain patients, however, fail to

respond and disease recurrence with resistance to treatment ensues with time, particularly with the most aggressive variants of the disease. About one-half of the patients die from the disease (Devesa et al., 1987, J. Nat'l Cancer Inst. 79:701).

[0020] Investigational therapies for the treatment of refractory B cell neoplasia include autologous and allogeneic bone marrow or stem cell transplantation and gene therapies. Recently, immunotherapy using monoclonal antibodies to target B-cell specific antigens has been introduced in the treatment of B cell neoplasia. The use of monoclonal antibodies to direct radionuclides, toxins, or other therapeutic agents offers the possibility that such agents can be delivered selectively to tumor sites, thus limiting toxicity to normal tissues.

[0021] There is a significant need for alternative cancer treatments, particularly for treatment of cancer that has proved refractory to standard cancer treatments, such as surgery, radiation therapy, chemotherapy, and hormonal therapy. A promising alternative is immunotherapy, in which cancer cells are specifically targeted by cancer antigen-specific antibodies. Major efforts have been directed at harnessing the specificity of the immune response, for example, hybridoma technology has enabled the development of tumor selective monoclonal antibodies (See Green M.C. et al., 2000 Cancer Treat Rev., 26: 269-286; Weiner LM, 1999 Semin Oncol. 26(suppl. 14):43-51), and in the past few years, the Food and Drug Administration has approved the first MAbs for cancer therapy: Rituxan (anti-CD20) for non-Hodgkin's Lymphoma, Campath (anti-CD52) for B-cell chronic lymphocytic leukemia (B-CLL) and Herceptin [anti-(c-erb-2/HER-2)] for metastatic breast cancer (Suzanne A. Eccles, 2001, Breast Cancer Res., 3: 86-90). NHL and B-CLL are two of the most common forms of B cell neoplasia. These antibodies have demonstrated clinical efficacy, but their use is not without side effects. The potency of antibody effector function, e.g., to mediate antibody-dependent cell-mediated cytotoxicity ("ADCC") is an obstacle to such treatment. Furthermore, with Rituxan and Campath, at least half the patients fail to respond and a fraction of responders may be refractory to subsequent treatments.

[0022] There is a need for alternative therapies for cancer, particularly, B-cell malignancies, especially for patients that are refractory to standard cancer treatments and new immunotherapies such as Rituxan.

2.2.2 INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES

[0023] Inflammation is a process by which the body's white blood cells and chemicals protect our bodies from infection by foreign substances, such as bacteria and viruses. It is usually characterized by pain, swelling, warmth and redness of the affected area. Chemicals known as cytokines and prostaglandins control this process, and are released in an ordered and self-limiting cascade into the blood or affected tissues. This release of chemicals increases the blood flow to the area of injury or infection, and may result in the redness and warmth. Some of the chemicals cause a leak of fluid into the tissues, resulting in swelling. This protective process may stimulate nerves and cause pain. These changes, when occurring for a limited period in the relevant area, work to the benefit of the body.

[0024] In autoimmune and/or inflammatory disorders, the immune system triggers an inflammatory response when there are no foreign substances to fight and the body's normally protective immune system causes damage to its own tissues by mistakenly attacking self. There are many different Autoimmune disorders which affect the body in different ways. For example, the brain is affected in individuals with multiple sclerosis, the gut is affected in individuals with Crohn's disease, and the synovium, bone and cartilage of various joints are affected in individuals with rheumatoid arthritis. As autoimmune disorders progress destruction of one or more types of body tissues, abnormal growth of an organ, or changes in organ function may result. The autoimmune disorder may affect only one organ or tissue type or may affect multiple organs and tissues. Organs and tissues commonly affected by autoimmune disorders include red blood cells, blood vessels, connective tissues, endocrine glands (e.g., the thyroid or pancreas), muscles, joints, and skin. Examples of autoimmune disorders include, but are not limited to, Hashimoto's thyroiditis, pernicious anemia, Addison's disease, type 1 diabetes, rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis, Sjogren's syndrome, dermatomyositis, lupus erythematosus, multiple sclerosis, autoimmune inner ear disease myasthenia gravis, Reiter's syndrome, Graves disease, autoimmune hepatitis, familial adenomatous polyposis and ulcerative colitis.

[0025] Rheumatoid arthritis (RA) and juvenile rheumatoid arthritis are types of inflammatory arthritis. Arthritis is a general term that describes inflammation in joints. Some, but not all, types of arthritis are the result of misdirected inflammation. Besides rheumatoid arthritis, other types of arthritis associated with inflammation include the following: psoriatic arthritis, Reiter's syndrome, ankylosing spondylitis arthritis, and gouty arthritis. Rheumatoid arthritis is a type of chronic arthritis that occurs in joints on both sides of the body (such as both hands, wrists or knees). This symmetry helps distinguish rheumatoid arthritis from other types of arthritis. In addition to affecting the joints, rheumatoid arthritis may occasionally affect the skin, eyes, lungs, heart, blood or nerves.

[0026] Rheumatoid arthritis affects about 1% of the world's population and is potentially disabling. There are approximately 2.9 million incidences of rheumatoid arthritis in the United States. Two to three times more women are affected than men. The typical age that rheumatoid arthritis occurs is between 25 and 50. Juvenile rheumatoid arthritis affects 71,000 young Americans (aged eighteen and under), affecting six times as many girls as boys.

[0027] Rheumatoid arthritis is an autoimmune disorder where the body's immune system improperly identifies the synovial membranes that secrete the lubricating fluid in the joints as foreign. Inflammation results, and the cartilage and tissues in and around the joints are damaged or destroyed. In severe cases, this inflammation extends to other joint tissues and surrounding cartilage, where it may erode or destroy bone and cartilage and lead to joint deformities. The body replaces damaged tissue with scar tissue, causing the normal spaces within the joints to become narrow and the bones to fuse together. Rheumatoid arthritis creates stiffness, swelling, fatigue, anemia, weight loss, fever, and often, crippling pain. Some common symptoms of rheumatoid arthritis include joint stiffness upon awakening that lasts an hour or longer; swelling in a specific finger or wrist joints; swelling in the soft tissue around the joints; and swelling on both sides of the joint. Swelling can occur with or without pain, and can worsen progressively or remain the same for years before progressing.

[0028] The diagnosis of rheumatoid arthritis is based on a combination of factors, including: the specific location and symmetry of painful joints, the presence of joint stiffness in the morning, the presence of bumps and nodules under the skin (rheumatoid nodules), results of X-ray tests that suggest rheumatoid arthritis, and/or positive results of a blood test called the rheumatoid factor. Many, but not all, people with rheumatoid arthritis have the rheumatoid-factor antibody in their blood. The rheumatoid factor may be present in people who do not have rheumatoid arthritis. Other diseases can also cause the rheumatoid factor to be produced in the blood. That is why the diagnosis of rheumatoid arthritis is based on a combination of several factors and not just the presence of the rheumatoid factor in the blood.

[0029] The typical course of the disease is one of persistent but fluctuating joint symptoms, and after about 10 years, 90% of sufferers will show structural damage to bone and cartilage. A small percentage will have a short illness that clears up completely, and another small percentage will have very severe disease with many joint deformities, and occasionally other manifestations of the disease. The inflammatory process causes erosion or destruction of bone and cartilage in the joints. In rheumatoid arthritis, there is an autoimmune cycle of persistent antigen presentation, T-cell stimulation, cytokine secretion, synovial cell activation, and joint destruction. The disease has a major impact on both the individual and society, causing significant pain, impaired function and disability, as well as costing millions of dollars in healthcare expenses and lost wages. (See, for example, the NIH website and the NIAID website).

[0030] Currently available therapy for arthritis focuses on reducing inflammation of the joints with anti-inflammatory or immunosuppressive medications. The first line of treatment of any arthritis is usually anti-inflammatories, such as aspirin, ibuprofen and Cox-2 inhibitors such as celecoxib and rofecoxib. "Second line drugs" include gold, methotrexate and steroids. Although these are well-established treatments for arthritis, very few patients remit on these lines of treatment alone. Recent advances in the understanding of the pathogenesis of rheumatoid arthritis have led to the use of methotrexate in combination with antibodies to cytokines or recombinant soluble receptors. For example, recombinant soluble receptors for tumor necrosis factor (TNF)- α have been used in combination with methotrexate in the treatment of arthritis. However, only about 50% of the patients treated with a combination of methotrexate and anti-TNF- α agents such as recombinant soluble receptors for TNF- α show clinically significant improvement. Many patients remain refractory despite treatment. Difficult treatment issues still remain for patients with rheumatoid arthritis. Many current treatments have a high incidence of side effects or cannot completely prevent disease progression. So far, no treatment is ideal, and there is no cure. Novel therapeutics are needed that more effectively treat rheumatoid arthritis and other autoimmune disorders.

2.2.3 ALLERGY

[0031] Immune-mediated allergic (hypersensitivity) reactions are classified into four types (I-IV) according to the underlying mechanisms leading to the expression of the allergic symptoms. Type I allergic reactions are characterized by IgE-mediated release of vasoactive substances such as histamine from mast cells and basophils. The release of these substances and the subsequent manifestation of allergic symptoms are initiated by the cross-linking of allergen-bound IgE to its receptor on the surface of mast cells and basophils. In individuals suffering from type I allergic reactions, exposure to an allergen for a second time leads to the production of high levels of IgE antibodies specific for the allergen as a result of the involvement of memory B and T cells in the 3-cell interaction required for IgE production. The high levels of IgE antibodies produced cause an increase in the cross-linking of IgE receptors on mast cells and basophils by allergen-bound IgE, which in turn leads to the activation of these cells and the release of the pharmacological mediators that are responsible for the clinical manifestations of type I allergic

diseases.

[0032] Two receptors with differing affinities for IgE have been identified and characterized. The high affinity receptor (Fc ϵ RI) is expressed on the surface of mast cells and basophils. The low affinity receptor (Fc ϵ RII/CD23) is expressed on many cell types including B cells, T cells, macrophages, eosinophils and Langerhan cells. The high affinity IgE receptor consists of three subunits (alpha, beta and gamma chains). Several studies demonstrate that only the alpha chain is involved in the binding of IgE, whereas the beta and gamma chains (which are either transmembrane or cytoplasmic proteins) are required for signal transduction events. The identification of IgE structures required for IgE to bind to the Fc ϵ RI on mast cells and basophils is of utmost importance in devising strategies for treatment or prevention of IgE-mediated allergies. For example, the elucidation of the IgE receptor-binding site could lead to the identification of peptides or small molecules that block the binding of IgE to receptor-bearing cells *in vivo*.

[0033] Currently, IgE-mediated allergic reactions are treated with drugs such as antihistamines and corticosteroids which attempt to alleviate the symptoms associated with allergic reactions by counteracting the effects of the vasoactive substances released from mast cells and basophils. High doses of antihistamines and corticosteroids have deleterious side effects (e.g., central nervous system disturbance, constipation, etc). Thus, other methods for treating type I allergic reactions are needed.

[0034] One approach to the treatment of type I allergic disorders has been the production of monoclonal antibodies which react with soluble (free) IgE in serum, block IgE from binding to its receptor on mast cells and basophils, and do not bind to receptor-bound IgE (i.e., they are non-anaphylactogenic). Two such monoclonal antibodies are in advanced stages of clinical development for treatment of IgE-mediated allergic reactions (see, e.g., Chang, T.W., 2000, *Nature Biotechnology* 18:157-62).

[0035] One of the most promising treatments for IgE-mediated allergic reactions is the active immunization against appropriate non-anaphylactogenic epitopes on endogenous IgE. Stanworth et al. (U.S. Patent No. 5,601,821) described a strategy involving the use of a peptide derived from the C ϵ H4 domain of the human IgE coupled to a heterologous carrier protein as an allergy vaccine. However, this peptide has been shown not to induce the production of antibodies that react with native soluble IgE. Further, Hellman (U.S. Patent No. 5,653,980) proposed anti-IgE vaccine compositions based on fusion of full length C ϵ H2-C ϵ H3 domains (approximately 220 amino acid long) to a foreign carrier protein. However, the antibodies induced by the anti-IgE vaccine compositions proposed in Hellman will most likely result in anaphylaxis since antibodies against some portions of the C ϵ H2 and C ϵ H3 domains of the IgE molecule have been shown to cross-link the IgE receptor on the surface of mast cell and basophils and lead to production of mediators of anaphylaxis (See, e.g., Stadler et al., 1993, *Int. Arch. Allergy and Immunology* 102:121-126). Therefore, a need remains for treatment of IgE-mediated allergic reactions which do not induce anaphylactic antibodies.

[0036] The significant concern over induction of anaphylaxis has resulted in the development of another approach to the treatment of type I allergic disorders consisting of mimotopes that could induce the production of anti-IgE polyclonal antibodies when administered to animals (See, e.g., Rudolf, et al., 1998, *Journal of Immunology* 160:3315-3321). Kricek et al. (International Publication No. WO 97/31948) screened phage-displayed peptide libraries with the monoclonal antibody BSWI7 to identify peptide mimotopes that could mimic the conformation of the IgE receptor binding. These mimotopes could presumably be used to induce polyclonal antibodies that react with free native IgE, but not with receptor-bound IgE as well as block IgE from binding to its receptor. Kriek et al. disclosed peptide mimotopes that are not homologous to any part of the IgE molecule and are thus different from peptides disclosed in the present invention.

[0037] As evidenced by a survey of the art, there remains a need for enhancing the therapeutic efficacy of current methods of treating or preventing disorders such as cancer, autoimmune disease, inflammatory disorder, or allergy. In particular, there is a need for enhancing the effector function, particularly, the cytotoxic effect of therapeutic antibodies used in treatment of cancer. The current state of the art is also lacking in treating or preventing allergy disorders (e.g., either by antibody therapy or vaccine therapy).

3. SUMMARY OF THE INVENTION

[0038] The extracellular domains of Fc γ RIIA and Fc γ RIIB are 95% identical and thus they share numerous epitopes. However, Fc γ RIIA and Fc γ RIIB exhibit very different activities. The fundamental difference is that the Fc γ RIIA initiates intracellular signaling leading to cell activation such as phagocytosis and respiratory burst, whereas the Fc γ RIIB initiates inhibitory signaling. In view of their distinctive activities and role in modulating immune responses, such antibodies that recognize native Fc γ RIIB, and not native Fc γ RIIA, are needed. The present invention is based, in part, on the discovery of such Fc γ RIIB-specific antibodies.

[0039] As specified by the claims, the present invention provides an isolated antibody, or an antigen-binding fragment thereof, wherein said isolated antibody or said antigen-binding fragment specifically binds the extracellular domain of native human Fc_YRIIB with greater affinity than said antibody or said antigen-binding fragment binds native human Fc_YRIIA, and wherein:

1. i) said antibody is 8B5.3.4 antibody produced by hybridoma cell line having ATCC accession number PTA-7610; or
2. ii) said antibody or said antigen-binding fragment comprises a heavy chain variable domain having the amino acid sequence of SEQ ID NO: 4 and a light chain variable domain having the amino acid sequence of SEQ ID NO: 3; or
3. iii) said antibody or said antigen-binding fragment comprises the six CDRs of the antibody produced by hybridoma clone 8B5.3.4 having ATCC accession number PTA-7610, said six CDRs having the amino acid sequences of SEQ ID NOs: 5-10, wherein said antibody or said antigen-binding fragment binds to the same epitope of Fc_YRIIB as that recognized by the antibody produced by hybridoma clone 8B5.3.4 having ATCC accession number PTA-7610 and competes with said antibody 8B5.3.4 for binding to native human Fc_YRIIB, and wherein said antibody or said antigen-binding fragment has a dissociation constant K_d (K_{off}/K_{on}) of less than 5×10^{-9} M as determined by surface plasmon resonance. As specified by the claims, the present invention also provides a pharmaceutical composition comprising (i) a therapeutically effective amount of the isolated antibody or antigen-binding fragment thereof of any one of claims 1-12; and (ii) a pharmaceutically acceptable carrier. The specification relates to an isolated antibody or a fragment thereof that specifically binds Fc_YRIIB, particularly human Fc_YRIIB, more particularly native human Fc_YRIIB, with a greater affinity than said antibody or a fragment thereof binds Fc_YRIIA, particularly human Fc_YRIIA, more particularly native human Fc_YRIIA. As specified by the claims, the antibodies of the invention bind the extracellular domain of native human Fc_YRIIB. In certain embodiments of the invention falling within the scope of the specified claims, the antibody or a fragment thereof binds Fc_YRIIB with at least 2 times greater affinity than said antibody or a fragment thereof binds Fc_YRIIA. In other embodiments of the invention falling within the scope of the specified claims, the antibody or a fragment thereof binds Fc_YRIIB with at least 4 times, at least 6 times, at least 8 times, at least 10 times, at least 100 times, at least 1000 times, at least 10^4 , at least 10^5 , at least 10^6 , at least 10^7 , for at least 10^8 times greater affinity than said antibody or a fragment thereof binds Fc_YRIIA. In a preferred embodiment falling within the scope of the specified claims, said antibody or a fragment thereof binds Fc_YRIIB with 100 times, 1000 times, 10^4 times, 10^5 times, 10^6 times, 10^7 times, or 10^8 times greater affinity than said antibody or a fragment thereof binds Fc_YRIIA. Preferably, these binding affinities are determined with the monomeric IgG, and not the aggregated IgG, and binding is via the variable domain (e.g., Fab fragments of the antibodies have binding characteristic similar to the full immunoglobulin molecule).

[0040] The invention relates, as specified by the claims, to an isolated antibody or a fragment thereof that specifically binds Fc_YRIIB with a greater affinity than said antibody or a fragment thereof binds Fc_YRIIA, as determined by any standard method known in the art for assessing specificities. The invention relates, as specified by the claims, to an isolated antibody or a fragment thereof that specifically binds Fc_YRIIB with a greater affinity than said antibody or a fragment thereof binds Fc_YRIIA, as determined, for example, by western blot, BIACore or radioimmunoassay. The specification relates to an isolated antibody or a fragment thereof that specifically binds Fc_YRIIB with a greater affinity than said antibody or a fragment thereof binds Fc_YRIIA, as determined in an ELISA assay, in the linear range for Fc_YRIIB binding. In one instance, the specification relates to an isolated antibody, or a fragment thereof that specifically binds Fc_YRIIB, produced in mammalian system, with a greater affinity than said antibody or a fragment thereof binds Fc_YRIIA, as determined in an ELISA assay.

[0041] In a particular instance, the invention relates to an isolated antibody or a fragment thereof that specifically binds Fc_YRIIB with a greater affinity than said antibody or a fragment thereof binds Fc_YRIIA, and the constant domain of said antibody further has an enhanced affinity for at least one or more Fc activation receptors. In yet another specific instance, said Fc activation receptor is Fc_YRIII.

[0042] In one instance said antibody or a fragment thereof blocks the IgG binding site of Fc_YRIIB and blocks the binding of aggregated labeled IgGs to Fc_YRIIB in, for example, a blocking ELISA assay. In one particular instance, said antibody or a fragment thereof blocks the binding of aggregated labeled IgGs in an ELISA blocking assay by at least 50%, 60%, 70%, 80%, 90%, 95%, 99%, or 99.9%. In yet another particular instance, the antibody or a fragment thereof completely blocks the binding of said aggregated labeled IgG in said ELISA assay.

[0043] In another instance, said antibody or a fragment thereof blocks the IgG binding site of Fc_YRIIB and blocks the binding of aggregated labeled IgG to Fc_YRIIB, as determined by a double-staining FACS assay.

[0044] The specification encompasses the use of antibodies that modulate (i.e., agonize or antagonize) the activity of Fc_YRIIB. In

one instance, the antibodies of the specification agonize at least one activity of Fc_YRIIB, *i.e.*, elicit signaling. Although not intending to be bound by any mechanism of action, agonistic antibodies of the specification may mimic clustering of Fc_YRIIB leading to dampening of the activating response to Fc_YR ligation and inhibition of cellular responsiveness.

[0045] In another instance, the antibodies of the specification antagonize at least one activity of Fc_YRIIB, *i.e.*, block signaling. For example, the antibodies of the specification block the binding of aggregated IgGs to Fc_YRIIB.

[0046] The specification provides antibodies that inhibit Fc_εRI-induced mast cell activation. The specification further provides anti-Fc_YRIIB antibodies that inhibit Fc_YRIIA-mediated macrophage activation in monocytic cells. The specification also provides anti-Fc_YRIIB antibodies that inhibit B-cell receptor mediated signaling.

[0047] In one particular instance, the anti-Fc_YRIIB antibodies block the ligand binding site of Fc_YRIIB. In a further specific instance, the blocking activity can block the negative regulation of immune-complex-triggered activation and consequently enhance the immune response. In a further instance, the enhanced immune response is an increase in antibody-dependent cellular response. In another instance, the anti-Fc_YRIIB antibodies of the specification block crosslinking of Fc_YRIIB receptors to B cell and/or Fc receptors, leading to B cell, mast cell, dendritic cell, or macrophage activation.

[0048] Also disclosed are methods for the production of antibodies of the invention or fragments thereof, particularly for the production of novel monoclonal antibodies ("MAb") with higher specificities for Fc_YRIIB relative to Fc_YRIIA. The antibodies of the invention or fragments thereof can be produced by any method known in the art for the production of antibodies, in particular, by secretion from cultured hybridoma cells, chemical synthesis or by recombinant expression techniques known in the art. One relates to a method for recombinantly producing a Fc_YRIIB-specific antibody, said method comprising: (i) culturing under conditions suitable for the expression of said antibody in a medium, a host cell containing a first nucleic acid molecule, operably linked to a heterologous promoter and a second nucleic acid operably linked to the same or a different heterologous promoter, said first nucleic acid and second nucleic acid encoding a heavy chain and a light chain, respectively, of an antibody or a fragment thereof that specifically binds Fc_YRIIB with greater affinity than said antibody or a fragment thereof binds Fc_YRIIA; and (ii) recovery of said antibody from said medium. Another is a method for producing Fc_YRIIB monoclonal antibodies that specifically bind Fc_YRIIB, particularly human Fc_YRIIB, with a greater affinity than said monoclonal antibodies bind Fc_YRIIA, particularly human Fc_YRIIA, said method comprising: (a) immunizing one or more Fc_YRIIA transgenic mice with purified Fc_YRIIB or an immunogenic fragment thereof; (b) producing hybridoma cells lines from spleen cells of said one or more mice; (c) screening said hybridoma cell lines for one or more hybridoma cell lines that produce antibodies that specifically bind Fc_YRIIB with a greater affinity than the antibodies bind Fc_YRIIA. Also described is a method for producing Fc_YRIIB monoclonal antibodies that specifically bind Fc_YRIIB, particularly human Fc_YRIIB, with a greater affinity than said monoclonal antibodies bind Fc_YRIIA, particularly human Fc_YRIIA, said method comprising: (a) immunizing one or more Fc_YRIIA transgenic mice with purified Fc_YRIIB or an immunogenic fragment thereof; (b) booster immunizing said mice for a time sufficient to elicit an immune response; (c) producing hybridoma cells lines from spleen cells of said one or more mice; (d) screening said hybridoma cell lines for one or more hybridoma cell lines that produce antibodies that specifically bind Fc_YRIIB with a greater affinity than the antibodies bind Fc_YRIIA. Preferably said mice are booster immunized at least four times over a period of four months. The mice can be immunized with purified Fc_YRIIB, which has been mixed with adjuvants known in the art to enhance immune response in said mice. The immunogenic fragment can be the soluble extracellular domain of Fc_YRIIB. The hybridoma cell lines can be screened using standard techniques known in the art (*e.g.*, ELISA).

[0049] In certain embodiments of the invention falling within the scope of the specified claims, the anti-Fc_YRIIB antibodies are Monoclonal antibodies, synthetic antibodies, recombinantly produced antibodies, multispecific antibodies, human antibodies, chimeric antibodies, camelized antibodies, single-chain Fvs (scFv), single chain antibodies, Fab fragments, F(ab') fragments, disulfide-linked Fvs (sdFv), intrabodies, or epitope-binding fragments of any of the above.

[0050] Preferably, the antibodies of the invention are monoclonal antibodies, and more preferably, humanized or human antibodies. As specified by the claims, the antibodies of the invention bind to the extracellular domain of native human Fc_YRIIB. In certain instances, the antibodies disclosed herein specifically or selectively recognize one or more epitopes of Fc_YRIIB, particularly native human Fc_YRIIB. The use of phage display technology is discussed to increase the affinity of the antibodies of the invention for Fc_YRIIB. Any screening method known in the art can be used to identify mutant antibodies with increased avidity for Fc_YRIIB (*e.g.*, ELISA). Antibodies of the invention can be screened using antibody screening assays well known in the art (*e.g.*, BIACORE assays) to identify antibodies with K_{off} rate less than $3 \times 10^{-3} \text{ s}^{-1}$.

[0051] In a preferred embodiment, the invention provides a monoclonal antibody produced by hybridoma clone 8B5.3.4, having ATCC accession number PTA-7610, or chimeric, humanized or other engineered versions thereof. In another instance, the

specification provides a monoclonal antibody produced by clones 2B6, 3H7, 1D5, 2E1, 2H9, 2D11, and 1F2 having ATCC Accession numbers PTA-4591, PTA-4592, PTA-5958, PTA-5961, PTA-5962, PTA-5960, and PTA-5959, respectively, or chimeric, humanized or other engineered versions thereof. In another embodiment the invention provides, as specified by the claims, an isolated antibody or a fragment thereof that competes for binding with the monoclonal antibody produced by clone 8B5.3.4 and binds native human Fc_YRIIB with a greater affinity than said antibody or a fragment thereof binds native human Fc_YRIIA and binds to the same epitope of Fc_YRIIB as the monoclonal antibody produced from clone 8B5.3.4 and binds Fc_YRIIB with a greater affinity than said antibody or a fragment thereof binds Fc_YRIIA. Furthermore, the specification provides hybridoma cell line 8B5.3.4, 2B6, 3H7, 1D5, 2E1, 2H9, 2D11, or 1F2 having ATCC accession numbers PTA-7610, PTA-4591, PTA-4592, PTA-5958, PTA-5961, PTA-5962, PTA-5960, and PTA-5959, respectively. In one specific instance, the specification provides the use of a 8B5.3.4, 2B6, 3H7, 1D5, 2E1, 2H9, 2D11, or 1F2 antibody, or chimeric, humanized or other engineered versions thereof, to prevent, treat, manage or ameliorate a B-cell malignancy, or one or more symptoms thereof. In one particular embodiment falling within the scope of the specified claims, an engineered version comprises one or more mutations in the Fc region. The one or more mutations in the Fc region may result in an antibody with an altered antibody-mediated effector function, an altered binding to other Fc receptors (e.g., Fc activation receptors), an altered ADCC activity, or an altered C1q binding activity, or an altered complement dependent cytotoxicity activity, or any combination thereof. In a preferred embodiment, a humanized 8B5.3.4 antibody comprises a heavy chain variable domain having the amino acid sequence of SEQ ID NO: 4 and a light chain variable domain having the amino acid sequence of SEQ ID NO: 3. In another preferred embodiment, the Fc domain of the heavy chain of the humanized 8B5.3.4 antibody is engineered to comprise at least one amino acid substitution at position 240, 243, 247, 255, 270, 292, 300, 316, 370, 392, 396, 416, 419, or 421 with another amino acid at that position. In a more preferred embodiment, the Fc domain of the heavy chain of the humanized 8B5.3.4 antibody has a leucine at position 247, a lysine at position 421 and a glutamic acid at position 270; a threonine at position 392, a leucine at position 396, and a glutamic acid at position 270; or a glutamic acid at position 270, an aspartic acid at position 316, and a glycine at position 416. In certain embodiments of the invention, the antibody is not a monoclonal antibody produced by hybridoma clone 8B5.3.4, or chimeric, humanized or other engineered versions thereof.

[0052] In certain embodiments of the invention falling within the scope of the specified claims, humanized 8B5.3.4 antibodies are provided, said humanized 8B5.3.4 antibodies comprising a heavy chain variable domain having the amino acid sequence of SEQ ID NO: 4 and a light chain variable domain having the amino acid sequence of SEQ ID NO: 3, wherein the Fc domain of the heavy chain of the humanized 8B5.3.4 antibody has a leucine at position 247, a lysine at position 421 and a glutamic acid at position 270; or a glutamic acid at position 270, an aspartic acid at position 316, and a glycine at position 416.

[0053] The specification also encompass polynucleotides that encode the antibodies of the invention. In one instance, the specification provides an isolated nucleic acid sequence encoding a heavy chain or a light chain of an antibody or a fragment thereof that specifically binds Fc_YRIIB with greater affinity than said antibody or a fragment thereof binds Fc_YRIIA. The specification also relates to a vector comprising said nucleic acid. The specification further provides a vector comprising a first nucleic acid molecule encoding a heavy chain and a second nucleic acid molecule encoding a light chain, said heavy chain and light chain being of an antibody or a fragment thereof that specifically binds Fc_YRIIB with greater affinity than said antibody or a fragment thereof binds Fc_YRIIA. In one specific instance, said vector is an expression vector. The specification further provides host cells containing the vectors or polynucleotides encoding the antibodies of the invention. Preferably, the specification encompasses polynucleotides encoding heavy and light chains of the antibodies produced by the deposited hybridoma clone 8B5.3.4, 2B6, 3H7, 1D5, 2E1, 2H9, 2D11, or 1F2 having ATCC accession numbers PTA-7610, PTA-4591, PTA-4592, PTA-5958, PTA-5961, PTA-5962, PTA-5960, and PTA-5959, respectively, or portions thereof, e.g., CDRs, variable domains, etc. and humanized versions thereof.

[0054] Activating and inhibitory Fc receptors, e.g., Fc_YRIIA and Fc_YRIIB, are critical for the balanced function of these receptors and proper cellular immune responses. The specification encompasses the use of the antibodies of the invention for the treatment of any disease related to loss of such balance and regulated control in the Fc receptor signaling pathway. Thus, the Fc_YRIIB antibodies of the invention have uses in regulating the immune response, e.g., in inhibiting immune response in connection with autoimmune or inflammatory disease, or allergic response. The Fc_YRIIB antibodies of the invention can also be used to alter certain effector functions to enhance, for example, therapeutic antibody-mediated cytotoxicity.

[0055] The antibodies of the invention are useful for prevention or treatment of cancer, for example, in one embodiments, as a single agent therapy. The antibodies of the invention can be used for the treatment and/or prevention of melanoma. The antibodies are also useful for prevention or treatment of cancer, particularly in potentiating the cytotoxic activity of cancer antigen-specific therapeutic antibodies with cytotoxic activity to enhance tumor cell killing and/or enhancing antibody-dependent cell-mediated cytotoxicity (ADCC"), complement-dependent cytotoxicity ("CDC"), or phagocytosis of the therapeutic antibodies. There is described a method of treating cancer in a patient having a cancer characterized by a cancer antigen, said method comprising administering to said patient a therapeutically effective amount of a first antibody or a fragment thereof that specifically binds

FcyRIIB with greater affinity than said antibody or a fragment thereof binds FcyRIIA, and a second antibody that specifically binds said cancer antigen and is cytotoxic. Also provided is a method of treating cancer in a patient having a cancer characterized by a cancer antigen, said method comprising administering to said patient a therapeutically effective amount of an antibody or a fragment thereof that specifically binds FcyRIIB, particularly native human FcyRIIB with greater affinity than said antibody or a fragment thereof binds FcyRIIA, preferably native human FcyRIIA, and the constant domain of which further has an increased affinity for one or more Fc activation receptors, such as FcyRIIIA, when the antibody is monomeric, and an antibody that specifically binds said cancer antigen and is cytotoxic. The said Fc activation receptor can be FcyRIIIA. The antibody of the invention may be administered at a dose such that the antibody does not detectably bind to neutrophils.

[0056] The antibodies of the invention are also useful for prevention or treatment of B-cell malignancies, particularly non-Hodgkin's lymphoma or chronic lymphocytic leukemia. Accordingly, methods of treating, managing, preventing, or ameliorating a B-cell malignancy are discussed by administering, either alone or in combination with one or more other therapeutics, antibodies that specifically bind FcyRIIB, and, preferably, do not specifically bind FcyRIIA, as well as derivatives, analogs and antigen binding fragments of such antibodies. In particular cases, the cancer of the subject is refractory to one or more standard or experimental therapies, particularly, to Rituxan treatment. The methods described may be used for the treatment, management, prevention, or amelioration of B-cell diseases, such as, B-cell chronic lymphocytic leukemia (B-CLL), non-Hodgkin's lymphoma, diffuse large B cell lymphoma, follicular lymphoma with areas of diffuse large B cell lymphoma, small lymphocytic lymphoma, mantle cell lymphoma, and diffuse small cleaved cell lymphoma.

[0057] The use of a FcyRIIB-specific antibody may be conjugated to a therapeutic agent or drug. Examples of therapeutic agents which may be conjugated to an anti-FcyRIIB antibody or an antigen-binding fragment thereof include, but are not limited to, cytokines, toxins, radioactive elements, and antimetabolites.

[0058] The use of an FcyRIIB-specific antibody may be in combination with a standard or experimental treatment regimen for B-cell malignancies (e.g., chemotherapy, radioimmunotherapy, or radiotherapy). Such combination therapy may enhance the efficacy of standard or experimental treatment. Examples of therapeutic agents that are particularly useful in combination with a FcyRIIB-specific antibody or an antigen-binding fragment thereof, for the prevention, treatment, management, or amelioration of B-cell malignancies, include, but are not limited to, Rituxan, interferon-alpha, and anti-cancer agents. Chemotherapeutic agents that can be used in combination with a FcyRIIB-specific antibody or an antigen-binding fragment thereof, include, but are not limited to alkylating agents, antimetabolites, natural products, and hormones. The combination therapies enable lower dosages of an anti-FcyRIIB antibody or an antigen-binding fragment thereof and/or less frequent administration of anti-FcyRIIB antibody or an antigen-binding fragment thereof to a subject with a B-cell malignancy, to achieve a therapeutic or prophylactic effect.

[0059] The use of an anti-FcyRIIB antibody or an antigen-binding fragment thereof prolongs the survival of a subject diagnosed with a B-cell malignancy.

[0060] A method of enhancing an antibody mediated cytotoxic effect in a subject being treated with a cytotoxic antibody is also disclosed, said method comprising administering to said patient an antibody of the invention or a fragment thereof, in an amount sufficient to enhance the cytotoxic effect of said cytotoxic antibody. Also discussed is a method of enhancing an antibody-mediated cytotoxic effect in a subject being treated with a cytotoxic antibody, said method comprising administering to said patient an antibody of the invention or a fragment thereof, further having an enhanced affinity for an Fc activation receptor, when monomeric, in an amount sufficient to enhance the cytotoxic effect of said cytotoxic antibody. Further disclosed is a method further comprising the administration of one or more additional cancer therapies.

[0061] The antibodies of the invention may be used in combination with any therapeutic antibody that mediates its therapeutic effect through cell killing to potentiate the antibody's therapeutic activity. The antibodies of the invention may potentiate the antibody's therapeutic activity by enhancing antibody-mediated effector function. The antibodies of the invention may potentiate the cytotoxic antibody's therapeutic activity by enhancing phagocytosis and opsonization of the targeted tumor cells. The antibodies of the invention may potentiate the antibody's therapeutic activity by enhancing antibody-dependent cell-mediated cytotoxicity ("ADCC") in destruction of the targeted tumor cells. In certain circumstances, the antibodies of the invention can be used in combination with Fc fusion proteins to enhance ADCC.

[0062] Also discussed is the use of the antibodies of the invention in combination with a therapeutic antibody that does not mediate its therapeutic effect through cell killing to potentiate the antibody's therapeutic activity. The use of the antibodies of the invention in combination with a therapeutic apoptosis-inducing antibody with agonistic activity, e.g., anti-Fas antibody is disclosed. Therapeutic apoptosis-inducing antibodies may be specific for any death receptor known in the art for the modulation of apoptotic pathway, e.g., TNFR receptor family member or a TRAIL family member.

[0063] The antibodies of the invention may block macrophage mediated tumor cell progression and metastasis. The antibodies of the invention are particularly useful in the treatment of solid tumors, where macrophage infiltration occurs. The antagonistic antibodies of the invention are particularly useful for controlling, e.g., reducing or eliminating, tumor cell metastasis, by reducing or eliminating the population of macrophages that are localized at the tumor site. The antibodies can also effectively deplete or eliminate immune effector cells other than macrophages that express Fc γ RIIB, e.g., dendritic cells. Effective depletion or elimination of immune effector cells using the antibodies of the invention may range from a reduction in population of the effector cells by 50%, 60%, 70%, 80%, preferably 90%, and most preferably 99%. The antibody of the invention can be administered at a dose such that the antibody does not detectably bind to neutrophils.

[0064] The agonistic antibodies of the invention can be particularly useful for the treatment of tumors of non-hematopoietic origin, including tumors of melanoma cells.

[0065] The antibodies of the invention can be used in combination with therapeutic antibodies that immunospecifically bind to tumor antigens that are not expressed on the tumor cells themselves, but rather on the surrounding reactive and tumor supporting, non-malignant cells comprising the tumor stroma. Preferably an antibody of the invention is used in combination with an antibody that immunospecifically binds a tumor antigen on a fibroblast cell, e.g., fibroblast activation protein (FAP).

[0066] There is discussed a method of treating an autoimmune disorder in a patient in need thereof, said method comprising administering to said patient a therapeutically effective amount of one or more antibodies of the invention. Also discussed is a method of treating an autoimmune disorder in a patient in need thereof, said method further comprising administering to said patient a therapeutically effective amount of one or more anti-inflammatory agents, and/or one or more immunomodulatory agents.

[0067] Also provided is a method of treating an inflammatory disorder in a patient in need thereof, said method comprising administering to said patient a therapeutically effective amount of one or more antibodies of the invention. Also discussed is a method of treating an inflammatory disorder in a patient in need thereof, said method further comprising administering to said patient a therapeutically effective amount of one or more anti-inflammatory agents, and/or one or more immunomodulatory agents.

[0068] There is also provided a method of enhancing an immune response to a vaccine composition in a subject, said method comprising administering to said subject an antibody or an antigen-binding fragment thereof that specifically binds Fc γ RIIB with greater affinity than said antibody or a fragment thereof binds Fc γ RIIA, and a vaccine composition, such that said antibody or a fragment thereof is administered in an amount effective to enhance the immune response to said vaccine composition in said subject. The antibodies of the invention may be used to enhance a humoral and/or cell mediated response against the antigen(s) of the vaccine composition. The antibodies of the invention may be used in combination with any vaccines known in the art. The use of the antibodies of the invention to either prevent or treat a particular disorder is discussed, where an enhanced immune response against a particular antigen or antigens is effective to treat or prevent the disease or disorder.

[0069] Also discussed is a method for treating or preventing an IgE-mediated allergic disorder in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of the agonistic antibodies of the invention. There is also provided a method for treating or preventing an IgE-mediated allergic disorder in a patient in need thereof, comprising administering to said patient the antibodies of the invention in combination with other therapeutic antibodies or vaccine compositions used for the treatment or prevention of IgE-mediated allergic disorders.

[0070] A method for enhancing immune therapy for an infectious agent wherein the antibodies of the invention are administered to a patient that is already infected by a pathogen, such as HIV, HCV or HSV, to enhance opsonization and phagocytosis of infected cells is disclosed.

[0071] A method of treating diseases with impaired apoptotic mediated signaling, e.g., cancer, autoimmune disease, is discussed. Such may include a method of treating a disease with deficient Fas-mediated apoptosis, said method comprising administering an antibody of the invention in combination with an anti-Fas antibody.

[0072] Further discussed is the use of the antibodies of the invention to detect the presence of Fc γ RIIB specifically (i.e., Fc γ RIIB and not Fc γ RIIA) in a biological sample.

[0073] There is also disclosed a method of diagnosis of an autoimmune disease in a subject comprising: (i) contacting a biological sample from said subject with an effective amount of an antibody of the invention; and (ii) detecting binding of said

antibody or a fragment thereof, wherein detection of said detectable marker above a background or standard level indicates that said subject has an autoimmune disease.

[0074] The invention further provides, as specified by the claims, a pharmaceutical composition comprising (i) a therapeutically effective amount of the antibody or a fragment thereof that specifically binds Fc_YRIIB with greater affinity than said antibody or a fragment thereof binds Fc_YRIIA; and (ii) a pharmaceutically acceptable carrier. Certain embodiments of the invention falling within the scope of the specified claims provide a pharmaceutical composition comprising (i) a therapeutically effective amount of the antibody or fragment thereof that specifically binds Fc_YRIIB with greater affinity than said antibody or fragment thereof binds Fc_YRIIA; (ii) a cytotoxic antibody that specifically binds a cancer antigen; and (iii) a pharmaceutically acceptable carrier.

[0075] In certain instances, pharmaceutical compositions are described for use in accordance with the methods of the specification, said pharmaceutical compositions comprising an anti-Fc_YRIIB antibody or an antigen-binding fragment thereof, in an amount effective to prevent, treat, manage, or ameliorate a B-cell malignancy, or one or more symptoms thereof, and a pharmaceutically acceptable carrier. Also provided are pharmaceutical compositions for use in accordance with the methods of the specification, said pharmaceutical compositions comprising an anti-Fc_YRIIB antibody or an antigen-binding fragment thereof, a prophylactic or therapeutic agent other than a Fc_YRIIB antagonist, and a pharmaceutically acceptable carrier.

3.1 DEFINITIONS

[0076] As used herein, the term "specifically binds to Fc_YRIIB" and analogous terms refer to antibodies or fragments thereof (or any other Fc_YRIIB binding molecules) that specifically bind to Fc_YRIIB or a fragment thereof and do not specifically bind to other Fc receptors, in particular to Fc_YRIIA. Further it is understood to one skilled in the art, that an antibody that specifically binds to Fc_YRIIB, may bind through the variable domain or the constant domain of the antibody. If the antibody that specifically binds to Fc_YRIIB binds through its variable domain, it is understood to one skilled in the art that it is not aggregated, *i.e.*, is monomeric. An antibody that specifically binds to Fc_YRIIB may bind to other peptides or polypeptides with lower affinity as determined by, *e.g.*, immunoassays, BIAcore, or other assays known in the art. Preferably, antibodies or fragments that specifically bind to Fc_YRIIB or a fragment thereof do not cross-react with other antigens. Antibodies or fragments that specifically bind to Fc_YRIIB can be identified, for example, by immunoassays, BIAcore, or other techniques known to those of skill in the art. An antibody or a fragment thereof binds specifically to a Fc_YRIIB when it binds to Fc_YRIIB with higher affinity than to any cross-reactive antigen as determined using experimental techniques, such as western blots, radioimmunoassays (RIA) and enzyme-linked immunosorbent assays (ELISAs). See, *e.g.*, Paul, ed., 1989, Fundamental Immunology Second Edition, Raven Press, New York at pages 332-336 for a discussion regarding antibody specificity.

[0077] As used herein, the term "native Fc_YRIIB" refers to Fc_YRIIB which is endogenously expressed and present on the surface of a cell. In some embodiments, "native Fc_YRIIB" encompasses a protein that is recombinantly expressed in a mammalian cell. Preferably, the native Fc_YRIIB is not expressed in a bacterial cell, *i.e.*, *E. coli*. Most preferably the native Fc_YRIIB is not denatured, *i.e.*, it is in its biologically active conformation.

[0078] As used herein, the term "native Fc_YRIIA" refers to Fc_YRIIA which is endogenously expressed and present on the surface of a cell. In some embodiments, "native Fc_YRIIA" encompasses a protein that is recombinantly expressed in a mammalian cell. Preferably, the native Fc_YRIIA is not expressed in a bacterial cell, *i.e.*, *E. coli*. Most preferably the native Fc_YRIIA is not denatured, *i.e.*, it is in its biologically active conformation.

[0079] As used herein, the term "endogenous" in the context of a cellular protein refers to protein naturally occurring and/or expressed by the cell in the absence of Recombinant manipulation; accordingly, the terms "endogenously expressed protein" or "endogenous protein" excludes cellular proteins expressed by means of recombinant technology.

[0080] As used herein, the term "analog" in the context of proteinaceous agents (*e.g.*, proteins, polypeptides, and antibodies) refers to a proteinaceous agent that possesses a similar or identical function as a second proteinaceous agent but does not necessarily comprise a similar or identical amino acid sequence of the second proteinaceous agent, or possess a similar or identical structure of the second proteinaceous agent. A proteinaceous agent that has a similar amino acid sequence refers to a second proteinaceous agent that satisfies at least one of the following: (a) a proteinaceous agent having an amino acid sequence that is at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% identical to the amino acid sequence of a second proteinaceous agent; (b) a proteinaceous agent encoded by a nucleotide sequence that hybridizes under stringent conditions to a nucleotide sequence encoding a second proteinaceous agent of at least 5 contiguous amino acid residues, at

least 10 contiguous amino acid residues, at least 15 contiguous amino acid residues, at least 20 contiguous amino acid residues, at least 25 contiguous amino acid residues, at least 40 contiguous amino acid residues, at least 50 contiguous amino acid residues, at least 60 contiguous amino acid residues, at least 70 contiguous amino acid residues, at least 80 contiguous amino acid residues, at least 90 contiguous amino acid residues, at least 100 contiguous amino acid residues, at least 125 contiguous amino acid residues, or at least 150 contiguous amino acid residues; and (c) a proteinaceous agent encoded by a nucleotide sequence that is at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% identical to the nucleotide sequence encoding a second proteinaceous agent. A proteinaceous agent with similar structure to a second proteinaceous agent refers to a proteinaceous agent that has a similar secondary, tertiary or quaternary structure to the second proteinaceous agent. The structure of a polypeptide can be determined by methods known to those skilled in the art, including but not limited to, peptide sequencing, X-ray crystallography, nuclear magnetic resonance, circular dichroism, and crystallographic electron microscopy.

[0081] To determine the percent identity of two amino acid sequences or of two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino acid or nucleic acid sequence). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences (i.e., % identity = number of identical overlapping positions/total number of positions x 100%). In one instance, the two sequences are the same length.

[0082] The determination of percent identity between two sequences can also be accomplished using a mathematical algorithm. A preferred, non-limiting example of a mathematical algorithm utilized for the comparison of two sequences is the algorithm of Karlin and Altschul, 1990, Proc. Natl. Acad. Sci. U.S.A. 87:2264-2268, modified as in Karlin and Altschul, 1993, Proc. Natl. Acad. Sci. U.S.A. 90:5873-5877. Such an algorithm is incorporated into the NBLAST and XBLAST programs of Altschul et al., 1990, J. Mol. Biol. 215:403. BLAST nucleotide searches can be performed with the NBLAST nucleotide program parameters set, e.g., for score=100, wordlength=12 to obtain nucleotide sequences homologous to a nucleic acid molecules of the present invention. BLAST protein searches can be performed with the XBLAST program parameters set, e.g., to score=50, wordlength=3 to obtain amino acid sequences homologous to a protein molecule of the present invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al., 1997, Nucleic Acids Res. 25:3389-3402. Alternatively, PSI-BLAST can be used to perform an iterated search which detects distant relationships between molecules (Id.). When utilizing BLAST, Gapped BLAST, and PSI-Blast programs, the default parameters of the respective programs (e.g., of XBLAST and NBLAST) can be used (see, e.g., the NCBI website). Another preferred, non-limiting example of a mathematical algorithm utilized for the comparison of sequences is the algorithm of Myers and Miller, 1988, CABIOS 4:11-17. Such an algorithm is incorporated in the ALIGN program (version 2.0) which is part of the GCG sequence alignment software package. When utilizing the ALIGN program for comparing amino acid sequences, a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 can be used.

[0083] The percent identity between two sequences can be determined using techniques similar to those described above, with or without allowing gaps. In calculating percent identity, typically only exact matches are counted.

[0084] As used herein, the term "analog" in the context of a non-proteinaceous agent refers to a second organic or inorganic molecule which possess a similar or identical function as a first organic or inorganic molecule and is structurally similar to the first organic or inorganic molecule.

[0085] As used herein, the terms "antagonist" and "antagonists" refer to any protein, polypeptide, peptide, antibody, antibody fragment, large molecule, or small molecule (less than 10 kD) that blocks, inhibits, reduces or neutralizes a function, activity and/or expression of another molecule, such as that of FcγRIIB. In various instances, an antagonist reduces a function, activity and/or expression of another molecule by at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% relative to a control such as phosphate buffered saline (PBS).

[0086] As used herein, the terms "antibody" and "antibodies" refer to monoclonal antibodies, multispecific antibodies, human antibodies, humanized antibodies, synthetic antibodies, chimeric antibodies, camelized antibodies, single-chain Fvs (scFv), single chain antibodies, Fab fragments, F(ab') fragments, disulfide-linked Fvs (sdFv), intrabodies, and anti-idiotypic (anti-Id) antibodies (including, e.g., anti-Id and anti-anti-Id antibodies to antibodies of the invention), and epitope-binding fragments of any of the above. In particular, antibodies include immunoglobulin molecules and immunologically active fragments of immunoglobulin molecules, i.e., molecules that contain an antigen binding site. Immunoglobulin molecules can be of any type (e.g., IgG, IgE, IgM,

IgD, IgA and IgY), class (e.g., IgG₁, IgG₂, IgG₃, IgG₄, IgA₁ and IgA₂) or subclass.

[0087] As used herein, the terms "B-cell malignancies" and "B-cell malignancy" refer to any B-cell lymphoproliferative disorder. B-cell malignancies include tumors of B-cell origin. B-cell malignancies include, but are not limited to, lymphomas, chronic lymphocytic leukemias, acute lymphoblastic leukemias, multiple myeloma, Hodgkin's and non-Hodgkin's disease, diffuse large B cell lymphoma, follicular lymphoma with areas of diffuse large B cell lymphoma, small lymphocytic lymphoma, mantle cell lymphoma, and diffuse small cleaved cell lymphoma.

[0088] Unless otherwise indicated, when referring to antibodies (as broadly defined herein), reference to antibody domains and/or amino acid positions within antibodies, or fragments thereof, is in accordance with the definition and assignment of amino acids to each domain in Kabat et al, SEQUENCES OF PROTEINS OF IMMUNOLOGICAL INTEREST, 5th Ed. Public Health Service (National Institutes of Health, Bethesda, Md., 1987 and 1991). Amino acids from the variable regions of the mature heavy and light chains of immunoglobulins are designated by the position of an amino acid in the chain. Kabat described numerous amino acid sequences for antibodies, identified an amino acid consensus sequence for each subgroup, and assigned a residue number to each amino acid. Kabat's numbering scheme is extendible to antibodies not included in his compendium by aligning the antibody in question with one of the consensus sequences in Kabat by reference to conserved amino acids. This method for assigning residue numbers has become standard in the field and readily identifies amino acids at equivalent positions in different antibodies, including chimeric or humanized variants. For example, an amino acid at position 50 of a human antibody light chain occupies the equivalent position to an amino acid at position 50 of a mouse antibody light chain. Thus, as used herein in the context of humanized antibodies, a reference such as "at position 297 of the Fc region" refers to the amino acid position in an immunoglobulin chain, region of an immunoglobulin chain, or region of a polypeptide derived from an immunoglobulin chain, that corresponds to position 297 of the corresponding human immunoglobulin.

[0089] As used herein, the term "cancer" refers to a neoplasm or tumor resulting from abnormal uncontrolled growth of cells. As used herein, cancer explicitly includes, leukemias and lymphomas. The term "cancer" refers to a disease involving cells that have the potential to metastasize to distal sites and exhibit phenotypic traits that differ from those of non-cancer cells, for example, formation of colonies in a three-dimensional substrate such as soft agar or the formation of tubular networks or weblike matrices in a three-dimensional basement membrane or extracellular matrix preparation. Non-cancer cells do not form colonies in soft agar and form distinct sphere-like structures in three-dimensional basement membrane or extracellular matrix preparations. Cancer cells acquire a characteristic set of functional capabilities during their development, albeit through various mechanisms. Such capabilities include evading apoptosis, self-sufficiency in growth signals, insensitivity to anti-growth signals, tissue invasion/metastasis, limitless explicative potential, and sustained angiogenesis. The term "cancer cell" is meant to encompass both pre-malignant and malignant cancer cells. In some embodiments, cancer refers to a benign tumor, which has remained localized. In other embodiments, cancer refers to a malignant tumor, which has invaded and destroyed neighboring body structures and spread to distant sites. In yet other embodiments, the cancer is associated with a specific cancer antigen.

[0090] As used herein, the term "derivative" in the context of polypeptides or proteins, including antibodies, refers to a polypeptide or protein that comprises an amino acid sequence which has been altered by the introduction of amino acid residue substitutions, deletions or additions. The term "derivative" as used herein also refers to a polypeptide or protein which has been modified, i.e., by the covalent attachment of any type of molecule to the polypeptide or protein. For example, but not by way of limitation, an antibody may be modified, e.g., by glycosylation, acetylation, pegylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to a cellular ligand or other protein, etc. A derivative polypeptide or protein may be produced by chemical modifications using techniques known to those of skill in the art, including, but not limited to specific chemical cleavage, acetylation, formylation, metabolic synthesis of tunicamycin, etc. Further, a derivative polypeptide or protein derivative possesses a similar or identical function as the polypeptide or protein from which it was derived.

[0091] The term "derivative" as used herein in conjunction with Fc_YRIIB refers to a polypeptide that comprises an amino acid sequence of a Fc_YRIIB polypeptide, a fragment of a Fc_YRIIB polypeptide, an antibody that immunospecifically binds to a Fc_YRIIB polypeptide, or an antibody fragment that immunospecifically binds to a Fc_YRIIB polypeptide, that has been altered by the introduction of amino acid residue substitutions, deletions or additions (i.e., mutations). In some instances, an antibody derivative or fragment thereof comprises amino acid residue substitutions, deletions or additions in one or more CDRs. The antibody derivative may have substantially the same binding, better binding, or worse binding when compared to a non-derivative antibody. In specific instances, one, two, three, four, or five amino acid residues of the CDR have been substituted, deleted or added (i.e., mutated). The term "derivative" as used herein in conjunction with Fc_YRIIB also refers to a Fc_YRIIB polypeptide, a fragment of a Fc_YRIIB polypeptide, an antibody that immunospecifically binds to a Fc_YRIIB polypeptide, or an antibody fragment that immunospecifically binds to a Fc_YRIIB polypeptide which has been modified, i.e., by the covalent attachment of any type of molecule to the polypeptide. For example, but not by way of limitation, a Fc_YRIIB polypeptide, a fragment of a Fc_YRIIB polypeptide,

an antibody, or antibody fragment may be modified, e.g., by glycosylation, acetylation, pegylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to a cellular ligand or other protein, etc. A derivative of a Fc_YRIIB polypeptide, a fragment of a Fc_YRIIB polypeptide, an antibody, or antibody fragment may be modified by chemical modifications using techniques known to those of skill in the art, including, but not limited to, specific chemical cleavage, acetylation, formulation, metabolic synthesis of tunicamycin, etc. Further, a derivative of a Fc_YRIIB polypeptide, a fragment of a Fc_YRIIB polypeptide, an antibody, or antibody fragment may contain one or more non-classical amino acids. In one embodiment, an antibody derivative possesses a similar or identical function as the parent antibody. In another embodiment, a derivative of an antibody, or antibody fragment has an altered activity when compared to an unaltered antibody. For example, a derivative antibody or fragment thereof can bind to its epitope more tightly or be more resistant to proteolysis.

[0092] As used herein, the terms "disorder" and "disease" are used interchangeably to refer to a condition in a subject. In particular, the term "autoimmune disease" is used interchangeably with the term "autoimmune disorder" to refer to a condition in a subject characterized by cellular, tissue and/or organ injury caused by an immunologic reaction of the subject to its own cells, tissues and/or organs. The term "inflammatory disease" is used interchangeably with the term "inflammatory disorder" to refer to a condition in a subject characterized by inflammation, preferably chronic inflammation. Autoimmune disorders may or may not be associated with inflammation. Moreover, inflammation may or may not be caused by an autoimmune disorder. Thus, certain disorders may be characterized as both autoimmune and inflammatory disorders.

[0093] As used herein, the term "epitope" refers to a region on an antigen molecule to which an antibody specifically binds.

[0094] As used herein, the term "fragment" refers to a peptide or polypeptide comprising an amino acid sequence of at least 5 contiguous amino acid residues, at least 10 contiguous amino acid residues, at least 15 contiguous amino acid residues, at least 20 contiguous amino acid residues, at least 25 contiguous amino acid residues, at least 40 contiguous amino acid residues, at least 50 contiguous amino acid residues, at least 60 contiguous amino acid residues, at least 70 contiguous amino acid residues, at least contiguous 80 amino acid residues, at least contiguous 90 amino acid residues, at least contiguous 100 amino acid residues, at least contiguous 125 amino acid residues, at least 150 contiguous amino acid residues, at least contiguous 175 amino acid residues, at least contiguous 200 amino acid residues, or at least contiguous 250 amino acid residues of the amino acid sequence of another polypeptide. In a specific embodiment, a fragment of a polypeptide retains at least one function of the polypeptide. Preferably, antibody fragments are epitope binding fragments.

[0095] As used herein, the term "humanized antibody" refers to an immunoglobulin comprising a human framework region and one or more CDR's from a non-human (usually a mouse or rat) immunoglobulin. The non-human immunoglobulin providing the CDR's is called the "donor" and the human immunoglobulin providing the framework is called the "acceptor". Constant regions need not be present, but if they are, they must be substantially identical to human immunoglobulin constant regions, *i.e.*, at least about 85-90%, preferably about 95% or more identical. Hence, all parts of a humanized immunoglobulin, except possibly the CDR's, are substantially identical to corresponding parts of natural human immunoglobulin sequences. A "humanized antibody" is an antibody comprising a humanized light chain and a humanized heavy chain immunoglobulin. For example, a humanized antibody would not encompass a typical chimeric antibody, because, *e.g.*, the entire variable region of a chimeric antibody is non-human. One says that the donor antibody has been "humanized", by the process of "humanization", because the resultant humanized antibody is expected to bind to the same antigen as the donor antibody that provides the CDR's. For the most part, humanized antibodies are human immunoglobulins (recipient antibody) in which hypervariable region residues of the recipient are replaced by hypervariable region residues from a non-human species (donor antibody) such as mouse, rat, rabbit or non-human primate having the desired specificity, affinity, and capacity. In some instances, Framework Region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, humanized antibodies may comprise residues which are not found in the recipient antibody or in the donor antibody. These modifications are made to further refine antibody performance. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable regions correspond to those of a non-human immunoglobulin and all or substantially all of the FRs are those of a human immunoglobulin sequence. The humanized antibody optionally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin that immunospecifically binds to a Fc_YRIIB polypeptide, that has been altered by the introduction of amino acid residue substitutions, deletions or additions (*i.e.*, mutations). In some embodiments, a humanized antibody is a derivative. Such a humanized antibody comprises amino acid residue substitutions, deletions or additions in one or more non-human CDRs. The humanized antibody derivative may have substantially the same binding, better binding, or worse binding when compared to a non-derivative humanized antibody. In specific instances, one, two, three, four, or five amino acid residues of the CDR have been substituted, deleted or added (*i.e.*, mutated). For further details in humanizing antibodies, see European Patent Nos. EP 239,400, EP 592,106, and EP 519,596; International Publication Nos. WO 91/09967 and WO 93/17105; U.S. Patent Nos. 5,225,539, 5,530,101, 5,565,332, 5,585,089, 5,766,886, and 6,407,213; and Padlan, 1991, Molecular Immunology 28(4/5):489-498; Studnicka et al., 1994, Protein Engineering 7(6):805-814; Roguska et al., 1994, Proc Natl Acad Sci USA 91:969-973; Tan et al., 2002, J. Immunol. 169:1119-25;

Caldas et al., 2000, Protein Eng. 13:353-60; Morea et al., 2000, Methods 20:267-79; Baca et al., 1997, J. Biol. Chem. 272:10678-84; Roguska et al., 1996, Protein Eng. 9:895-904; Couto et al., 1995, Cancer Res. 55 (23 Supp):5973s-5977s; Couto et al., 1995, Cancer Res. 55:1717-22; Sandhu, 1994, Gene 150:409-10; Pedersen et al., 1994, J. Mol. Biol. 235:959-73; Jones et al., 1986, Nature 321:522-525; Reichmann et al., 1988, Nature 332:323-329; and Presta, 1992, Curr. Op. Struct. Biol. 2:593-596.

[0096] As used herein, the term "hypervariable region" refers to the amino acid residues of an antibody which are responsible for antigen binding. The hypervariable region comprises amino acid residues from a "Complementarity Determining Region" or "CDR" (i.e., residues 24-34 (L1), 50-56 (L2) and 89-97 (L3) in the light chain variable domain and 31-35 (H1), 50-65 (H2) and 95-102 (H3) in the heavy chain variable domain; Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD. (1991)) and/or those residues from a "hypervariable loop" (i.e., residues 26-32 (L1), 50-52 (L2) and 91-96 (L3) in the light chain variable domain and 26-32 (H1), 53-55 (H2) and 96-101 (H3) in the heavy chain variable domain; Chothia and Lesk, 1987, J. Mol. Biol. 196:901-917). CDR residues for Eph099B-208.261 and Eph099B-233.152 are listed in Table 1. "Framework Region" or "FR" residues are those variable domain residues other than the hypervariable region residues as herein defined.

[0097] As used herein, the term "immunomodulatory agent" and variations thereof including, but not limited to, immunomodulatory agents, refer to an agent that modulates a host's immune system. In certain embodiments falling within the scope of specified claims, an immunomodulatory agent is an immunosuppressant agent. In certain other embodiments falling within the scope of specified claims, an immunomodulatory agent is an immunostimulatory agent. Immunomodulatory agents include, but are not limited to, small molecules, peptides, polypeptides, fusion proteins, antibodies, inorganic molecules, mimetic agents, and organic molecules.

[0098] As used herein, the terms "manage," "managing" and "management" refer to the beneficial effects that a subject derives from administration of a prophylactic or therapeutic agent, which does not result in a cure of the disease. In certain instances, a subject is administered one or more prophylactic or therapeutic agents to "manage" a disease so as to prevent the progression or worsening of the disease.

[0099] As used herein, the terms "nucleic acids" and "nucleotide sequences" include DNA molecules (e.g., cDNA or genomic DNA), RNA molecules (e.g., mRNA), combinations of DNA and RNA molecules or hybrid DNA/RNA molecules, and analogs of DNA or RNA molecules. Such analogs can be generated using, for example, nucleotide analogs, which include, but are not limited to, inosine or tritylated bases. Such analogs can also comprise DNA or RNA molecules comprising modified backbones that lend beneficial attributes to the molecules such as, for example, nuclease resistance or an increased ability to cross cellular membranes. The nucleic acids or nucleotide sequences can be single-stranded, double-stranded, may contain both single-stranded and double-stranded portions, and may contain triple-stranded portions, but preferably is double-stranded DNA.

[0100] As used herein, the terms "prevent", "preventing" and "prevention" refer to the prevention of the occurrence and/or recurrence or onset of one or more symptoms of a disorder in a subject resulting from the administration of a prophylactic or therapeutic agent.

[0101] As used herein, the terms "prophylactic agent" and "prophylactic agents" refer to any agent(s) which can be used in the prevention of a disorder, or prevention of recurrence or spread of a disorder. A prophylactically effective amount may refer to the amount of prophylactic agent sufficient to prevent the recurrence or spread of hyperproliferative disease, particularly cancer, or the occurrence of such in a patient, including but not limited to those predisposed to hyperproliferative disease, for example those genetically predisposed to cancer or previously exposed to carcinogens. A prophylactically effective amount may also refer to the amount of the prophylactic agent that provides a prophylactic benefit in the prevention of disease. Further, a prophylactically effective amount with respect to a prophylactic agent of the specification means that amount of prophylactic agent alone, or in combination with other agents, that provides a prophylactic benefit in the prevention of disease. Used in connection with an amount of an FcγRIIB antibody of the invention, the term can encompass an amount that improves overall prophylaxis or enhances the prophylactic efficacy of or synergies with another prophylactic agent, such as but not limited to a therapeutic antibody. In certain instances, the term "prophylactic agent" refers to an agonistic FcγRIIB-specific antibody. In other instances, the term "prophylactic agent" refers to an antagonistic FcγRIIB-specific antibody. In certain other instances, the term "prophylactic agent" refers to cancer chemotherapeutics, radiation therapy, hormonal therapy, biological therapy (e.g., immunotherapy), and/or FcγRIIB antibodies of the invention. In other instances, more than one prophylactic agent may be administered in combination.

[0102] As used herein, the phrase "side effects" encompasses unwanted and adverse effects of a prophylactic or therapeutic agent. Adverse effects are always unwanted, but unwanted effects are not necessarily adverse. An adverse effect from a prophylactic or therapeutic agent might be harmful or uncomfortably or risky. Side effects from chemotherapy include, but are not

limited to, gastrointestinal toxicity such as, but not limited to, early and late-forming diarrhea and flatulence, nausea, vomiting, anorexia, leukopenia, anemia, neutropenia, asthenia, abdominal cramping, fever, pain, loss of body weight, dehydration, alopecia, dyspnea, insomnia, dizziness, mucositis, xerostomia, and kidney failure, as well as constipation, nerve and muscle effects, temporary or permanent damage to kidneys and bladder, flu-like symptoms, fluid retention, and temporary or permanent infertility. Side effects from radiation therapy include but are not limited to fatigue, dry mouth, and loss of appetite. Side effects from biological therapies/immunotherapies include but are not limited to rashes or swellings at the site of administration, flu-like symptoms such as fever, chills and fatigue, digestive tract problems and allergic reactions. Side effects from hormonal therapies include but are not limited to nausea, fertility problems, depression, loss of appetite, eye problems, headache, and weight fluctuation. Additional undesired effects typically experienced by patients are numerous and known in the art, see, e.g., the Physicians' Desk Reference (56th ed., 2002).

[0103] As used herein, the terms "single-chain Fv" or "scFv" refer to antibody fragments comprise the VH and VL domains of antibody, wherein these domains are present in a single polypeptide chain. Generally, the Fv polypeptide further comprises a polypeptide linker between the VH and VL domains which enables the scFv to form the desired structure for antigen binding. For a review of sFv see Pluckthun in *The Pharmacology of Monoclonal Antibodies*, vol. 113, Rosenburg and Moore eds. Springer-Verlag, New York, pp. 269-315 (1994). In specific embodiments falling within the scope of specified claims, scFvs include bi-specific scFvs and humanized scFvs.

[0104] As used herein, the terms "subject" and "patient" are used interchangeably. As used herein, a subject is preferably a mammal such as a non-primate (e.g., cows, pigs, horses, cats, dogs, rats etc.) and a primate (e.g., monkey and human), most preferably a human.

[0105] As used herein, a "therapeutically effective amount" refers to that amount of the therapeutic agent sufficient to treat or manage a disease or disorder associated with FcγRIIB and any disease related to the loss of regulation in the Fc receptor signaling pathway or to enhance the therapeutic efficacy of another therapy, e.g., therapeutic antibody, vaccine therapy or prophylaxis, etc. A therapeutically effective amount may refer to the amount of therapeutic agent sufficient to delay or minimize the onset of disease, e.g., delay or minimize the spread of cancer. A therapeutically effective amount may also refer to the amount of the therapeutic agent that provides a therapeutic benefit in the treatment or management of a disease. Further, a therapeutically effective amount with respect to a therapeutic agent of the invention means that amount of therapeutic agent alone, or in combination with other therapies, that provides a therapeutic benefit in the treatment or management of a disease, e.g., sufficient to enhance the therapeutic efficacy of a therapeutic antibody sufficient to treat or manage a disease. Used in connection with an amount of FcγRIIB antibody of the invention, the term can encompass an amount that improves overall therapy, reduces or avoids unwanted effects, or enhances the therapeutic efficacy of or synergies with another therapeutic agent.

[0106] As used herein, the terms "treat," "treating" and "treatment" refer to the eradication, reduction or amelioration of symptoms of a disease or disorder related to the loss of regulation in the Fc receptor signaling pathway or to enhance the therapeutic efficacy of another therapy, e.g., a therapeutic antibody, vaccine therapy or prophylaxis. In some instances, treatment refers to the eradication, removal, modification, or control of primary, regional, or metastatic cancer tissue that results from the administration of one or more therapeutic agents. In certain instances, such terms refer to the minimizing or delaying the spread of cancer resulting from the administration of one or more therapeutic agents to a subject with such a disease. In other instances, such terms refer to elimination of disease causing cells.

[0107] As used herein, the term "in combination" refers to the use of more than one prophylactic and/or therapeutic agents. The use of the term "in combination" does not restrict the order in which prophylactic and/or therapeutic agents are administered to a subject with a disorder, e.g., hyperproliferative cell disorder, especially cancer. A first prophylactic or therapeutic agent can be administered prior to (e.g., 1 minute, 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks before), concomitantly with, or subsequent to (e.g., 1 minute, 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks after) the administration of a second prophylactic or therapeutic agent to a subject which had, has, or is susceptible to a disorder. The prophylactic or therapeutic agents are administered to a subject in a sequence and within a time interval such that the agent of the specification can act together with the other agent to provide an increased benefit than if they were administered otherwise. Any additional prophylactic or therapeutic agent can be administered in any order with the other additional prophylactic or therapeutic agents.

4. BRIEF DESCRIPTION OF THE DRAWINGS

[0108]

FIG. 1: Immunoreactivity of 8B5.3.4 Antibody Against Fc γ RIIA and Fc γ RIIB. The direct binding of the antibody produced by the 8B5.3.4 hybridoma cell line clone (MAb 8B5.3.4) to Fc γ RIIB and Fc γ RIIA was tested (in duplicate) in an ELISA assay using plates coated with the receptors Fc γ RIIA and Fc γ RIIB. The bound antibodies were detected with a goat anti-mouse HRP conjugated antibody, and the absorbance was monitored at 650 nm.

FIG. 2: Isotype Characterization of the MAb 8B5.3.4. The isotype of the MAb 8B5.3.4 produced by hybridoma clone 8B5.3.4 was determined by ELISA assay. Antibodies against the various isotypes were assayed, and the absorbance values are reported.

FIG. 3: The nucleotide (SEQ ID NO: 1) and amino acid (SEQ ID NO: 3) sequences for the variable light chain of the monoclonal antibody produced by clone 8B5.3.4 are represented.

FIG. 4: The nucleotide (SEQ ID NO: 2) and amino acid (SEQ ID NO: 4) sequences for the variable heavy chain of the monoclonal antibody produced by clone 8B5.3.4 are represented.

5. DESCRIPTION OF THE PREFERRED EMBODIMENTS

5.1 Fc γ RIIB-SPECIFIC ANTIBODIES

[0109] As specified by the claims, the present invention provides an isolated antibody, or an antigen-binding fragment thereof, wherein said isolated antibody or said antigen-binding fragment specifically binds the extracellular domain of native human Fc γ RIIB with greater affinity than said antibody or said antigen-binding fragment binds native human Fc γ RIIA, and wherein:

1. i) said antibody is 8B5.3.4 antibody produced by hybridoma cell line having ATCC accession number PTA-7610; or
2. ii) said antibody or said antigen-binding fragment comprises a heavy chain variable domain having the amino acid sequence of SEQ ID NO: 4 and a light chain variable domain having the amino acid sequence of SEQ ID NO: 3; or
3. iii) said antibody or said antigen-binding fragment comprises the six CDRs of the antibody produced by hybridoma clone 8B5.3.4 having ATCC accession number PTA-7610, said six CDRs having the amino acid sequences of SEQ ID NOs: 5-10, wherein said antibody or said antigen-binding fragment binds to the same epitope of Fc γ RIIB as that recognized by the antibody produced by hybridoma clone 8B5.3.4 having ATCC accession number PTA-7610 and competes with said antibody 8B5.3.4 for binding to native human Fc γ RIIB, and wherein said antibody or said antigen-binding fragment has a dissociation constant K_d (K_{off}/K_{on}) of less than 5×10^{-9} M as determined by surface plasmon resonance. The present specification encompasses antibodies (preferably monoclonal antibodies) or fragments thereof that specifically bind Fc γ RIIB, preferably human Fc γ RIIB, more preferably native human Fc γ RIIB with a greater affinity than said antibodies or fragments thereof bind Fc γ RIIA, preferably human Fc γ RIIA, more preferably native human Fc γ RIIA. Representative antibodies are disclosed in U.S. Patent Application Publication No. 2004/0185045 and U.S. Patent Publication Application No. 2006/0013810. The present specification encompasses the use of a Fc γ RIIB-specific antibody, an analog, derivative or an antigen-binding fragment thereof (e.g., one or more complementarity determining regions ("CDRs") of a Fc γ RIIB-specific antibody) in the prevention, treatment, management or amelioration of a disease, such as cancer, in particular, a B-cell malignancy, or one or more symptoms thereof. As specified by the claims, the antibodies of the invention bind the extracellular domain of native human Fc γ RIIB. In certain embodiments falling within the scope of the specified claims, the antibodies or fragments thereof bind to Fc γ RIIB with an affinity greater than two-fold, four fold, 6 fold, 10 fold, 20 fold, 50 fold, 100 fold, 1000 fold, 10^4 fold, 10^5 fold, 10^6 fold, 10^7 fold, or 10^8 fold than said antibodies or fragments thereof bind Fc γ RIIA. In yet other instances, the specification encompasses the use of Fc γ RIIB antibodies that bind exclusively to Fc γ RIIB and have no affinity for Fc γ RIIB using standard methods known in the art and disclosed herein. In a preferred embodiment, the antibodies are human or humanized.

[0110] In a particular instance, the antibodies of the specification, or fragments thereof agonize at least one activity of Fc γ RIIB. In one instance, said activity is inhibition of B cell receptor-mediated signaling. In another instance, the agonistic antibodies of the specification inhibit activation of B cells, B cell proliferation, antibody production, intracellular calcium influx of B cells, cell cycle progression, or activity of one or more downstream signaling molecules in the Fc γ RIIB signal transduction pathway. In yet another

instance, the agonistic antibodies of the specification enhance phosphorylation of Fc γ RIIB or SHIP recruitment. In a further instance, the agonistic antibodies inhibit MAP kinase activity or Akt recruitment in the B cell receptor-mediated signaling pathway. In another instance, the agonistic antibodies of the specification agonize Fc γ RIIB-mediated inhibition of Fc ϵ RI signaling. In a particular instance, said antibodies inhibit Fc ϵ RI-induced mast cell activation, calcium mobilization, degranulation, cytokine production, or serotonin release. In another instance, the agonistic antibodies of the specification stimulate phosphorylation of Fc γ RIIB, stimulate recruitment of SHIP, stimulate SHIP phosphorylation and its association with Shc, or inhibit activation of MAP kinase family members (e.g., Erk1, Erk2, JNK, p38, etc.). In yet another instance, the agonistic antibodies of the specification enhance tyrosine phosphorylation of p62dok and its association with SHIP and rasGAP. In another instance, the agonistic antibodies of the specification inhibit Fc γ R-mediated phagocytosis in monocytes or macrophages.

[0111] In another instance, the antibodies of the specification, or fragments thereof antagonize at least one activity of Fc γ RIIB. In one instance, said activity is activation of B cell receptor-mediated signaling. In a particular instance, the antagonistic antibodies of the specification enhance B cell activity, B cell proliferation, antibody production, intracellular calcium influx, or activity of one or more downstream signaling molecules in the Fc γ RIIB signal transduction pathway. In yet another particular instance, the antagonistic antibodies of the specification decrease phosphorylation of Fc γ RIIB or SHIP recruitment. In a further instance of the specification, the antagonistic antibodies enhance MAP kinase activity or Akt recruitment in the B cell receptor mediated signaling pathway. In another instance, the antagonistic antibodies of the specification antagonize Fc γ RIIB-mediated inhibition of Fc ϵ RI signaling. In a particular instance, the antagonistic antibodies of the specification enhance Fc ϵ RI-induced mast cell activation, calcium mobilization, degranulation, cytokine production, or serotonin release. In another instance, the antagonistic antibodies of the specification inhibit phosphorylation of Fc γ RIIB, inhibit recruitment of SHIP, inhibit SHIP phosphorylation and its association with Shc, enhance activation of MAP kinase family members (e.g., Erk1, Erk2, JNK, p38, etc.). In yet another instance, the antagonistic antibodies of the specification inhibit tyrosine phosphorylation of p62dok and its association with SHIP and rasGAP. In another instance, the antagonistic antibodies of the specification enhance Fc γ R-mediated phagocytosis in monocytes or macrophages. In another instance, the antagonistic antibodies of the specification prevent phagocytosis, clearance of opsonized particles by splenic macrophages.

[0112] In other instances, the antibodies of the specification, or fragments thereof can be used to target one population of cells, but not others. Without being bound by any theory, the present inventors have discovered that Fc γ RIIB is not highly expressed on neutrophils, as previously thought. High concentrations of an anti-Fc γ RIIB antibody react with neutrophils. However, neutrophil reactivity rapidly disappears with decreasing concentrations of anti-Fc γ RIIB. At low concentrations of anti-Fc γ RIIB antibody, reactivity with CD20+ B cells was preserved. Thus, reactivity of an antibody of the specification with neutrophils can be reduced so as to not affect irrelevant populations, such as neutrophils or platelets. Accordingly, in certain instances, an antibody of the specification is employed at levels that fully recognize its target populations, but not other cells.

[0113] Antibodies of the invention include, but are not limited to, monoclonal antibodies, synthetic antibodies, recombinantly produced antibodies, multispecific antibodies, human antibodies, humanized antibodies, chimeric antibodies, camelized antibodies, single-chain Fvs (scFv), single chain antibodies, Fab fragments, F(ab') fragments, disulfide-linked Fvs (sdFv), intrabodies, and epitope-binding fragments of any of the above. In particular, antibodies used in the methods of the present invention include immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, *i.e.*, molecules that contain an antigen binding site that immunospecifically bind to Fc γ RIIB with greater affinity than said immunoglobulin molecules bind Fc γ RIIA. Antibody analogs may also include Fc γ RIIB-specific T-cell receptors, for example, chimeric T-cell receptors (see, e.g., U.S. Patent Application Publication No. 2004/0043401), a single-chain T-cell receptor linked to a single-chain antibody (see, e.g., U.S. Patent No. 6,534,633), and protein scaffolds (see, e.g., U.S. Patent No. 6,818,418). In certain embodiments, an antibody analog of the invention is not a monoclonal antibody.

[0114] The antibodies used in the methods described herein may be from any animal origin including birds and mammals (e.g., human, non-human primate, murine, donkey, sheep, rabbit, goat, guinea pig, camel, horse, or chicken). Preferably, the antibodies are human or humanized monoclonal antibodies. As used herein, "human" antibodies include antibodies having the amino acid sequence of a human immunoglobulin and include antibodies isolated from human immunoglobulin libraries or libraries of synthetic human immunoglobulin coding sequences or from mice that express antibodies from human genes.

[0115] The antibodies used in the methods described herein may be monospecific, bispecific, trispecific or of greater multispecificity. Multispecific antibodies may immunospecifically bind to different epitopes of Fc γ RIIB or immunospecifically bind to both an epitope of Fc γ RIIB as well a heterologous epitope, such as a heterologous polypeptide or solid support material. See, e.g., International Publication Nos. WO 93/17715, WO 92/08802, WO 91/00360, and WO 92/05793; Tutt, et al., 1991, *J. Immunol.* 147:60-69; U.S. Patent Nos. 4,474,893, 4,714,681, 4,925,648, 5,573,920, and 5,601,819; and Kostelnik et al., 1992, *J. Immunol.* 148:1547-1553; Todorovska et al., 2001 *Journal of Immunological Methods*, 248:47-66.

[0116] In particular embodiments, the antibodies of the invention are multi-specific with specificities for Fc_YRIIB and for a cancer antigen or any other cell surface marker specific for a cell (e.g., an immune cell such as a T-cell or B-cell) designed to be killed, e.g., in treating or preventing a particular disease or disorder, or for other Fc receptors, e.g., Fc_YRIIA, Fc_YRIIB, etc.

[0117] In one particular embodiment, the antibody is derived from a mouse monoclonal antibody produced by hybridoma clone, having ATCC accession number PTA-7610. Hybridomas producing antibodies 8B5.3.4 have been deposited with the American Type Culture Collection (10801 University Blvd., Manassas, VA. 20110-2209) on May 23, 2006 under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedures, and assigned accession number PTA-7610 (for hybridoma producing the 8B5.3.4 antibody). In a specific embodiment, the invention encompasses an antibody with the heavy chain variable region having the amino acid sequence of SEQ ID NO: 4 and the light chain variable region having the amino acid sequence of SEQ ID NO: 3. In a preferred embodiment, the antibodies of the invention are human or have been humanized, preferably a humanized version of the antibody produced by hybridoma clone 8B5.3.4.

[0118] The specification also encompasses the use of other antibodies, preferably monoclonal antibodies or fragments thereof that specifically bind Fc_YRIIB, preferably human Fc_YRIIB, more preferably native human Fc_YRIIB, that are derived from clones including but not limited to 2B6 and 3H7, 1D5, 2E1, 2H9, 2D11, and 1F2 having ATCC Accession numbers, PTA-4591, PTA-4592, PTA-5958, PTA-5961, PTA-5962, PTA-5960, and PTA-5959, respectively. Hybridomas producing the 2B6 and 3H7 clones were deposited under the provisions of the Budapest Treaty with the American Type Culture Collection (10801 University Blvd., Manassas, VA. 20110-2209) on August 13, 2002, and are incorporated herein by reference. Hybridomas producing the 1D5, 2E1, 2H9, 2D11, and 1F2 clones were deposited under the provisions of the Budapest Treaty with the American Type Culture Collection (10801 University Blvd., Manassas, VA. 20110-2209) on May 7, 2004. In preferred embodiments, the antibodies described above are chimerized or humanized.

[0119] A particular antibody used in the methods described is an antibody or an antigen-binding fragment thereof (e.g., comprising one or more complementarily determining regions (CDRs), preferably all 6 CDRs) of the antibody produced by clone 8B5.3.4 with ATCC accession number PTA-7610 (e.g., the heavy chain CDR3). A further particular antibody used in the methods described is an antibody or an antigen-binding fragment thereof (e.g., comprising one or more complementarily determining regions (CDRs), preferably all 6 CDRs) of the antibody produced by clone 2B6, 3H7, 1D5, 2E1, 2H9, 2D11, and 1F2 having ATCC Accession numbers, PTA-4591, PTA-4592, PTA-5958, PTA-5961, PTA-5962, PTA-5960, and PTA-5959, respectively (e.g., the heavy chain CDR3). Antibodies or antigen-binding fragments thereof comprising less than 6 CDRs with high affinity and specificity for a particular antigen as well as methods for producing and identifying such antibodies are commonly known in the art (see, e.g., Ward et al., 1989, *Nature* 341:544-546; Dumoulin et al., 2002, *Protein Sci.* 11:500-515; Davies et al., 1995, *Bio/Technol.* 13:475-479; Van den Beucken et al., 2001, *J. Mol. Biol.* 310:591-601; and Pereira et al., 1998, *Biochem.* 37:1430-1437). Antibodies specific for a particular antigen that were generated by combining one or two CDRs from an antibody known to specifically bind to the antigen with other CDRs have been described and are commonly known in the art (see, e.g., Marks et al., 1992, *Bio/Technol.* 10:779-783; Klimka et al., 2000, *Brit. J. Cancer* 83(2):252-260; and Rader et al., 1998, *Proc. Natl. Acad. Sci. USA* 95:8910-8915). Thus, the specification contemplates antibodies having one, two, three, four, or five of the CDRs of clone 8B5.3.4 that bind Fc_YRIIB specifically and which may be identified using the screening methods disclosed herein.

[0120] In one embodiment, an antibody fragment of the invention is a polypeptide comprising one or more CDRs of the antibody produced by clone 8B5.3.4 with ATCC accession number PTA-7610 (e.g., the heavy chain CDR3) that specifically binds the extracellular domain of native human Fc_YRIIB with greater affinity than said polypeptide binds native human Fc_YRIIA. The polypeptide may comprise an amino acid sequence of SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, or any combination thereof (see, e.g., Davies et al., 1995, *Bio/Technol.* 13:475-479; Pereira et al., 1998, *Biochemistry* 37:1430-1437; Tsumoto et al., 2002, *FEBS Letters* 525:77-82; van den Beucken et al., 2001, *J. Mol. Biol.* 310:591-601; Ward et al.; 1989, *Nature* 341:544-546; and Dumoulin et al., 2002, *Protein Sci.* 11:500-515).

[0121] An antibody used in the methods described herein can bind to the same epitope as the mouse monoclonal antibody produced by clone 8B5.3.4 with ATCC accession number PTA-7610, respectively and/or competes with the mouse monoclonal antibody produced by clone 8B5.3.4 with ATCC accession number PTA-7610, respectively as determined, e.g., in an ELISA assay or other appropriate competitive immunoassay, and also binds Fc_YRIIB with a greater affinity than said antibody or a fragment thereof binds Fc_YRIIA. An antibody used in the methods described herein can bind to the same epitope as the mouse monoclonal antibody produced by hybridoma clones 2B6, 3H7, 1D5, 2E1, 2H9, 2D11, and 1F2 having ATCC Accession numbers PTA-4591, PTA-4592, PTA-5958, PTA-5961, PTA-5962, PTA-5960, and PTA-5959, respectively, and/or competes with the mouse monoclonal antibody produced by clone 2B6, 3H7, 1D5, 2E1, 2H9, 2D11, and 1F2 having ATCC Accession numbers, PTA-4591, PTA-4592, PTA-5958, PTA-5961, PTA-5962, PTA-5960, and PTA-5959, respectively, as determined, e.g., in an ELISA assay or

other appropriate competitive immunoassay, and also binds Fc_YRIIB with a greater affinity than said antibody or a fragment thereof binds Fc_YRIIA.

[0122] The present specification also encompasses antibodies or fragments thereof comprising an amino acid sequence of a variable heavy chain and/or variable light chain that is at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical to the amino acid sequence of the variable heavy chain and/or light chain of the mouse monoclonal antibody produced by clone 8B5.3.4, 2B6, 3H7, 1D5, 2E1, 2H9, 2D11, or 1F2 having ATCC accession numbers PTA-7610, PTA-4591, PTA-4592, PTA-5958, PTA-5961, PTA-5962, PTA-5960, and PTA-5959, respectively. The present specification further encompasses antibodies or fragments thereof that specifically bind Fc_YRIIB with greater affinity than said antibody or fragment thereof binds Fc_YRIIA, said antibodies or antibody fragments comprising an amino acid sequence of one or more CDRs that is at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% identical to the amino acid sequence of one or more CDRs of the mouse monoclonal antibody produced by clone 8B5.3.4, 2B6, 3H7, 1D5, 2E1, 2H9, 2D11, or 1F2 having ATCC accession numbers PTA-7610, PTA-4591, PTA-4592, PTA-5958, PTA-5961, PTA-5962, PTA-5960, and PTA-5959, respectively. The determination of percent identity of two amino acid sequences can be determined by any method known to one skilled in the art, including BLAST protein searches.

[0123] The present specification also encompasses the use of antibodies or antibody fragments that specifically bind Fc_YRIIB with greater affinity than said antibodies or fragments thereof binds Fc_YRIIA, wherein said antibodies or antibody fragments are encoded by a nucleotide sequence that hybridizes to the nucleotide sequence of the mouse monoclonal antibody produced by clone 8B5.3.4, 2B6, 3H7, 1D5, 2E1, 2H9, 2D11, or 1F2 having ATCC accession numbers PTA-4591, PTA-4592, PTA-5958, PTA-5961, PTA-5962, PTA-5960, and PTA-5959, respectively, under stringent conditions. In a preferred instance, the invention provides antibodies or fragments thereof that specifically bind Fc_YRIIB with greater affinity than said antibodies or fragments thereof bind Fc_YRIIA, said antibodies or antibody fragments comprising a variable light chain and/or variable heavy chain encoded by a nucleotide sequence that hybridizes under stringent conditions to the nucleotide sequence of the variable light chain and/or variable heavy chain of the mouse monoclonal antibody produced by clone 8B5.3.4, 2B6, 3H7, 1D5, 2E1, 2H9, 2D11, or 1F2 having ATCC accession numbers PTA-7610, PTA-4591, PTA-4592, PTA-5958, PTA-5961, PTA-5962, PTA-5960, and PTA-5959, respectively, under stringent conditions. In another preferred instance, the invention provides antibodies or fragments thereof that specifically bind Fc_YRIIB with greater affinity than said antibodies or fragments thereof bind Fc_YRIIA, said antibodies or antibody fragments comprising one or more CDRs encoded by a nucleotide sequence that hybridizes under stringent conditions to the nucleotide sequence of one or more CDRs of the mouse monoclonal antibody produced by clone 8B5.3.4, 2B6, 3H7, 1D5, 2E1, 2H9, 2D11, or 1F2 having ATCC accession numbers PTA-7610, PTA-4591, PTA-4592, PTA-5958, PTA-5961, PTA-5962, PTA-5960, and PTA-5959, respectively. Stringent hybridization conditions include, but are not limited to, hybridization to filter-bound DNA in 6X sodium chloride/sodium citrate (SSC) at about 45°C followed by one or more washes in 0.2X SSC/0.1% SDS at about 50-65°C, highly stringent conditions such as hybridization to filter-bound DNA in 6X SSC at about 45°C followed by one or more washes in 0.1X SSC/0.2% SDS at about 60°C, or any other stringent hybridization conditions known to those skilled in the art (see, for example, Ausubel, F.M. et al., eds. 1989 Current Protocols in Molecular Biology, vol. 1, Green Publishing Associates, Inc. and John Wiley and Sons, Inc., NY at pages 6.3.1 to 6.3.6 and 2.10.3).

[0124] The constant domains of the antibodies may be selected with respect to the proposed function of the antibody, in particular with regard to the effector function which may be required. In some embodiments, the constant domains of the antibodies are human IgA, IgE, IgG or IgM domains.

[0125] The antibodies used in the methods described herein can include derivatives that are modified, i.e., by the covalent attachment of any type of molecule to the antibody. For example, but not by way of limitation, the antibody derivatives include antibodies that have been modified, e.g., by glycosylation, acetylation, pegylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to a cellular ligand or other protein, etc. Any of numerous chemical modifications may be carried out by known techniques, including, but not limited to, specific chemical cleavage, acetylation, formylation, metabolic synthesis of tunicamycin, etc. Additionally, the derivative may contain one or more non-classical amino acids.

[0126] Further, the antibodies of the invention can, in turn, be utilized to generate anti-idiotype antibodies using techniques well known to those skilled in the art. (See, e.g., Greenspan & Bona, 1989, FASEB J. 7:437-444; and Nissinoff, 1991, J. Immunol. 147:2429-2438). The specification provides methods employing the use of polynucleotides comprising a nucleotide sequence encoding an antibody of the invention or a fragment thereof.

[0127] The methods described herein also include the use of antibodies or fragments thereof that have half-lives (e.g., serum

half-lives) in a mammal, preferably a human, of greater than 15 days, preferably greater than 20 days, greater than 25 days, greater than 30 days, greater than 35 days, greater than 40 days, greater than 45 days, greater than 2 months, greater than 3 months, greater than 4 months, or greater than 5 months. The increased half-lives of the antibodies of the present invention or fragments thereof in a mammal, preferably a human, results in a higher serum titer of said antibodies or antibody fragments in the mammal, and thus, reduces the frequency of the administration of said antibodies or antibody fragments and/or reduces the concentration of said antibodies or antibody fragments to be administered. Antibodies or fragments thereof having increased *in vivo* half-lives can be generated by techniques known to those of skill in the art. For example, antibodies or fragments thereof with increased *in vivo* half-lives can be generated by modifying (e.g., substituting, deleting or adding) amino acid residues identified as involved in the interaction between the Fc domain and the FcRn receptor. The antibodies of the invention may be engineered by methods described in Ward et al. to increase biological half-lives (See U.S. Patent No. 6,277,375 B1). For example, antibodies of the invention may be engineered in the Fc-hinge domain to have increased *in vivo* or serum half-lives.

[0128] Antibodies or fragments thereof with increased *in vivo* half-lives can be generated by attaching to said antibodies or antibody fragments polymer molecules such as high molecular weight polyethyleneglycol (PEG). PEG can be attached to said antibodies or antibody fragments with or without a multifunctional linker either through site-specific conjugation of the PEG to the N- or C- terminus of said antibodies or antibody fragments or via epsilon-amino groups present on lysine residues. Linear or branched polymer derivatization that results in minimal loss of biological activity will be used. The degree of conjugation will be closely monitored by SDS-PAGE and mass spectrometry to ensure proper conjugation of PEG molecules to the antibodies. Unreacted PEG can be separated from antibody-PEG conjugates by, e.g., size exclusion or ion-exchange chromatography.

[0129] The antibodies of the invention may also be modified by the methods and coupling agents described by Davis et al. (See U.S. Patent No. 4,179,337) in order to provide compositions that can be injected into the mammalian circulatory system with substantially no immunogenic response.

[0130] The present specification also encompasses the use of antibodies or antibody fragments comprising the amino acid sequence of any of the antibodies of the invention with mutations (e.g., one or more amino acid substitutions) in the framework or CDR regions. Preferably, mutations in these antibodies maintain or enhance the avidity and/or affinity of the antibodies for FcγRIIB to which they immunospecifically bind. Standard techniques known to those skilled in the art (e.g., immunoassays) can be used to assay the affinity of an antibody for a particular antigen.

[0131] Also described are methods of modifying an effector function of an antibody of the invention, wherein the method comprises modifying the carbohydrate content of the antibody using the methods disclosed herein or known in the art.

[0132] Standard techniques known to those skilled in the art can be used to introduce mutations in the nucleotide sequence encoding an antibody, or fragment thereof, including, e.g., site-directed mutagenesis and PCR-mediated mutagenesis, which results in amino acid substitutions. Preferably, the derivatives include less than 15 amino acid substitutions, less than 10 amino acid substitutions, less than 5 amino acid substitutions, less than 4 amino acid substitutions, less than 3 amino acid substitutions, or less than 2 amino acid substitutions relative to the original antibody or fragment thereof. In a preferred embodiment, the derivatives have conservative amino acid substitutions made at one or more predicted non-essential amino acid residues.

[0133] For some uses, including *in vivo* use of antibodies in humans and *in vitro* detection assays, it may be preferable to use human, chimeric or humanized antibodies. Completely human antibodies are particularly desirable for therapeutic treatment of human subjects. Human antibodies can be made by a variety of methods known in the art including phage display methods described above using antibody libraries derived from human immunoglobulin sequences. See also U.S. Patent Nos. 4,444,887 and 4,716,111; and International Publication Nos. WO 98/46645, WO 98/50433, WO 98/24893, WO 98/16654, WO 96/34096, WO 96/33735, and WO 91/10741.

5.1.1 Humanized antibodies

[0134] In preferred embodiments, the antibodies are humanized antibodies. A humanized antibody is an antibody, a variant or a fragment thereof which is capable of binding to a predetermined antigen and which comprises a framework region having substantially the amino acid sequence of a human immunoglobulin and a CDR having substantially the amino acid sequence of a non-human immunoglobulin. A humanized FcγRIIB specific antibody may comprise substantially all of at least one, and typically two, variable domains in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin (*i.e.*, donor antibody) and all or substantially all of the framework regions are those of a human immunoglobulin consensus sequence. Preferably, a humanized antibody of the invention also comprises at least a portion of an immunoglobulin constant

region (Fc), typically that of a human immunoglobulin. The constant domains of the humanized antibodies of the invention may be selected with respect to the proposed function of the antibody, in particular the effector function which may be required. In some embodiments, the constant domains of the humanized antibodies of the invention are human IgA, IgE, IgG or IgM domains. In a specific embodiment falling within the scope of the specified claims, human IgG constant domains, especially of the IgG1 and IgG3 isotypes are used, when the humanized antibodies of the invention is intended for therapeutic uses and antibody effector functions are needed. In alternative embodiments, IgG2 and IgG4 isotypes are used when the humanized antibody of the invention is intended for therapeutic purposes and antibody effector function is not required. Humanized Fc_YRIIB specific antibodies are disclosed in U.S. Provisional Application Serial Nos. 60/569,882 and 60/582,043, filed May 10, 2004 and June 21, 2004, respectively, and U.S. Patent Application No. 11/126,978, filed May 10, 2005.

[0135] In some embodiments, the antibody contains both the light chain as well as at least the variable domain of a heavy chain. In other embodiments, the antibody may further comprise one or more of the CH1, hinge, CH2, CH3, and CH4 regions of the heavy chain. The humanized antibody can be selected from any class of immunoglobulins, including IgM, IgG, IgD, IgA and IgE, and any isotype, including IgG1, IgG2, IgG3 and IgG4. In some embodiments, the constant domain is a complement fixing constant domain where it is desired that the humanized antibody exhibit cytotoxic activity, and the class is typically IgG1. In other embodiments, where such cytotoxic activity is not desirable, the constant domain may be of the IgG2 class. The humanized antibody may comprise sequences from more than one class or isotype, and selecting particular constant domains to optimize desired effector functions is within the ordinary skill in the art.

[0136] The framework and CDR regions of a humanized antibody need not correspond precisely to the parental sequences, e.g., the donor CDR or the consensus framework may be mutagenized by substitution, insertion or deletion of at least one residue so that the CDR or framework residue at that site does not correspond to either the consensus or the donor antibody. Such mutations, however, are preferably not extensive. Usually, at least 75% of the humanized antibody residues will correspond to those of the parental framework region (FR) and CDR sequences, more often 90%, and most preferably greater than 95%. Humanized antibodies can be produced using variety of techniques known in the art, including but not limited to, CDR-grafting (European Patent No. EP 239,400; International Publication No. WO 91/09967; and U.S. Patent Nos. 5,225,539, 5,530,101, and 5,585,089), veneering or resurfacing (European Patent Nos. EP 592,106 and EP 519,596; Padlan, 1991, Molecular Immunology 28(4/5):489-498; Studnicka et al., 1994, Protein Engineering 7(6):805-814; and Roguska et al., 1994, Proc Natl Acad Sci USA 91:969-973), chain shuffling (U.S. Patent No. 5,565,332), and techniques disclosed in, e.g., U.S. Patent Nos. 6,407,213, 5,766,886, 5,585,089, International Publication No. WO 9317105, Tan et al., 2002, J. Immunol. 169:1119-25, Caldas et al., 2000, Protein Eng. 13:353-60, Morea et al., 2000, Methods 20:267-79, Baca et al., 1997, J. Biol. Chem. 272:10678-84, Roguska et al., 1996, Protein Eng. 9:895-904, Couto et al., 1995, Cancer Res. 55 (23 Supp):5973s-5977s, Couto et al., 1995, Cancer Res. 55:1717-22, Sandhu, 1994, Gene 150:409-10, Pedersen et al., 1994, J. Mol. Biol. 235:959-73, Jones et al., 1986, Nature 321:522-525, Riechmann et al., 1988, Nature 332:323, and Presta, 1992, Curr. Op. Struct. Biol. 2:593-596. Often, framework residues in the framework regions will be substituted with the corresponding residue from the CDR donor antibody to alter, preferably improve, antigen binding. These framework substitutions are identified by methods well known in the art, e.g., by modeling of the interactions of the CDR and framework residues to identify framework residues important for antigen binding and sequence comparison to identify unusual framework residues at particular positions. (See, e.g., Queen et al., U.S. Patent No. 5,585,089; U.S. Publication Nos. 2004/0049014 and 2003/0229208; U.S. Patent Nos. 6,350,861; 6,180,370; 5,693,762; 5,693,761; 5,585,089; and 5,530,101 and Riechmann et al., 1988, Nature 332:323).,

[0137] The present specification provides for the use of humanized antibody molecules specific for Fc_YRIIB in which one or more regions of one or more CDRs of the heavy and/or light chain variable regions of a human antibody (the recipient antibody) have been substituted by analogous parts of one or more CDRs of a donor monoclonal antibody which specifically binds Fc_YRIIB, with a greater affinity than Fc_YRIIA, e.g., a monoclonal antibody produced by clone 8B5.3.4, having ATCC accession number PTA-7610, respectively. In other instances, the humanized antibodies bind to the same epitope as the 8B5.3.4 antibody. In a most preferred instance, the humanized antibody specifically binds to the same epitope as the donor murine antibody. It will be appreciated by one skilled in the art that the invention encompasses CDR grafting of antibodies in general. Thus, the donor and acceptor antibodies may be derived from animals of the same species and even same antibody class or sub-class. More usually, however, the donor and acceptor antibodies are derived from animals of different species. Typically the donor antibody is a non-human antibody, such as a rodent MAb, and the acceptor antibody is a human antibody.

[0138] In some instances, at least one CDR from the donor antibody is grafted onto the human antibody. In other instances, at least two and preferably all three CDRs of each of the heavy and/or light chain variable regions are grafted onto the human antibody. The CDRs may comprise the Kabat CDRs, the structural loop CDRs or a combination thereof. In some instances, the specification encompasses a humanized Fc_YRIIB antibody comprising at least one CDR grafted heavy chain and at least one CDR-grafted light chain.

[0139] In a preferred embodiment, the CDR regions of the humanized Fc_YRIIB specific antibody are derived from a murine antibody specific for Fc_YRIIB. In some embodiments, the humanized antibodies described herein comprise alterations, including but not limited to amino acid deletions, insertions, modifications, of the acceptor antibody, i.e., human, heavy and/or light chain variable domain framework regions that are necessary for retaining binding specificity of the donor monoclonal antibody. In some embodiments, the framework regions of the humanized antibodies described herein does not necessarily consist of the precise amino acid sequence of the framework region of a natural occurring human antibody variable region, but contains various alterations, including but not limited to amino acid deletions, insertions, modifications that alter the property of the humanized antibody, for example, improve the binding properties of a humanized antibody region that is specific for the same target as the murine Fc_YRIIB specific antibody. In most preferred embodiments, a minimal number of alterations are made to the framework region in order to avoid large-scale introductions of non-human framework residues and to ensure minimal immunogenicity of the humanized antibody in humans. The donor monoclonal antibody is preferably a monoclonal antibody produced by clone 8B5.3.4 (having ATCC accession number PTA-7610) which binds Fc_YRIIB.

[0140] In a specific instance, the specification encompasses the use of a CDR-grafted antibody which specifically binds Fc_YRIIB with a greater affinity than said antibody binds Fc_YRIIA, wherein the CDR-grafted antibody comprises a heavy chain variable region domain comprising framework residues of the recipient antibody and residues from the donor Monoclonal antibody, which specifically binds Fc_YRIIB with a greater affinity than said antibody binds Fc_YRIIA, e.g., monoclonal antibody produced from clone 8B5.3.4. In another specific instance, the specification encompasses the use of a CDR-grafted antibody which specifically binds Fc_YRIIB with a greater affinity than said antibody binds Fc_YRIIA, wherein the CDR-grafted antibody comprises a light chain variable region domain comprising framework residues of the recipient antibody and residues from the donor monoclonal antibody, which specifically binds Fc_YRIIB with a greater affinity than said antibody binds Fc_YRIIA, e.g., monoclonal antibody produced from clones 8B5.3.4, 2B6, 3H7, 1D5, 2E1, 2H9, 2D11, or 1F2.

[0141] Preferably the humanized antibodies bind the extracellular domain of native human Fc γ RIIB. The humanized anti- Fc γ RIIB antibodies of the specification may have a heavy chain variable region comprising the amino acid sequence of CDR1 (SEQ ID NO: 8) and/or CDR2 (SEQ ID NO: 9) and/or CDR3 (SEQ ID NO: 10) and/or a light chain variable region comprising the amino acid sequence of CDR1 (SEQ ID NO: 5) and/or a CDR2 (SEQ ID NO: 6) and/or CDR3 (SEQ ID NO: 7).

[0142] In a specific instance, the specification encompasses the use of a humanized antibody comprising the CDRs of the 8B5.3.4 antibody in the prevention, treatment, management or amelioration of a B-cell malignancy, or one or more symptoms thereof. In particular, an antibody with the heavy chain variable domain having the amino acid sequence of SEQ ID NO: 4 and the light chain variable domain having the amino acid sequence of SEQ ID NO: 3 is used in the prevention, treatment, management or amelioration of a B-cell malignancy, or one or more symptoms thereof. In yet another preferred instance, the humanized antibodies further do not bind Fc activation receptors, e.g., FcγIIIa, FcγIIIb, etc.

[0143] In one specific instance, a humanized 8B5.3.4 antibody is provided, wherein the VH region consists of the FR segments from the human germline VH segment VH1-18 (Matsuda et al., 1998, J. Exp. Med. 188:2151062) and JH6 (Ravetch et al., 1981, Cell 27(3 Pt. 2): 583-91), and one or more VH CDR regions of the 8B5.3.4 antibody, having the amino acid sequence of SED ID NO: 8, SED ID NO: 9, or SED ID NO: 10. In another specific instance, the humanized 8B5.3.4 antibody further comprises a VL region, which consists of the FR segments of the human germline VL segment VK-A26 (Lautner-Rieske et al., 1992, Eur. J. Immunol. 22:1023-1029) and JK4 (Hieter et al., 1982, J. Biol. Chem. 257:1516-22), and one or more VL CDR regions of the 8B5.3.4 antibody, having the amino acid sequence of SEQ ID NO: 5, SEQ ID NO: 6, or SEQ ID NO: 7.

CDR3; a VH CDR1, a VH CDR3, a VL CDR1, a VL CDR2, and a VL CDR3; a VH CDR2, a VH CDR3, a VL CDR1, a VL CDR2, and a VL CDR3; or any combination thereof of the VH CDRs and VL CDRs disclosed herein.

5.1.2 Human antibodies

[0145] Human antibodies can also be produced using transgenic mice which are incapable of expressing functional endogenous immunoglobulins, but which can express human immunoglobulin genes. For example, the human heavy and light chain immunoglobulin gene complexes may be introduced randomly or by homologous recombination into mouse embryonic stem cells. Alternatively, the human variable region, constant region, and diversity region may be introduced into mouse embryonic stem cells in addition to the human heavy and light chain genes. The mouse heavy and light chain immunoglobulin genes may be rendered non-functional separately or simultaneously with the introduction of human immunoglobulin loci by homologous recombination. In particular, homozygous deletion of the J_H region prevents endogenous antibody production. The modified embryonic stem cells are expanded and microinjected into blastocysts to produce chimeric mice. The chimeric mice are then bred to produce homozygous offspring which express human antibodies. The transgenic mice are immunized using conventional methodologies with a selected antigen, e.g., all or a portion of a polypeptide of the invention. Monoclonal antibodies directed against the antigen can be obtained from the immunized, transgenic mice using conventional hybridoma technology. The human immunoglobulin transgenes harbored by the transgenic mice rearrange during B cell differentiation, and subsequently undergo class switching and somatic mutation. Thus, using such a technique, it is possible to produce therapeutically useful IgG, IgA, IgM and IgE antibodies. For an overview of this technology for producing human antibodies, see Lonberg and Huszar (1995, *Int. Rev. Immunol.* 13:65-93). For a detailed discussion of this technology for producing human antibodies and human monoclonal antibodies and protocols for producing such antibodies, see, e.g., International Publication Nos. WO 98/24893, WO 96/34096, and WO 96/33735; and U.S. Patent Nos. 5,413,923, 5,625,126, 5,633,425, 5,569,825, 5,661,016, 5,545,806, 5,814,318, and 5,939,598. In addition, companies such as Abgenix, Inc. (Freemont, CA) and Medarex (Princeton, NJ) can be engaged to provide human antibodies directed against a selected antigen using technology similar to that described above.

5.1.3 Chimeric antibodies

[0146] A chimeric antibody is a molecule in which different portions of the antibody are derived from different immunoglobulin molecules such as antibodies having a variable region derived from a non-human antibody and a human immunoglobulin constant region. The present specification provides chimeric antibodies derived from antibodies produced from Hybridoma clones 8B5.3.4, 2B6, 3H7, 1D5, 2E1, 2H9, 2D11, or 1F2 having ATCC accession numbers PTA-7610, PTA-4591, PTA-4592, PTA-5958, PTA-5961, PTA-5962, PTA-5960, and PTA-5959, respectively. Methods for producing chimeric antibodies are known in the art. See e.g., Morrison, 1985, *Science* 229:1202; Oi et al., 1986, *BioTechniques* 4:214; Gillies et al., 1989, *J. Immunol. Methods* 125:191-202; and U.S. Patent Nos. 6,311,415, 5,807, 715, 4,816, 567, and 4,816,397. Chimeric antibodies comprising one or more CDRs from a non-human species and framework regions from a human immunoglobulin molecule can be produced using a variety of techniques known in the art including, for example, CDR-grafting (EP 239,400; International Publication No. WO 91/09967; and U.S. Patent Nos. 5,225,539, 5,530,101, and 5,585,089), veneering or resurfacing (EP 592,106; EP 519,596; Padlan, 1991, *Molecular Immunology* 28(4/5):489-498; Studnicka et al., 1994, *Protein Engineering* 7:805; and Roguska et al., 1994, *PNAS* 91:969), and chain shuffling (U.S. Patent No. 5,565,332).

[0147] Often, framework residues in the framework regions will be substituted with the corresponding residue from the CDR donor antibody to alter, preferably improve, antigen binding. These framework substitutions are identified by methods well known in the art, e.g., by modeling of the interactions of the CDR and framework residues to identify framework residues important for antigen binding and sequence comparison to identify unusual framework residues at particular positions. (See, e.g., U.S. Patent No. 5,585,089; and Riechmann et al., 1988, *Nature* 332:323).

5.1.4 Fc Region Modifications

[0148] The invention encompasses antibodies with Fc constant domains comprising one or more amino acid modifications which alter antibody effector functions such as those disclosed in U.S. Patent Application Publication Nos. U.S. 2005/0037000 and U.S. 2005/0064514; U.S. Patent Nos. 5,624,821 and 5,648,260 and European Patent No. EP 0 307 434. These antibodies may exhibit improved ADCC activity (i.e., 2-fold, 10-fold, 100-fold, 500-fold, etc.) compared to comparable antibodies without amino acid modification.

[0149] The present invention encompasses antibodies comprising modifications preferably, in the Fc region that modify the binding affinity of the antibody to one or more FcγR. Methods for modifying antibodies with modified binding to one or more FcγR are known in the art, see, e.g., PCT Publication Nos. WO 04/029207, WO 04/029092, WO 04/028564, WO 99/58572, WO 99/51642, WO 98/23289, WO 89/07142, WO 88/07089, and U.S. Patent Nos. 5,843,597 and 5,642,821. In some embodiments, the invention encompasses antibodies that have altered affinity for an activating FcγR, e.g., FcγRIIIA. Preferably such modifications also have an altered Fc-mediated effector function. Modifications that affect Fc-mediated effector function are known in the art (See U.S. Patent No. 6,194,551). The amino acids that can be modified in accordance with the method of the specification include but are not limited to Proline 329, Proline 331, and Lysine 322. Proline 329, Proline 331 and Lysine 322 are preferably replaced with alanine, however, substitution with any other amino acid is contemplated. See International Publication No. WO 00/42072 and U.S. Patent No. 6,194,551.

[0150] In one particular embodiment, the modification of the Fc region comprises one or more mutations in the Fc region. The one or more mutations in the Fc region may result in an antibody with an altered antibody-mediated effector function, an altered binding to other Fc receptors (e.g., Fc activation receptors), an altered ADCC activity, or an altered C1q binding activity, or an altered complement dependent cytotoxicity activity, or any combination thereof.

[0151] In some embodiments falling within the scope of specified claims, the invention encompasses molecules comprising a variant Fc region having an amino acid modification at one or more of the following positions: 119, 125, 132, 133, 141, 142, 147, 149, 162, 166, 185, 192, 202, 205, 210, 214, 215, 216, 217, 218, 219, 221, 222, 223, 224, 225, 227, 229, 231, 232, 233, 235, 240, 241, 242, 243, 244, 246, 247, 248, 250, 251, 252, 253, 254, 255, 256, 258, 261, 262, 263, 268, 269, 270, 272, 274, 275, 276, 279, 280, 281, 282, 284, 287, 288, 289, 290, 291, 292, 293, 295, 298, 301, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 315, 316, 317, 318, 319, 320, 323, 326, 327, 328, 330, 333, 334, 335, 337, 339, 340, 343, 344, 345, 347, 348, 352, 353, 354, 355, 358, 359, 360, 361, 362, 365, 366, 367, 369, 370, 371, 372, 375, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 404, 406, 407, 408, 409, 410, 411, 412, 414, 415, 416, 417, 419, 420, 421, 422, 423, 424, 427, 428, 431, 433, 435, 436, 438, 440, 441, 442, 443, 446, or 447. Preferably, engineering of the Fc portion results in increased cell-mediated killing and/or complement mediated killing of the tumor cells.

[0152] The invention encompasses molecules, falling within the scope of specified claims, comprising variant Fc regions consisting of or comprising any of the mutations listed in the table below in Table 2.

TABLE 2. EXEMPLARY MUTATIONS

SINGLE SITE MUTANTS	DOUBLE SITE MUTANTS
K392R	Q347H, A339V
N315I	S415I, L251F
S132I	K290E, L142P
P396L	G285E, P247H
P396H	K409R, S166N
A162V	E334A, K334A
R292L	R292L, K334E
T359N	K288N, A330S
T366S	R255L, E318K
V379L	F243L, E318K
K288N	V279L, P395S
A330S	K246T, Y319F
F243L	F243I, V379L
E318K	K288M, K334E
V379M	K334E, E308D
S219Y	E233D, K334E
V282M	K246T, P396H
D401V	H268D, E318D
K222N	K246I, K334N

SINGLE SITE MUTANTS	DOUBLE SITE MUTANTS
K334I	K320E, K326E
K334E	S375C, P396L
1377F	K288N, K326N
P247L	P247L, N421K
F372Y	S298N, W381R
K326E	R255Q, K326E
H224L	V284A, F372L
F275Y	T394M, V397M
L398V	P247L, E389G
K334N	K290T, G371D
S400P	P247L, L398Q
S407I	P247L, I377F
F372Y	K326E, G385E
T366N	S298N, S407R
K414N	E258D, N384K
M352L	F241L, E258G
T225S	K370N, S440N
I377N	K317N, F423-DELETED
K248M	P227S, K290E
R292G	K334E, E380D
S298N	P291S, P353Q
D270E	V240I, V281M
E233G	P232S, S304G
	P247L, L406F
	D399E, M428L
	L251F, F372L
	D399E, G402D
	D399E, M428L
	K392T, P396L
	H268N, P396L
	K326I, P396L
	H268D, P396L
	K210M, P396L
	L358P, P396L
	K334N, P396L
	V379M, P396L
	P227S, P396L
	P217S, P396L
	Q419H, P396L
	K370E, P396L
	L242F, P396L
	R255L, P396L
	V240A, P396L

SINGLE SITE MUTANTS	DOUBLE SITE MUTANTS
	T250A, P396L
	P247S, P396L
	L410H, P396L
	Q419L, P396L
	V427A, P396L
	E258D, P396L
	N384K, P396L
	V323I, P396L
	P244H, P396L
	V305L, P396L
	S400F, P396L
	V303I, P396L
	A330V, Q419H
	V263Q, E272D
	K326E, A330T

[0153] In yet other embodiments falling within the scope of specified claims, the invention encompasses molecules comprising variant Fc regions having more than two amino acid modifications. A non-limiting example of such variants is listed in the table below (Table 3). The invention encompasses mutations listed in Table 3 which further comprise one or more amino acid modifications such as those disclosed herein.

TABLE 3. EXEMPLARY COMBINATION VARIANTS

D399E, R292L, V185M
R301C, M252L, S192T
P291S, K288E, H268L, A141V
S383N, N384K, T256N, V262L, K218E, R214I, K205E, F149Y, K133M
S408I, V215I, V125L
G385E, P247H
V348M, K334N, F275I, Y202M, K147T
H310Y, T289A, Y407V, E258D
R292L, P396L, T359N
F275I, K334N, V348M
F243L, R255L, E318K
K334E, T359N, T366S
T256S, V305I, K334E, N390S
T335N, K370E, A378V, T394M, S424L
K334E, T359N, T366S, Q386R
K288N, A330S, P396L
P244H, L358M, V379M, N384K, V397M
P217S, A378V, S408R
P247L, I253N, K334N
D312E, K327N, I378S
D280E, S354F, A431D, L441I
K218R, G281D, G385R
P247L, A330T, S440G

T355N, P387S, H435Q
P247L, A431V, S442F
P343S, P353L, S375I, S383N
E216D, E345K, S375I
K288N, A330S, P396L
K222N, T335N, K370E, A378V, T394M
G316D, A378V, D399E
N315I, V379M, T394M
K326Q, K334E, T359N, T366S
A378V, N390I, V422I
V282E, V369I, L406F
V397M, T411A, S415N
T223I, T256S, L406F
L235P, V382M, S304G, V305J, V323I
P247L, W313R, E388G
D221Y, M252I, A330G, A339T, T359N, V422I, H433L
F243I, V379L, G420V
A231V, Q386H, V412M
T215P, K274N, A287G, K334N, L365V, P396L
P244A, K326I, C367R, S375I, K447T
R301H, K340E, D399E
C229Y, A287T, V379M, P396L, L443V
E269K, K290N, Q311R, H433Y
E216D, K334R, S375I
T335N, P387S, H435Q
K246I, Q362H, K370E
K334E, E380D, G446V
V303I, V369F, M428L
K246E, V284M, V308A
E293V, Q295E, A327T
Y319F, P352L, P396L
D221E, D270E, V308A, Q311H, P396L, G402D
K290T, N390I, P396L
K288R, T307A, K344E, P396L
V273I, K326E, L328I, P396L
K326I, S408N, P396L
K261N, K210M, P396L
F243L, V305I, A378D, F404S, P396L
K290E, V369A, T393A, P396L
K210N, K222I, K320M, P396L
P217S, V305I, I309L, N390H, P396L
K246N, Q419R, P396L
P217A, T359A, P396L
V215I, K290V, P396L
F275L, Q362H, N384K, P396L

A330V, H433Q, V427M
V263Q, E272D, Q419H
N276Y, T393N, W417R
V282L, A330V, H433Y, T436R
V284M, S298N, K334E, R355W
A330V, G427M, K438R
S219T, T225K, D270E, K360R
K222E, V263Q, S298N
E233G, P247S, L306P
S219T, T225K, D270E
S254T, A330V, N361D, P243L
V284M, S298N, K334E, R355W R416T
D270E, G316D, R416G
K392T, P396L, D270E
R255L, P396L, D270E
V240A, P396L, D270E
Q419H, P396L, D270E
K370E, P396L, D270E
P247L, N421K, D270E
R292P, V305I
R292P, V305I, F243L
V284M, R292L, K370N
F243L, R292L, Y300L

[0154] In most preferred embodiments falling within the scope of specified claims, an anti-FcγRIIB antibody of the invention has a modified Fc region with altered affinity for activating and/or inhibitory receptors, wherein the Fc domain has one or more amino acid modifications, wherein said one or more amino acid modifications is a substitution at position 288 with asparagine, at position 330 with serine and at position 396 with leucine (MgFc10) (see, Tables 2 and 3); or a substitution at position 334 with glutamic acid, at position 359 with asparagine, and at position 366 with serine (MgFc13); or a substitution at position 316 with aspartic acid, at position 378 with valine, and at position 399 with glutamic acid (MgFc27); or a substitution at position 392 with threonine, and at position 396 with leucine (MgFc38); or a substitution at position 221 with glutamic acid, at position 270 with glutamic acid, at position 308 with alanine, at position 311 with histidine, at position 396 with leucine, and at position 402 with aspartic acid (MgFc42); or a substitution at position 240 with alanine, and at position 396 with leucine (MgFc52); or a substitution at position 410 with histidine, and at position 396 with leucine (MgFc53); or a substitution at position 243 with leucine, at position 305 with isoleucine, at position 378 with aspartic acid, at position 404 with serine, and at position 396 with leucine (MgFc54); or a substitution at position 255 with leucine, and at position 396 with leucine (MgFc55); or a substitution at position 370 with glutamic acid and at position 396 with leucine (MgFc59); or a substitution at position 243 with leucine, at position 292 with proline, at position 300 with leucine, at position 305 with isoleucine, and at position 396 with leucine (MgFc88); or a substitution at position 243 with leucine, at position 292 with proline, at position 300 with leucine, and at position 396 with leucine (MgFc88A); or a substitution at position 243 with leucine, at position 292 with proline, and at position 300 with leucine (MgFc155). (See, also, Tables 2, 3A and 3B of U.S. Patent Application Publication No. 2005/0064514 A1, to Stavenhagen et al., filed July 28, 2004).

[0155] In a preferred embodiment, the anti-FcγRIIB antibody, such as the 8B5.3.4 antibody, has a modified Fc region with a leucine at position 243, a proline at position 292, a leucine at position 300, an isoleucine at position 305 and a leucine at position 396.

[0156] In specific embodiments falling within the scope of specified claims, the variant Fc region has a leucine at position 247, a lysine at position 421 and a glutamic acid at position 270 (MgFc31/60); a threonine at position 392, a leucine at position 396, and a glutamic acid at position 270 (MgFc38/60); a threonine at position 392, a leucine at position 396, a glutamic acid at position 396.

270, and a leucine at position 243 (MgFc38/60/F243L); a histidine at position 419, a leucine at position 396, and a glutamic acid at position 270 (MgFc51/60); a histidine at position 419, a leucine at position 396, a glutamic acid at position 270, and a leucine at position 243 (MgFc51/60/F243L); a lysine at position 255, a leucine at position 396, and a glutamic acid at position 270 (MgFc55/60); a lysine at position 255, a leucine at position 396, a glutamic acid at position 270, and a lysine at position 300 (MgFc55/60/Y300L); a lysine at position 255, a leucine at position 396, a glutamic acid at position 270, and a leucine at position 243 (MgFc55/60/F243L); a glutamic acid at position 370, a leucine at position 396, and a glutamic acid at position 270 (MgFc59/60); a glutamic acid at position 270, an aspartic acid at position 316, and a glycine at position 416 (MgFc71); a leucine at position 243, a proline at position 292, an isoleucine at position 305, and a leucine at position 396 (MgFc74/P396L); a glutamine at position 297, or any combination of the individual substitutions.

5.1.5 Carbohydrate Modifications

[0157] The invention also provides antibodies with altered oligosaccharide content. Oligosaccharides as used herein refer to carbohydrates containing two or more simple sugars and the two terms may be used interchangeably herein. Carbohydrate moieties of the instant invention will be described with reference to commonly used nomenclature in the art. For a review of carbohydrate chemistry, see, e.g., Hubbard et al., 1981 Ann. Rev. Biochem., 50: 555-583. This nomenclature includes for example, Man which represents mannose; GlcNAc which represents 2-N-acetylglucosamine; Gal which represents galactose; Fuc for fucose and Glc for glucose. Sialic acids are described by the shorthand notation NeuNAc for 5-N-acetylneurameric acid, and NeuNGc for 5-glycolneurameric.

[0158] In general, antibodies contain carbohydrate moieties at conserved positions in the constant region of the heavy chain, and up to 30% of human IgGs have a glycosylated Fab region. IgG has a single N-linked biantennary carbohydrate structure at Asn 297 which resides in the CH2 domain (Jefferis et al., 1998, Immunol. Rev. 163: 59-76; Wright et al., 1997, Trends Biotech 15: 26-32). Human IgG typically has a carbohydrate of the following structure; GlcNAc(Fucose)-GlcNAc-Man-(ManGlcNAc)₂. However variations among IgGs in carbohydrate content does occur which leads to altered function, see, e.g., Jassal et al., 2001 Biochem. Biophys. Res. Commun. 288: 243-9; Groenink et al., 1996 J. Immunol. 26: 1404-7; Boyd et al., 1995 Mol. Immunol. 32: 1311-8; Kumpel et al., 1994, Human Antibody Hybridomas, 5: 143-51. The invention encompasses antibodies comprising a variation in the carbohydrate moiety that is attached to Asn 297. In one embodiment falling within the scope of specified claims, the carbohydrate moiety has a galactose and/or galactose-sialic acid at one or both of the terminal GlcNAc and/or a third GlcNAc arm (bisecting GlcNAc).

[0159] In some embodiments falling within the scope of specified claims, the antibodies of the invention are substantially free of one or more selected sugar groups, e.g., one or more sialic acid residues, one or more galactose residues, one or more fucose residues. An antibody that is substantially free of one or more selected sugar groups may be prepared using common methods known to one skilled in the art, including for example recombinantly producing an antibody of the invention in a host cell that is defective in the addition of the selected sugar group(s) to the carbohydrate moiety of the antibody, such that about 90-100% of the antibody in the composition lacks the selected sugar group(s) attached to the carbohydrate moiety. Alternative methods for preparing such antibodies include for example, culturing cells under conditions which prevent or reduce the addition of one or more selected sugar groups, or post-translational removal of one or more selected sugar groups.

[0160] In a specific instance, the specification encompasses a method of producing a substantially homogenous antibody preparation, wherein about 80-100% of the antibody in the composition lacks a fucose on its carbohydrate moiety, e.g., the carbohydrate attachment on Asn 297. The antibody may be prepared for example by (a) use of an engineered host cell that is deficient in fucose metabolism such that it has a reduced ability to fucosylate proteins expressed therein; (b) culturing cells under conditions which prevent or reduce fucosylation; (c) post-translational removal of fucose, e.g., with a fucosidase enzyme; or (d) purification of the antibody so as to select for the product which is not fucosylated. Most preferably, nucleic acid encoding the desired antibody is expressed in a host cell that has a reduced ability to fucosylate the antibody expressed therein. Preferably the host cell is a dihydrofolate reductase deficient Chinese hamster ovary cell (CHO), e.g., a Lec 13 CHO cell (lectin resistant CHO mutant cell line; Ribka & Stanley, 1986, Somatic Cell & Molec. Gen. 12(1): 51-62; Ripka et al., 1986 Arch. Biochem. Biophys. 249(2): 533-45), CHO-K1, DUX-B11, CHO-DP12 or CHO-DG44, which has been modified so that the antibody is not substantially fucosylated. Thus, the cell may display altered expression and/or activity for the fucosyltransferase enzyme, or another enzyme or substrate involved in adding fucose to the N-linked oligosaccharide so that the enzyme has a diminished activity and/or reduced expression level in the cell. For methods to produce antibodies with altered fucose content, see, e.g., WO 03/035835 and Shields et al., 2002, J. Biol. Chem. 277(30): 26733-40.

[0161] In some embodiments falling within the scope of specified claims, the altered carbohydrate modifications modulate one or

more of the following: solubilization of the antibody, facilitation of subcellular transport and secretion of the antibody, promotion of antibody assembly, conformational integrity, and antibody-mediated effector function. In a specific embodiment the altered carbohydrate modifications enhance antibody mediated effector function relative to the antibody lacking the carbohydrate modification. Carbohydrate modifications that lead to altered antibody mediated effector function are well known in the art (for e.g., see Shields R.L. et al., 2001, *J. Biol. Chem.* 277(30): 26733-40; Davies J. et al., 2001, *Biotechnology & Bioengineering*, 74(4): 288-294). In another specific embodiment, the altered carbohydrate modifications enhance the binding of antibodies of the invention to FcγRIIB receptor. Altering carbohydrate modifications in accordance with the methods of the specification includes, for example, increasing the carbohydrate content of the antibody or decreasing the carbohydrate content of the antibody. Methods of altering carbohydrate contents are known to those skilled in the art, see, e.g., Wallick et al., 1988, *Journal of Exp. Med.* 168(3): 1099-1109; Tao et al., 1989 *Journal of Immunology*, 143(8): 2595-2601; Routledge et al., 1995 *Transplantation*, 60(8): 847-53; Elliott et al. 2003; *Nature Biotechnology*, 21: 414-21; Shields et al. 2002 *Journal of Biological Chemistry*, 277(30): 26733-40.

[0162] In some embodiments falling within the scope of specified claims, the invention encompasses antibodies comprising one or more glycosylation sites, so that one or more carbohydrate moieties are covalently attached to the antibody. In other embodiments falling within the scope of specified claims, the invention encompasses antibodies comprising one or more glycosylation sites and one or more modifications in the Fc region, such as those disclosed supra and those known to one skilled in the art. In preferred embodiments falling within the scope of specified claims, the one or more modifications in the Fc region enhance the affinity of the antibody for an activating FcγR, e.g., FcγRIIA, relative to the antibody comprising the wild type Fc regions. Antibodies of the invention with one or more glycosylation sites and/or one or more modifications in the Fc region have an enhanced antibody mediated effector function, e.g., enhanced ADCC activity. In some embodiments falling within the scope of specified claims, the invention further comprises antibodies comprising one or more modifications of amino acids that are directly or indirectly known to interact with a carbohydrate moiety of the antibody, including but not limited to amino acids at positions 241, 243, 244, 245, 245, 249, 256, 258, 260, 262, 264, 265, 296, 299, and 301. Amino acids that directly or indirectly interact with a carbohydrate moiety of an antibody are known in the art, see, e.g., Jefferis et al., 1995 *Immunology Letters*, 44: 111-7.

[0163] The invention encompasses antibodies that have been modified by introducing one or more glycosylation sites into one or more sites of the antibodies, preferably without altering the functionality of the antibody, e.g., binding activity to FcγRIIB. Glycosylation sites may be introduced into the variable and/or constant region of the antibodies of the invention. As used herein, "glycosylation sites" include any specific amino acid sequence in an antibody to which an oligosaccharide (i.e., carbohydrates containing two or more simple sugars linked together) will specifically and covalently attach. Oligosaccharide side chains are typically linked to the backbone of an antibody via either N- or O-linkages. N-linked glycosylation refers to the attachment of an oligosaccharide moiety to the side chain of an asparagine residue. O-linked glycosylation refers to the attachment of an oligosaccharide moiety to a hydroxyamino acid, e.g., serine, threonine. The antibodies of the invention may comprise one or more glycosylation sites, including N-linked and O-linked glycosylation sites. Any glycosylation site for N-linked or O-linked glycosylation known in the art may be used in accordance with the instant invention. An exemplary N-linked glycosylation site that is useful in accordance with the methods of the present invention, is the amino acid sequence: Asn-X-Thr/Ser, wherein X may be any amino acid and Thr/Ser indicates a threonine or a serine. Such a site or sites may be introduced into an antibody of the invention using methods well known in the art to which this invention pertains. See, for example, "In vitro Mutagenesis," Recombinant DNA: A Short Course, J. D. Watson, et al. W.H. Freeman and Company, New York, 1983, chapter 8, pp. 106-116. An exemplary method for introducing a glycosylation site into an antibody of the invention may comprise: modifying or mutating an amino acid sequence of the antibody so that the desired Asn-X-Thr/Ser sequence is obtained.

[0164] Methods of modifying the carbohydrate content of an antibody of the invention by adding or deleting a glycosylation site are disclosed as are methods for modifying the carbohydrate content of antibodies which are well known in the art, see, e.g., U.S. Patent No. 6,218,149; EP 0 359 096 B1; U.S. Publication No. US 2002/0028486; WO 03/035835; U.S. Publication No. 2003/0115614; U.S. Patent No. 6,218,149; U.S. Patent No. 6,472,511. Also included are methods of modifying the carbohydrate content of an antibody of the invention by deleting one or more endogenous carbohydrate moieties of the antibody.

[0165] There is also provided the use of modified FcγRIIB antibodies wherein the N-glycosylation consensus site Asn₅₀-Val-Ser of the CDR2 region has been modified, so that the glycosylation site at position 50 is eliminated. Although not intending to be bound by a particular mechanism of action, removal of the glycosylation site may limit potential variation in production of the antibody as well as potential immunogenicity in a pharmaceutical application. In a specific embodiment, the invention encompasses the use of a humanized FcγRIIB antibody wherein the amino acid at position 50 has been modified, e.g., deleted or substituted. In another specific instance, the specification further encompasses the use of an antibody with an amino acid modification, e.g., deletion or substitution, at position 51. In one specific instance, the specification encompasses the use of a humanized FcγRIIB antibody wherein the amino acid at position 50 has been replaced with tyrosine. In another more specific

instance, the specification encompasses the use of a Fc_YRIIB antibody wherein the amino acid at position 50 has been replaced with tyrosine and the amino acid at position 51 has been replaced with alanine.

5.1.6 Fc_YRIIB AGONISTS AND ANTAGONISTS

[0166] In addition to the use of a Fc_YRIIB-specific antibody, an analog, derivative, or an antigen-binding fragment thereof in the methods described and compositions of the invention, other Fc_YRIIB agonist and antagonists may be used in accordance with the methods described. Fc_YRIIB agonists and antagonists include, but are not limited to, proteinaceous molecules (e.g., proteins, polypeptides (e.g., soluble Fc_YRIIB polypeptides), peptides, fusion proteins (e.g., soluble Fc_YRIIB polypeptides conjugated to a therapeutic moiety), nucleic acid molecules (e.g., Fc_YRIIB antisense nucleic acid molecules, triple helices, dsRNA that mediates RNAi, or nucleic acid molecules encoding proteinaceous molecules), organic molecules, inorganic molecules, small organic molecules, drugs, and small inorganic molecules that block, inhibit, reduce or neutralize a function, an activity and/or the expression of a Fc_YRIIB polypeptide, expressed by an immune cell, preferably a B-cell. In some instances, a Fc_YRIIB agonist or antagonist used in accordance with the methods of the specification is not a small organic molecule, a drug or an antisense molecule. Fc_YRIIB agonists and antagonists can be identified using techniques well-known in the art or described herein.

[0167] Prophylactic and therapeutic compounds of the invention include, but are not limited to, proteinaceous molecules, including, but not limited to, peptides, polypeptides, proteins, including post-translationally modified proteins, antibodies, etc.; small molecules (less than 1000 daltons), inorganic or organic compounds; nucleic acid molecules including, but not limited to, double-stranded or single-stranded DNA, double-stranded or single-stranded RNA, as well as triple helix nucleic acid molecules. Prophylactic and therapeutic compounds can be derived from any known organism (including, but not limited to, animals, plants, bacteria, fungi, and protista, or viruses) or from a library of synthetic molecules.

[0168] In certain instances, Fc_YRIIB antagonists reduce a function, activity, and/or expression of a Fc_YRIIB polypeptide in a subject with a B-cell malignancy. In other instances, the Fc_YRIIB antagonists directly bind to a Fc_YRIIB polypeptide and directly or indirectly modulate an activity and/or function of B-lymphocytes. In particular instances, Fc_YRIIB antagonists inhibit or reduce B-cell proliferation in a subject with a B-cell malignancy as determined by standard *in vivo* and/or *in vitro* assays described herein or well-known to those skilled in the art. In a specific instance, Fc_YRIIB antagonists mediate the depletion of lymphocytes, in particular peripheral blood B-cells, in a subject with a B-cell malignancy as determined by standard *in vivo* and/or *in vitro* assays described herein or well-known to those skilled in the art. In another instance, Fc_YRIIB antagonists directly or indirectly modulate an activity and/or function of B-lymphocytes by utilizing antibody-dependent cell-mediated cytotoxicity (ADCC).

[0169] In a preferred instance, proteins, polypeptides or peptides (including antibodies and fusion proteins) that are utilized as Fc_YRIIB antagonists are derived from the same species as the recipient of the proteins, polypeptides or peptides so as to reduce the likelihood of an immune response to those proteins, polypeptides or peptides. In another preferred instance, when the subject is a human, the proteins, polypeptides, or peptides that are utilized as Fc_YRIIB antagonists are human or humanized.

[0170] Nucleic acid molecules encoding proteins, polypeptides, or peptides that function as Fc_YRIIB antagonists can be administered to a subject with a B-cell malignancy, in accordance with the methods of the specification. Further, nucleic acid molecules encoding derivatives, analogs, fragments or variants of proteins, polypeptides, or peptides that function as Fc_YRIIB antagonists can be administered to a subject with a B-cell malignancy in accordance with the methods of the specification. Preferably, such derivatives, analogs, variants and fragments retain the Fc_YRIIB antagonist activity of the full-length wild-type protein, polypeptide, or peptide.

5.2 ANTIBODY CONJUGATES

[0171] The present invention encompasses antibodies recombinantly fused or chemically conjugated (including both covalently and non-covalently conjugations) to heterologous polypeptides (i.e., an unrelated polypeptide; or portion thereof, preferably at least 10, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90 or at least 100 amino acids of the polypeptide) to generate fusion proteins. The fusion does not necessarily need to be direct, but may occur through linker sequences. Antibodies may be used for example to target heterologous polypeptides to particular cell types, either *in vitro* or *in vivo*, by fusing or conjugating the antibodies to antibodies specific for particular cell surface receptors. Antibodies fused or conjugated to heterologous polypeptides may also be used in *in vitro* immunoassays and purification methods using methods known in the art. See e.g., PCT Publication No. WO 93/21232; EP 439,095; Naramura et al., 1994, *Immunol. Lett.*, 39:91-99; U.S. Patent No. 5,474,981; Gillies et al., 1992, *Proc Natl Acad Sci*, 89:1428-1432; and Fell et al., 1991, *J. Immunol.*, 146:2446-2452.

[0172] Further, an antibody may be conjugated to a therapeutic agent or drug moiety that modifies a given biological response. Therapeutic agents or drug moieties are not to be construed as limited to classical chemical therapeutic agents. For example, the drug moiety may be a protein or polypeptide possessing a desired biological activity. Such proteins may include, for example, a toxin such as abrin, ricin A, pseudomonas exotoxin (*i.e.*, PE-40), or diphtheria toxin, ricin, gelonin, and pokeweed antiviral protein, a protein such as tumor necrosis factor, interferons including, but not limited to, α -interferon (IFN- α), β -interferon (IFN- β), nerve growth factor (NGF), platelet derived growth factor (PDGF), tissue plasminogen activator (TPA), an apoptotic agent (*e.g.*, TNF- α , TNF- β , AIM I as disclosed in PCT Publication No. WO 97/33899), AIM II (*see, e.g.*, PCT Publication No. WO 97/34911), Fas Ligand (Takahashi et al., 1994 *J. Immunol.*, 6:1567-1574), and VEGI (PCT Publication No. WO 99/23105), a thrombotic agent or an anti-angiogenic agent (*e.g.*, angiostatin or endostatin), or a biological response modifier such as, for example, a lymphokine (*e.g.*, interleukin-1 ("IL-1"), interleukin-2 ("IL-2"), interleukin-6 ("IL-6"), granulocyte macrophage colony stimulating factor ("GM-CSF"), and granulocyte colony stimulating factor ("G-CSF")), macrophage colony stimulating factor, ("M-CSF"), or a growth factor (*e.g.*, growth hormone ("GH")); a protease, or a ribonuclease).

[0173] Antibodies can be fused to marker sequences, such as a peptide, to facilitate purification. In preferred embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311), among others, many of which are commercially available. As described in Gentz et al., 1989 *Proc. Natl. Acad. Sci. USA*, 86:821-824, for instance, hexa-histidine provides for convenient purification of the fusion protein. Other peptide tags useful for purification include, but are not limited to, the hemagglutinin "HA" tag, which corresponds to an epitope derived from the influenza hemagglutinin protein (Wilson et al., 1984 *Cell*, 37:767) and the "flag" tag (Knappik et al., 1994 *Biotechniques*, 17(4):754-761).

[0174] Also discussed is the use of compositions comprising heterologous polypeptides fused or conjugated to antibody fragments. For example, the heterologous polypeptides may be fused or conjugated to a Fab fragment, Fd fragment, Fv fragment, F(ab)2 fragment, or portion thereof. Methods for fusing or conjugating polypeptides to antibody portions are known in the art. See, *e.g.*, U.S. Patent Nos. 5,336,603, 5,622,929, 5,359,046, 5,349,053, 5,447,851, and 5,112,946; EP 307,434; EP 367,166; International Publication Nos. WO 96/04388 and WO 91/06570; Ashkenazi et al., 1991, *Proc. Natl. Acad. Sci. USA* 88: 10535-10539; Zheng et al., 1995, *J. Immunol.* 154:5590-5600; and Vil et al., 1992, *Proc. Natl. Acad. Sci. USA* 89:11337- 11341.

[0175] Additional fusion proteins may be generated through the techniques of gene-shuffling, motif-shuffling, exon-shuffling, and/or codon-shuffling (collectively referred to as "DNA shuffling"). DNA shuffling may be employed to alter the activities of antibodies of the invention or fragments thereof (*e.g.*, antibodies or fragments thereof with higher affinities and lower dissociation rates). See, generally, U.S. Patent Nos. 5,605,793; 5,811,238; 5,830,721; 5,834,252; and 5,837,458, and Patten et al., 1997, *Curr. Opinion Biotechnol.* 8:724-33; Harayama, 1998, *Trends Biotechnol.* 16:76; Hansson, et al., 1999, *J. Mol. Biol.* 287:265; and Lorenzo and Blasco, 1998, *BioTechniques* 24:308. Antibodies or fragments thereof, or the encoded antibodies or fragments thereof, may be altered by being subjected to random mutagenesis by error-prone PCR, random nucleotide insertion or other methods prior to recombination. One or more portions of a polynucleotide encoding an antibody or antibody fragment, which portions specifically bind to Fc_YRIIB may be recombined with one or more components, motifs, sections, parts, domains, fragments, etc. of one or more heterologous molecules.

[0176] The present invention also encompasses antibodies conjugated to a diagnostic or therapeutic agent or any other molecule for which serum half-life is desired to be increased. The antibodies can be used diagnostically to, for example, monitor the development or progression of a disease, disorder or infection as part of a clinical testing procedure to, *e.g.*, determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, radioactive materials, positron emitting metals, and nonradioactive paramagnetic metal ions. The detectable substance may be coupled or conjugated either directly to the antibody or indirectly, through an intermediate (such as, for example, a linker known in the art) using techniques known in the art. See, for example, U.S. Patent No. 4,741,900 for metal ions which can be conjugated to antibodies for use as diagnostics according to the present specification. Such diagnosis and detection can be accomplished by coupling the antibody to detectable substances including, but not limited to, various enzymes, enzymes including, but not limited to, horseradish peroxidase, alkaline phosphatase, beta-galactosidase, or acetylcholinesterase; prosthetic group complexes such as, but not limited to, streptavidin/biotin and avidin/biotin; fluorescent materials such as, but not limited to, umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; luminescent material such as, but not limited to, luminol; bioluminescent materials such as, but not limited to, luciferase, luciferin, and aequorin; radioactive material such as, but not limited to, bismuth (²¹³Bi), carbon (¹⁴C), chromium (⁵¹Cr), cobalt (⁵⁷Co), fluorine (¹⁸F), gadolinium (¹⁵³Gd, ¹⁵⁹Gd), gallium (⁶⁸Ga, ⁶⁷Ga), germanium (⁶⁸Ge), holmium (¹⁶⁶Ho), indium (¹¹⁵In, ¹¹³In, ¹¹²In, ¹¹¹In), iodine (¹³¹I, ¹²⁵I, ¹²³I, ¹²¹I), lanthanum (¹⁴⁰La), lutetium (¹⁷⁷Lu), manganese (⁵⁴Mn), molybdenum

(⁹⁹Mo), palladium (¹⁰³Pd), phosphorous (³²P), praseodymium (¹⁴²Pr), promethium (¹⁴⁹Prm), rhenium (¹⁸⁶Re, ¹⁸⁸Re), rhodium (¹⁰⁵Rh), ruthenium (⁹⁷Ru), samarium (¹⁵³Sm), scandium (⁴⁷Sc), selenium (⁷⁵Se), strontium (⁸⁵Sr), sulfur (³⁵S), technetium (⁹⁹Tc), thallium (²⁰¹Tl), tin (¹¹³Sn, ¹¹⁷Sn), tritium (³H), xenon (¹³³Xe), ytterbium (¹⁶⁹Yb, ¹⁷⁵Yb), yttrium (⁹⁰Y), zinc (⁶⁵Zn); positron emitting metals using various positron emission tomographies, and nonradioactive paramagnetic metal ions.

[0177] An antibody may be conjugated to a therapeutic moiety such as a cytotoxin (e.g., a cytostatic or cytoidal agent), a therapeutic agent or a radioactive element (e.g., alpha-emitters, gamma-emitters, etc.). Cytotoxins or cytotoxic agents include any agent that is detrimental to cells. Examples include paclitaxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin and analogs or homologs thereof. Therapeutic agents include, but are not limited to, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating agents (e.g., mechlorethamine, thioepa chlorambucil, melphalan, carmustine (BSNU) and lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis dichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (e.g., daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC)), and anti-mitotic agents (e.g., vincristine and vinblastine).

[0178] Moreover, an antibody can be conjugated to therapeutic moieties such as a radioactive materials or macrocyclic chelators useful for conjugating radiometal ions (see above for examples of radioactive materials). In certain embodiments falling within the scope of specified claims, the macrocyclic chelator is 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA) which can be attached to the antibody via a linker molecule. Such linker molecules are commonly known in the art and described in Denardo et al., 1998, Clin Cancer Res. 4:2483-90; Peterson et al., 1999, Bioconjug. Chem. 10:553; and Zimmerman et al., 1999, Nucl. Med. Biol. 26:943-50.

[0179] Techniques for conjugating such therapeutic moieties to antibodies are well known; see, e.g., Arnon et al., "Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy", in Monoclonal Antibodies And Cancer Therapy, Reisfeld et al. (eds.), 1985, pp. 243-56, Alan R. Liss, Inc.); Hellstrom et al., "Antibodies For Drug Delivery", in Controlled Drug Delivery (2nd Ed.), Robinson et al. (eds.), 1987, pp. 623-53, Marcel Dekker, Inc.); Thorpe, "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review", in Monoclonal Antibodies '84: Biological And Clinical Applications, Pinchera et al. (eds.), 1985, pp. 475-506); "Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy", in Monoclonal Antibodies For Cancer Detection And Therapy, Baldwin et al. (eds.), 1985, pp. 303-16, Academic Press; and Thorpe et al., Immunol. Rev., 62:119-58, 1982.

[0180] An antibody or fragment thereof, with or without a therapeutic moiety conjugated to it, administered alone or in combination with cytotoxic factor(s) and/or cytokine(s) can be used as a therapeutic.

[0181] Alternatively, an antibody can be conjugated to a second antibody to form an antibody heteroconjugate as described by Segal in U.S. Patent No. 4,676,980.

[0182] Antibodies may also be attached to solid supports, which are particularly useful for immunoassays or purification of the target antigen. Such solid supports include, but are not limited to, glass, cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene.

5.3 PREPARATION AND CHARACTERIZATION OF MONOCLONAL ANTIBODIES OF THE INVENTION

[0183] Monoclonal antibodies can be prepared using a wide variety of techniques known in the art including the use of hybridoma, recombinant, and phage display technologies, or a combination thereof. For example, monoclonal antibodies can be produced using hybridoma techniques including those known in the art and taught, for example, in Harlow et al., Antibodies: A Laboratory Manual, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988); Hammerling, et al., in: Monoclonal Antibodies and T-Cell Hybridomas, pp. 563-681 (Elsevier, N.Y., 1981). The term "monoclonal antibody" as used herein is not limited to antibodies produced through hybridoma technology. The term "Monoclonal antibody" refers to an antibody that is derived from a single clone, including any eukaryotic, prokaryotic, or phage clone, and not the method by which it is produced.

[0184] Methods for producing and screening for specific antibodies using hybridoma technology are routine and well known in the art. In a non-limiting example, mice can be immunized with an antigen of interest or a cell expressing such an antigen. Once an immune response is detected, e.g., antibodies specific for the antigen are detected in the mouse serum, the mouse spleen is

harvested and splenocytes isolated. The splenocytes are then fused by well known techniques to any suitable myeloma cells. Hybridomas are selected and cloned by limiting dilution. The hybridoma clones are then assayed by methods known in the art for cells that secrete antibodies capable of binding the antigen. Ascites fluid, which generally contains high levels of antibodies, can be generated by inoculating mice intraperitoneally with positive Hybridoma clones.

[0185] There is described a method for producing monoclonal antibodies that specifically bind Fc_YRIIB with greater affinity than said monoclonal antibodies bind Fc_YRIIA comprising: immunizing one or more Fc_YRIIA transgenic mice (See U.S. 5,877,396 and U.S. 5,824,487) with the purified extracellular domain of human Fc_YRIIB, amino acids 1-180; producing hybridoma cell lines from spleen cells of said mice, screening said hybridoma cells lines for one or more hybridoma cell lines that produce antibodies that specifically bind Fc_YRIIB with greater affinity than said antibodies bind Fc_YRIIA. There is also provided a method for producing Fc_YRIIB monoclonal antibodies that specifically bind Fc_YRIIB, particularly human Fc_YRIIB, with a greater affinity than said monoclonal antibodies bind Fc_YRIIA, said method further comprising: immunizing one or more Fc_YRIIA transgenic mice with purified Fc_YRIIB or an immunogenic fragment thereof, booster immunizing said mice sufficient number of times to elicit an immune response, producing hybridoma cells lines from spleen cells of said one or more mice, screening said hybridoma cell lines for one or more hybridoma cell lines that produce antibodies that specifically bind Fc_YRIIB with a greater affinity than said antibodies bind Fc_YRIIA. The said mice can be immunized with purified Fc_YRIIB which has been mixed with any adjuvant known in the art to enhance immune response. Adjuvants that can be used in the methods described include, but are not limited to, protein adjuvants; bacterial adjuvants, e.g., whole bacteria (BCG, *Corynebacterium parvum*, *Salmonella minnesota*) and bacterial components including cell wall skeleton, trehalose dimycolate, monophosphoryl lipid A, methanol extractable residue (MER) of tubercle bacillus, complete or incomplete Freund's adjuvant; viral adjuvants; chemical adjuvants, e.g., aluminum hydroxide, iodoacetate and cholestryl hemisuccinate; naked DNA adjuvants. Other adjuvants that can be used in the methods described include, Cholera toxin, paropox proteins, MF-59 (Chiron Corporation; See also Bieg et al., 1999, *Autoimmunity*, 31(1):15-24), MPL® (Corixa Corporation; See also Lodmell D.I. et al., 2000 *Vaccine*, 18: 1059-1066; Ulrich et al., 2000, *Methods in Molecular Medicine*, 273-282; Johnson et al., 1999, *Journal of Medicinal Chemistry*, 42: 4640-4649; Baldridge et al., 1999 *Methods*, 19: 103-107), RC-529 adjuvant (Corixa Corporation; the lead compound from Corixa's aminoalkyl glucosaminide 4-phosphate (AGP) chemical library, see also www.corixa.com), and DETOX™ adjuvant (Corixa Corporation; DETOX™ adjuvant includes MPL® adjuvant (monophosphoryl lipid A) and mycobacterial cell wall skeleton; See also Eton et al., 1998, *Clin. Cancer Res*, 4(3):619-27; and Gubta R. et al., 1995, *Vaccine*, 13(14): 1263-76).

[0186] Antibody fragments which recognize specific epitopes may be generated by known techniques. For example, Fab and F(ab')₂ fragments may be produced by proteolytic cleavage of immunoglobulin molecules, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')₂ fragments). F(ab')₂ fragments contain the complete light chain, and the variable region, the CH1 region and at least a portion of the hinge region of the heavy chain.

[0187] For example, antibodies can also be generated using various phage display methods known in the art. In phage display methods, functional antibody domains are displayed on the surface of phage particles which carry the polynucleotide sequences encoding them. Such phage can be utilized to display antigen binding domains, such as Fab and Fv or disulfide-bond stabilized Fv, expressed from a repertoire or combinatorial antibody library (e.g., human or murine). Phage expressing an antigen binding domain that binds the antigen of interest can be selected or identified with antigen, e.g., using labeled antigen or antigen bound or captured to a solid surface or bead. Phage used in these methods are typically filamentous phage, including fd and M13. The antigen binding domains are expressed as a recombinantly fused protein to either the phage gene III or gene VIII protein. Examples of phage display methods that can be used to make the immunoglobulins, or fragments thereof, of the present invention include those disclosed in Brinkman et al., *J. Immunol. Methods*, 182:41-50, 1995; Ames et al., *J. Immunol. Methods*, 184:177-186, 1995; Kettleborough et al., *Eur. J. Immunol.*, 24:952-958, 1994; Persic et al., *Gene*, 187:9-18, 1997; Burton et al., *Advances in Immunology*, 57:191-280, 1994; PCT publication WO9201047; PCT Publications WO 90/02809; WO 91/10737; WO 92/01047; WO 92/18619; WO 93/11236; WO 95/15982; WO 95/20401; and U.S. Patent Nos. 5,698,426; 5,223,409; 5,403,484; 5,580,717; 5,427,908; 5,750,753; 5,821,047; 5,571,698; 5,427,908; 5,516,637; 5,780,225; 5,658,727; 5,733,743 and 5,969,108.

[0188] As described in the above references, after phage selection, the antibody coding regions from the phage can be isolated and used to generate whole antibodies, including human antibodies, or any other desired fragments, and expressed in any desired host, including mammalian cells, insect cells, plant cells, yeast, and bacteria, e.g., as described in detail below. For example, techniques to recombinantly produce Fab, Fab' and F(ab')₂ fragments can also be employed using methods known in the art such as those disclosed in PCT Publication WO 92/22324; Mullinax et al., *BioTechniques*, 12(6):864-869, 1992; and Sawai et al., *AJRI*, 34:26-34, 1995; and Better et al., *Science*, 240:1041-1043, 1988. Examples of techniques which can be used to produce single-chain Fvs and antibodies include those described in U.S. Patent Nos. 4,946,778 and 5,258,498; Huston et al., *Methods in Enzymology*, 203:46-88, 1991; Shu et al., *Proc Natl Acad Sci USA*, 90:7995-7999, 1993; and Skerra et al., *Science*, 240:1038-1040, 1988.

[0189] Phage display technology can be used to increase the affinity of an antibody of the invention for Fc_YRIIB. This technique would be useful in obtaining high affinity antibodies that could be used in the combinatorial methods of the invention. The technology, referred to as affinity maturation, employs mutagenesis or CDR walking and re-selection using Fc_YRIIB or an antigenic fragment thereof to identify antibodies that bind with higher affinity to the antigen when compared with the initial or parental antibody (See, e.g., Glaser et al., 1992, J. Immunology 149:3903). Mutagenizing entire codons rather than single nucleotides results in a semi-randomized repertoire of amino acid mutations. Libraries can be constructed consisting of a pool of variant clones each of which differs by a single amino acid alteration in a single CDR and which contain variants representing each possible amino acid substitution for each CDR residue. Mutants with increased binding affinity for the antigen can be screened by contacting the immobilized mutants with labeled antigen. Any screening method known in the art can be used to identify mutant antibodies with increased avidity to the antigen (e.g., ELISA) (See Wu et al., 1998, Proc Natl. Acad. Sci. USA 95:6037; Yelton et al., 1995, J. Immunology 155:1994). CDR walking which randomizes the light chain is also possible (See Schier et al., 1996, J. Mol. Bio. 263:551).

[0190] Antibodies of the invention may be further characterized by epitope mapping, so that antibodies may be selected that have the greatest specificity for Fc_YRIIB compared to Fc_YRIIA. Epitope mapping methods of antibodies are well known in the art and encompassed within the methods of the invention. In certain instances fusion proteins comprising one or more regions of Fc_YRIIB may be used in mapping the epitope of an antibody of the invention. In a specific instance, the fusion protein contains the amino acid sequence of a region of an Fc_YRIIB fused to the Fc portion of human IgG2. Each fusion protein may further comprise amino acid substitutions and/or replacements of certain regions of the receptor with the corresponding region from a homolog receptor, e.g., Fc_YRIIA, as shown in Table 4 below. pMGX125 and pMGX132 contain the IgG binding site of the Fc_YRIIB receptor, the former with the C-terminus of Fc_YRIIB and the latter with the C-terminus of Fc_YRIIA and can be used to differentiate C-terminus binding. The others have Fc_YRIIA substitutions in the IgG binding site and either the Fc_YIIA or Fc_YIIIB N-terminus. These molecules can help determine the part of the receptor molecule where the antibodies bind.

[0191] Table 4. List of the fusion proteins that may be used to investigate the epitope of the monoclonal anti-Fc_YRIIB antibodies. Residues 172 to 180 belong to the IgG binding site of Fc_YRIIA and B. The specific amino acids from Fc_YRIIA sequence are in bold. The C-terminus sequence APSSS is SEQ ID NO: 11 and the C-terminus sequence VPSMGSSS is SEQ ID NO: 12.

Plasmid	Receptor	N-terminus	172-180	SEQ ID NO:	C-terminus
pMGX125	Rllb	llb	KKFSRSDPN	51	APS—SS (llb)
pMGX126	Rlla/b	lla	Q KFSRLDPN	52	APS—SS (llb)
pMGX127		lla	Q KFSRLDPT	53	APS—SS (llb)
pMGX128		llb	KK FSRLDPT	54	APS—SS (llb)
pMGX129		na	Q KFSHLDPT	55	APS—SS (llb)
pMGX130		llb	KK FSHLDPT	56	APS—SS (llb)
pMGX131		lla	Q KFSRLDPN	52	VPSMGSSS(lla)
pMGX132		llb	KK FSRSDPN	51	VPSMGSSS(lla)
pMGX133	Rlla-131R	lla	Q KFSRLDPT	53	VPSMGSSS(lla)
pMGX134	Rlla-131H	lla	Q KFSHLDPT	55	VPSMGSSS(lla)
pMGX135		llb	KK FSRLDPT	54	VPSMGSSS(lla)
pMGX136		llb	KK FSHLDPT	56	VPSMGSSS(lla)

[0192] The fusion proteins may be used in any biochemical assay for determination of binding to an anti-Fc_YRIIB antibody of the invention, e.g., an ELISA. In other instances, further confirmation of the epitope specificity may be done by using peptides with specific residues replaced with those from the Fc_YRIIA sequence.

[0193] The antibodies of the invention may be characterized for specific binding to Fc_YRIIB using any immunological or biochemical based method known in the art for characterizing including quantitating, the interaction of the antibody to Fc_YRIIB. Specific binding of an antibody of the invention to Fc_YRIIB may be determined for example using immunological or biochemical based methods including, but not limited to, an ELISA assay, surface plasmon resonance assays, immunoprecipitation assay, affinity chromatography, and equilibrium dialysis. Immunoassays which can be used to analyze immunospecific binding and cross-reactivity of the antibodies of the invention include, but are not limited to, competitive and non-competitive assay systems using

techniques such as western blots, radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich" immunoassays, immunoprecipitation assays, precipitin reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, complement-fixation assays, immunoradiometric assays, fluorescent immunoassays, protein A immunoassays, to name but a few. Such assays are routine and well known in the art (see, e.g., Ausubel et al., eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York).

[0194] Antibodies of the invention may also be assayed using any surface plasmon resonance based assays known in the art for characterizing the kinetic parameters of the interaction of the antibody with FcγRIIB. Any SPR instrument commercially available including, but not limited to, BIACore Instruments, available from Biacore AB (Uppsala, Sweden); IAsys instruments available from Affinity Sensors (Franklin, MA.); IBIS system available from Windsor Scientific Limited (Berks, UK), SPR-CELLIA systems available from Nippon Laser and Electronics Lab (Hokkaido, Japan), and SPR Detector Spreeta available from Texas Instruments (Dallas, TX) can be used in the instant invention. For a review of SPR-based technology see Mullet et al., 2000, Methods 22: 77-91; Dong et al., 2002, Review in Mol. Biotech., 82: 303-23; Fivash et al., 1998, Current Opinion in Biotechnology 9: 97-101; Rich et al., 2000, Current Opinion in Biotechnology 11: 54-61. Additionally, any of the SPR instruments and SPR based methods for measuring protein-protein interactions described in U.S. Patent Nos. 6,373,577; 6,289,286; 5,322,798; 5,341,215; 6,268,125 are contemplated in the methods of the invention.

[0195] Briefly, SPR based assays involve immobilizing a member of a binding pair on a surface, and monitoring its interaction with the other member of the binding pair in solution in real time. SPR is based on measuring the change in refractive index of the solvent near the surface that occurs upon complex formation or dissociation. The surface onto which the immobilization occurs is the sensor chip, which is at the heart of the SPR technology; it consists of a glass surface coated with a thin layer of gold and forms the basis for a range of specialized surfaces designed to optimize the binding of a molecule to the surface. A variety of sensor chips are commercially available especially from the companies listed supra, all of which may be used in the methods of the specification. Examples of sensor chips include those available from BIACore AB, Inc., e.g., Sensor Chip CM5, SA, NTA, and HPA. A molecule of the invention may be immobilized onto the surface of a sensor chip using any of the immobilization methods and chemistries known in the art, including but not limited to, direct covalent coupling via amine groups, direct covalent coupling via sulfhydryl groups, biotin attachment to avidin coated surface, aldehyde coupling to carbohydrate groups, and attachment through the histidine tag with NTA chips.

[0196] The binding specificity of the antibodies of the invention may be evaluated by any method known in the art for determining binding-pair interactions, including, but not limited to ELISA, western blot, surface plasmon resonance (e.g., BIACore) and radioimmunoassay. Any method known in the art for assessing binding specificity may be used to identify antibodies of the specification that exhibit a K_d of greater than 0.001 nM but not greater than 5 nM, not greater than 10 nM, not greater than 15 nM, not greater than 20 nM, not greater than 25 nM, not greater than 30 nM, not greater than 35 nM, not greater than 40 nM, not greater than 45 nM, or not greater than 50 nM as determined by BIACore assay.

[0197] The present specification also provides for antibodies of the invention, or fragments thereof, that have a high binding affinity for the antigen of interest. In a specific instance, an immunospecific polypeptide of the present specification or fragment thereof has an association rate constant or k_{on} rate (antibody (Ab)+antigen (Ag) Ab-Ag) of at least $10^5 \text{ M}^{-1} \text{ s}^{-1}$, at least $5 \times 10^5 \text{ M}^{-1} \text{ s}^{-1}$, at least $10^6 \text{ M}^{-1} \text{ s}^{-1}$, at least $5 \times 10^6 \text{ M}^{-1} \text{ s}^{-1}$, at least $10^7 \text{ M}^{-1} \text{ s}^{-1}$, at least $5 \times 10^7 \text{ M}^{-1} \text{ s}^{-1}$, or at least $10^8 \text{ M}^{-1} \text{ s}^{-1}$. In a preferred instance, an antibody of the present specification or fragment thereof has a k_{on} of at least $2 \times 10^5 \text{ M}^{-1} \text{ s}^{-1}$, at least $5 \times 10^5 \text{ M}^{-1} \text{ s}^{-1}$, at least $10^6 \text{ M}^{-1} \text{ s}^{-1}$, at least $5 \times 10^6 \text{ M}^{-1} \text{ s}^{-1}$, at least $10^7 \text{ M}^{-1} \text{ s}^{-1}$, at least $5 \times 10^7 \text{ M}^{-1} \text{ s}^{-1}$, or at least $10^8 \text{ M}^{-1} \text{ s}^{-1}$.

[0198] In another instance, an antibody of the present specification or fragment thereof has a k_{off} rate (antibody (Ab)+antigen (Ag) Ab-Ag) of less than 10^{-1} s^{-1} , less than $5 \times 10^{-1} \text{ s}^{-1}$, less than 10^{-2} s^{-1} , less than $5 \times 10^{-2} \text{ s}^{-1}$, less than 10^{-3} s^{-1} , less than $5 \times 10^{-3} \text{ s}^{-1}$, less than 10^{-4} s^{-1} , less than $5 \times 10^{-4} \text{ s}^{-1}$, less than 10^{-5} s^{-1} , less than $5 \times 10^{-5} \text{ s}^{-1}$, less than 10^{-6} s^{-1} , less than $5 \times 10^{-6} \text{ s}^{-1}$, less than 10^{-7} s^{-1} , less than $5 \times 10^{-7} \text{ s}^{-1}$, less than 10^{-8} s^{-1} , less than $5 \times 10^{-8} \text{ s}^{-1}$, less than 10^{-9} s^{-1} , less than $5 \times 10^{-9} \text{ s}^{-1}$, or less than 10^{-10} s^{-1} . In a preferred instance, an antibody of the present specification or fragment thereof has a k_{off} of less than $5 \times 10^{-4} \text{ s}^{-1}$, less than 10^{-5} s^{-1} , less than $5 \times 10^{-5} \text{ s}^{-1}$, less than 10^{-6} s^{-1} , less than $5 \times 10^{-6} \text{ s}^{-1}$, less than 10^{-7} s^{-1} , less than $5 \times 10^{-7} \text{ s}^{-1}$, less than 10^{-8} s^{-1} , less than $5 \times 10^{-8} \text{ s}^{-1}$, less than 10^{-9} s^{-1} , less than $5 \times 10^{-9} \text{ s}^{-1}$, or less than 10^{-10} s^{-1} .

[0199] In still other instances, an antibody of the present specification or fragment thereof has an affinity constant or K_a (k_{on} / k_{off}) of at least 10^2 M^{-1} , at least $5 \times 10^2 \text{ M}^{-1}$, at least 10^3 M^{-1} , at least $5 \times 10^3 \text{ M}^{-1}$, at least 10^4 M^{-1} , at least $5 \times 10^4 \text{ M}^{-1}$, at least 10^5 M^{-1} at least $5 \times 10^5 \text{ M}^{-1}$, at least 10^6 M^{-1} , at least $5 \times 10^6 \text{ M}^{-1}$, at least 10^7 M^{-1} , at least $5 \times 10^7 \text{ M}^{-1}$, at least 10^8 M^{-1} , at least $5 \times 10^8 \text{ M}^{-1}$, at

least 10^9 M^{-1} , at least $5 \times 10^9 \text{ M}^{-1}$, at least 10^{10} M^{-1} , at least $5 \times 10^{10} \text{ M}^{-1}$, at least 10^{11} M^{-1} , at least $5 \times 10^{11} \text{ M}^{-1}$, at least 10^{12} M^{-1} , at least $5 \times 10^{12} \text{ M}^{-1}$, at least 10^{13} M^{-1} , at least $5 \times 10^{13} \text{ M}^{-1}$, at least 10^{14} M^{-1} , at least $5 \times 10^{14} \text{ M}^{-1}$, at least 10^{15} M^{-1} , or at least $5 \times 10^{15} \text{ M}^{-1}$. In yet another instance, an antibody of the present specification or fragment thereof has a dissociation constant or K_d (k_{off}/k_{on}) of less than 10^{-2} M , less than $5 \times 10^{-2} \text{ M}$, less than 10^{-3} M , less than $5 \times 10^{-3} \text{ M}$, less than 10^{-4} M , less than $5 \times 10^{-4} \text{ M}$, less than 10^{-5} M , less than $5 \times 10^{-5} \text{ M}$, less than 10^{-6} M , less than $5 \times 10^{-6} \text{ M}$, less than 10^{-7} M , less than $5 \times 10^{-7} \text{ M}$, less than 10^{-8} M , less than $5 \times 10^{-8} \text{ M}$, less than 10^{-9} M . In embodiments falling within the scope of the specified claims, an antibody of the present invention or fragment thereof has a dissociation constant or K_d (k_{off}/k_{on}) of less than $5 \times 10^{-9} \text{ M}$, less than 10^{-10} M , less than $5 \times 10^{-10} \text{ M}$, less than 10^{-11} M , less than $5 \times 10^{-11} \text{ M}$, less than 10^{-12} M , less than $5 \times 10^{-12} \text{ M}$, less than 10^{-13} M , less than $5 \times 10^{-13} \text{ M}$, less than 10^{-14} M , less than $5 \times 10^{-14} \text{ M}$, less than 10^{-15} M , or less than $5 \times 10^{-15} \text{ M}$.

[0200] Also described is the characterization of the antibodies produced by the methods herein described using certain characterization assays for identifying the function of the antibodies of the invention, particularly the activity to modulate Fc γ RIIB signaling. For example, characterization assays of the specification can measure phosphorylation of tyrosine residues in the ITIM motif of Fc γ RIIB, or measure the inhibition of B cell receptor-generated calcium mobilization. The characterization assays can be cell-based or cell-free assays.

[0201] It has been well established in the art that in mast cells coaggregation of Fc γ RIIB with the high affinity IgE receptor, Fc ϵ RI, leads to inhibition of antigen-induced degranulation, calcium mobilization, and cytokine production (Metcalfe D.D. et al. 1997, *Physiol. Rev.* 77:1033; Long E.O. 1999 *Annu Rev. Immunol.* 17: 875). The molecular details of this signaling pathway have been recently elucidated (Ott V. L., 2002, *J. Immunol.* 162(9):4430-9). Once coaggregated with Fc ϵ RI, Fc γ RIIB is rapidly phosphorylated on tyrosine in its ITIM motif, and then recruits Src Homology-2 containing inositol-5-phosphatase (SHIP); an SH2 domain-containing inositol polyphosphate 5-phosphatase, which is in turn phosphorylated and associates with Shc and p62^{dok} (p62^{dok} is the prototype of a family of adaptor molecules, which includes signaling domains such as an aminoterminal pleckstrin homology domain (PH domain), a PTB domain, and a carboxy terminal region containing PXXP motifs and numerous phosphorylation sites (Carpino et al., 1997 *Cell*, 88: 197; Yamanshi et al., 1997, *Cell*, 88:205)).

[0202] The anti-Fc γ RIIB antibodies of the invention can be characterized in modulating one or more IgE-mediated responses. Preferably, cells lines co-expressing the high affinity receptor for IgE and the low affinity receptor for Fc γ RIIB will be used in characterizing the anti-Fc γ RIIB antibodies of the invention in modulating IgE-mediated responses. In a specific embodiment, cells from a rat basophilic leukemia cell line (RBL-H23; Barsumian E.L. et al. 1981 *Eur. J. Immunol.* 11:317) transfected with full length human Fc γ RIIB will be used in the methods of the specification. RBL-2H3 is a well characterized rat cell line that has been used extensively to study the signaling mechanisms following IgE-mediated cell activation. When expressed in RBL-2H3 cells and coaggregated with Fc ϵ RI, Fc γ RIIB inhibits Fc ϵ RI-induced calcium mobilization, degranulation, and cytokine production (Malbec et al., 1998, *J. Immunol.* 160:1647; Daeron et al., 1995 *J. Clin. Invest.* 95:577; Ott et al., 2002 *J. of Immunol.* 168:4430-4439).

[0203] The anti-Fc γ RIIB antibodies of the invention can be characterized for inhibition of Fc ϵ RI induced mast cell activation. For example, cells from a rat basophilic leukemia cell line (RBL-H23; Barsumian E.L. et al. 1981 *Eur. J. Immunol.* 11:317) that have been transfected with Fc γ RIIB are sensitized with IgE and stimulated either with F(ab')₂ fragments of rabbit anti-mouse IgG, to aggregate Fc ϵ RI alone, or with whole rabbit anti-mouse IgG to coaggregate Fc γ RIIB and Fc ϵ RI. In this system, indirect modulation of down stream signaling molecules can be assayed upon addition of antibodies of the invention to the sensitized and stimulated cells. For example, tyrosine phosphorylation of Fc γ RIIB and recruitment and phosphorylation of SHIP, activation of MAP kinase family members, including but not limited to Erk1, Erk2, JNK, or p38; and tyrosine phosphorylation of p62^{dok} and its association with SHIP and RasGAP can be assayed.

[0204] One exemplary assay for determining the inhibition of Fc ϵ RI induced mast cell activation by the antibodies of the invention can comprise of the following: transfecting RBL-H23 cells with human Fc γ RIIB; sensitizing the RBL-H23 cells with IgE; stimulating RBL-H23 cells with either F(ab')₂ of rabbit anti-mouse IgG (to aggregate Fc ϵ RI alone and elicit Fc ϵ RI-mediated signaling, as a control), or stimulating RBL-H23 cells with whole rabbit anti-mouse IgG (to coaggregate Fc γ RIIB and Fc ϵ RI, resulting in inhibition of Fc ϵ RI-mediated signaling). Cells that have been stimulated with whole rabbit anti-mouse IgG antibodies can be further pre-incubated with the antibodies of the invention. Measuring Fc ϵ RI-dependent activity of cells that have been pre-incubated with the antibodies of the invention and cells that have not been pre-incubated with the antibodies of the invention, and comparing levels of Fc ϵ RI-dependent activity in these cells, would indicate a modulation of Fc ϵ RI-dependent activity by the antibodies of the invention.

[0205] The exemplary assay described above can be for example, used to identify antibodies that block ligand (IgG) binding to Fc γ RIIB receptor and antagonize Fc γ RIIB-mediated inhibition of Fc ϵ RI signaling by preventing coaggregating of Fc γ RIIB and Fc ϵ RI. This assay likewise identifies antibodies that enhance coaggregation of Fc γ RIIB and Fc ϵ RI and agonize Fc γ RIIB-mediated inhibition of Fc ϵ RI signaling by promoting coaggregating of Fc γ RIIB and Fc ϵ RI.

[0206] Preferably Fc ϵ RI-dependent activity is at least one or more of the following: modulation of downstream signaling molecules (e.g., modulation of phosphorylation state of Fc γ RIIB, modulation of SHIP recruitment, modulation of MAP Kinase activity, modulation of phosphorylation state of SHIP, modulation of SHIP and Shc association SHIP and She, modulation of the phosphorylation state of p62^{dok}, modulation of p62^{dok} and SHIP association, modulation of p62^{dok} and RasGAP association, modulation of calcium mobilization, modulation of degranulation, and modulation of cytokine production). In yet another preferred instance, Fc ϵ RI-dependent activity is serotonin release and/or extracellular Ca⁺⁺ influx and/or IgE dependent mast cell activation. It is known to one skilled in the art that coaggregation of Fc γ RIIB and Fc ϵ RI stimulates Fc γ RIIB tyrosine phosphorylation, stimulates recruitment of SHIP, stimulates SHIP tyrosine phosphorylation and association with She, and inhibits activation of MAP kinase family members including, but not limited to, Erk1, Erk2, JNK, p38. It is also known to those skilled in the art that coaggregation of Fc γ RIIB and Fc ϵ RI stimulates enhanced tyrosine phosphorylation of p62^{dok} and its association with SHIP and RasGAP.

[0207] The anti-Fc γ RIIB antibodies of the invention can be characterized for their ability to modulate an IgE-mediated response by monitoring and/or measuring degranulation of mast cells or basophils, preferably in a cell-based assay. Preferably, mast cells or basophils for use in such assays have been engineered to contain human Fc γ RIIB using standard recombinant methods known to one skilled in the art. In a specific instance the anti-Fc γ RIIB antibodies of the invention are characterized for their ability to modulate an IgE-mediated response in a cell-based β -hexosaminidase (enzyme contained in the granules) release assay. β -hexosaminidase release from mast cells and basophils is a primary event in acute allergic and inflammatory condition (Aketani et al., 2001 Immunol. Lett. 75: 185-9; Aketani et al., 2000 Anal. Chem. 72: 2653-8). Release of other inflammatory mediators including but not limited to serotonin and histamine may be assayed to measure an IgE-mediated response in accordance with the methods of the invention. Although not intending to be bound by a particular mechanism of action, release of granules such as those containing β -hexosaminidase from mast cells and basophils is an intracellular calcium concentration dependent process that is initiated by the cross-linking of Fc γ Rs with multivalent antigen.

[0208] One exemplary assay for characterizing the anti-Fc γ RIIB antibodies of the invention in mediating an IgE-mediated response is a β -hexosaminidase release assay comprising the following: transfecting RBL-H23 cells with human, Fc γ RIIB; sensitizing the cells with mouse IgE alone or with mouse IgE and an anti-Fc γ RIIB antibody of the invention; stimulating the cells with various concentrations of goat anti-mouse F(ab)₂, preferably in a range from 0.03 μ g/mL to 30 μ g/mL for about 1 hour; collecting the supernatant; lysing the cells; and measuring the β -hexosaminidase activity released in the supernatant by a colorometric assay, e.g., using p-nitrophenyl N-acetyl- β -D-glucosaminide. The released β -hexosaminidase activity is expressed as a percentage of the released activity to the total activity. The released β -hexosaminidase activity will be measured and compared in cells treated with antigen alone; IgE alone; IgE and an anti-Fc γ RIIB antibody of the invention. Although not intending to be bound by a particular mechanism of action, once cells are sensitized with mouse IgE alone and challenged with F(ab)₂ fragments of a polyclonal goat anti-mouse IgG, aggregation and cross linking of Fc γ RI occurs since the polyclonal antibody recognizes the light chain of the murine IgE bound to the Fc ϵ RI; which in turn leads to mast cell activation and degranulation. On the other hand, when cells are sensitized with mouse IgE and an anti-Fc γ RIIB antibody of the invention and challenged with F(ab)₂ fragments of a polyclonal goat anti-mouse IgG; cross linking of Fc γ RI and Fc γ RIIB occurs, resulting in inhibition of Fc γ RI induced degranulation. In either case, goat anti-mouse F(ab)₂ induces a dose-dependent β -hexoaminidase release. In some cases, the anti-Fc γ RIIB antibodies bound to the Fc γ RIIB receptor and cross linked to Fc γ RI do not affect the activation of the inhibitory pathway, i.e., there is no alteration in the level of degranulation in the presence of an anti-Fc γ RIIB antibody. In other embodiments, the anti-Fc γ RIIB antibodies mediate a stronger activation of the inhibitory receptor, Fc γ RIIB, when bound by the anti-Fc γ RIIB antibody, allowing effective cross linking to Fc γ RI and activation of the inhibitory pathway of homo-aggregated Fc γ RIIB.

[0209] Also disclosed is characterizing the effect of the anti-Fc γ RIIB antibodies of the invention on IgE-mediated cell response using calcium mobilization assays using methodologies known to one skilled in the art. An exemplary calcium mobilization assay may comprise the following: priming basophils or mast cells with IgE; incubating the cells with a calcium indicator, e.g., Fura 2; stimulating cells as described supra; and monitoring and/or quantitating intracellular calcium concentration for example by using flow cytometry. Monitoring and/or quantitating intracellular calcium concentration can be by any method known to one skilled in the art see, e.g., Immunology Letters, 2001, 75:185-9; British J. of Pharm, 2002, 136:837-45; J. of Immunology, 168:4430-9 and J. of Cell Biol., 153(2):339-49.

[0210] Preferably anti-Fc γ RIIB antibodies of the invention inhibit IgE-mediated cell activation. In other instances, the anti-Fc γ RIIB antibodies of the invention block the inhibitory pathways regulated by Fc γ RIIB or block the ligand binding site on Fc γ RIIB and thus enhance immune response.

[0211] The ability to study human mast cells has been limited by the absence of suitable long term human mast cell cultures. Recently two novel stem cell factor dependent human mast cell lines, designated LAD 1 and LAD2, were established from bone marrow aspirates from a patient with mast cell sarcoma/leukemia (Kirshenbaum et al., 2003, Leukemia research, 27:677-82). Both cell lines have been described to express Fc ϵ RI and several human mast cell markers. The invention encompasses using LAD 1 and 2 cells in the methods of the invention for assessing the effect of the antibodies of the invention on IgE-mediated responses. In a specific instance, cell-based β -hexosaminidase release assays such as those described supra may be used in LAD cells to determine any modulation of the IgE-mediated response by the anti-Fc γ RIIB antibodies of the invention. In an exemplary assay, human mast cells, e.g., LAD 1, are primed with chimeric human IgE anti-nitrophenol (NP) and challenged with BSA-NP, the polyvalent antigen, and cell degranulation is monitored by measuring the β -hexosaminidase released in the supernatant (Kirshenbaum et al., 2003, Leukemia research, 27:677-682).

[0212] If human mast cells have a low expression of endogenous Fc γ RIIB, as determined using standard methods known in the art, e.g., FACS staining, it may be difficult to monitor and/or detect differences in the activation of the inhibitory pathway mediated by the anti-Fc γ RIIB antibodies of the invention. There are also alternative methods, whereby the Fc γ RIIB expression may be upregulated using cytokines and particular growth conditions. Fc γ RIIB has been described to be highly up-regulated in human monocyte cell lines, e.g., THP1 and U937, (Tridandapani et al., 2002, J. Biol. Chem., 277(7): 5082-5089) and in primary human monocytes (Pricop et al., 2001, J. of Immunol., 166: 531-537) by IL4. Differentiation of U937 cells with dibutyryl cyclic AMP has been described to increase expression of Fc γ RII (Cameron et al., 2002 Immunology Letters 83, 171-179). Thus the endogenous Fc γ RIIB expression in human mast cells for use in the methods of the specification may be up-regulated using cytokines, e.g., IL-4, IL-13, in order to enhance sensitivity of detection.

[0213] The anti-Fc γ RIIB antibodies of the invention can be characterized for inhibition of B-cell receptor (BCR)-mediated signaling. BCR-mediated signaling can include at least one or more down stream biological responses, such as activation and proliferation of B cells, antibody production, etc. Coaggregation of Fc γ RIIB and BCR leads to inhibition of cell cycle progression and cellular survival. Further, coaggregation of Fc γ RIIB and BCR leads to inhibition of BCR-mediated signaling.

[0214] Specifically, BCR-mediated signaling comprises at least one or more of the following: modulation of down stream signaling molecules (e.g., phosphorylation state of Fc γ RIIB, SHIP recruitment, localization of Btk and/or PLC γ , MAP kinase activity, recruitment of Akt (anti-apoptotic signal), calcium mobilization, cell cycle progression, and cell proliferation).

[0215] Although numerous effector functions of Fc γ RIIB-mediated inhibition of BCR signaling are mediated through SHIP, recently it has been demonstrated that lipopolysaccharide (LPS)-activated B cells from SHIP deficient mice exhibit significant Fc γ RIIB-mediated inhibition of calcium mobilization, Ins(1,4,5)P₃ production, and Erk and Akt phosphorylation (Brauweiler A. et al., 2001, Journal of Immunology, 167(1): 204-211). Accordingly, ex vivo B cells from SHIP deficient mice can be used to characterize the antibodies of the invention. One exemplary assay for determining Fc γ RIIB-mediated inhibition of BCR signaling by the antibodies of the invention can comprise the following: isolating splenic B cells from SHIP deficient mice, activating said cells with lipopolysaccharide, and stimulating said cells with either F(ab')₂ anti-IgM to aggregate BCR or with anti-IgM to coaggregate BCR with Fc γ RIIB. Cells that have been stimulated with intact anti-IgM to coaggregate BCR with Fc γ RIIB can be further pre-incubated with the antibodies of the invention. Fc γ RIIB-dependent activity of cells can be measured by standard techniques known in the art. Comparing the level of Fc γ RIIB-dependent activity in cells that have been pre-incubated with the antibodies of the invention and cells that have not been pre-incubated, and comparing the levels would indicate a modulation of Fc γ RIIB-dependent activity by the antibodies of the invention.

[0216] Measuring Fc γ RIIB-dependent activity can include, for example, measuring intracellular calcium mobilization by flow cytometry, measuring phosphorylation of Akt and/or Erk, measuring BCR-mediated accumulation of PI(3,4,5)P₃, or measuring Fc γ RIIB-mediated proliferation B cells.

[0217] The assays can be used, for example, to identify antibodies that modulate Fc γ RIIB-mediated inhibition of BCR signaling by blocking the ligand (IgG) binding site to Fc γ RIIB receptor and antagonizing Fc γ RIIB-mediated inhibition of BCR signaling by preventing coaggregation of Fc γ RIIB and BCR. The assays can also be used to identify antibodies that enhance coaggregation of Fc γ RIIB and BCR and agonize Fc γ RIIB-mediated inhibition of BCR signaling.

[0218] Also discussed is characterizing the anti-Fc γ RIIB antibodies of the invention for Fc γ RII-mediated signaling in human

monocytes/macrophages. Coaggregation of Fc γ RIIB with a receptor bearing the immunoreceptor tyrosine-based activation motif (ITAM) acts to down-regulate Fc γ R-mediated phagocytosis using SHIP as its effector (Tridandapani et al. 2002, J. Biol. Chem. 277(7):5082-9). Coaggregation of Fc γ RIIA with Fc γ RIIB results in rapid phosphorylation of the tyrosine residue on Fc γ RIIB's ITIM motif, leading to an enhancement in phosphorylation of SHIP, association of SHIP with She, and phosphorylation of proteins having the molecular weight of 120 and 60-65 kDa. In addition, coaggregation of Fc γ RIIA with Fc γ RIIB results in down-regulation of phosphorylation of Akt, which is a serine-threonine kinase that is involved in cellular regulation and serves to suppress apoptosis.

[0219] Also included is characterizing the anti-Fc γ RIIB antibodies of the invention for their inhibition of Fc γ R-mediated phagocytosis in human monocytes/macrophages. For example, cells from a human monocytic cell line, THP-1 can be stimulated either with Fab fragments of mouse monoclonal antibody IV.3 against Fc γ RII and goat anti-mouse antibody (to aggregate Fc γ RIIA alone), or with whole IV.3 mouse monoclonal antibody and goat anti-mouse antibody (to coaggregate Fc γ RIIA and Fc γ RIIB). In this system, modulation of down stream signaling molecules, such as tyrosine phosphorylation of Fc γ RIIB, phosphorylation of SHIP, association of SHIP with She, phosphorylation of Akt, and phosphorylation of proteins having the molecular weight of 120 and 60-65 kDa can be assayed upon addition of antibodies of the invention to the stimulated cells. In addition, Fc γ RIIB-dependent phagocytic efficiency of the monocyte cell line can be directly measured in the presence and absence of the antibodies of the invention.

[0220] Another exemplary assay for determining inhibition of Fc γ R-mediated phagocytosis in human monocytes/macrophages by the antibodies of the invention can comprise the following: stimulating THP-1 cells with either Fab of IV.3 mouse anti-Fc γ RII antibody and goat anti-mouse antibody (to aggregate Fc γ RIIA alone and elicit Fc γ RIIA-mediated signaling); or with mouse anti-Fc γ RII antibody and goat anti-mouse antibody (to coaggregate Fc γ RIIA and Fc γ RIIB and inhibiting Fc γ RIIA-mediated signaling). Cells that have been stimulated with mouse anti-Fc γ RII antibody and goat anti-mouse antibody can be further pre-incubated with the antibodies of the invention. Measuring Fc γ RIIA-dependent activity of stimulated cells that have been pre-incubated with antibodies of the invention and cells that have not been pre-incubated with the antibodies of the invention and comparing levels of Fc γ RIIA-dependent activity in these cells would indicate a modulation of Fc γ RIIA-dependent activity by the antibodies of the invention.

[0221] The exemplary assay described can be used for example, to identify antibodies that block ligand binding of Fc γ RIIB receptor and antagonize Fc γ RIIB-mediated inhibition of Fc γ RIIA signaling by preventing coaggregation of Fc γ RIIB and Fc γ RIIA. This assay likewise identifies antibodies that enhance coaggregation of Fc γ RIIB and Fc γ RIIA and agonize Fc γ RIIB-mediated inhibition of Fc γ RIIA signaling.

[0222] The characterizing of the function of the antibodies of the invention by measuring the ability of THP-1 cells to phagocytose fluoresceinated IgG-opsonized sheep red blood cells (SRBC) is also disclosed by methods previously described (Tridandapani et al., 2000, J. Biol. Chem. 275: 20480-7). For example, an exemplary assay for measuring phagocytosis comprises of: treating THP-1 cells with the antibodies of the invention or with a control antibody that does not bind to Fc γ RII, comparing the activity levels of said cells, wherein a difference in the activities of the cells (e.g., resetting activity (the number of THP-1 cells binding IgG-coated SRBC), adherence activity (the total number of SRBC bound to THP-1 cells), and phagocytic rate) would indicate a modulation of Fc γ RIIA-dependent activity by the antibodies of the invention. This assay can be used to identify, for example, antibodies that block ligand binding of Fc γ RIIB receptor and antagonize Fc γ RIIB-mediated inhibition of phagocytosis. This assay can also identify antibodies that enhance Fc γ RIIB-mediated inhibition of Fc γ RIIA signaling.

[0223] In a preferred instance, the antibodies of the invention modulate Fc γ RIIB-dependent activity in human monocytes/macrophages in at least one or more of the following ways: modulation of downstream signaling molecules (e.g., modulation of phosphorylation state of Fc γ RIIB, modulation of SHIP phosphorylation, modulation of SHIP and She association, modulation of phosphorylation of Akt, modulation of phosphorylation of additional proteins around 120 and 60-65 kDa) and modulation of phagocytosis.

[0224] Characterization of the antibodies of the invention using assays known to those skilled in the art for identifying the effect of the antibodies on effector cell function of therapeutic antibodies, e.g., their ability to enhance tumor-specific ADCC activity of therapeutic antibodies is discussed. Therapeutic antibodies that may be used in accordance with the methods of the specification include but are not limited to anti-tumor antibodies, anti-viral antibodies, anti-microbial antibodies (e.g., bacterial and unicellular parasites), examples of which are disclosed herein (Section 5.4.6). In particular, the invention encompasses characterizing the antibodies of the invention for their effect on Fc γ R-mediated effector cell function of therapeutic antibodies, e.g., tumor-specific monoclonal antibodies. Examples of effector cell functions that can be assayed in accordance with the invention, include but are not limited to, antibody-dependent cell-mediated cytotoxicity, phagocytosis, opsonization, opsonophagocytosis, C1q binding, and complement dependent cell mediated cytotoxicity. Any cell-based or cell free assay known to those skilled in the art for

determining effector cell function activity can be used (For effector cell assays, see Perussia et al., 2000, *Methods Mol. Biol.* 121: 179-92; Baggolini et al., 1998 *Experientia*, 44(10): 841-8; Lehmann et al., 2000 *J. Immunol. Methods*, 243(1-2): 229-42; Brows EJ. 1994, *Methods Cell Biol.*, 45: 147-64; Munn et al., 1990 *J. Exp. Med.*, 172: 231-237, Abdul-Majid et al., 2002 *Scand. J. Immunol.* 55: 70-81; Ding et al., 1998, *Immunity* 8:403-411).

[0225] Antibodies of the invention can be assayed for their effect on Fc γ R-mediated ADCC activity of therapeutic antibodies in effector cells, e.g., natural killer cells, using any of the standard methods known to those skilled in the art (See e.g., Perussia et al., 2000, *Methods Mol. Biol.* 121: 179-92). "Antibody-dependent cell-mediated cytotoxicity" and "ADCC" as used herein carry their ordinary and customary meaning in the art and refer to an *in vitro* cell-mediated reaction in which nonspecific cytotoxic cells that express Fc γ Rs (e.g., monocytic cells such as Natural Killer (NK) cells and macrophages) recognize bound antibody on a target cell and subsequently cause lysis of the target cell. In principle, any effector cell with an activating Fc γ R can be triggered to mediate ADCC. The primary cells for mediating ADCC are NK cells which express only Fc γ RIII, whereas monocytes, depending on their state of activation, localization, or differentiation, can express Fc γ RI, Fc γ RII, and Fc γ RIII. For a review of Fc γ R expression on hematopoietic cells see, e.g., Ravetch et al., 1991, *Annu. Rev. Immunol.*, 9:457-92.

[0226] Effector cells are leukocytes which express one or more Fc γ Rs and perform effector functions. Preferably, the cells express at least Fc γ RIII and perform ADCC effector function. Effector cells that may be used in the methods of the specification include but are not limited to peripheral blood mononuclear cells (PBMC), natural killer (NK) cells, monocytes, and neutrophils; with PBMCs and NK cells being preferred. The effector cells may be isolated from a native source thereof, e.g., from blood or PBMCs as described herein. Preferably, the effector cells used in the ADCC assays of the specification are peripheral blood mononuclear cells (PBMC) that are preferably purified from normal human blood, using standard methods known to one skilled in the art, e.g., using Ficoll-Paque density gradient centrifugation. For example, PBMCs may be isolated by layering whole blood onto Ficoll-Hypaque and spinning the cells at 500g, at room temperature for 30 minutes. The leukocyte layer can be harvested as effector cells. Other effector cells that may be used in the ADCC assays of the invention include but are not limited to monocyte-derived macrophages (MDMs). MDMs that are used as effector cells in the methods of the specification, are preferably obtained as frozen stocks or used fresh, (e.g., from Advanced Biotechnologies, MD). In most preferred instances, elutriated human monocytes are used as effector cells in the methods of the specification. Elutriated human monocytes express activating receptors, Fc γ RIIA and Fc γ RIIA and the inhibitory receptor, Fc γ RIIB. Human monocytes are commercially available and may be obtained as frozen stocks, thawed in basal medium containing 10% human AB serum or in basal medium with human serum containing cytokines. Levels of expression of Fc γ Rs in the cells may be directly determined; e.g. using FACS analysis. Alternatively, cells may also be allowed to mature to macrophages in culture. The level of Fc γ RIIB expression may be increased in macrophages. Antibodies that may be used in determining the expression level of Fc γ Rs include but are not limited to antihuman Fc γ RIIA antibodies, e.g., IV.3-FITC; anti- Fc γ RI antibodies, e.g., 32.2 FITC; and anti- Fc γ RIIA antibodies, e.g., 3G8-PE.

[0227] Target cells used in the ADCC assays of the specification include, but are not limited to, breast cancer cell lines, e.g., SK-BR-3 with ATCC accession number HTB-30 (see, e.g., Tremp et al., 1976, *Cancer Res.* 33:41); B-lymphocytes; cells derived from Burkitts lymphoma, e.g., Raji cells with ATCC accession number CCL-86 (see, e.g., Epstein et al., 1965, *J. Natl. Cancer Inst.* 34: 231-240), Daudi cells with ATCC accession number CCL-213 (see, e.g., Klein et al., 1968, *Cancer Res.* 28: 1300-10); ovarian carcinoma cell lines, e.g., OVCAR-3 with ATCC accession number HTB-161 (see, e.g., Hamilton, Young et al., 1983), SK-OV-3, PA-1, CAOV3, OV-90, and IGROV-1 (available from the NCI repository Benard et al., 1985, *Cancer Research*, 45:4970-9. The target cells must be recognized by the antigen binding site of the antibody to be assayed. The target cells for use in the methods of the specification may have low, medium, or high expression level of a cancer antigen. The expression levels of the cancer antigen may be determined using common methods known to one skilled in the art, e.g., FACS analysis. For example, the specification encompasses the use of ovarian cancer cells such as IGROV-1, wherein Her2/neu is expressed at different levels, or OVCAR-3 (ATCC Assession Number HTB-161; characterized by a lower expression of Her2/neu than SK-BR-3, the breast carcinoma cell line). Other ovarian carcinoma cell lines that may be used as target cells in the methods of the specification include OVCAR-8 (Hamilton et al., 1983, *Cancer Res.* 43:5379-89); SK-OV-3 (ATCC Accession Number HTB-77); Caov-3 (ATCC Accession Number HTB-75); PA-1 (ATCC Accession Number CRL-1572); OV-90 (ATCC Accession Number CRL-11732); and OVCAR-4. Other breast cancer cell lines that may be used in the methods of the specification include BT-549 (ATCC Accession Number HTB-122), MCF7 (ATCC Accession Number HTB-22), and Hs578T (ATCC Accession Number HTB-126), all of which are available from the NCI repository and ATCC. Other cell lines that may be used in the methods of the specification include but are not limited to CCRF-CEM (leukemia); HL-60 (TB, leukemia); MOLT-4 (leukemia); RPMI-8226 (leukemia); SR (leukemia); A549 (Non-small cell lung); EKVX (Non-small cell lung); HOP-62 (Non-small cell lung); HOP-92 (Non-small cell lung); NC1-H226 (Non-small cell lung); NCI-H23 (Non-small cell lung); NCI-H322M (Non-small cell lung); NCI-H460 (Non-small cell lung); NCI-H522 (Non-small cell lung); COLO 205 (Colon); HCC-2998 (Colon); HCT-116 (Colon); HCT-15 (Colon); HT29 (Colon); KM12 (Colon); SW-620 (Colon); SF-268 (CNS); SF-295 (CNS); SF-539 (CNS); SNB-19 (CNS); SNB-75 (CNS); U251 (CNS); LOX 1MV1 (Melanoma); MALME-3M (Melanoma); M14 (Melanoma); SK-MEL-2 (Melanoma); SK-MEL-28 (Melanoma); SK-MEL-5 (Melanoma); UACC-257

(Melanoma); UACC-62 (Melanoma); IGR-OV1 (Ovarian); OVCAR-3, 4, 5, 8 (Ovarian); SK-OV-3 (Ovarian); 786-0 (Renal); A498 (Renal); ACHN (Renal); CAK1-1 (Renal); SN12C(Renal); TK-10 (Renal); UO-31 (Renal); PC-3C (Prostate); DU-145 (Prostate); NCI/ADR-RES (Breast); MDA-MB-231/ATCC (Breast); MDA-MB-435 (Breast); DMS 114 (Small-cell lung); and SHP-77 (Small-cell lung); all of which are available from the NCI.

[0228] An exemplary assay for determining the effect of the antibodies of the invention on the ADCC activity of therapeutic antibodies is based on a ^{51}Cr release assay comprising of: labeling target cells with $[^{51}\text{Cr}]\text{Na}_2\text{CrO}_4$ (this cell-membrane permeable molecule is commonly used for labeling since it binds cytoplasmic proteins and although spontaneously released from the cells with slow kinetics, it is released massively following target cell lysis); preferably, the target cells express one or more tumor antigens, opsonizing the target cells with one or more antibodies that immunospecifically bind the tumor antigens expressed on the cell surface of the target cells, in the presence and absence of an antibody of the invention, e.g., 8B5.3.4, combining the opsonized radiolabeled target cells with effector cells in a microtitre plate at an appropriate ratio of target cells to effector cells; incubating the mixture of cells preferably for 16-18 hours, preferably at 37°C; collecting supernatants; and analyzing the radioactivity in the supernatant samples. The cytotoxicity of the therapeutic antibodies in the presence and absence of the antibodies of the invention can then be determined, for example using the following formula: Percent specific lysis = (Experimental lysis-antibody-independent lysis/maximal lysis - antibody independent lysis) \times 100%. A graph can be generated by varying either the target: effector cell ratio or antibody concentration.

[0229] The antibodies of the invention can be characterized for antibody-dependent cell-mediated cytotoxicity (ADCC) in accordance with the method described earlier, see, e.g., Ding et al., *Immunity*, 1998, 8:403-11.

[0230] The antibodies of the invention can also be characterized for the function of enhancing ADCC activity of therapeutic antibodies in an *in vitro* based assay and/or in an animal model.

[0231] Also included is determining the function of the antibodies of the invention in enhancing tumor specific ADCC using an ovarian cancer model and/or breast cancer model.

[0232] Preferably, the ADCC assays are done using more than one cancer cell line, characterized by the expression of at least one cancer antigen, wherein the expression level of the cancer antigen is varied among the cancer cell lines used. Although not intending to be bound by a particular mechanism of action, performing ADCC assays in more than one cell line wherein the expression level of the cancer antigen is varied, will allow determination of stringency of tumor clearance of the antibodies of the invention. In one embodiment, the ADCC assays are done using cancer cell lines with different levels of expression of a cancer antigen.

[0233] In an exemplary assay, OVCAR3, an ovarian carcinoma cell line can serve as the tumor target expressing the tumor antigens, Her2/neu and TAG-72; human monocytes, that express the activating Fc γ RIIIA and Fc γ RIIA and inhibitory Fc γ RIIB, can be used as effectors; and tumor specific murine antibodies, ch4D5 and chCC49, can be used as the tumor specific antibodies. OVCAR-3 cells are available from ATCC (Accession Number HTB-161). Preferably, OVCAR-3 cells are propagated in medium supplemented with 0.01 mg/ml bovine insulin. 5×10^6 viable OVCAR-3 cells may be injected subcutaneously (s.c.) into age and weight matched nude athymic mice with Matrigel (Becton Dickinson). The estimated weight of the tumor can be calculated by the formula: length-(width) $^2/2$, and preferably does not exceed 3 grams. Anchorage-dependent tumor can be isolated after 6-8 weeks, and the cells can be dissociated by adding 1 μ g of Collagenase (Sigma) per gram of tumor and a 5 mg/mL RNase, passed through a cell strainer and nylon mesh to isolate cells. Cells can then be frozen for long-term storage for s.c. injection for establishment of the xenograft model.

[0234] Hybridomas secreting CC49 and 4D5 antibodies are available with ATCC Accession Numbers HB-9459 and CRL-3D463 and the heavy chain and light chain nucleotide sequences are in the public domain (Murray et al., 1994 *Cancer* 73 (35):1057-66, Yamamoto et al., 1986 *Nature*, 319:230-4). Preferably, the 4D5 and CC49 antibodies are chimerized using standard methods known to one skilled in the art so that the human Fc sequence, e.g., human constant region of IgG1, is grafted onto the variable region of the murine antibodies in order to provide the effector function. The chimeric 4D5 and CC49 antibodies bind via their variable region to the target cell lines and via their Fc region to Fc γ Rs expressed on human effector cells. CC49 is directed to TAG-72; a high molecular weight mucin that is highly expressed on many adenocarcinoma cells and ovarian carcinoma (Lottich et al., 1985 *Breast Cancer Res. Treat.* 6(1):49-56; Mansi et al., 1989 *Int. J. Rad. Appl. Instrum. B.* 16(2):127-35; Colcher et al., 1991 *Int. J. Rad. Appl. Instrum. B.* 18:395-41). The 4D5 antibody is directed to human epidermal growth factor receptor 2 (Carter et al., 1992, *Proc. Natl. Acad. Sci. USA*, 89: 4285-9). Antibodies of the invention can then be utilized to investigate the enhancement of ADCC activity of the tumor specific antibodies, by blocking the inhibitory Fc γ RIIB. Although not intending to be bound by a particular mechanism of action, upon activation of effector cells that express at least one activating Fc γ R, e.g., Fc γ RIIA, the

expression of the inhibitory receptor (Fc_YRIIB) is enhanced and this limits the clearance of tumors as the ADCC activity of Fc_YRIIA is suppressed. However, antibodies of the invention can serve as a blocking antibody, *i.e.*, an antibody that will prevent the inhibitory signal from being activated and thus the activation signal, *e.g.*, ADCC activity, will be sustained for a longer period and may result in potent tumor clearance.

[0235] Preferably, the antibodies of the specification for use in enhancement of ADCC activity have been modified to comprise at least one amino acid modification, so that their binding to Fc_YR has been diminished, most preferably abolished. In some instances, the antibodies of the specification have been modified to comprise at least one amino acid modification which reduces the binding of the constant domain to an activating Fc_YR, *e.g.*, Fc_YRIIA, Fc_YRIIB, as compared to a wild type antibody of the specification while retaining maximal Fc_YRIIB blocking activity. Antibodies of the specification may be modified in accordance with any method known to one skilled in the art or disclosed herein. Any amino acid modification which is known to disrupt effector function may be used in accordance with the methods of the specification such as those disclosed in U.S. Publication

[0236] Nos. US2005/0037000 (filed January 9, 2004) and US2005/0064514 (filed July 28, 2004). In some instances, antibodies of the specification are modified so that position 265 is modified, *e.g.*, position 265 is substituted with alanine. In preferred instances, the murine constant region of an antibody of the specification is swapped with the corresponding human constant region comprising a substitution of the amino acid at position 265 with alanine, so that the effector function is abolished while Fc_YRIIB blocking activity is maintained. A single amino acid change at position 265 of IgG1 heavy chain has been shown to significantly reduce binding to Fc_YR based on ELISA assays, Sheilds et al., 2001, *J. Biol. Chem.*, 276(9):6591-604 and has resulted in tumor mass reduction. In other instances, antibodies of the specification are modified so that position 297 is modified, *e.g.*, position 297 is substituted with glutamine, so that the N-linked glycosylation site is eliminated (see, *e.g.*, Jefferies et al., 1995, *Immunol. Lett.* 44:111-7; Lund et al., 1996, *J. Immunol.*, 157:4963-69; Wright et al., 1994, *J. Exp. Med.* 180:1087-96; White et al., 1997; *J. Immunol.* 158:426-35. Modification at this site has been reported to abolish all interaction with Fc_YRs. In preferred instances, the murine constant region of an antibody of the specification is swapped with the corresponding human constant region comprising a substitution of the amino acid at position 265 and/or 297, so that the effector function is abolished while Fc_YRIIB blocking activity is maintained.

[0237] An exemplary assay for determining the ADCC activity of the tumor specific antibodies in the presence and absence of the antibodies of the invention is a non-radioactive europium based fluorescent assay (BATDA, Perkin Elmer) and may comprise the following: labeling the targets cells with an acteoxymethyl ester of fluorescence-enhancing ester that forms a hydrophilic ligand (TDA) with the membrane of cells by hydrolysis of the esters; this complex is unable to leave the cell and is released only upon lysis of the cell by the effectors; adding the labeled targets to the effector cells in presence of anti-tumor antibodies and an antibody of the invention; incubating the mixture of the target and effector cells a for 6 to 16 hours, preferably at 37 °C. The extent of ADCC activity can be assayed by measuring the amount of ligand that is released and interacts with europium (DELFIA reagent; PerkinElmer). The ligand and the europium form a very stable and highly fluorescent chelate (EuTDA) and the measured fluorescence is directly proportional to the number of cells lysed. Percent specific lysis can be calculated using the formula: (Experimental lysis-antibody-independent lysis/maximal lysis antibody-independent lysis x 100%).

[0238] In some embodiments, if the sensitivity of the fluorescence-based ADCC assay is too low to detect ADCC activity of the therapeutic antibodies, the invention encompasses radioactive-based ADCC assays, such as ⁵¹Cr release assay. Radioactive-based assays may be done instead of or in combination with fluorescent-based ADCC assays.

[0239] An exemplary ⁵¹Cr release assay for characterizing the antibodies of the invention can comprise the following: labeling 1-2 x10⁶ target cells such as OVCAR-3 cells with ⁵¹Cr; opsonizing the target cells with antibodies 4D5 and CC49 in the presence and absence of an antibody of the invention and adding 5 x 10³ cells to 96 well plate. Preferably 4D5 and CC49 are at a concentration varying from 1-15 µg/mL; adding the opsonized target cells to monocyte-derived macrophages (MDM) (effector cells); preferably at a ratio varying from 10:1 to 100:1; incubating the mixture of cells for 16-18 hours at 37°C; collecting supernatants; and analyzing the radioactivity in the supernatant. The cytotoxicity of 4D5 and CC49 in the presence and absence of an antibody of the invention can then be determined, for example using the following formula percent specific lysis = (experimental lysis - antibody independent lysis/maximal lysis - antibody independent lysis) x 100%.

[0240] The *in vivo* activity of the Fc_YRIIB antibodies can be determined in xenograft human tumor models. Tumors may be established using any of the cancer cell lines described supra. In some instances, the tumors will be established with two cancer cell lines, wherein the first cancer cell line is characterized by a low expression of a cancer antigen and a second cancer cell line, wherein the second cancer cell line is characterized by a high expression of the same cancer antigen. Tumor clearance may then be determined using methods known to one skilled in the art, using an anti-tumor antibody which immunospecifically binds the cancer antigen on the first and second cancer cell line, and an appropriate mouse model, *e.g.*, a Balb/c nude mouse model (*e.g.*,

Jackson Laboratories, Taconic), with adoptively transferred human monocytes and MDMs as effector cells. Any of the antibodies described supra may then be tested in this animal model to evaluate the role of anti-Fc γ RIIB antibody of the invention in tumor clearance. Mice that may be used include for example Fc γ RIII -/- (where Fc γ RIIIA is knocked out); Fc γ /- nude mice (where Fc γ RI and Fc γ RIIIA are knocked out); or human Fc γ RIIB knock in mice or a transgenic knock-in mice, where mouse fcgr2 and fcgr3 loci on chromosome 1 are inactivated and the mice express human Fc γ RIIA, human Fc γ RIIA human Fc γ RIIB, human Fc γ RIIC, human Fc γ RIIIA, and human Fc γ RIIB.

[0241] An exemplary method for testing the *in vivo* activity of an antibody of the invention may comprise the following: establishing a xenograft murine model using a cancer cell line characterized by the expression of a cancer antigen and determining the effect of an antibody of the invention on an antibody specific for the cancer antigen expressed in the cancer cell line in mediating tumor clearance. Preferably, the *in vivo* activity is tested parallel using two cancer cell lines, wherein the first cancer cell line is characterized by a first cancer antigen expressed at low levels and a second cancer cell line, characterized by the same cancer antigen expressed at a higher level relative to the first cancer cell line. These experiments will thus increase the stringency of the evaluation of the role of an antibody of the invention in tumor clearance. For example, tumors may be established with the IGROV-1 cell line and the effect of an anti-Fc γ RIIB antibody of the invention in tumor clearance of a Her2/neu specific antibody may be assessed. In order to establish the xenograft tumor models, 5x10⁶ viable cells, e.g., IGROV-1, SKBR3, may be injected, e.g., s.c. into mice, e.g., 8 age and weight matched female nude athymic mice using for example Matrigel (Becton Dickinson). The estimated weight of the tumor may be determined by the formula: length x (width)²/2; and preferably does not exceed 3 grams. Injection of IGROV-1 cells s.c. gives rise to fast growing tumors while the i.p. route induces a peritoneal carcinomatosis which kills mice in 2 months (Benard et al., 1985, Cancer Res. 45:4970-9). Since the IGROV-1 cells form tumors within 5 weeks, at day 1 after tumor cell injection, monocytes as effectors are co-injected i.p. along with a therapeutic antibody specific for Her2/neu, e.g., Ch4D5, and an antibody of the invention; e.g. chimeric 8B5.3.4 antibody ("ch8B5.3.4") as described supra. Preferably, the antibodies are injected at 4 μ g each per gram of mouse body weight (mbw). The initial injection will be followed by weekly injections of antibodies for 4-6 weeks thereafter at 2 μ g/wk. Human effector cells will be replenished once in 2 weeks. A group of mice will receive no therapeutic antibody but will be injected with a chimeric 4D5 comprising a N297A mutation and human IgG 1 as isotype control antibodies for the anti-tumor and anti- Fc γ RIIB antibodies, respectively. Mice may be placed in groups of 4 and monitored three times weekly.

[0242] Table 5 below is an exemplary setup for tumor clearance studies in accordance with the invention. As shown in Table 5, six groups of 8 mice each will be needed for testing the role of an antibody of the invention in tumor clearance, wherein one target and effector cell combination is used and wherein two different combinations of the antibody concentration are used. In group A, only tumor cells are injected; in group B tumor cells and monocytes are injected; in group C, tumor cells, monocytes, an anti-tumor antibody (ch4D5) are injected; in group D, tumor cells, monocytes, anti-tumor antibody, and an anti-Fc γ RII antibody are injected; in group E, tumor cells, monocytes and an anti-Fc γ RIIB antibody are injected; in group F, tumor cells, monocytes, Ch4D5 (N297Q), and human IgG1 are injected. It will be appreciated by one skilled in the art that various antibody concentrations of various antibody combinations may be tested in the tumor models described. Preferably, studies using a breast cancer cell line, e.g., SKBR3, is carried out in parallel to the above-described experiment.

TABLE 5 EXEMPLARY EXPERIMENTAL SET UP IN MICE

8 mice/group	Tumor cell s.c day 0	Monocytes i.p at day 1	ch4D5 at 4 μ g/gm of mbw day 1 i.p	ch4D5 N297Q at 4 μ g/gm of mbw day 1 i.p	ch8B5.3.4 N297Q at 4 μ g/gm of mbw day 1 i.p	Human IgG 1 4 μ g/gm of mbw day 1 i.p
A	+	-		-	-	-
B	+	+	-	-	-	-
C	+	+	+	-	-	-
D	+	+	+	-	+	-
E	+	+	-	-	+	-
F	+	+	-	+	-	+

[0243] The endpoint of the xenograft tumor models is determined based on the size of the tumors, weight of mice, survival time and histochemical and histopathological examination of the cancer, using methods known to one skilled in the art. Each of the groups of mice in Table 5 will be evaluated. Mice are preferably monitored three times a week. Criteria for tumor growth may be abdominal distention, presence of palpable mass in the peritoneal cavity. Preferably estimates of tumor weight versus days after inoculation will be calculated. A comparison of the aforementioned criteria of mice in Group D compared to those in other groups will define the role of an antibody of the invention in enhancement of tumor clearance. Preferably, antibody-treated animals will be

under observation for an additional 2 months after the control group.

[0244] In alternative examples, human Fc γ RIIB "knock in" mice expressing human Fc β RIIB on murine effector cells may be used in establishing the *in vivo* activity of the antibodies of the invention, rather than adoptively transferring effector cells. Founder mice expressing the human Fc γ RIIB may be generated by "knocking in" the human Fc γ RIIB onto the mouse Fc γ RIIB locus. The founders can then be back-crossed onto the nude background and will express the human Fc γ RIIB receptor. The resulting murine effector cells will express endogenous activating Fc γ RI and Fc γ RIIA and inhibitory human Fc γ RIIB receptors.

[0245] The *in vivo* activity of the antibodies of the invention may be further tested in a xenograft murine model with human primary tumor derived cells, such as human primary ovarian and breast carcinoma derived cells. Ascites and pleural effusion samples from cancer patients may be tested for expression of Her2/neu, using methods known to one skilled in the art. Samples from ovarian carcinoma patients may be processed by spinning down the ascites at 6370g for 20 minutes at 4°C, lysing the red blood cells, and washing the cells with PBS. Once the expression of Her2/neu in tumor cells is determined, two samples, a median and a high expressor may be selected for s.c. inoculation to establish the xenograft tumor model. The isolated tumor cells will then be injected i.p. into mice to expand the cells. Approximately 10 mice may be injected i.p. and each mouse ascites further passaged into two mice to obtain ascites from a total of 20 mice which can be used to inject a group of 80 mice. Pleural effusion samples may be processed using a similar method as ascites. The Her2/neu+ tumor cells from pleural effusion samples may be injected into the upper right & left mammary pads of the mice.

[0246] In some examples, if the percentage of neoplastic cells in the ascites or pleural effusion samples is low compared to other cellular subsets, the neoplastic cells may be expanded *in vitro*. In other examples, tumor cells may be purified using CC49 antibody (anti-TAG-72)-coated magnetic beads as described previously, see, e.g., Barker et al., 2001, Gynecol. Oncol. 82:57, 63. Briefly, magnetic beads coated with CC49 antibody can be used to separate the ovarian tumor cells that will be detached from the beads by an overnight incubation at 37°C. In some embodiments, if the tumor cells lack the TAG-72 antigen, negative depletion using a cocktail of antibodies, such as those provided by Stem Cell Technologies, Inc., Canada, may be used to enrich the tumor cells.

[0247] Other tumors markers besides Her2/neu may be used to separate tumor cells obtained from the ascites and pleural effusion samples from non-tumor cells. In the case of pleural effusion or breast tissue, it has been recently reported that CD44 (an adhesion molecule), B38.1(a breast/ovarian cancer-specific marker), CD24 (an adhesion molecule) may be used as markers, see, e.g., Al Hajj, et al., 2003, Proc. Natl. Acad. Sci. USA 100:3983, 8. Once tumor cells are purified they may be injected s.c. into mice for expansion.

[0248] Preferably, immunohistochemistry and histochemistry is performed on ascites and pleural effusion of patients to analyze structural characteristics of the neoplasia. Such methods are known to one skilled in the art and encompassed within the invention. The markers that may be monitored include for example cytokeratin (to identify ovarian neoplastic and mesothelial cells from inflammatory and mesenchymal cells); calretinin (to separate mesothelial from Her2neu positive neoplastic cells); and CD45 (to separate inflammatory cells from the rest of the cell population in the samples). Additional markers that may be followed include CD3 (T cells), CD20 (B cells), CD56 (NK cells), and CD 14 (monocytes). It will be appreciated by one skilled in the art that the immunohistochemistry and histochemistry methods described supra, are analogously applied to any tumor cell for use in the methods of the invention. After s.c. inoculation of tumor cells, mice are followed for clinical and anatomical changes. As needed, mice may be necropsied to correlate total tumor burden with specific organ localization.

[0249] In a specific example, tumors are established using carcinoma cell lines such as IGROV-1, OVCAR-8, SK-B, and OVCAR-3 cells and human ovarian carcinoma ascites and pleural effusion from breast cancer patients. The ascites preferably contain both the effectors and the tumor targets for the antibodies being tested. Human monocytes will be transferred as effectors.

[0250] The *in vivo* activity of the antibodies of the invention may also be tested in an animal model, e.g., Balb/c nude mice, injected with cells expressing Fc γ RIIB, including but not limited to SK-BR-3 with ATCC accession number HTB-30 (see, e.g., Tremp et al., 1976, Cancer Res. 33:41); B-lymphocytes; cells derived from Burkitts lymphoma, e.g., Raji cells with ATCC accession number CCL-86 (see, e.g., Epstein et al., 1965, J. Natl. Cancer Inst. 34: 231-240), Daudi cells with ATCC accession number CCL-213 (see, e.g., Klein et al., 1968, Cancer Res. 28: 1300-10); ovarian carcinoma cell lines, e.g., OVCAR-3 with ATCC accession number HTB-161 (see, e.g., Hamilton, Young et al., 1983), SK-OV-3, PA-1, CAOV3, OV-90, and IGROV-1 (available from the NCI repository Benard et al., 1985, Cancer Research, 45:4970-9).

[0251] An exemplary assay for measuring the *in vivo* activity of the antibodies of the invention may comprise the following: Balb/c Nude female mice (Taconic, MD) are injected at day 0 with cells expressing Fc γ RIIB such as 5×10^6 Daudi cells for example by the

subcutaneous route. Mice (e.g., 5 mice per group) also receive i.p. injection of PBS (negative control), ch 4.4.20 (anti-FITC antibody) as a negative control, and as a positive control another therapeutic cancer antibody such as those disclosed herein, e.g., Rituxan, (e.g., at 10 µg/g) or 10 µg/g ch8B5.3.4 once a week starting at day 0. Mice are observed, e.g., twice a week following injection, and tumor size (length and width) is determined using for example a caliper. Tumor weight in mg is estimated using the formula: (length x width²)/2.

[0252] Preferably, the antibodies of the invention have an enhanced efficacy in decreasing tumor relative to a cancer therapeutic antibody when administered at the same dose, e.g., 10 µg /g, over a time period of at least 14 days, at least 21 days, at least 28 days, or at least 35 days. In most preferred instances, the antibodies of the invention reduce tumor size by at least 10 fold, at least 100 fold, at least 1000 fold relative to administration of a cancer therapeutic antibody at the same dose. In yet another preferred instance, the antibodies of the invention completely abolish the tumor.

5.3.1 POLYNUCLEOTIDES ENCODING AN ANTIBODY

[0253] The present specification also includes polynucleotides that encode the antibodies of the specification (e.g., mouse monoclonal antibody produced from hybridoma clone 8B5.3.4, 2B6, 3H7, 1D5, 2E1, 2H9, 2D11, or 1F2 having ATCC accession numbers PTA-7610, PTA-4591, PTA-4592, PTA-5958, PTA-5961, PTA-5962, PTA-5960, and PTA-5959, respectively), or other monoclonal antibodies produced by immunization methods of the specification, and humanized versions thereof, and methods for producing same.

[0254] The present specification encompass the polynucleotide encoding the variable heavy chain of the 8B5.3.4 antibody, with ATCC accession number PTA-7610, as disclosed in SEQ ID NO: 2. The present specification also encompasses the polynucleotide encoding the variable light chain of the 8B5.3.4 antibody with ATCC accession number PTA-7610, as disclosed in SEQ ID NO: 1.

[0255] The methods of the specification also encompass polynucleotides that hybridize under various stringency, e.g., high stringency, intermediate or lower stringency conditions, to polynucleotides that encode an antibody of the invention. The hybridization can be performed under various conditions of stringency. By way of example and not limitation, procedures using conditions of low stringency are as follows (see also Shilo and Weinberg, 1981, Proc. Natl. Acad. Sci. U.S.A. 78, 6789-6792). Filters containing DNA are pretreated for 6 h at 40°C in a solution containing 35% formamide, 5X SSC, 50 mM Tris-HCl (pH 7.5), 5 mM EDTA, 0.1% PVP, 0.1% Ficoll, 1% BSA, and 500 µg/ml denatured salmon sperm DNA. Hybridizations are carried out in the same solution with the following modifications: 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100 µg/ml salmon sperm DNA, 10% (wt/vol) dextran sulfate, and 5-20 X 10⁶ cpm ³²P-labeled probe is used. Filters are incubated in hybridization mixture for 18-20 h at 40°C, and then washed for 1.5 h at 55°C in a solution containing 2X SSC, 25 mM Tris-HCl (pH 7.4), 5 mM EDTA, and 0.1% SDS. The wash solution is replaced with fresh solution and incubated an additional 1.5 h at 60°C. Filters are blotted dry and exposed for autoradiography. If necessary, filters are washed for a third time at 65-68°C and re-exposed to film. Other conditions of low stringency which may be used are well known in the art (e.g., as employed for cross-species hybridizations). By way of example and not limitation, procedures using conditions of high stringency are as follows. Prehybridization of filters containing DNA is carried out for 8 h to overnight at 65°C in buffer composed of 6X SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 µg/ml denatured salmon sperm DNA. Filters are hybridized for 48 h at 65°C in prehybridization mixture containing 100 µg/ml denatured salmon sperm DNA and 5-20 X 10⁶ cpm of ³²P-labeled probe. Washing of filters is done at 37°C for 1 h in a solution containing 2X SSC, 0.01% PVP, 0.01% Ficoll, and 0.01% BSA. This is followed by a wash in 0.1X SSC at 50°C for 45 min before autoradiography. Other conditions of high stringency which may be used are well known in the art. Selection of appropriate conditions for such stringencies is well known in the art (see e.g., Sambrook et al., 1989, Molecular Cloning, A Laboratory Manual, 2d Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York; see also, Ausubel et al., eds., in the Current Protocols in Molecular Biology series of laboratory technique manual, © 1987-1997, Current Protocols, © 1994-1997 John Wiley and Sons, Inc.; see especially, Dyson, 1991, "Immobilization of nucleic acids and hybridization analysis," In: Essential Molecular Biology: A Practical Approach, Vol. 2, T.A. Brown, ed., pp. 111-156, IRL Press at Oxford University Press, Oxford, UK).

[0256] The polynucleotides may be obtained, and the nucleotide sequence of the polynucleotides determined, by any method known in the art.

[0257] A polynucleotide encoding an antibody may be generated from nucleic acid from a suitable source (e.g., a cDNA library generated from, or nucleic acid, preferably poly A+ RNA, isolated from, any tissue or cells expressing the antibody, such as hybridoma cells selected to express an antibody of the invention, e.g., 8B5.3.4) by hybridization with Ig specific probes and/or PCR amplification using synthetic primers hybridizable to the 3' and 5' ends of the sequence or by cloning using an

oligonucleotide probe specific for the particular gene sequence to identify, e.g., a cDNA clone from a cDNA library that encodes the antibody. Amplified nucleic acids generated by PCR may then be cloned into replicable cloning vectors using any method well known in the art.

[0258] Once the nucleotide sequence of the antibody is determined, the nucleotide sequence of the antibody may be manipulated using methods well known in the art for the manipulation of nucleotide sequences, e.g., recombinant DNA techniques, site directed mutagenesis, PCR, etc. (see, for example, the techniques described in Sambrook et al., 1990, Molecular Cloning, A Laboratory Manual, 2d Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY and Ausubel et al., eds., 1998, Current Protocols in Molecular Biology, John Wiley & Sons, NY), to generate antibodies having a different amino acid sequence, for example to create amino acid substitutions, deletions, and/or insertions.

[0259] In a specific instance, one or more of the CDRs are inserted within framework regions using routine recombinant DNA techniques. The framework regions may be naturally occurring or consensus framework regions, and preferably human framework regions (see, e.g., Chothia et al., 1998, *J. Mol. Biol.* 278: 457-479 for a listing of human framework regions). Preferably, the polynucleotide generated by the combination of the framework regions and CDRs encodes an antibody that specifically binds to Fc_YRIIB with greater affinity than said antibody binds Fc_YRIIA. Preferably, as discussed supra, one or more amino acid substitutions may be made within the framework regions, and, preferably, the amino acid substitutions improve binding of the antibodies of the invention to Fc_YRIIB.

[0260] In another instance, human libraries or any other libraries available in the art, can be screened by standard techniques known in the art, to clone the nucleic acids encoding the antibodies of the invention.

5.3.2 RECOMBINANT EXPRESSION OF ANTIBODIES

[0261] Once a nucleic acid sequence encoding an antibody of the invention has been obtained, the vector for the production of the antibody may be produced by recombinant DNA technology using techniques well known in the art. Methods which are well known to those skilled in the art can be used to construct expression vectors containing the antibody coding sequences and appropriate transcriptional and translational control signals. These methods include, for example, *in vitro* recombinant DNA techniques, synthetic techniques, and *in vivo* genetic recombination. (See, for example, the techniques described in Sambrook et al., 1990, Molecular Cloning, A Laboratory Manual, 2d Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY and Ausubel et al. eds., 1998, Current Protocols in Molecular Biology, John Wiley & Sons, NY).

[0262] An expression vector comprising the nucleotide sequence of an antibody can be transferred to a host cell by conventional techniques (e.g., electroporation, liposomal transfection, and calcium phosphate precipitation) and the transfected cells are then cultured by conventional techniques to produce the antibody of the invention. In specific instances, the expression of the antibody is regulated by a constitutive, an inducible or a tissue, specific promoter.

[0263] The host cells used to express the recombinant antibodies of the invention may be either bacterial cells such as *Escherichia coli*, or, preferably, eukaryotic cells, especially for the expression of whole recombinant immunoglobulin molecule. In particular, mammalian cells such as Chinese hamster ovary cells (CHO), in conjunction with a vector such as the major intermediate early gene promoter element from human cytomegalovirus is an effective expression system for immunoglobulins (Foecking et al., 1998, *Gene* 45:101; Cockett et al., 1990, *Bio/Technology* 8:2).

[0264] A variety of host-expression vector systems may be utilized to express the antibodies of the invention. Such host-expression systems represent vehicles by which the coding sequences of the antibodies may be produced and subsequently purified, but also represent cells which may, when transformed or transfected with the appropriate nucleotide coding sequences, express the antibodies of the invention *in situ*. These include, but are not limited to, microorganisms such as bacteria (e.g., *E. coli* and *B. subtilis*) transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing immunoglobulin coding sequences; yeast (e.g., *Saccharomyces Pichia*) transformed with recombinant yeast expression vectors containing immunoglobulin coding sequences; insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus) containing the immunoglobulin coding sequences; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus (CaMV) and tobacco mosaic virus (TMV)) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing immunoglobulin coding sequences; or mammalian cell systems (e.g., COS, CHO, BHK, 293, 293T, 3T3 cells, lymphotic cells (see U.S. 5,807,715), Per C.6 cells (rat retinal cells developed by Crucell)) harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the adenovirus late promoter; the vaccinia virus 7.5K promoter).

[0265] In bacterial systems, a number of expression vectors may be advantageously selected depending upon the use intended for the antibody being expressed. For example, when a large quantity of such a protein is to be produced, for the generation of pharmaceutical compositions of an antibody, vectors which direct the expression of high levels of fusion protein products that are readily purified may be desirable. Such vectors include, but are not limited, to the *E. coli* expression vector pUR278 (Ruther et al., 1983, EMBO J. 2:1791), in which the antibody coding sequence may be ligated individually into the vector in frame with the lac Z coding region so that a fusion protein is produced; pIN vectors (Inouye & Inouye, 1985, Nucleic Acids Res. 13 :3101-3109; Van Heeke & Schuster, 1989, J. Biol. Chem. 24:5503-5509). pGEX vectors may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption and binding to a matrix glutathione-agarose beads followed by elution in the presence of free glutathione. The pGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned target gene product can be released from the GST moiety.

[0266] In an insect system, *Autographa californica* nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes. The virus grows in *Spodoptera frugiperda* cells. The antibody coding sequence may be cloned individually into non-essential regions (e.g., the polyhedrin gene) of the virus and placed under control of an AcNPV promoter (e.g., the polyhedrin promoter).

[0267] In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, the antibody coding sequence of interest may be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric gene may then be inserted in the adenovirus genome by *in vitro* or *in vivo* recombination. Insertion in a non-essential region of the viral genome (e.g., region E1 or E3) will result in a recombinant virus that is viable and capable of expressing the immunoglobulin molecule in infected hosts. (e.g., see Logan & Shenk, 1984, Proc. Natl. Acad. Sci. USA 81:355-359). Specific initiation signals may also be required for efficient translation of inserted antibody coding sequences. These signals include the ATG initiation codon and adjacent sequences. Furthermore, the initiation codon must be in phase with the reading frame of the desired coding sequence to ensure translation of the entire insert. These exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements, transcription terminators, etc. (see Bittner et al., 1987, Methods in Enzymol. 153:51-544).

[0268] In addition, a host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (e.g., glycosylation) and processing (e.g., cleavage) of protein products may be important for the function of the protein. Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins and gene products. Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed. To this end, eukaryotic host cells which possess the cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of the gene product may be used. Such mammalian host cells include but are not limited to CHO, VERY, BHK, HeLa, COS, MDCK, 293, 293T, 3T3, WI38, BT483, Hs578T, HTB2, BT20 and T47D, CRL7030 and Hs578Bst.

[0269] For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express an antibody of the invention may be engineered. Rather than using expression vectors which contain viral origins of replication, host cells can be transformed with DNA controlled by appropriate expression control elements (e.g., promoter, enhancer, sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker. Following the introduction of the foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines. This method may advantageously be used to engineer cell lines which express the antibodies of the invention. Such engineered cell lines may be particularly useful in screening and evaluation of compounds that interact directly or indirectly with the antibodies of the invention.

[0270] A number of selection systems may be used, including but not limited to the herpes simplex virus thymidine kinase (Wigler et al., 1977, Cell 11:223), hypoxanthine-guanine phosphoribosyltransferase (Szybalska & Szybalski, 1992, Proc. Natl. Acad. Sci. USA 89:202), and adenine phosphoribosyltransferase (Lowy et al., 1980, Cell 22:817) genes can be employed in tk-, hprt- or aprt- cells, respectively. Also, antimetabolite resistance can be used as the basis of selection for the following genes: dhfr, which confers resistance to methotrexate (Wigler et al., 1980, Proc. Natl. Acad. Sci. USA 77:357 ; O'Hare et al., 1981, Proc. Natl. Acad. Sci. USA 78:1527); gpt, which confers resistance to mycophenolic acid (Mulligan & Berg, 1981, Proc. Natl. Acad. Sci. USA 78:2072); neo, which confers resistance to the aminoglycoside G-418 Clinical Pharmacy 12:488-505; Wu and Wu, 1991, 3:87-95; Tolstoshev, 1993, Ann. Rev. Pharmacol. Toxicol. 32:573-596 ; Mulligan, 1993, Science 260:926-932; and Morgan and Anderson,

1993, Ann. Rev. Biochem. 62:191-217; May, 1993, TIB TECH 11(5):155-215). Methods commonly known in the art of recombinant DNA technology which can be used are described in Ausubel et al. (eds.), 1993, Current Protocols in Molecular Biology, John Wiley & Sons, NY; Kriegler, 1990, Gene Transfer and Expression, A Laboratory Manual, Stockton Press, NY; and in Chapters 12 and 13, Dracopoli et al. (eds), 1994, Current Protocols in Human Genetics, John Wiley & Sons, NY.; Colberre-Garapin et al., 1981, J. Mol. Biol. 150:1; and hygro, which confers resistance to hygromycin (Santerre et al., 1984, Gene 30:147).

[0271] The expression levels of an antibody of the invention can be increased by vector amplification (for a review, see Bebbington and Hentschel, The use of vectors based on gene amplification for the expression of cloned genes in mammalian cells in DNA cloning, Vol.3. (Academic Press, New York, 1987)). When a marker in the vector system expressing an antibody is amplifiable, increase in the level of inhibitor present in culture of host cell will increase the number of copies of the marker gene. Since the amplified region is associated with the nucleotide sequence of the antibody, production of the antibody will also increase (Crouse et al., 1983, Mol. Cell. Biol. 3:257).

[0272] The host cell may be co-transfected with two expression vectors of the invention, the first vector encoding a heavy chain derived polypeptide and the second vector encoding a light chain derived polypeptide. The two vectors may contain identical selectable markers which enable equal expression of heavy and light chain polypeptides. Alternatively, a single vector may be used which encodes both heavy and light chain polypeptides. In such situations, the light chain should be placed before the heavy chain to avoid an excess of toxic free heavy chain (Proudfoot, 1986, Nature 322:52; Kohler, 1980, Proc. Natl. Acad. Sci. USA 77:2197). The coding sequences for the heavy and light chains may comprise cDNA or genomic DNA.

[0273] Once the antibody of the invention has been recombinantly expressed, it may be purified by any method known in the art for purification of an antibody, for example, by chromatography (e.g., ion exchange, affinity, particularly by affinity for the specific antigen after Protein A, and sizing column chromatography), centrifugation, differential solubility, or by any other standard technique for the purification of proteins.

5.4 PROPHYLACTIC AND THERAPEUTIC METHODS

[0274] Also discussed are antibody-based therapies which involve administering one or more of the antibodies of the invention to an animal, preferably a mammal, and most preferably a human, for preventing, treating, or ameliorating symptoms associated with a disease, disorder, or infection, associated with aberrant levels or activity of Fc_YRIIB and/or treatable by altering immune function associated with Fc_YRIIB activity or enhancing cytotoxic activity of a second therapeutic antibody or enhancing efficacy of a vaccine composition. In some instances, therapy by administration of one or more antibodies of the invention is combined with administration of one or more therapies such as, but not limited to, chemotherapies, radiation therapies, hormonal therapies, and/or biological therapies/immunotherapies.

[0275] Antibodies may be provided in pharmaceutically acceptable compositions as known in the art or as described herein. As detailed below, the antibodies of the invention can be used in methods of treating cancer (particularly to enhance passive immunotherapy or efficacy of a cancer vaccine), autoimmune disease, inflammatory disorders or allergies (e.g., to enhance efficacy of a vaccine for treatment of allergy).

[0276] Fc_YRIIB (CD32B) has been found to be expressed in the following tissue types: adipose, b-cell, bone, brain, cartilage, colon, endocrine, eye, fetus, gastrointestinal tract, genitourinary, germ cell, head and neck, kidney, lung, lymph node, lymphoreticular, mammary gland, muscle, nervous, ovary, pancreas, pancreatic islet, pituitary gland, placenta, retina, skin, soft tissue, synovium, and uterus (data collected from the Cancer Genome Anatomy Project of the National Cancer Institute). Thus, the antibodies of the invention can be used to agonize or antagonize the activity of Fc_YRIIB in any of these tissues. For example, Fc_YRIIB is expressed in the placenta and may play a role in transport of IgG to the fetus and also in scavenging immune complexes (Lyden et al., 2001, J. Immunol. 166:3882-3889). In certain instances of the invention, an anti-Fc_YRIIB antibody can be used as an abortifacient.

[0277] The present inventors have found that neutrophils surprisingly do not express significant levels of FC_YRIIB. Accordingly, there is provided methods and pharmaceutical compositions for use in these methods, comprising an amount of CD32-specific antibody that binds to and has activity on tumor cells or non-neutrophil cell types, such as macrophages, but does not detectably bind or have detectable activity on neutrophils. In certain instances, the antibodies of the invention can be used to deplete CD32B⁺ cells, such as macrophages or CD32B-expressing tumor cells.

[0278] Antibodies of the present invention that function as a prophylactic and/or therapeutic agent of a disease, disorder, or

infection can be administered to an animal, preferably a mammal, and most preferably a human, to treat, prevent or ameliorate one or more symptoms associated with the disease, disorder, or infection. Antibodies of the invention can be administered in combination with one or more other prophylactic and/or therapeutic agents useful in the treatment, prevention or management of a disease, disorder, or infection associated with aberrant levels or activity of Fc γ RIIB and/or treatable by altering immune function associated with Fc γ RIIB activity. One or more antibodies of the invention can be administered to a mammal, preferably a human, concurrently with one or more other therapeutic agents useful for the treatment of cancer. The term "concurrently" is not limited to the administration of prophylactic or therapeutic agents at exactly the same time, but rather it is meant that antibodies of the invention and the other agent are administered to a subject in a sequence and within a time interval such that the antibodies of the invention can act together with the other agent to provide an increased benefit than if they were administered otherwise. For example, each prophylactic or therapeutic agent may be administered at the same time or sequentially in any order at different points in time; however, if not administered at the same time, they should be administered sufficiently close in time so as to provide the desired therapeutic or prophylactic effect. Each therapeutic agent can be administered separately, in any appropriate form and by any suitable route.

[0279] In various instances, the prophylactic or therapeutic agents are administered less than 1 hour apart, at about 1 hour apart, at about 1 hour to about 2 hours apart, at about 2 hours to about 3 hours apart, at about 3 hours to about 4 hours apart, at about 4 hours to about 5 hours apart, at about 5 hours to about 6 hours apart, at about 6 hours to about 7 hours apart, at about 7 hours to about 8 hours apart, at about 8 hours to about 9 hours apart, at about 9 hours to about 10 hours apart, at about 10 hours to about 11 hours apart, at about 11 hours to about 12 hours apart, no more than 24 hours apart or no more than 48 hours apart. In preferred instances, two or more components are administered within the same patient visit.

[0280] The dosage amounts and frequencies of administration provided herein are encompassed by the terms therapeutically effective and prophylactically effective. The dosage and frequency further will typically vary according to factors specific for each patient depending on the specific therapeutic or prophylactic agents administered, the severity and type of cancer, the route of administration, as well as age, body weight, response, and the past medical history of the patient. Suitable regimens can be selected by one skilled in the art by considering such factors and by following, for example, dosages reported in the literature and recommended in the Physician's Desk Reference (56th ed., 2002).

[0281] The antibodies of this invention may also be advantageously utilized in combination with other monoclonal or chimeric antibodies, Fc fusion proteins, or with lymphokines, cytokines or hematopoietic growth factors (such as, e.g., IL-2, IL-3, IL-4, IL-7, IL-10 and TGF- β), which enhance Fc γ RIIB, for example, serve to increase the number or activity of effector cells which interact with the antibodies and, increase immune response. In certain embodiments, a cytokine is conjugated to an anti-Fc γ RIIB antibody.

[0282] The antibodies of this invention may also be advantageously utilized in combination with one or more drugs used to treat a disease, disorder, or infection such as, for example anti-cancer agents, anti-inflammatory agents or anti-viral agents, e.g., as detailed in sections 5.4.6 and 5.4.5 below.

5.4.1 CANCERS

[0283] Antibodies of the invention can be used alone or in combination with other therapeutic antibodies known in the art to prevent, inhibit or reduce the growth of primary tumors or metastasis of cancerous cells. Antibodies of the invention can be used in combination with antibodies used in cancer immunotherapy and can include the use of the antibodies of the invention in combination with another therapeutic antibody to enhance the efficacy of such immunotherapy by increasing the potency of the therapeutic antibody's effector function, e.g., ADCC, CDC, phagocytosis, opsonization, etc. Although not intending to be bound by a particular mechanism of action antibodies of the invention block Fc γ RIIB, preferably on monocytes and macrophages and thus enhance the therapeutic benefits a clinical efficacy of tumor specific antibodies by, for example, enhancing clearance of the tumors mediated by activating Fc γ Rs. Accordingly, the specification provides methods of preventing or treating cancer characterized by a cancer antigen, when administered in combination with another antibody that specifically binds a cancer antigen and is cytotoxic. The antibodies of the invention are useful for prevention or treatment of cancer, particularly in potentiating the cytotoxic activity of cancer antigen-specific therapeutic antibodies with cytotoxic activity to enhance tumor cell killing by the antibodies of the invention and/or enhancing for example, ADCC activity or CDC activity of the therapeutic antibodies. Antibodies of the invention can be administered with Fc fusion proteins. An antibody of the invention can, when administered alone or in combination with a cytotoxic therapeutic antibody, inhibit or reduce the growth of primary tumor or metastasis of cancerous cells by at least 99%, at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 60%, at least 50%, at least 45%, at least 40%, at least 45%, at least 35%, at least 30%, at least 25%, at least 20%, or at least 10% relative to the growth of primary tumor or metastasis in absence of said antibody of the invention. In a preferred

instance, antibodies of the invention in combination with a cytotoxic therapeutic antibody inhibit or reduce the growth of primary tumor or metastasis of cancer by at least 99%, at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 60%, at least 50%, at least 45%, at least 40%, at least 45%, at least 35%, at least 30%, at least 25%, at least 20%, or at least 10% relative to the growth or metastasis in absence of said antibodies.

[0284] The transition from a normal to a malignant state is a multistep process involving genetic and epigenetic changes. In fact, numerous alterations occur in the cellular regulatory circuits that facilitate this progression which enables tumor cells to evade the commitment to terminal differentiation and quiescence that normally regulate tissue homeostasis. Certain genes have been implicated in invasiveness and metastatic potential of cancer cells such as CSF-1 (colony stimulating factor 1 or macrophage colony stimulating factor). Although not intending to be bound by a particular mechanism of action, CSF-1 may mediate tumor progression and metastasis by recruiting macrophages to the tumor site where they promote progression of tumor. It is believed that macrophages have a trophic role in mediating tumor progression and metastasis perhaps by the secretion of angiogenic factors, e.g., thymidine phosphorylase, vascular endothelial-derived growth factor; secretion of growth factors such as epidermal growth factor that could act as a paracrine factor on tumor cells, and thus promoting tumor cell migration and invasion into blood vessels. (See, e.g., Lin et al., 2001, *J. Exp. Med.* 193(6): 727-739; Lin et al., 2002, *Journal of Mammary Gland Biology and Neoplasia* 7(2): 147-162; Scholl et al., 1993, *Molecular Carcinogenesis*, 7: 207-11; Clynes et al., 2000, *Nature Medicine*, 6(4): 443-446; Fidler et al., 1985, *Cancer Research*, 45: 4714-26).

[0285] The antibodies of the invention can block macrophage mediated tumor cell progression and metastasis. The antibodies of the invention are particularly useful in the treatment of solid tumors, where macrophage infiltration occurs. The antagonistic antibodies of the invention are particularly useful for controlling, e.g., reducing or eliminating, tumor cell metastasis, by reducing or eliminating the population of macrophages that are localized at the tumor site. The antibodies of the invention can be used alone to control tumor cell metastasis. Although not intending to be bound by a particular mechanism of action the antagonistic antibodies of the invention, when administered alone bind the inhibitory Fc_YRIIB on macrophages and effectively reduce the population of macrophages and thus restrict tumor cell progression. The antagonistic antibodies of the invention reduce, or preferably eliminate macrophages that are localized at the tumor site, since Fc_YRIIB is preferentially expressed on activated monocytes and macrophages including tumor-infiltrating macrophages. The antibodies of the invention can be used in the treatment of cancers that are characterized by the overexpression of CSF-1, including but not limited to breast, uterine, and ovarian cancers.

[0286] Also described are antibodies that effectively deplete or eliminate immune cells other than macrophages that express Fc_YRIIB, e.g., dendritic cells and B-cells. Effective depletion or elimination of immune cells using the antibodies of the invention may range from a reduction in population of the immune cells by 50%, 60%, 70%, 80%, preferably 90%, and most preferably 99%. Thus, the antibodies of the invention have enhanced therapeutic efficacy either alone or in combination with a second antibody, e.g., a therapeutic antibody such as anti-tumor antibodies, anti-viral antibodies, and anti-microbial antibodies. The therapeutic antibodies can have specificity for a cancer cell or an inflammatory cell. The second antibody may bind a normal cell. Although not intending to be bound by a particular mechanism of action, when the antibodies of the invention are used alone to deplete Fc_YRIIB-expressing immune cells, the population of cells is redistributed so that effectively the cells that are remaining have the activating Fc receptors and thus the suppression by Fc_YRIIB is alleviated. When used in combination with a second antibody, e.g., a therapeutic antibody the efficacy of the second antibody is enhanced by increasing the Fc-mediated effector function of the antibody.

[0287] Cancers and related disorders that can be treated or prevented by methods described and compositions of the present invention include, but are not limited to, the following: Leukemias including, but not limited to, acute leukemia, acute lymphocytic leukemia, acute myelocytic leukemias such as myeloblastic, promyelocytic, myelomonocytic, monocytic, erythroleukemia leukemias and myelodysplastic syndrome, chronic leukemias such as but not limited to, chronic myelocytic (granulocytic) leukemia, chronic lymphocytic leukemia, hairy cell leukemia; polycythemia vera; lymphomas such as but not limited to Hodgkin's disease, non-Hodgkin's disease; multiple myelomas such as but not limited to smoldering multiple myeloma, nonsecretory myeloma, osteosclerotic myeloma, plasma cell leukemia, solitary plasmacytoma and extramedullary plasmacytoma; Waldenstrom's macroglobulinemia; monoclonal gammopathy of undetermined significance; benign monoclonal gammopathy; heavy chain disease; bone and connective tissue sarcomas such as but not limited to bone sarcoma, osteosarcoma, chondrosarcoma, Ewing's sarcoma, malignant giant cell tumor, fibrosarcoma of bone, chordoma, periosteal sarcoma, soft-tissue sarcomas, angiosarcoma (hemangiosarcoma), fibrosarcoma, Kaposi's sarcoma, leiomyosarcoma, liposarcoma, lymphangiosarcoma, neurilemmoma, rhabdomyosarcoma, synovial sarcoma; brain tumors including but not limited to, glioma, astrocytoma, brain stem glioma, ependymoma, oligodendrogloma, nonglial tumor, acoustic neurinoma, craniopharyngioma, medulloblastoma, meningioma, pineocytoma, pineoblastoma, primary brain lymphoma; breast cancer including, but not limited to, adenocarcinoma, lobular (small cell) carcinoma, intraductal carcinoma, medullary breast cancer, mucinous breast cancer, tubular breast cancer, papillary breast cancer, Paget's disease, and inflammatory breast cancer; adrenal cancer, including but not limited to, pheochromocytoma and

adrenocortical carcinoma; thyroid cancer such as but not limited to papillary or follicular thyroid cancer, medullary thyroid cancer and anaplastic thyroid cancer; pancreatic cancer, including but not limited to, insulinoma, gastrinoma, glucagonoma, vipoma, somatostatin-secreting tumor, and carcinoid or islet cell tumor; pituitary cancers including but not limited to, Cushing's disease, prolactin-secreting tumor, acromegaly, and diabetes insipidus; eye cancers including but not limited to, ocular melanoma such as iris melanoma, choroidal melanoma, and ciliary body melanoma, and retinoblastoma; vaginal cancers, including but not limited to, squamous cell carcinoma, adenocarcinoma, and melanoma; vulvar cancer, including but not limited to, squamous cell carcinoma, melanoma, adenocarcinoma, basal cell carcinoma, sarcoma, and Paget's disease; cervical cancers including but not limited to, squamous cell carcinoma, and adenocarcinoma; uterine cancers including but not limited to, endometrial carcinoma and uterine sarcoma; ovarian cancers including but not limited to, ovarian epithelial carcinoma, borderline tumor, germ cell tumor, and stromal tumor; esophageal cancers including but not limited to, squamous cancer, adenocarcinoma, adenoid cystic carcinoma, mucoepidermoid carcinoma, adenosquamous carcinoma, sarcoma, melanoma, plasmacytoma, verrucous carcinoma, and oat cell (small cell) carcinoma; stomach cancers including but not limited to, adenocarcinoma, fungating (polypoid), ulcerating, superficial spreading, diffusely spreading, malignant lymphoma, liposarcoma, fibrosarcoma, and carcinosarcoma; colon cancers; rectal cancers; liver cancers including but not limited to hepatocellular carcinoma and hepatoblastoma, gallbladder cancers including but not limited to, adenocarcinoma; cholangiocarcinomas including but not limited to, papillary, nodular, and diffuse; lung cancers including but not limited to, non-small cell lung cancer, squamous cell carcinoma (epidermoid carcinoma), adenocarcinoma, large-cell carcinoma and small-cell lung cancer; testicular cancers including but not limited to, germinal tumor, seminoma, anaplastic, classic (typical), spermatocytic, nonseminoma, embryonal carcinoma, teratoma carcinoma, choriocarcinoma (yolk-sac tumor), prostate cancers including but not limited to, adenocarcinoma, leiomyosarcoma, and rhabdomyosarcoma; penile cancers; oral cancers including but not limited to, squamous cell carcinoma; basal cancers; salivary gland cancers including but not limited to, adenocarcinoma, mucoepidermoid carcinoma, and adenoidcystic carcinoma; pharynx cancers including but not limited to, squamous cell cancer, and verrucous; skin cancers including but not limited to, basal cell carcinoma, squamous cell carcinoma and melanoma, superficial spreading melanoma, nodular melanoma, lentigo malignant melanoma, acral lentiginous melanoma; kidney cancers including but not limited to, renal cell cancer, adenocarcinoma, hypernephroma, fibrosarcoma, transitional cell cancer (renal pelvis and/ or uterus); Wilms' tumor; bladder cancers including but not limited to, transitional cell carcinoma, squamous cell cancer, adenocarcinoma, carcinosarcoma. In addition, cancers include myxosarcoma, osteogenic sarcoma, endotheliosarcoma, lymphangiomyomatosis, mesothelioma, synovioma, hemangioblastoma, epithelial carcinoma, cystadenocarcinoma, bronchogenic carcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma and papillary adenocarcinomas (for a review of such disorders, see Fishman et al., 1985, Medicine, 2d Ed., J.B. Lippincott Co., Philadelphia and Murphy et al., 1997, Informed Decisions: The Complete Book of Cancer Diagnosis, Treatment, and Recovery, Viking Penguin, Penguin Books U.S.A., Inc., United States of America).

[0288] Accordingly, the methods described herein and compositions of the invention are also useful in the treatment or prevention of a variety of cancers or other abnormal proliferative diseases, including (but not limited to) the following: carcinoma, including that of the bladder, breast, colon, kidney, liver, lung, ovary, pancreas, stomach, cervix, thyroid and skin; including squamous cell carcinoma; hematopoietic tumors of lymphoid lineage, including leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell lymphoma, Burkitt's lymphoma; hematopoietic tumors of myeloid lineage, including acute and chronic myelogenous leukemias and promyelocytic leukemia; tumors of mesenchymal origin, including fibrosarcoma and rhabdomyosarcoma; other tumors, including melanoma, seminoma, teratocarcinoma, neuroblastoma and glioma; tumors of the central and peripheral nervous system, including astrocytoma, neuroblastoma, glioma, and schwannomas; tumors of mesenchymal origin, including fibrosarcoma, rhabdomyosarcoma, and osteosarcoma; and other tumors, including melanoma, xanthoma, xanthelasma, keratoacanthoma, seminoma, thyroid follicular cancer and teratocarcinoma. It is also contemplated that cancers caused by aberrations in apoptosis would also be treated by the methods described and compositions of the invention. Such cancers may include but not be limited to follicular lymphomas, carcinomas with p53 mutations, hormone dependent tumors of the breast, prostate and ovary, and precancerous lesions such as familial adenomatous polyposis, and myelodysplastic syndromes. In some cases, malignancy or dysproliferative changes (such as metaplasias and dysplasias), or hyperproliferative disorders, are treated or prevented by the methods described herein and compositions of the invention in the ovary, bladder, breast, colon, lung, skin, pancreas, or uterus. In other cases, sarcoma, melanoma, or leukemia is treated or prevented by the methods described herein and compositions of the invention.

[0289] Cancers associated with the cancer antigens may be treated or prevented by administration of the antibodies of the invention in combination with an antibody that binds the cancer antigen and is cytotoxic. The antibodies of the invention can enhance the antibody mediated cytotoxic effect of the antibody directed at the particular cancer antigen. For example, but not by way of limitation, cancers associated with the following cancer antigen may be treated or prevented by the methods and compositions of the invention. KS 1/4 pancarcinoma antigen (Perez and Walker, 1990, J. Immunol. 142:32-37; Bumal, 1988, Hybridoma 7(4):407-415), ovarian carcinoma antigen (CA125) (Yu et al., 1991, Cancer Res. 51(2):48-475), prostatic acid phosphate (Tailor et al., 1990, Nucl. Acids Res. 18(1):4928), prostate specific antigen (Henttu and Vihko, 1989, Biochem.

Biophys. Res. Comm. 10(2):903-910; Israeli et al., 1993, Cancer Res. 53:227-230), melanoma-associated antigen p97 (Estin et al., 1989, J. Natl. Cancer Inst. 81(6):445-44), melanoma antigen gp75 (Vijayasaradahl et al., 1990, J. Exp. Med. 171(4):1375-1380), high molecular weight melanoma antigen (HMW-MAA) (Natali et al., 1987, Cancer 59:55-3; Mittelman et al., 1990, J. Clin. Invest. 86:2136-2144)), prostate specific membrane antigen, carcinoembryonic antigen (CEA) (Foon et al., 1994, Proc. Am. Soc. Clin. Oncol. 13:294), polymorphic epithelial mucin antigen, human milk fat globule antigen, Colorectal tumor-associated antigens such as: CEA, TAG-72 (Yokata et al., 1992, Cancer Res. 52:3402-3408), CO17-1A (Ragnhammar et al., 1993, Int. J. Cancer 53:751-758); GICA 19-9 (Herlyn et al., 1982, J. Clin. Immunol. 2:135), CTA-1 and LEA, Burkitt's lymphoma antigen-38.13, CD19 (Ghetie et al., 1994, Blood 83:1329-1336), human B-lymphoma antigen-CD20 (Reff et al., 1994, Blood 83:435-445), CD33 (Sgouros et al., 1993, J. Nucl. Med. 34:422-430), melanoma specific antigens such as ganglioside GD2 (Saleh et al., 1993, J. Immunol., 151, 3390-3398), ganglioside GD3 (Shitara et al., 1993, Cancer Immunol. Immunother. 36:373-380), ganglioside GM2 (Livingston et al., 1994, J. Clin. Oncol. 12:1036-1044), ganglioside GM3 (Hoon et al., 1993, Cancer Res. 53:5244-5250), tumor-specific transplantation type of cellsurface antigen (TSTA) such as virally-induced tumor antigens including T-antigen DNA tumor viruses and envelope antigens of RNA tumor viruses, oncofetal antigen-alphafetoprotein such as CEA of colon, bladder tumor oncofetal antigen (Hellstrom et al., 1985, Cancer. Res. 45:2210-2188), differentiation antigen such as human lung carcinoma antigen L6, L20 (Hellstrom et al., 1986, Cancer Res. 46:3917-3923), antigens of fibrosarcoma, human leukemia T cell antigen-Gp37 (Bhattacharya-Chatterjee et al., 1988, J. of Immun. 141:1398-1403), neoglycoprotein, sphingolipids, breast cancer antigen such as EGFR (Epidermal growth factor receptor), HER2 antigen (p185^{HER2}), polymorphic epithelial mucin (PEM) (Hilkens et al., 1992, Trends in Bio. Chem. Sci. 17:359), malignant human lymphocyte antigen-APO-1 (Bernhard et al., 1989, Science 245:301-304), differentiation antigen (Feizi, 1985, Nature 314:53-57) such as I antigen found in fetal erythrocytes and primary endoderm, I(Ma) found in gastric adenocarcinomas, M18 and M39 found in breast epithelium, SSEA-1 found in myeloid cells, VEP8, VEP9, Myl, VIM-D5, and D156-22 found in colorectal cancer, TRA-1-85 (blood group H), C 14 found in colonic adenocarcinoma, F3 found in lung adenocarcinoma, AH6 found in gastric cancer, Y hapten, Le^Y found in embryonal carcinoma cells, TL5 (blood group A), EGF receptor found in A431 cells, E1 series (blood group B) found in pancreatic cancer, FC10.2 found in embryonal carcinoma cells, gastric adenocarcinoma, CO-514 (blood group Le^a) found in adenocarcinoma, NS-10 found in adenocarcinomas, CO-43 (blood group Le^b), G49, EGF receptor, (blood group ALe^b/Le^Y) found in colonic adenocarcinoma, 19.9 found in colon cancer, gastric cancer mucins, T5A7 found in myeloid cells, R₂₄ found in melanoma, 4.2, Gd₃, D1.1, OFA-1, GM2, OFA-2, G_{D2}, M1:22:25:8 found in embryonal carcinoma cells and SSEA-3, SSEA-4 found in 4-8-cell stage embryos. The antigen can be a T cell receptor derived peptide from a cutaneous T cell lymphoma (see Edelson, 1998, The Cancer Journal 4:62).

[0290] The antibodies of the invention can be used in combination with any therapeutic cancer antibodies known in the art to enhance the efficacy of treatment. For example, the antibodies of the invention can be used with any of the antibodies in Table 7, that have demonstrated therapeutic utility in cancer treatment. The antibodies of the invention enhance the efficacy of treatment of the therapeutic cancer antibodies by enhancing at least one antibody-mediated effector function of said therapeutic cancer antibodies. The antibodies can be utilized to enhance the efficacy of treatment by enhancing the complement dependent cascade of said therapeutic cancer antibodies. The antibodies of the invention can be utilized to enhance the efficacy of treatment by enhancing the phagocytosis and opsonization of the targeted tumor cells. The antibodies of the invention can be utilized to enhance the efficacy of treatment by enhancing antibody-dependent cell-mediated cytotoxicity ("ADCC") in destruction of the targeted tumor cells.

[0291] Antibodies of the invention can also be used in combination with cytosine-guanine dinucleotides ("CpG")-based products that have been developed (Coley Pharmaceuticals) or are currently being developed as activators of innate and acquired immune responses. For example, the invention encompasses the use of CpG 7909, CpG 8916, CpG 8954 (Coley Pharmaceuticals) in the methods and compositions of the invention for the treatment and/or prevention of cancer (See also Warren et al., 2002, Semin Oncol., 29(1 Suppl 2):93-7; Warren et al., 2000, Clin Lymphoma, 1(1):57-61.

[0292] Antibodies of the invention can be used in combination with a therapeutic antibody that does not mediate its therapeutic effect through cell killing to potentiate the antibody's therapeutic activity. Also discussed is the use of the antibodies of the invention in combination with a therapeutic apoptosis inducing antibody with agonistic activity, e.g., an anti-Fas antibody. Anti-Fas antibodies are known in the art and include for example, Jo2 (Ogasawara et al., 1993, Nature 364: 806) and HFE7 (Ichikawa et al., 2000, Int. Immunol. 12: 555). Although not intending to be bound by a particular mechanisms of action, Fc_YRIIB has been implicated in promoting anti-Fas mediated apoptosis, see, e.g., Xu et al., 2003, Journal of Immunology, 171: 562-568. In fact the extracellular domain of Fc_YRIIB may serve as a cross-linking agent for Fas receptors, leading to a functional complex and promoting Fas dependent apoptosis. In some instances, the antibodies of the invention block the interaction of anti-Fas antibodies and Fc_YRIIB, leading to a reduction in Fas-mediated apoptotic activity. Antibodies of the invention that result in a reduction in Fas-mediated apoptotic activity are particularly useful in combination with anti-Fas antibodies that have undesirable

side effects, e.g., hepatotoxicity. In other instances, the antibodies of the invention enhance the interaction of anti-Fas antibodies and Fc_YRIIB, leading to an enhancement of Fas-mediated apoptotic activity. Combination of the antibodies of the invention with therapeutic apoptosis inducing antibodies with agonistic activity have an enhanced therapeutic efficacy.

[0293] Therapeutic apoptosis inducing antibodies used in the methods described herein may be specific for any death receptor known in the art for the modulation of apoptotic pathway, e.g., TNFR receptor family.

[0294] A method of treating diseases with impaired apoptotic mediated signaling, e.g., cancer, autoimmune disease is discussed such as a method of treating a disease with deficient Fas-mediated apoptosis, said method comprising administering an antibody of the invention in combination with an anti-Fas antibody.

[0295] The agonistic antibodies of the invention can be particularly useful for the treatment of tumors of non-hematopoietic origin, including tumors of melanoma cells. Although not intending to be bound by a particular mechanism of action, the efficacy of the agonistic antibodies of the invention is due, in part, to activation of Fc_YRIIB inhibitory pathway, as tumors of non-hematopoietic origin, including tumors of melanoma cells express Fc_YRIIB. Recent experiments have in fact shown that expression of Fc_YRIIB in melanoma cells modulates tumor growth by direct interaction with anti-tumor antibodies (e.g., by binding the Fc region of the anti-tumor antibodies) in an intracytoplasmic-dependent manner (Cassard et al., 2002, Journal of Clinical Investigation, 110(10): 1549-1557).

[0296] The antibodies of the invention can be used in combination with therapeutic antibodies that immunospecifically bind to tumor antigens that are not expressed on the tumor cells themselves, but rather on the surrounding reactive and tumor supporting, non-malignant cells comprising the tumor stroma. The tumor stroma comprises endothelial cells forming new blood vessels and stromal fibroblasts surrounding the tumor vasculature. An antibody of the invention can be used in combination with an antibody that immunospecifically binds a tumor antigen on an endothelial cell. An antibody of the invention can be used in combination with an antibody that immunospecifically binds a tumor antigen on a fibroblast cell, e.g., fibroblast activation protein (FAP). FAP is a 95 KDa homodimeric type II glycoprotein which is highly expressed in stromal fibroblasts of many solid tumors, including, but not limited to lung, breast, and colorectal carcinomas. (See, e.g., Scanlan et al., 1994; Proc. Natl. Acad. USA, 91: 5657-61; Park et al., 1999, J. Biol. Chem., 274: 36505-12; Rettig et al., 1988, Proc. Natl. Acad. Sci. USA 85: 3110-3114 ; Garin-Chesea et al., 1990, Proc. Natl. Acad. Sci. USA 87: 7235-7239). Antibodies that immunospecifically bind FAP are known in the art and encompassed within the invention, see, e.g., Wuest et al., 2001, Journal of Biotechnology, 159-168; Mersmann et al., 2001, Int. J. Cancer, 92: 240-248; U.S. Patent No. 6,455,677.

[0297] Recently IgE's have been implicated as mediators of tumor growth and in fact IgE-targeted immediate hypersensitivity and allergic inflammation reactions have been proposed as possible natural mechanisms involved in anti-tumor responses (For a review see, e.g., Mills et al., 1992, Am. Journal of Epidemiol. 122: 66-74; Eriksson et al., 1995, Allergy 50: 718-722). In fact a recent study has shown loading tumor cells with IgEs reduces tumor growth, leading in some instances to tumor rejection. According to the study, IgE loaded tumor cells not only possess a therapeutic potential but also confer long term antitumor immunity, including activation of innate immunity effector mechanism and T-cell mediated adaptive immune response, see Reali et al., 2001, Cancer Res. 61: 5516-22; which is incorporated herein by reference in its entirety. The antagonistic antibodies of the invention may be used in the treatment and/or prevention of cancer in combination with administration of IgEs in order to enhance the efficacy of IgE-mediated cancer therapy. Although not intending to be bound by a particular mechanism of action the antibodies of the invention enhance the therapeutic efficacy of IgE treatment of tumors, by blocking the inhibitory pathway. The antagonistic antibodies of the invention may enhance the therapeutic efficacy of IgE-mediated cancer therapy by (i) enhancing the delay in tumor growth; (ii) enhancing the decrease in the rate of tumor progression; (iii) enhancing tumor rejection; or (iv) enhancing protective immune relative to treatment of cancer with IgE alone.

[0298] Cancer therapies and their dosages, routes of administration and recommended usage are known in the art and have been described in the literature, see, e.g., Physician's Desk Reference (56th ed., 2002).

5.4.1.1 B CELL MALIGNANCIES

[0299] Also discussed are therapies which involve administering an anti-Fc_YRIIB antibody, to an animal, preferably a mammal, and most preferably a human, to prevent, treat, manage or ameliorate a B-cell malignancy, or one or more symptoms thereof. These therapies are an enhancement over current therapies. In certain cases, patients who are refractory to current therapies can be treated with the methods of the invention. In some examples, therapy by administration of one or more antibodies of the invention is combined with administration of one or more therapies such as, but not limited to, chemotherapies, radiation

therapies, hormonal therapies, and/or biological therapies/immunotherapies.

[0300] Also discussed are treatment protocols that provide better prophylactic and therapeutic profiles than current single agent therapies or combination therapies for a B-cell malignancy, or one or more symptoms thereof. There are provided Fc_YRIIB antibody based therapies for the prevention, treatment, management, or amelioration of a B-cell malignancy, or one or more symptoms thereof. In particular, there are provided prophylactic and therapeutic protocols for the prevention, treatment, management, or amelioration of a B-cell malignancy, or one or more symptoms thereof, comprising the administration of a Fc_YRIIB-specific antibody, an analog, derivative or an antigen-fragment thereof to a subject in need thereof.

[0301] The agonistic antibodies of the invention are useful for treating or preventing any B cell malignancies, particularly non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Other B-cell malignancies include small lymphocytic lymphoma, Burkitt's lymphoma, mantle cell lymphomas diffuse small cleaved cell lymphomas, most follicular lymphomas and some diffuse large B cell lymphomas (DLBCL). Fc_YRIIB, is a target for deregulation by chromosomal translocation in malignant lymphoma, particularly in B-cell non-Hodgkin's lymphoma (See Callanan M.B. et al., 2000 Proc. Natl. Acad. Sci. U.S.A., 97(1):309-314). Thus, the antibodies of the invention are useful for treating or preventing any chronic lymphocytic leukemia of the B cell lineage. Chronic lymphocytic leukemia of the B cell lineage are reviewed by Freedman (See review by Freedman, 1990, Hematol. Oncol. Clin. North Am. 4:405). Although not intending to be bound by any mechanism of action, the agonistic antibodies of the invention inhibit or prevent B cell malignancies inhibiting B cell proliferation and/or activation. Also discussed is the use of the agonistic antibodies of the invention in combination with other therapies known (e.g., chemotherapy and radiotherapy) in the art for the prevention and/or treatment of B cell malignancies. Further discussed is the use of the agonistic antibodies of the invention in combination with other antibodies known in the art for the treatment and or prevention of B-cell malignancies. For example, the agonistic antibodies of the invention can be used in combination with the antiC22 or anti-CD19 antibodies disclosed by Goldenberg et al. (U.S. Patent No. 6,306,393), anti-CD20 antibodies, anti-CD33 antibodies, or anti-CD52 antibodies.

[0302] Antibodies of the invention can also be used in combination with for example but not by way of limitation, Oncoscint (target: CEA), Verluma (target: GP40), Prostascint (target: PSMA), CEA-SCAN(target: CEA), Rituxin (target: CD20), Herceptin (target: HER-2), Campath (target: CD52), Mylotarge (target: CD33), LymphoCide (CD22), Lymphocide Y-90 (CD22) and Zevalin (target: CD20).

5.4.2 AUTOIMMUNE DISEASE AND INFLAMMATORY DISEASES

[0303] The agonistic antibodies of the invention may be used to treat or prevent autoimmune diseases or inflammatory diseases. Methods of preventing, treating, or managing one or more symptoms associated with an Autoimmune or inflammatory disorder in a subject, comprising administering to said subject a therapeutically effective amount of the antibodies or fragments thereof of the invention are described. Also provided are methods for preventing, treating, or managing one or more symptoms associated with an inflammatory disorder in a subject further comprising, administering to said subject a therapeutically effective amount of one or more anti-inflammatory agents. Further provided are methods for preventing, treating, or managing one or more symptoms associated with an autoimmune disease further comprising, administering to said subject a therapeutically effective amount of one or more immunomodulatory agents. Section 5.4.5 provides non-limiting examples of anti-inflammatory agents and immunomodulatory agents.

[0304] The antibodies of the invention can also be used in combination with any of the antibodies known in the art for the treatment and/or prevention of autoimmune disease or inflammatory disease. A non-limiting example of the antibodies or Fc fusion proteins that are used for the treatment or prevention of inflammatory disorders is presented in Table 6A, and a non-limiting example of the antibodies or Fc fusion proteins that are used for the treatment or prevention of autoimmune disorder is presented in Table 6B. The antibodies of the invention can for example, enhance the efficacy of treatment of the therapeutic antibodies or Fc fusion proteins presented in Tables 6A and 6B. For example, but not by way of limitation, the antibodies of the invention can enhance the immune response in the subject being treated with any of the antibodies or Fc fusion proteins in Tables 6A or 6B.

[0305] Antibodies of the invention can also be used in combination with for example but not by way of limitation, Orthoclone OKT3, ReoPro, Zenapax, Simulect, Rituximab, Synagis, and Remicade.

[0306] Antibodies of the invention can also be used in combination with cytosine-guanine dinucleotides ("CpG")-based products that have been developed (Coley Pharmaceuticals) or are currently being developed as activators of innate and acquired immune responses. For example, the specification encompasses the use of CpG 7909, CpG 8916, CpG 8954 (Coley Pharmaceuticals) in

the methods and compositions described herein for the treatment and/or prevention of autoimmune or inflammatory disorders (Weeratna et al., 2001, FEMS Immunol Med Microbiol., 32(1):65-71).

[0307] Examples of autoimmune disorders that may be treated by administering the antibodies of the present invention include, but are not limited to, alopecia areata, ankylosing spondylitis, antiphospholipid syndrome, Autoimmune Addison's disease, autoimmune diseases of the adrenal gland, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune oophoritis and orchitis, autoimmune thrombocytopenia, Behcet's disease, bullous pemphigoid, cardiomyopathy, celiac sprue-dermatitis, chronic fatigue immune dysfunction syndrome (CFIDS), chronic inflammatory demyelinating polyneuropathy, Churg-Strauss syndrome, cicatrical pemphigoid, CREST syndrome, cold agglutinin disease, Crohn's disease, discoid lupus, essential mixed cryoglobulinemia, fibromyalgia-fibromyositis, glomerulonephritis, Graves' disease, Guillain-Barre, Hashimoto's thyroiditis, idiopathic pulmonary fibrosis, idiopathic thrombocytopenia purpura (ITP), IgA neuropathy, juvenile arthritis, lichen planus, lupus erythematosus, Ménière's disease, mixed connective tissue disease, multiple sclerosis, type 1 or immune-mediated diabetes mellitus, myasthenia gravis, pemphigus vulgaris, pernicious anemia, polyarteritis nodosa, polychondritis, polyglandular syndromes, polymyalgia rheumatica, polymyositis and dermatomyositis, primary agammaglobulinemia, primary biliary cirrhosis, psoriasis, psoriatic arthritis, Raynaud's phenomenon, Reiter's syndrome, Rheumatoid arthritis, sarcoidosis, scleroderma, Sjögren's syndrome, stiff-man syndrome, systemic lupus erythematosus, lupus erythematosus, takayasu arteritis, temporal arteritis/ giant cell arteritis, ulcerative colitis, uveitis, vasculitides such as dermatitis herpetiformis vasculitis, vitiligo, and Wegener's granulomatosis. Examples of inflammatory disorders include, but are not limited to, asthma, encephalitis, inflammatory bowel disease, chronic obstructive pulmonary disease (COPD), allergic disorders, septic shock, pulmonary fibrosis, undifferentiated spondyloarthropathy, undifferentiated arthropathy, arthritis, inflammatory osteolysis, and chronic inflammation resulting from chronic viral or bacteria infections. As described herein in Section 3.1, some autoimmune disorders are associated with an inflammatory condition. Thus, there is overlap between what is considered an autoimmune disorder and an inflammatory disorder. Therefore, some autoimmune disorders may also be characterized as inflammatory disorders. Examples of inflammatory disorders which can be prevented, treated or managed in accordance with the methods of the specification include, but are not limited to, asthma, encephalitis, inflammatory bowel disease, chronic obstructive pulmonary disease (COPD), allergic disorders, septic shock, pulmonary fibrosis, undifferentiated spondyloarthropathy, undifferentiated arthropathy, arthritis, inflammatory osteolysis, and chronic inflammation resulting from chronic viral or bacteria infections.

[0308] The antibodies of the invention may be used to treat an autoimmune disease that is more prevalent in one sex. For example, the prevalence of Graves' disease in women has been associated with expression of FcγRIIB2 (see Estienne et al., 2002, FASEB J. 16:1087-1092).

[0309] Antibodies of the invention can also be used to reduce the inflammation experienced by animals, particularly mammals, with inflammatory disorders. In a specific example, an antibody reduces the inflammation in an animal by at least 99%, at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 60%, at least 50%, at least 45%, at least 40%, at least 35%, at least 30%, at least 25%, at least 20%, or at least 10% relative to the inflammation in an animal in the not administered said antibody. In another example, a combination of antibodies reduce the inflammation in an animal by at least 99%, at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 60%, at least 50%, at least 45%, at least 40%, at least 35%, at least 30%, at least 25%, at least 20%, or at least 10% relative to the inflammation in an animal in not administered said antibodies.

Table 6A: Antibodies for Inflammatory Diseases and Autoimmune Diseases that can be used in combination with the antibodies of the invention.

Antibody Name	Target Antigen	Product Type	Isotype	Sponsors	Indication
5G1.1	Complement (C5)	Humanised	IgG	Alexion Pharm Inc	Rheumatoid Arthritis
5G1.1	Complement (C5)	Humanised	IgG	Alexion Pharm Inc	SLE
5G1.1	Complement (C5)	Humanised	IgG	Alexion Pharm Inc	Nephritis
5G1.1-SC	Complement (C5)	Humanised	ScFv	Alexion Pharm Inc	Cardiopulmano Bypass
5G1.1-SC	Complement (C5)	Humanised	ScFv	Alexion Pharm Inc	Myocardial Infarction
5G1.1-SC	Complement (C5)	Humanised	ScFv	Alexion Pharm Inc	Angioplasty
ABX-CBL	CBL	Human		Abgenix Inc	GvHD

Antibody Name	Target Antigen	Product Type	Isotype	Sponsors	Indication
ABX-CBL	CD 147	Murine	IgG	Abgenix Inc	Allograft rejection
ABX-IL8	IL-8	Human	IgG2	Abgenix Inc	Psoriasis
Antegren	VLA-4	Humanised	IgG	Athena/Elan	Multiple Sclerosis
Anti-CD 11 a	CD11a	Humanised	IgG1	Genentech Inc/Xoma	Psoriasis
Anti-CD18	CD18	Humanised	Fab'2	Genentech Inc	Myocardial infarction
Anti-LFA1	CD18	Murine	Fab'2	Pasteur-Merieux/ Immunotech	Allograft rejection
Antova	CD40L	Humanised	IgG	Biogen	Allograft rejection
Antova	CD40L	Humanised	IgG	Biogen	SLE
BTI-322	CD2	Rat	IgG	Medimmune Inc	GvHD, Psoriasis
CDP571	TNF-alpha	Humanised	IgG4	Celltech	Crohn's
CDP571	TNF-alpha	Humanised	IgG4	Celltech	Rheumatoid Arthritis
CDP850 Corsevin M	E-selectin Fact VII	Humanised Chimeric		Celltech Centocor	Psoriasis Anticoagulant
D2E7	TNF-alpha	Human		CAT/BASF	Rheumatoid Arthritis
Hu23F2G	CD11/18	Humanised		ICOS Pharm Inc	Multiple Sclerosis
Hu23F2G	CD11/18	Humanised	IgG	ICOS Pharm Inc	Stroke
IC14	CD14			ICOS Pharm Inc	Toxic shock
ICM3	ICAM-3	Humanised		ICOS Pharm Inc	Psoriasis
IDEC-114	CD80	Primatised		IDEC Pharm/Mitsub ishi	Psoriasis
IDEC-131	CD40L	Humanised		IDEC Pharm/Eisai	SLE
IDEC-131	CD40L	Humanised		IDEC Pharm/Eisai	Multiple Sclerosis
IDEC-151 IDEC-152	CD4 CD23	Primatised	IgG 1	IDEC Pharm/Glaxo SmithKline IDEC Pharm	Rheumatoid Arthritis Asthma/Allergy
Infliximab	TNF-alpha	Chimeric	IgG 1	Centocor	Rheumatoid Arthritis
Infliximab	TNF-alpha	Chimeric	IgG 1	Centocor	Crohn's
LDP-01	beta2-integrin	Humanised	IgG	Millennium Inc (LeukoSite Inc.)	Stroke
LDP-01	beta2-integrin	Humanised	IgG	Millennium Inc (LeukoSite Inc.)	Allograft rejection
LDP-02	alpha4beta7	Humanized		Millennium Inc (LeukoSite Inc.)	Ulcerative Colitis
MAK-195F	TNF alpha	Murine	Fab'2	Knoll Pharm, BASF	Toxic shock
MDX-33	CD64 (FcR)	Human		Medarex/Cent eon	Autoimmune haematological disorders
MDX-CD4	CD4	Human	IgG	Medarex/Eisai / Genmab	Rheumatoid Arthritis
MEDI-507	CD2	Humanised		Medimmune Inc	Psoriasis
MEDI-507	CD2	Humanised		Medimmune Inc	GvHD
OKT4A	CD4	Humanised	IgG	Ortho Biotech	Allograft rejection
OrthoClone e OKT4A	CD4	Humanised	IgG	Ortho Biotech	Autoimmune disease
Orthoclone / anti-CD3 OKT3	CD3	Murine	mlgG2a	Ortho Biotech	Allograft rejection
RepPro/ Abciximab	gpllbilla	Chimeric	Fab	Centocor/Lilly	Complications of coronary angioplasty
rhuMab-E25	IgE	Humanised	IgG 1	Genentech/Novartis/Tanox Biosystems	Asthma/Allergy

Antibody Name	Target Antigen	Product Type	Isotype	Sponsors	Indication
SB-240563	IL5	Humanised		GlaxoSmithKline	Asthma/Allergy
SB-240683	IL-4	Humanised		GlaxoSmithKline	Asthma/Allergy
SCH55700	IL-5	Humanised		Celltech/Schering	Asthma/Allergy
Simulect	CD25	Chimeric	IgG 1	Novartis Pharma	Allograft rejection
SMART a-CD3	CD3	Humanised		Protein Design Lab	Autoimmune disease
SMART a-CD3	CD3	Humanised		Protein Design Lab	Allograft rejection
SMART a-CD3	CD3	Humanised	IgG	Protein Design Lab	Psoriasis
Zenapax	CD25	Humanised	IgG 1	Protein Design Lab/Hoffman-La Roche	Allograft rejection

Table 6B: Antibodies and Fc fusion proteins for Autoimmune Disorders

Antibody	Indication	Target Antigen
ABX-RB2		antibody to CBL antigen on T cells, B cells and NK cells fully human antibody from the Xenomouse
IL1-ra	rheumatoid arthritis	recombinant anti-inflammatory protein
sTNF-RI	chronic inflammatory disease rheumatoid arthritis	soluble tumor necrosis factor a - receptor type I blocks TNF action
5c8 (Anti CD-40 ligand antibody)	Phase II trials were halted in Oct. 99 examine "adverse events"	CD-40
IDECA 131	systemic lupus erythematosus (SLE)	anti CD40 humanized
IDECA 151	rheumatoid arthritis	primatized ; anti-CD4
IDECA 152	asthma	primatized; anti-CD23
IDECA 114	psoriasis	primatized anti-CD80
MEDI-507	rheumatoid arthritis; multiple sclerosis Crohn's disease psoriasis	anti-CD2
LDP-02 (anti-b7 mAb)	inflammatory bowel disease Chron's disease ulcerative colitis	a4b7 integrin receptor on white blood cells (leukocytes)
SMART Anti-Gamma Interferon antibody	autoimmune disorders	Anti-Gamma Interferon
Verteportin	rheumatoid arthritis	
Thalomid (thalidomide)	leprosy - approved for market Chron's disease rheumatoid arthritis	inhibitor of tumor necrosis factor alpha (TNF alpha)
SelCIDs (selective cytokine inhibitory drugs)		highly specific inhibitors of phosphodiesterase type 4 enzyme (PDE-4) increases levels of cAMP (cyclic adenosine monophosphate) activates protein kinase A (PKA) blocks transcription factor NF- κ B prevents transcription of TNF-a gene
		decreases production of TNF-a
IMiDs (immunomodulatory drugs)	general autoimmune disorders	structural analogues of thalidomide inhibit TNF-a
MDX-33	blood disorders caused by Autoimmune reactions Idiopathic Thrombocytopenia Purpura (ITP) Autoimmune hemolytic anemia	monoclonal antibody against FcRI receptors
MDX-CD4	treat rheumatoid arthritis and other autoimmunity	monoclonal antibody against CD4 receptor molecule
VX-497	Autoimmune disorders multiple sclerosis Rheumatoid arthritis inflammatory bowel disease lupus psoriasis	inhibitor of inosine monophosphate dehydrogenase (enzyme needed to make new RNA and DNA used in production of nucleotides needed for lymphocyte proliferation)

Antibody	Indication	Target Antigen
VX-740	rheumatoid arthritis	inhibitor of ICE interleukin-1 beta (converting enzyme controls pathways leading to aggressive immune response regulates cytokines)
VX-745	specific to inflammation involved in chemical signaling of immune response onset and progression of inflammation	inhibitor of P38MAP kinase mitogen activated protein kinase
Enbrel (etanercept)		targets TNF (tumor necrosis factor)
IL-8		fully human MAB against IL-8 (interleukin 8) (blocks IL-8 blocks inflammatory response)
5G1.1	rheumatoid arthritis pemphigoid (dangerous skin rash) psoriasis lupus	a C5 complement inhibitor
Apogen MP4		recombinant antigen selectively destroys disease associated T-cells induces apoptosis T-cells eliminated by programmed cell death no longer attack body's own cells specific apogens target specific T-cells

5.4.3 ALLERGY

[0310] There are discussed methods for treating or preventing an IgE-mediated and or Fc γ RI mediated allergic disorder in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of the agonistic antibodies or fragments thereof of the invention. Although not intending to be bound by a particular mechanism of action, antibodies of the invention are useful in inhibiting Fc ϵ RI-induced mast cell activation, which contributes to acute and late-phase allergic responses (Metcalfe D. et al. 1997, *Physiol. Rev.* 77:1033). Preferably, the agonistic antibodies of the invention have enhanced therapeutic efficacy and/or reduced side effects in comparison with the conventional methods used in the art for the treatment and/or prevention of IgE-mediated allergic disorders. Conventional methods for the treatment and/or prevention of IgE-mediated allergic disorders include, but are not limited to, anti-inflammatory drugs (e.g., oral and inhaled corticosteroids for asthma), antihistamines (e.g., for allergic rhinitis and atopic dermatitis), cysteinyl leukotrienes (e.g., for the treatment of asthma); anti-IgE antibodies; and specific immunotherapy or desensitization.

[0311] Examples of IgE-mediated allergic responses include, but are not limited to, asthma, allergic rhinitis, gastrointestinal allergies, eosinophilia, conjunctivitis, atopic dermatitis, urticaria, anaphylaxis, or golmerular nephritis.

[0312] Also described are molecules, e.g., immunoglobulins, engineered to form complexes with Fc γ RI and human Fc γ RIIB, i.e., specifically bind Fc γ RI and human Fc γ RIIB. Preferably, such molecules have therapeutic efficacy in IgE and Fc γ RI-mediated disorders. Although not intending to be bound by a particular mechanism of action, the therapeutic efficacy of these engineered molecules is, in part, due to their ability to inhibit mast cell and basophil function.

[0313] Molecules that specifically bind Fc γ RI and human Fc γ RIIB can be chimeric fusion proteins comprising a binding site for Fc γ RI and a binding site for Fc γ RIIB. Such molecules may be engineered in accordance with standard recombinant DNA methodologies known to one skilled in the art. Preferably a chimeric fusion protein for use in the methods of the specification comprises an F(ab') single chain of an anti-Fc γ RIIB monoclonal antibody of the invention fused to a region used as a bridge to link the huFc γ to the C-terminal region of the F(ab') single chain of the anti-Fc γ RIIB monoclonal antibody. One exemplary chimeric fusion protein for use in the methods of the specification comprises the following: V_L/C_H (Fc γ RIIB) - hinge-V_H/C_H (Fc γ RIIB)-LINKER -C_H ε 2-C_H ε 3-C_H ε 4. The linker for the chimeric molecules may be five, ten, preferably fifteen amino acids in length. The length of the linker may vary to provide optimal binding of the molecule to both Fc γ RIIB and Fc γ RI. In a specific embodiment, the linker is a 15 amino acid linker, consisting of the sequence:

(Gly₄Ser)₃. Although not intending to be bound by a particular mechanism of action, the flexible peptide linker facilitates chain pairing and minimizes possible refolding and it will also allow the chimeric molecule to reach the two receptors, i.e., Fc γ RIIB and Fc γ RI on the cells and cross-link them. Preferably, the chimeric molecule is cloned into a mammalian expression vector, e.g., pCI-neo, with a compatible promoter, e.g., cytomegalovirus promoter. The fusion protein prepared in accordance with the methods of

the specification will contain the binding site for Fc ϵ RI (CH ϵ 2CH ϵ 3) and for Fc γ RIIB (VL/CL, - hinge-VH/CH). The nucleic acid encoding the fusion protein prepared in accordance with the methods of the specification is preferably transfected into 293 cells and the secreted protein is purified using common methods known in the art.

[0314] Binding of the chimeric molecules to both human Fc ϵ RI and Fc γ RIIB may be assessed using common methods known to one skilled in the art for determining binding to an Fc γ R. Preferably, the chimeric molecules of the invention have therapeutic efficacy in treating IgE-mediated disorders, for example, by inhibiting antigen-driven degranulation and inhibition of cell activation. The efficacy of the chimeric molecules of the invention in blocking IgE driven Fc ϵ RI-mediated mast cell degranulation may be determined in transgenic mice, which have been engineered to express the human Fc ϵ RI and human Fc γ RIIB, prior to their use in humans.

[0315] The specification provides the use of bispecific antibodies for the treatment and/or prevention of IgE-mediated and/or Fc γ RI-mediated allergic disorders. A bispecific antibody (BsAb) binds to two different epitopes usually on distinct antigens. BsAbs have potential clinical utility and they have been used to target viruses, virally infected cells and bacterial pathogens as well as to deliver thrombolytic agents to blood clots (Cao Y, 1998 *Bioconj. Chem* 9: 635-644; Koelemij et al., 1999, *J. Immunother.*, 22, 514-524; Segal et al., *Curr. Opin. Immunol.*, 11, 558-562). The technology for the production of BsIgG and other related bispecific molecules is available (see, e.g., Carter et al., 2001 *J. of Immunol. Methods*, 248, 7-15; Segal et al., 2001, *J. of Immunol. Methods*, 248, 7-15). The instant invention provides bispecific antibodies containing one F(ab') of the anti-Fc γ RIIB antibody and one F(ab') of an available monoclonal anti-hulgE antibody which aggregates two receptors, Fc γ RIIB and Fc ϵ RI, on the surface of the same cell. Any methodology known in the art and disclosed herein may be employed to generate bispecific antibodies for use in the methods of the specification. In a specific embodiment, the BsAbs will be produced by chemically cross-linking F(ab') fragments of an anti-Fc γ RIIB antibody and an anti-hulgE antibody as described previously, see, e.g., Glennie et al., 1995, *Tumor Immunobiology*, Oxford University press, Oxford, p. 225). The F(ab') fragments may be produced by limited proteolysis with pepsin and reduced with mercaptoethanol amine to provide Fab' fragments with free hinge-region sulfhydryl (SH) groups. The SH group on one of the Fab' (SH) fragments may be alkylated with excess 0-phenylenedimaleimide (0-PDM) to provide a free maleimide group (mal). The two preparations Fab'(mal) and Fab'(SH) may be combined at an appropriate ratio, preferably 1:1 to generate heterodimeric constructs. The BsAbs can be purified by size exclusion chromatography and characterized by HPLC using methods known to one skilled in the art.

[0316] In particular, the invention encompasses bispecific antibodies comprising a first heavy chain-light chain pair that binds Fc γ RIIB with greater affinity than said heavy chain-light chain pair binds Fc γ RIIA, and a second heavy chain-light chain pair that binds IgE receptor, with the provision that said first heavy chain-light chain pair binds Fc γ RIIB first. The bispecific antibodies of the invention can be engineered using standard techniques known in the art to ensure that the binding to Fc γ RIIB precedes the binding to the IgE receptor. It will be understood to one skilled in the art to engineer the bispecific antibodies, for example, such that said bispecific antibodies bind Fc γ RIIB with greater affinity than said antibodies bind IgE receptor. Additionally, the bispecific antibodies can be engineered by techniques known in the art, such that the hinge size of the antibody can be increased in length, for example, by adding linkers, to provide the bispecific antibodies with flexibility to bind the IgE receptor and Fc γ RIIB receptor on the same cell.

[0317] The antibodies of the invention can also be used in combination with other therapeutic antibodies or drugs known in the art for the treatment or prevention of IgE-mediated allergic disorders. For example, the antibodies of the invention can be used in combination with any of the following: azelastine, Astelin, beclomethasone dipropionate inhaler, Vanceril, beclomethasone dipropionate nasal inhaler/spray, Vancenase, Beconase budesonide nasal inhaler/spray, Rhinocort cetirizine, Zyrtec chlorpheniramine, pseudoephedrine, Deconamine, Sudafed, cromolyn, Nasalcrom, Intal, Opticrom, desloratadine, Clarinex, fexofenadine and pseudoephedrine, Allegra-D, fexofenadine, Allegra flunisolide nasal spray, Nasalide fluticasone propionate nasal inhaler/spray, Flonase fluticasone propionate oral inhaler, Flovent, hydroxyzine, Vistaril, Ataraxloratadine, pseudoephedrine, Claritin-D, loratadine, Claritin, prednisolone, Prednisolone, Pediapred Oral Liquid, Medrol prednisone, Deltasone, Liquid Predsalmeterol, Serevent triamcinolone acetonide inhaler, Azmacort triamcinolone acetonide nasal inhaler/spray, Nasacort, or NasacortAQ. Antibodies of the invention can be used in combination with cytosine-guanine dinucleotides ("CpG")-based products that have been developed (Coley Pharmaceuticals) or are currently being developed as activators of innate and acquired immune responses. For example, the use of CpG 7909, CpG 8916, CpG 8954 (Coley Pharmaceuticals) in the methods and compositions of the specification for the treatment and/or prevention of IgE-mediated allergic disorders (See also Weeratna et al., 2001, *FEMS Immunol Med Microbiol*, 32(1):65-71) is also discussed.

[0318] Further described is the use of the antibodies of the invention in combination with any therapeutic antibodies known in the art for the treatment of allergy disorders, e.g., XolairTM (Omalizumab; Genentech); rhuMAB-E25 (BioWorld Today, Nov. 10, 1998,

p. 1; Genentech); CGP-51901 (humanized anti-IgE antibody), etc.

[0319] Additionally, the antibodies of the invention can be used in combination with other compositions known in the art for the treatment of allergy disorders. In particular methods and compositions disclosed in Carson et al. (US 6,426,336; US 2002/0035109 A1; US 2002/0010343).

5.4.4 IMMUNOMODULATORY AGENTS AND ANTI-INFLAMMATORY AGENTS

[0320] Also discussed are methods of treatment for autoimmune diseases and inflammatory diseases comprising administration of the antibodies of the present invention in conjunction with other treatment agents. Examples of immunomodulatory agents include, but are not limited to, methotrexate, ENBREL, REMICADE™, leflunomide, cyclophosphamide, cyclosporine A, and macrolide antibiotics (e.g., FK506 (tacrolimus)), methylprednisolone (MP), corticosteroids, steriods, mycophenolate mofetil, rapamycin (sirolimus), mizoribine, deoxyspergualin, brequinar, malononitriloamindes (e.g., leflunamide), T cell receptor modulators, and cytokine receptor modulators.

[0321] Anti-inflammatory agents have exhibited success in treatment of inflammatory and autoimmune disorders and are now a common and a standard treatment for such disorders. Any anti-inflammatory agent well-known to one of skill in the art can be used in the methods of the specification. Non-limiting examples of anti-inflammatory agents include non-steroidal anti-inflammatory drugs (NSAIDs), steroid anti-inflammatory drugs, beta-agonists, anticholinergic agents, and methyl xanthines. Examples of NSAIDs include, but are not limited to, aspirin, ibuprofen, celecoxib (CELEBREX™), diclofenac (VOLTAREN™), etodolac (LODINE™), fenoprofen (NALFON™), indomethacin (INDOCIN™), ketorolac (TORADOL™), oxaprozin (DAYPRO™), nabumetone (RELAFEN™), sulindac (CLINORIL™), tolmentin (TOLECTIN™), rofecoxib (VIOXX™), naproxen (ALEVE™, NAPROSYN™), ketoprofen (ACTRON™) and nabumetone (RELAFEN™). Such NSAIDs function by inhibiting a cyclooxygenase enzyme (e.g., COX-1 and/or COX-2). Examples of steroid anti-inflammatory drugs include, but are not limited to, glucocorticoids, dexamethasone (DECADRON™), cortisone, hydrocortisone, prednisone (DELTASONE™), prednisolone, triamcinolone, azulfidine, and eicosanoids such as prostaglandins, thromboxanes, and leukotrienes.

5.4.5 ANTI-CANCER AGENTS AND THERAPEUTIC ANTIBODIES

[0322] Further disclosed is the administration of one or more angiogenesis inhibitors such as but not limited to: Angiostatin (plasminogen fragment); antiangiogenic antithrombin III; Angiozyme; ABT-627; Bay 12-9566; Benefin; Bevacizumab; BMS-275291; cartilage-derived inhibitor (CDI); CAI; CD59 complement fragment; CEP-7055; Col 3; Combretastatin A-4; Endostatin (collagen XVIII fragment); EGFr blockers/inhibitors (Iressa®, Tarceva®, Erbitux®, and ABX-EGF); Fibronectin fragment; Gro-beta; Halofuginone; Heparinases; Heparin hexasaccharide fragment; HMV833; Human chorionic gonadotropin (hCG); IM-862; Interferon alpha/beta/gamma; Interferon inducible protein (IP-10); Interleukin-12; Kringle 5 (plasminogen fragment); Marimastat; Metalloproteinase inhibitors (TIMPs); 2-Methoxyestradiol; MMI 270 (CGS 27023A); MoAb IMC-1C11; Neovastat; NM-3; Panzem; PI-88; Placental ribonuclease inhibitor; Plasminogen activator inhibitor; Platelet factor-4 (PF4); Prinomastat; Prolactin 16kD fragment; Proliferin-related protein (PRP); PTK 787/ZK 222594; Retinoids; Solimastat; Squalamine; SS 3304; SU 5416; SU6668; SU11248; Tetrahydrocortisol-S; tetrathiomolybdate; thalidomide; Thrombospondin-1 (TSP-1); TNP-470; Transforming growth factor-beta (TGF-β); Vasculostatin; Vasostatin (calreticulin fragment); ZD6126; ZD 6474; farnesyl transferase inhibitors (FTI); and bisphosphonates.

[0323] Anti-cancer agents that can be used in combination with antibodies of the invention in the various instances of the specification, including pharmaceutical compositions and dosage forms and kits of the specification, include, but are not limited to: acivicin; aclarubicin; acodazole hydrochloride; acronine; adozelesin; aldesleukin; altretamine; ambomycin; ametantrone acetate; aminoglutethimide; amsacrine; anastrozole; anthramycin; asparaginase; asperlin; azacitidine; azetepa; azotomycin; batimastat; benzodepa; bicalutamide; bisantrene hydrochloride; bisnafide dimesylate; bizelesin; bleomycin sulfate; brequinar sodium; bropirimine; busulfan; cactinomycin; calusterone; caracemide; carbetimer; carboplatin; carmustine; carubicin hydrochloride; carzelesin; cedefengol; chlorambucil; cirolemycin; cisplatin; cladribine; crisnatol mesylate; cyclophosphamide; cytarabine; dacarbazine; dactinomycin; daunorubicin hydrochloride; decitabine; dexormaplatin; dezaguanine; dezaguanine mesylate; diaziquone; docetaxel; doxorubicin; doxorubicin hydrochloride; droloxfene; droloxfene citrate; dromostanolone propionate; duazomycin; edatrexate; eflornithine hydrochloride; elsamitrucin; enloplatin; enpromate; epipropidine; epirubicin hydrochloride; erbulazole; esorubicin hydrochloride; estramustine; estramustine phosphate sodium; etanidazole; etoposide; etoposide phosphate; etoprine; fadrozole hydrochloride; fazarabine; fenretinide; floxuridine; fludarabine phosphate; fluorouracil; flurocitabine; fosquidone; fostriecin sodium; gemcitabine; gemcitabine hydrochloride; hydroxyurea; idarubicin hydrochloride;

ifosfamide; ilmofosine; interleukin II (including recombinant interleukin II, or rIL2), interferon alfa-2a; interferon alfa-2b; interferon alfa-n1 ; interferon alfa-n3; interferon beta-1 a; interferon gamma-1 b; iproplatin; irinotecan hydrochloride; lanreotide acetate; letrozole; leuprolide acetate; liarozole hydrochloride; lometrexol sodium; lomustine; losoxantrone hydrochloride; masoprolol; maytansine; mechlorethamine hydrochloride; megestrol acetate; melengestrol acetate; melphalan; menogaril; mercaptoperine; methotrexate; methotrexate sodium; metoprine; meturedepa; mitindomide; mitocarcin; mitocromin; mitogillin; mitomalcin; mitomycin; mitosper; mitotane; mitoxantrone hydrochloride; mycophenolic acid; nocodazole; nogalamycin; ormaplatin; oxisuran; paclitaxel; pegaspargase; peliomycin; pentamustine; peplomycin sulfate; perfosfamide; pipobroman; piposulfan; piroxantrone hydrochloride; plicamycin; plomestane; porfimer sodium; porfiromycin; prednimustine; procarbazine hydrochloride; puromycin; puromycin hydrochloride; pyrazofurin; riboprine; rogletimide; safingol; safingol hydrochloride; semustine; simtrazene; sparfosate sodium; sparsomycin; spirogermanium hydrochloride; spiomustine; spiroplatin; streptonigrin; streptozocin; sulofenur; talisomycin; tecogalan sodium; tegafur; teloxantrone hydrochloride; temoporfin; teniposide; teroxirone; testolactone; thiamiprime; thioguanine; thiotapec; tiazofurin; tirapazamine; toremifene citrate; trestolone acetate; triciribine phosphate; trimetrexate; trimetrexate glucuronate; triptorelin; tubulozole hydrochloride; uracil mustard; uredepa; vapreotide; verteporfin; vinblastine sulfate; vincristine sulfate; vindesine; vindesine sulfate; vinepidine sulfate; vinglycinate sulfate; vinleurosine sulfate; vinorelbine tartrate; vinrosidine sulfate; vinzolidine sulfate; vorozole; zeniplatin; zinostatin; zorubicin hydrochloride. Other anti-cancer drugs include, but are not limited to: 20-epi-1,25 dihydroxyvitamin D3; 5-ethynyluracil; abiraterone; aclarubicin; acylfulvene; adecyepenol; adozelesin; aldesleukin; ALL-TK antagonists; altretamine; ambamustine; amodox; amifostine; aminolevulinic acid; amrubicin; amsacrine; anagrelide; anastrozole; andrographolide; angiogenesis inhibitors; antagonist D; antagonist G; antarelix; anti-dorsalizing morphogenetic protein-1; antiandrogen, prostatic carcinoma; antiestrogen; antineoplaston; antisense oligonucleotides; aphidicolin glycinate; apoptosis gene modulators; apoptosis regulators; apurinic acid; ara-CDP-DL-PTBA; arginine deaminase; asulacrine; atamestane; atrimustine; axinastatin 1; axinastatin 2; axinastatin 3; azasetron; azatoxin; azatyrosine; baccatin III derivatives; balanol; batimastat; BCR/ABL antagonists; benzochlorins; benzoylstaurosporine; beta lactam derivatives; beta-alethine; betaclamycin B; betulinic acid; bFGF inhibitor; bicalutamide; bisantrene; bisaziridinylspermine; bisnafide; bistratene A; bizelesin; breflate; bropirimine; budotitane; buthionine sulfoximine; calcipotriol; calphostin C; camptothecin derivatives; canarypox IL-2; capecitabine; carboxamide-amino-triazole; carboxyamidotriazole; CaRest M3; CARN 700; cartilage derived inhibitor; carzelesin; casein kinase inhibitors (ICOS); castanospermine; cecropin B; cetrorelix; chlorlins; chloroquinoxaline sulfonamide; cicaprost; cis-porphyrin; cladribine; clomifene analogues; clotrimazole; collismycin A; collismycin B; combretastatin A4; combretastatin analogue; conagenin; crambescidin 816; crisnatol; cryptophycin 8; cryptophycin A derivatives; curacin A; cyclopentanthraquinones; cycloplatan; cypemycin; cytarabine ocfosfate; cytolytic factor; cytostatin; dacliximab; decitabine; dehydrodidemnin B; deslorelin; dexamethasone; dexifosfamide; dextrazoxane; dexverapamil; diaziquone; didemnin B; didox; diethylnorspermine; dihydro-5-azacytidine; dihydrotaxol, 9-; dioxamycin; diphenyl spiromustine; docetaxel; docosanol; dolasetron; doxifluridine; droloxifene; dronabinol; duocarmycin SA; ebselen; ecomustine; edelfosine; edrecolomab; eflornithine; elemene; emitefur; epirubicin; epristeride; estramustine analogue; estrogen agonists; estrogen antagonists; etanidazole; etoposide phosphate; exemestane; fadrozole; fazarabine; fenretinide; filgrastim; finasteride; flavopiridol; flezelastine; fluasterone; fludarabine; fluorodaunorubicin hydrochloride; forfenimex; formestane; fostriecin; fotemustine; gadolinium texaphyrin; gallium nitrate; galocitabine; ganirelix; gelatinase inhibitors; gemcitabine; glutathione inhibitors; hepsulfam; heregulin; hexamethylene bisacetamide; hypericin; ibandronic acid; idarubicin; idoxifene; idramantone; ilmofosine; ilomastat; imidazoacridones; imiquimod; immunostimulant peptides; insulin-like growth factor-1 receptor inhibitor; interferon agonists; interferons; interleukins; iboguane; iododoxorubicin; ipomeanol, 4-; iroplact; irsogladine; isobengazole; isohomohalicondrin B; itasetron; jasplakinolide; kahalalide F; lamellarin-N triacetate; lanreotide; leinamycin; lenograstim; lentinan sulfate; leptolstatin; letrozole; leukemia inhibiting factor; leukocyte alpha interferon; leuprolide+estrogen+progesterone; leuprorelin; levamisole; liarozole; linear polyamine analogue; lipophilic disaccharide peptide; lipophilic platinum compounds; lissoclinamide 7; lobaplatin; lombricine; lometrexol; lonidamine; losoxantrone; lovastatin; loxoribine; luritotecan; lutetium texaphyrin; lysofylline; lytic peptides; maitansine; manostatin A; marimastat; masoprolol; maspin; matrilysin inhibitors; matrix metalloproteinase inhibitors; menogaril; merbarone; meterelin; methioninase; metoclopramide; MIF inhibitor; mifepristone; nultefosine; mirimostim; mismatched double stranded RNA; mitoguazone; mitolactol; mitomycin analogues; mitonafide; mitotoxin fibroblast growth factor-saporin; mitoxantrone; mofarotene; molgramostim; monoclonal antibody, human chorionic gonadotrophin; monophosphoryl lipid A+mycobacterium cell wall sk; molidamol; multiple drug resistance gene inhibitor; multiple tumor suppressor 1-based therapy; mustard anticancer agent; mycaperoxide B; mycobacterial cell wall extract; myriaporone; N-acetyldinaline; N-substituted benzamides; nafarelin; nagestip; naloxone+pentazocine; napavin; naphterpin; nartograstim; nedaplatin; nemorubicin; neridronic acid; neutral endopeptidase; nilutamide; nisamycin; nitric oxide modulators; nitroxide antioxidant; nitrulyn; 06-benzylguanine; octreotide; okicenone; oligonucleotides; onapristone; ondansetron; ondansetron; oracin; oral cytokine inducer; ormaplatin; osaterone; oxaliplatin; oxaunomycin; paclitaxel; paclitaxel analogues; paclitaxel derivatives; palauamine; palmitoylribosin; parimduronic acid; panaxytriol; panomifene; parabactin; pazelliptine; pegaspargase; peldesine; pentosan polysulfate sodium; pentostatin; pentozole; perflubron; perfosfamide; perillyl alcohol; phenazinomycin; phenylacetate; phosphatase inhibitors; picibanil; pilocarpine hydrochloride; pirarubicin; piritrexim; placetin A; placetin B; plasminogen activator inhibitor; platinum complex; platinum compounds; platinum-triamine complex; porfimer sodium; porfiromycin; prednisone; propyl bis-acridone; prostaglandin J2; proteasome inhibitors; protein A-based immune modulator; protein kinase C inhibitor; protein kinase C inhibitors, microalgal; protein tyrosine phosphatase inhibitors; purine nucleoside

phosphorylase inhibitors; purpurins; pyrazoloacridine; pyridoxylated hemoglobin polyoxyethylene conjugate; raf antagonists; raltitrexed; ramosetron; ras farnesyl protein transferase inhibitors; ras inhibitors; ras-GAP inhibitor; retelliptine demethylated; rhenium Re 186 etidronate; rhizoxin; ribozymes; RII retinamide; rogletimide; rohitukine; romurtide; roquinimex; rubiginone B1; ruboxyl; safingol; saintopin; SarCNU; sarcophytol A; sargramostim; Sdi 1 mimetics; semustine; senescence derived inhibitor 1; sense oligonucleotides; signal transduction inhibitors; signal transduction modulators; single chain antigen binding protein; sizofiran; sobuzoxane; sodium borocaptate; sodium phenylacetate; solverol; somatomedin binding protein; sonermin; sparfosic acid; spicamycin D; spiomustine; splenopentin; spongistatin 1; squalamine; stem cell inhibitor; stem-cell division inhibitors; stipiamide; stromelysin inhibitors; sulfinosine; superactive vasoactive intestinal peptide antagonist; suradista; suramin; swainsonine; synthetic glycosaminoglycans; tallimustine; tamoxifen methiodide; tamoxifene; tazozole; tecogalan sodium; tegafur; tellurapyrylium; telomerase inhibitors; temoporfin; temozolamide; teniposide; tetrachlorodecaoxide; tetrazomine; thaliblastine; thiocoraline; thrombopoietin; thrombopoietin mimetic; thymalfasin; thymopoietin receptor agonist; thymotrinan; thyroid stimulating hormone; tin ethyl etiopurpurin; tirapazamine; titanocene bichloride; topsentin; toremifene; totipotent stem cell factor; translation inhibitors; tretinoin; triacetyluridine; triciribine; trimetrexate; triptorelin; tropisetron; turosteride; tyrosine kinase inhibitors; tyrophostins; UBC inhibitors; ubenimex; urogenital sinus-derived growth inhibitory factor; urokinase receptor antagonists; vapreotide; variolin B; vector system, erythrocyte gene therapy; velaresol; veramine; verdins; verteporfin; vinorelbine; vinxaltine; vitaxin; vorozole; zanoterone; zeniplatin; zilascorb; and zinostatin stimalamer. Preferred additional anti-cancer drugs are 5-fluorouracil and leucovorin.

[0324] Examples of therapeutic antibodies that can be used in methods described herein include but are not limited to HERCEPTIN® (Trastuzumab) (Genentech, CA) which is a humanized anti-HER2 monoclonal antibody for the treatment of patients with metastatic breast cancer; REOPRO® (abciximab) (Centocor) which is an anti-glycoprotein IIb/IIIa receptor on the platelets for the prevention of clot formation; ZENAPAX® (daclizumab) (Roche Pharmaceuticals, Switzerland) which is an immunosuppressive, humanized anti-CD25 monoclonal antibody for the prevention of acute renal allograft rejection; PANOREX™ (edrecolomab) which is a murine anti-17-IA cell surface antigen IgG2a antibody (Glaxo Wellcome/Centocor); BEC2 which is a murine anti-idiotype (GD3 epitope) IgG antibody (ImClone System); Erbitux® (cetuximab) which is a chimeric anti-EGFR IgG antibody (ImClone System); VITAXIN™ which is a humanized anti- α V β 3 integrin antibody (Applied Molecular Evolution/MedImmune); Campath 1H/LDP-03 which is a humanized anti CD52 IgG1 antibody (Leukosite); Smart M195 which is a humanized anti-CD33 IgG antibody (Protein Design Lab/Kanebo); RITUXAN™ (rituximab) which is a chimeric anti-CD20 IgG1 antibody (IDEC Pharm/Genentech, Roche/Zettyaku); LYMPHOCIDE™ (epratuzumab) which is a humanized anti-CD22 IgG antibody (Immunomedics); ICM3 which is a humanized anti-ICAM3 antibody (ICOS Pharm); IDEC-114 which is a primatized anti-CD80 antibody (IDEC Pharm/Mitsubishi); ZEVALIN™ which is a radiolabelled murine anti-CD20 antibody (IDEC/Schering AG); IDEC-131 which is a humanized anti-CD40L antibody (IDEC/Eisai); IDEC-151 which is a primatized anti-CD4 antibody (IDEC); IDEC-152 which is a primatized anti-CD23 antibody (IDEC/Seikagaku); SMART anti-CD3 which is a humanized anti-CD3 IgG (Protein Design Lab); 5G1.1 which is a humanized anti-complement factor 5 (C5) antibody (Alexion Pharm); Humira® which is a human anti-TNF- α antibody (Abbott Laboratories); CDP870 which is a humanized anti-TNF- α Fab fragment (Celltech); IDEC-151 which is a primatized anti-CD4 IgG1 antibody (IDEC Pharm/SmithKline Beecham); MDX-CD4 which is a human anti-CD4 IgG antibody (Medarex/Eisai/Genmab); CDP571 which is a humanized anti-TNF- α IgG4 antibody (Celltech); LDP-02 which is a humanized anti- α 4 β 7 antibody (LeukoSite/Genentech); OrthoClone OKT4A which is a humanized anti-CD4 IgG antibody (Ortho Biotech); ANTOVA™ which is a humanized anti-CD40L IgG antibody (Biogen); ANTEGREN™ which is a humanized anti-VLA-4 IgG antibody (Elan); and CAT-152 which is a human anti-TGF- β 2 antibody (Cambridge Ab Tech).

[0325] Other examples of therapeutic antibodies that can be used in combination with the antibodies of the invention are presented in Table 7.

Table 7: Monoclonal antibodies for Cancer Therapy that can be used in combination with the antibodies of the invention.

Company	Product	Disease	Target
Abgenix	ABX-EGF	Cancer	EGF receptor
AltaRex	OvaRex	ovarian cancer	tumor antigen CA125
	BravaRex	metastatic cancers	tumor antigen MUC1
Antisoma	Theragyn (pemtumomabibrium-90)	ovarian cancer	PEM antigen
	Therex	breast cancer	PEM antigen
Boehringer Ingelheim	blvatuzumab	head & neck cancer	CD44

Company	Product	Disease	Target
Centocor/J&J	Panorex	Colorectal cancer	17-1A
	ReoPro	PTCA	gp IIIb/IIIa
	ReoPro	Acute MI	gp IIIb/IIIa
	ReoPro	Ischemic stroke	gp IIIb/IIIa
Corixa	Bexocar	NHL	CD20
CRC Technology	MAb, idiotypic 105AD7	colorectal cancer vaccine	gp72
Crucell	Anti-EpCAM	cancer	Ep-CAM
Cytoclonal	MAb, lung cancer	non-small cell lung cancer	NA
Genentech	Herceptin	metastatic breast cancer	HER-2
	Herceptin	early stage breast cancer	HER-2
IDEC	Rituxan	Relapsed/refractory low-grade or follicular NHL	CD20
	Rituxan	intermediate & high-grade NHL	CD20
	MAb-VEGF	NSCLC, metastatic	VEGF
	MAb-VEGF	Colorectal cancer, metastatic	VEGF
ImClone	AMD Fab	age-related macular degeneration	CD18
	E-26 (2nd gen. IgE)	allergic asthma & rhinitis	IgE
	Zevalin (Rituxan + yttrium-90)	low grade of follicular, relapsed or refractory, CD20-positive, B-cell NHL and Rituximab-refractory NHL	CD20
	Cetuximab + innotecan	refractory colorectal carcinoma	EGF receptor
	Cetuximab + cisplatin & radiation	newly diagnosed or recurrent head & neck cancer	EGF receptor
ImmonoGen	Cetuximab + gemcitabine	newly diagnosed metastatic pancreatic carcinoma	EGF receptor
	Cetuximab + cisplatin + 5FU or Taxol	recurrent or metastatic head & neck cancer	EGF receptor
	Cetuximab + carboplatin + paclitaxel	newly diagnosed non-small cell lung carcinoma	EGF receptor
	Cetuximab + cisplatin	head & neck cancer (extensive incurable local-regional disease & distant metastases)	EGF receptor
	Cetuximab + radiation	locally advanced head & neck carcinoma	EGF receptor
	BEC2 + Bacillus Calmette Guerin	small cell lung carcinoma	mimics ganglioside GD3
	BEC2 + Bacillus Calmette Guerin	melanoma	mimics ganglioside GD3
ImmunoMedics	IMC-1C11	colorectal cancer with liver metastases	VEGF-receptor
	nuC242-DM1	Colorectal, gastric, and pancreatic cancer	nuC242
	LymphoCide	Non-Hodgkins lymphoma	CD22
	LymphoCide Y-90	Non-Hodgkins lymphoma	CD22
	CEA-Cide	metastatic solid tumors	CEA
	CEA-Cide Y-90	metastatic solid tumors	CEA
	CEA-Scan (Tc-99m-labeled arcitumomab)	colorectal cancer (radioimaging)	CEA
	CEA-Scan (Tc-99m-labeled arcitumomab)	Breast cancer (radioimaging)	CEA

Company	Product	Disease	Target
	CEA-Scan (Tc-99m-labeled arcitumomab)	lung cancer (radioimaging)	CEA
	CEA-Scan (Tc-99m-labeled arcitumomab)	intraoperative tumors (radio imaging)	CEA
	LeukoScan (Tc-99m-labeled sulesomab)	soft tissue infection (radioimaging)	CEA
	LymphoScan (Tc-99m-labeled)	lymphomas (radioimaging)	CD22
	AFP-Scan (Tc-99m-labeled)	liver 7 gem-cell cancers (radioimaging)	AFP
Intracel	HumaRAD-HN (+ yttrium-90)	head & neck cancer	NA
	HumaSPECT	colorectal imaging	NA
Medarex	MDX-101 (CTLA-4)	Prostate and other cancers	CTLA-4
	MDX-210 (her-2 overexpression)	Prostate cancer	HER-2
	MDX-210/MAK	Cancer	HER-2
MedImmune	Vitaxin	Cancer	avß3
Merck KGaA	MAb 425	Various cancers	EGF receptor
	IS-IL-2	Various cancers	Ep-CAM
Millennium	Campath (alemtuzumab)	chronic lymphocytic leukemia	CD52
NeoRx	CD20-streptavidin (+ biotin- yttrium 90)	Non-Hodgkins lymphoma	CD20
	Avidin (albumin + NRU13)	metastatic cancer	NA
Peregrine	Oncolym (+ iodine-131)	Non-Hodgkins lymphoma	HLA-DR 10 beta
	Cotara (+ iodine-131)	unresectable malignant glioma	DNA-associated proteins
Pharmacia Corporation	C215 (+ staphylococcal enterotoxin)	pancreatic cancer	NA
	MAb, lung/kidney cancer	lung & kidney cancer	NA
	nacolomab tafenatox (C242 + staphylococcal enterotoxin)	colon & pancreatic cancer	NA
Protein Design Labs	Nuvion	T cell malignancies	CD3
	SMART M195	AML	CD33
	SMART 1D10	NHL	HLA-DR antigen
Titan	CEAVac	colorectal cancer, advanced	CEA
	TriGem	metastatic melanoma & small cell lung cancer	GD2-ganglioside
	TriAb	metastatic breast cancer	MUC-1
Trilex	CEAVac	colorectal cancer, advanced	CEA
	TriGem	metastatic melanoma & small cell lung cancer	GD2-ganglioside
	TriAb	metastatic breast cancer	MUC-1
Viventia Biotech	NovoMAb-G2 radiolabeled	Non-Hodgkins lymphoma	NA
	Monopharm C	colorectal & pancreatic carcinoma	SK-1 antigen
	GlioMAb-H (+ gelonin toxin)	glioma, melanoma & neuroblastoma	NA
Xoma	Rituxan	Relapsed/refractory low-grade or follicular NHL	CD20
	Rituxan	intermediate & high-grade NHL	CD20
	ING-1	adenocarcinoma	Ep-CAM

5.4.6 VACCINE THERAPY

[0326] There is described a method for enhancing an immune response to a vaccine composition in a subject, said method comprising administering to said subject an antibody or a fragment thereof that specifically binds Fc_YRIIB with greater affinity than said antibody or a fragment thereof binds Fc_YRIIA, and a vaccine composition, wherein said antibody or a fragment thereof enhances the immune response to said vaccine composition. The said antibody or a fragment thereof can enhance the immune response to said vaccine composition by enhancing antigen presentation/and or antigen processing of the antigen to which the vaccine is directed at. Any vaccine composition known in the art is useful in combination with the antibodies or fragments thereof of the invention.

[0327] The antibodies of the invention can be used in combination with any cancer vaccine known in the art, e.g., CanvaxinTM (Cancer Vax, Corporation, melanoma and colon cancer); Oncophage (HSPPC-96; Antigenics; metastatic melanoma); HER-2/neu cancer vaccine, etc. The cancer vaccines used in the methods described herein and compositions of the invention can be, for example, antigen-specific vaccines, anti-idiotypic vaccines, dendritic cell vaccines, or DNA vaccines. Also described is the use of the antibodies of the invention with cell-based vaccines as described by Segal et al. (U.S. Patent No. 6,403,080). The cell based vaccines used in combination with the antibodies of the invention can be either autologous or allogeneic. Briefly, the cancer-based vaccines as described by Segal et al. are based on Opsonokine (TM) product by Genitrix, LLC. Opsonokines(TM) are genetically engineered cytokines that, when mixed with tumor cells, automatically attach to the surface of the cells. When the "decorated" cells are administered as a vaccine, the cytokine on the cells activates critical antigen presenting cells in the recipient, while also allowing the antigen presenting cells to ingest the tumor cells. The antigen presenting cells are then able to instruct "killer" T cells to find and destroy similar tumor cells throughout the body. Thus, the Opsonokine(TM) product converts the tumor cells into a potent anti-tumor immunotherapeutic.

[0328] The antibodies of the invention can be used in combination with any allergy vaccine known in the art. The antibodies of the invention, can be used, for example, in combination with recombinant hybrid molecules coding for the major timothy grass pollen allergens used for vaccination against grass pollen allergy, as described by Linhart et al. (2000, FASEB Journal, 16(10):1301-3). In addition the antibodies of the invention can be used in combination with DNA-based vaccinations described by Horner et al. (2002, Allergy, 57 Suppl, 72:24-9). Antibodies of the invention can be used in combination with Bacille Clamett-Guerin ("BCG") vaccination as described by Choi et al. (2002, Ann. Allergy Asthma Immunology, 88(6): 584-91) and Barlan et al. (2002, Journal Asthma, 39(3):239-46) to downregulate IgE secretion. The antibodies of the invention are useful in treating food allergies. In particular the antibodies of the invention can be used in combination with vaccines or other immunotherapies known in the art (see Hourihane et al., 2002, Curr. Opin. Allergy Clin. Immunol. 2(3):227-31) for the treatment of peanut allergies.

[0329] The methods described herein and compositions of the invention can be used in combination with vaccines, in which immunity for the antigen(s) is desired. Such antigens may be any antigen known in the art. The antibodies of the invention can be used to enhance an immune response, for example, to infectious agents, diseased or abnormal cells such as, but not limited to, bacteria (e.g., gram positive bacteria, gram negative bacteria, aerobic bacteria, Spirochetes, Mycobacteria, Rickettsias, Chlamydias, etc.), parasites, fungi (e.g., Candida albicans, Aspergillus, etc.), viruses (e.g., DNA viruses, RNA viruses, etc.), or tumors. Viral infections include, but are not limited to, human immunodeficiency virus (HIV); hepatitis A virus, hepatitis B virus, hepatitis C virus, hepatitis D virus, or other hepatitis viruses; cytomegaloviruses, herpes simplex virus-1 (-2,-3,-4,-5,-6), human papilloma viruses; Respiratory syncytial virus (RSV), Parainfluenza virus (PIV), Epstein Barr virus, human metapneumovirus (HMPV), influenza virus, Severe Acute Respiratory Syndrome(SARS) or any other viral infections.

[0330] Also discussed are methods and vaccine compositions comprising combinations of an antibody of the invention, an antigen and a cytokine. Preferably, the cytokine is IL-4, IL-10, or TGF- β .

[0331] The use of the antibodies of the invention to enhance a humoral and/or cell mediated response against the antigen(s) of the vaccine composition is also discussed, as is the use of the antibodies of the invention to either prevent or treat a particular disorder, where an enhanced immune response against a particular antigen or antigens is effective to treat or prevent the disease or disorder. Such diseases and disorders include, but are not limited to, viral infections, such as HIV, CMV, hepatitis, herpes virus, measles, etc., bacterial infections, fungal and parasitic infections, cancers, and any other disease or disorder amenable to treatment or prevention by enhancing an immune response against a particular antigen or antigens.

5.5 COMPOSITIONS AND METHODS OF ADMINISTERING

[0332] The invention provides pharmaceutical compositions comprising antibodies of the invention. Specifically, the invention provides a pharmaceutical composition comprising (i) a therapeutically effective amount of the isolated antibody or antigen-binding fragment thereof of any one of claims 1-12; and (ii) a pharmaceutically acceptable carrier. Methods are also described for the treatment, prophylaxis, and amelioration of one or more symptoms associated with a disease, disorder or infection by administering to a subject an effective amount of a fusion protein or a conjugated molecule of the invention, or a pharmaceutical composition comprising a fusion protein or conjugated molecules of the invention. It is preferred that an antibody or fusion protein or conjugated molecule, is substantially purified (*i.e.*, substantially free from substances that limit its effect or produce undesired side-effects). Specifically the subject can be an animal, preferably a mammal such as non-primate (*e.g.*, cows, pigs, horses, cats, dogs, rats etc.) and a primate (*e.g.*, monkey such as, a cynomolgous monkey and a human). It is preferred that the subject is a human.

[0333] Various delivery systems are known and can be used to administer a composition comprising antibodies of the invention, *e.g.*, encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing the antibody or fusion protein, receptor-mediated endocytosis (See, *e.g.*, Wu and Wu, 1987, *J. Biol. Chem.* 262:4429-4432), construction of a nucleic acid as part of a retroviral or other vector, etc.

[0334] In some cases, the antibodies of the invention are formulated in liposomes for targeted delivery of the antibodies of the invention. Liposomes are vesicles comprised of concentrically ordered phospholipid bilayers which encapsulate an aqueous phase. Liposomes typically comprise various types of lipids, phospholipids, and/or surfactants. The components of liposomes are arranged in a bilayer configuration, similar to the lipid arrangement of biological membranes. Liposomes are particularly preferred delivery vehicles due, in part, to their biocompatibility, low immunogenicity, and low toxicity. Methods for preparation of liposomes are known in the art, see, *e.g.*, Epstein et al., 1985, *Proc. Natl. Acad. Sci. USA*, 82: 3688; Hwang et al., 1980 *Proc. Natl. Acad. Sci. USA*, 77: 4030-4; U.S. Patent Nos. 4,485,045 and 4,544,545.

[0335] Also described are methods of preparing liposomes with a prolonged serum half-life, *i.e.*, enhanced circulation time, such as those disclosed in U.S. Patent No. 5,013,556. Preferred liposomes used in the methods described herein are not rapidly cleared from circulation, *i.e.*, are not taken up into the mononuclear phagocyte system (MPS). Sterically stabilized liposomes which are prepared using common methods known to one skilled in the art can be used. Although not intending to be bound by a particular mechanism of action, sterically stabilized liposomes contain lipid components with bulky and highly flexible hydrophilic moieties, which reduces the unwanted reaction of liposomes with serum proteins, reduces opsonization with serum components and reduces recognition by MPS. Sterically stabilized liposomes are preferably prepared using polyethylene glycol. For preparation of liposomes and sterically stabilized liposome see, *e.g.*, Bendas et al., 2001 *BioDrugs*, 15(4): 215-224; Allen et al., 1987 *FEBS Lett.* 223: 42-6; Klibanov et al., 1990 *FEBS Lett.*, 268: 235-7; Blum et al., 1990, *Biochim. Biophys. Acta.*, 1029: 91-7; Torchilin et al., 1996, *J. Liposome Res.* 6: 99-116; Litzinger et al., 1994, *Biochim. Biophys. Acta*, 1190: 99-107; Maruyama et al., 1991, *Chem. Pharm. Bull.*, 39: 1620-2; Klibanov et al., 1991, *Biochim Biophys Acta*, 1062; 142-8; Allen et al., 1994, *Adv. Drug Deliv. Rev.*, 13: 285-309. Liposomes that are adapted for specific organ targeting, see, *e.g.*, U.S. Patent No. 4,544,545, or specific cell targeting, see, *e.g.*, U.S. Patent Application Publication No. 2005/0074403 can also be used. Particularly useful liposomes for use in the compositions of the invention and methods described herein can be generated by reverse phase evaporation method with a lipid composition comprising phosphatidylcholine, cholesterol, and PEG derivatized phosphatidylethanolamine (PEG-PE). Liposomes are extruded through filters of defined pore size to yield liposomes with the desired diameter. In some cases, a fragment of an antibody of the invention, *e.g.*, F(ab'), may be conjugated to the liposomes using previously described methods, see, *e.g.*, Martin et al., 1982, *J. Biol. Chem.* 257: 286-288.

[0336] The antibodies of the invention may also be formulated as immunoliposomes. Immunoliposomes refer to a liposomal composition, wherein an antibody of the invention or a fragment thereof is linked, covalently or non-covalently to the liposomal surface. The chemistry of linking an antibody to the liposomal surface is known in the art, see, *e.g.*, U.S. Patent No. 6,787,153; Allen et al., 1995, *Stealth Liposomes*, Boca Raton: CRC Press, 233-44; Hansen et al., 1995, *Biochim. Biophys. Acta*, 1239: 133-44. It is preferred that immunoliposomes for use in the methods described herein and compositions of the invention are further sterically stabilized. Preferably, the antibodies of the invention are linked covalently or non-covalently to a hydrophobic anchor, which is stably rooted in the lipid bilayer of the liposome. Examples of hydrophobic anchors include but are not limited to phospholipids, *e.g.*, phosoatidylethanolamine (PE), phospahtidylinositol (PI). To achieve a covalent linkage between an antibody and a hydrophobic anchor, any of the known biochemical strategies in the art may be used, see, *e.g.*, J. Thomas August, ed., 1997, *Gene Therapy: Advances in Pharmacology*, Volume 40, Academic Press, San Diego, CA., p. 399-435, which is incorporated herein by reference in its entirety. For example, a functional group on an antibody molecule may react with an active group on a liposome associated hydrophobic anchor, *e.g.*, an amino group of a lysine side chain on an antibody may be coupled to liposome associated N-glutaryl-phosphatidylethanolamine activated with watersoluble carbodiimide; or a thiol group of a

reduced antibody can be coupled to liposomes via thiol reactive anchors such as pyridylthiopropionyl- phosphatidylethanolamine. See, e.g., Dietrich et al., 1996, *Biochemistry*, 35: 1100-1105 ; Loughrey et al., 1987, *Biochim. Biophys. Acta*, 901: 157-160; Martin et al., 1982, *J. Biol. Chem.* 257: 286-288; Martin et al., 1981, *Biochemistry*, 20: 4429-38. Although not intending to be bound by a particular mechanism of action, immunoliposomal formulations comprising an antibody of the invention are particularly effective as therapeutic agents, since they deliver the antibody to the cytoplasm of the target cell, *i.e.*, the cell comprising the Fc_YRIIB receptor to which the antibody binds. The immunoliposomes preferably have an increased half-life in blood, specifically target cells, and can be internalized into the cytoplasm of the target cells thereby avoiding loss of the therapeutic agent or degradation by the endolysosomal pathway.

[0337] There is described an antibody of the invention or a fragment thereof. The immunoliposomes may further comprise one or more additional therapeutic agents, such as those disclosed herein.

[0338] The immunoliposomal compositions described herein comprise one or more vesicle forming lipids, an antibody of the invention or a fragment or derivative thereof, and optionally a hydrophilic polymer. A vesicle forming lipid is preferably a lipid with two hydrocarbon chains, such as acyl chains and a polar head group. Examples of vesicle forming lipids include phospholipids, e.g., phosphatidylcholine, phosphatidylethanolamine, phosphatidic acid, phosphatidylinositol, sphingomyelin, and glycolipids, e.g., cerebrosides, gangliosides. The immunoliposomal compositions may further comprise a hydrophilic polymer, e.g., polyethylene glycol, and ganglioside GM1, which increases the serum half life of the liposome. Methods of conjugating hydrophilic polymers to liposomes are well known in the art and encompassed within the invention. For a review of immunoliposomes and methods of preparing them, see, e.g., U.S. Patent Application Publication No. 2003/0044407; PCT International Publication No. WO 97/38731, Vingerhoeeds et al., 1994, *Immunomethods*, 4: 259-72; Maruyama, 2000, *Biol. Pharm. Bull.* 23(7): 791-799; Abra et al., 2002, *Journal of Liposome Research*, 12(1&2): 1-3; Park, 2002, *Bioscience Reports*, 22(2): 267-281; Bendas et al., 2001 *BioDrugs*, 14(4): 215-224, J. Thomas August, ed., 1997, *Gene Therapy: Advances in Pharmacology*, Volume 40, Academic Press, San Diego, CA., p. 399-435.

[0339] Methods of administering an antibody of the invention include, but are not limited to, parenteral administration (e.g., intradermal, intramuscular, intraperitoneal, intravenous and subcutaneous), epidural, and mucosal (e.g., intranasal and oral routes). It is preferred that the antibodies of the invention are administered intramuscularly, intravenously, or subcutaneously. The compositions may be administered by any convenient route, for example, by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents. Administration can be systemic or local. In addition, pulmonary administration can also be employed, e.g., by use of an inhaler or nebulizer, and formulation with an aerosolizing agent. See, e.g., U.S. Patent Nos. 6,019,968; 5,985, 20; 5,985,309; 5,934,272; 5,874,064; 5,855,913; 5,290,540; and 4,880,078; and PCT Publication Nos. WO 92/19244; WO 97/32572; WO 97/44013; WO 98/31346; and WO 99/66903.

[0340] The invention also provides that the antibodies of the invention are packaged in a hermetically sealed container such as an ampoule or sachette indicating the quantity of antibody. The antibodies of the invention can be supplied as a dry sterilized lyophilized powder or water free concentrate in a hermetically sealed container and can be reconstituted, e.g., with water or saline to the appropriate concentration for administration to a subject. Preferably, the antibodies of the invention are supplied as a dry sterile lyophilized powder in a hermetically sealed container at a unit dosage of at least 5 mg, more preferably at least 10 mg, at least 15 mg, at least 25 mg, at least 35 mg, at least 45 mg, at least 50 mg, or at least 75 mg. The lyophilized antibodies of the invention should be stored at between 2 and 8°C in their original container and the antibodies should be administered within 12 hours, preferably within 6 hours, within 5 hours, within 3 hours, or within 1 hour after being reconstituted. Alternatively the antibodies of the invention can be supplied in liquid form in a hermetically sealed container indicating the quantity and concentration of the antibody, fusion protein, or conjugated molecule. Preferably, the liquid form of the antibodies are supplied in a hermetically sealed container at least 1 mg/ml, more preferably at least 2.5 mg/ml, at least 5 mg/ml, at least 8 mg/ml, at least 10 mg/ml, at least 15 mg/kg, at least 25 mg/ml, at least 50 mg/ml, at least 100 mg/ml, at least 150 mg/ml, at least 200 mg/ml of the antibodies.

[0341] The amount of the composition of the invention which will be effective in the treatment, prevention or amelioration of one or more symptoms associated with a disorder can be determined by standard clinical techniques. The precise dose to be employed in the formulation will also depend on the route of administration, and the seriousness of the condition, and should be decided according to the judgment of the practitioner and each patient's circumstances. Effective doses may be extrapolated from dose-response curves derived from *in vitro* or animal model test systems.

[0342] For antibodies encompassed by the invention, the dosage administered to a patient is typically 0.0001 mg/kg to 100 mg/kg of the patient's body weight. Preferably, the dosage administered to a patient is between 0.0001 mg/kg and 20 mg/kg,

0.0001 mg/kg and 10 mg/kg, 0.0001 mg/kg and 5 mg/kg, 0.0001 and 2 mg/kg, 0.0001 and 1 mg/kg, 0.0001 mg/kg and 0.75 mg/kg, 0.0001 mg/kg and 0.5 mg/kg, 0.0001 mg/kg to 0.25 mg/kg, 0.0001 to 0.15 mg/kg, 0.0001 to 0.10 mg/kg, 0.001 to 0.5 mg/kg, 0.01 to 0.25 mg/kg or 0.01 to 0.10 mg/kg of the patient's body weight. Generally, human antibodies have a longer half-life within the human body than antibodies from other species due to the immune response to the foreign polypeptides. Thus, lower dosages of human antibodies and less frequent administration is often possible. Further, the dosage and frequency of administration of antibodies of the invention or fragments thereof may be reduced by enhancing uptake and tissue penetration of the antibodies by modifications such as, for example, lipidation.

[0343] The dosage of the antibodies of the invention administered to a patient can be 0.01 mg to 1000 mg/day, when used as single agent therapy. The antibodies of the invention can be used in combination with other therapeutic compositions and the dosage administered to a patient are lower than when said antibodies are used as a single agent therapy.

[0344] It may be desirable to administer the pharmaceutical compositions of the invention locally to the area in need of treatment; this may be achieved by, for example, and not by way of limitation, local infusion, by injection, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers. Preferably, when administering an antibody of the invention, care must be taken to use materials to which the antibody or the fusion protein does not absorb.

[0345] The compositions can be delivered in a vesicle, in particular a liposome (See Langer, *Science* 249:1527-1533 (1990); Treat et al., in *Liposomes in the Therapy of Infectious Disease and Cancer*, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 353-365 (1989); Lopez-Berestein, *ibid.*, pp. 3 17-327; see generally *ibid.*).

[0346] The compositions can be delivered in a controlled release or sustained release system. Any technique known to one of skill in the art can be used to produce sustained release formulations comprising one or more antibodies of the invention. See, e.g., U.S. Patent No. 4,526,938; PCT publication WO 91/05548; PCT publication WO 96/20698; Ning et al., 1996, "Intratumoral Radioimmunotherapy of a Human Colon Cancer Xenograft Using a Sustained-Release Gel," *Radiotherapy & Oncology* 39:179-189, Song et al., 1995, "Antibody Mediated Lung Targeting of Long-Circulating Emulsions," *PDA Journal of Pharmaceutical Science & Technology* 50:372-397; Cleek et al., 1997, "Biodegradable Polymeric Carriers for a bFGF Antibody for Cardiovascular Application," *Pro. Int'l. Symp. Control. Rel. Bioact. Mater.* 24:853-854; and Lam et al., 1997, "Microencapsulation of Recombinant Humanized Monoclonal Antibody for Local Delivery," *Proc. Int'l. Symp. Control Rel. Bioact. Mater.* 24:759-760. A pump may be used in a controlled release system (See Langer, *supra*; Sefton, 1987, *CRC Crit. Ref. Biomed. Eng.* 14:20; Buchwald et al., 1980, *Surgery* 88:507; and Saudek et al., 1989, *N. Engl. J. Med.* 321:574). Polymeric materials can be used to achieve controlled release of antibodies (see e.g., *Medical Applications of Controlled Release*, Langer and Wise (eds.), CRC Pres., Boca Raton, Florida (1974); *Controlled Drug Bioavailability, Drug Product Design and Performance*, Smolen and Ball (eds.), Wiley, New York (1984); Ranger and Peppas, 1983, *J. Macromol. Sci. Rev. Macromol. Chem.* 23:61; See also Levy et al., 1985, *Science* 228:190; During et al., 1989, *Ann. Neurol.* 25:351; Howard et al., 1989, *J. Neurosurg.* 71:105); U.S. Patent No. 5,679,377; U.S. Patent No. 5,916,597; U.S. Patent No. 5,912,015; U.S. Patent No. 5,989,463; U.S. Patent No. 5,128,326; PCT Publication No. WO 99/15154; and PCT Publication No. WO 99/20253). Examples of polymers used in sustained release formulations include, but are not limited to, poly(2-hydroxy ethyl methacrylate), poly(methyl methacrylate), poly(acrylic acid), poly(ethylene-co-vinyl acetate), poly(methacrylic acid), polyglycolides (PLG), polyanhydrides, poly(N-vinyl pyrrolidone), poly(vinyl alcohol), polyacrylamide, poly(ethylene glycol), polylactides (PLA), poly(lactide-co-glycolides) (PLGA), and polyorthoesters. A controlled release system can be placed in proximity of the therapeutic target (e.g., the lungs), thus requiring only a fraction of the systemic dose (see, e.g., Goodson, in *Medical Applications of Controlled Release*, *supra*, vol. 2, pp. 115-138 (1984)). Polymeric compositions useful as controlled release implants are used according to Dunn et al. (See U.S. 5,945,155). This particular method is based upon the therapeutic effect of the *in situ* controlled release of the bioactive material from the polymer system. The implantation can generally occur anywhere within the body of the patient in need of therapeutic treatment. A non-polymeric sustained delivery system can be used, whereby a non-polymeric implant in the body of the subject is used as a drug delivery system. Upon implantation in the body, the organic solvent of the implant will dissipate, disperse, or leach from the composition into surrounding tissue fluid, and the non-polymeric material will gradually coagulate or precipitate to form a solid, microporous matrix (See U.S. 5,888,533).

[0347] Controlled release systems are discussed in the review by Langer (1990, *Science* 249:1527-1533). Any technique known to one of skill in the art can be used to produce sustained release formulations comprising one or more therapeutic agents of the invention. See, e.g., U.S. Patent No. 4,526,938; International Publication Nos. WO 91/05548 and WO 96/20698; Ning et al., 1996, *Radiotherapy & Oncology* 39:179-189; Song et al., 1995, *PDA Journal of Pharmaceutical Science & Technology* 50:372-397; Cleek et al., 1997, *Pro. Int'l. Symp. Control. Rel. Bioact. Mater.* 24:853-854; and Lam et al., 1997, *Proc. Int'l. Symp. Control Rel. Bioact. Mater.* 24:759-760.

[0348] Where the composition of the specification is a nucleic acid encoding an antibody, the nucleic acid can be administered *in vivo* to promote expression of its encoded antibody, by constructing it as part of an appropriate nucleic acid expression vector and administering it so that it becomes intracellular, *e.g.*, by use of a retroviral vector (See U.S. Patent No. 4,980,286), or by direct injection, or by use of microparticle bombardment (*e.g.*, a gene gun; Biostatic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, or by administering it in linkage to a homeobox-like peptide which is known to enter the nucleus (See *e.g.*, Joliot et al., 1991, Proc. Natl. Acad. Sci. USA 88:1864-1868), etc. Alternatively, a nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression by homologous recombination.

[0349] For antibodies, the therapeutically or prophylactically effective dosage administered to a subject is typically 0.1 mg/kg to 200 mg/kg of the subject's body weight. Preferably, the dosage administered to a subject is between 0.1 mg/kg and 20 mg/kg of the subject's body weight and more preferably the dosage administered to a subject is between 1 mg/kg to 10 mg/kg of the subject's body weight. The dosage and frequency of administration of antibodies of the invention may be reduced also by enhancing uptake and tissue penetration (*e.g.*, into the lung) of the antibodies or fusion proteins by modifications such as, for example, lipidation.

[0350] Treatment of a subject with a therapeutically or prophylactically effective amount of antibodies of the invention can include a single treatment or, preferably, can include a series of treatments. In a preferred example, a subject is treated with antibodies of the invention in the range of between about 0.1 to 30 mg/kg body weight, one time per week for between about 1 to 10 weeks, preferably between 2 to 8 weeks, more preferably between about 3 to 7 weeks, and even more preferably for about 4, 5, or 6 weeks. In other examples, the pharmaceutical compositions of the invention are administered once a day, twice a day, or three times a day. In yet further examples, the pharmaceutical compositions are administered once a week, twice a week, once every two weeks, once a month, once every six weeks, once every two months, twice a year or once per year. It will also be appreciated that the effective dosage of the antibodies used for treatment may increase or decrease over the course of a particular treatment.

5.5.1 PHARMACEUTICAL COMPOSITIONS

[0351] The compositions of the invention include bulk drug compositions useful in the manufacture of pharmaceutical compositions (*e.g.*, impure or non-sterile compositions) and pharmaceutical compositions (*i.e.*, compositions that are suitable for administration to a subject or patient) which can be used in the preparation of unit dosage forms. Such compositions comprise a prophylactically or therapeutically effective amount of a prophylactic and/or therapeutic agent disclosed herein or a combination of those agents and a pharmaceutically acceptable carrier. Preferably, compositions comprise a prophylactically or therapeutically effective amount of antibodies of the invention and a pharmaceutically acceptable carrier.

[0352] In one particular embodiment falling within the scope of specified claims, the pharmaceutical composition comprises of a therapeutically effective amount of an antibody or a fragment thereof that binds Fc_YRIIB with a greater affinity than said antibody or a fragment thereof binds Fc_YRIIA, a cytotoxic antibody that specifically binds a cancer antigen, and a pharmaceutically acceptable carrier. In another embodiment falling within the scope of specified claims, said pharmaceutical composition further comprises one or more anti-cancer agents.

[0353] In a specific instance, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term "carrier" refers to a diluent, adjuvant (*e.g.*, Freund's adjuvant (complete and incomplete), excipient, or vehicle with which the therapeutic is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, and sesame oil. Water is a preferred carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, and ethanol. The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, and sustained-release formulations.

[0354] Generally, the ingredients of compositions of the invention are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the composition is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.

[0355] The compositions of the invention can be formulated as neutral or salt forms. Pharmaceutically acceptable salts include, but are not limited to those formed with anions such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those formed with cations such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol, histidine, procaine, etc.

[0356] The present specification also provides pharmaceutical compositions and kits comprising a Fc_YRIIB antagonist for use in the prevention, treatment, management, or amelioration of a B-cell malignancy, or one or more symptoms thereof. In particular, the present specification provides pharmaceutical compositions and kits comprising a Fc_YRIIB antagonist, an analog, derivative or an anti-Fc_YRIIB antibody or an antigen-binding fragment thereof.

5.5.2 GENE THERAPY

[0357] Nucleic acids comprising sequences encoding antibodies or fusion proteins, can be administered to treat, prevent or ameliorate one or more symptoms associated with a disease, disorder, or infection, by way of gene therapy. Gene therapy refers to therapy performed by the administration to a subject of an expressed or expressible nucleic acid. The nucleic acids produce their encoded antibody or fusion protein that mediates a therapeutic or prophylactic effect.

[0358] Any of the methods for gene therapy available in the art can be used herein. Exemplary methods are described below.

[0359] For general reviews of the methods of gene therapy, see Goldspiel et al., 1993, Clinical Pharmacy 12:488-505; Wu and Wu, 1991, Biotherapy 3:87-95; Tolstoshev, 1993, Ann. Rev. Pharmacol. Toxicol. 32:573-596 ; Mulligan, Science 260:926-932 (1993); Morgan and Anderson, 1993, Ann. Rev. Biochem. 62:191-217 ; May, 1993, TIBTECH 11(5):155-215; and Scholl, 2003, J. Biomed Biotechnol 2003:35-47. Methods commonly known in the art of recombinant DNA technology which can be used are described in Ausubel et al. (eds.), Current Protocols in Molecular Biology, John Wiley & Sons, NY (1993); and Kriegler, Gene Transfer and Expression, A Laboratory Manual, Stockton Press, NY (1990).

[0360] A composition of the specification may comprise nucleic acids encoding an antibody, said nucleic acids being part of an expression vector that expresses the antibody in a suitable host. In particular, such nucleic acids have promoters, preferably heterologous promoters, operably linked to the antibody coding region, said promoter being inducible or constitutive, and, optionally, tissue-specific. Nucleic acid molecules can be used in which the antibody coding sequences and any other desired sequences are flanked by regions that promote homologous recombination at a desired site in the genome, thus providing for intrachromosomal expression of the antibody encoding nucleic acids (Koller and Smithies, 1989, Proc. Natl. Acad. Sci. USA 86:8932-8935; and Zijlstra et al., 1989, Nature 342:435-438).

[0361] A composition of the specification may comprise nucleic acids encoding a fusion protein, said nucleic acids being a part of an expression vector that express the fusion protein in a suitable host. In particular, such nucleic acids have promoters, preferably heterologous promoters, operably linked to the coding region of a fusion protein, said promoter being inducible or constitutive, and optionally, tissue-specific. In another particular instance, nucleic acid molecules are used in which the coding sequence of the fusion protein and any other desired sequences are flanked by regions that promote homologous recombination at a desired site in the genome, thus providing for intrachromosomal expression of the fusion protein encoding nucleic acids.

[0362] Delivery of the nucleic acids into a subject may be either direct, in which case the subject is directly exposed to the nucleic acid or nucleic acid-carrying vectors, or indirect, in which case, cells are first transformed with the nucleic acids *in vitro*, then transplanted into the subject. These two approaches are known, respectively, as *in vivo* or *ex vivo* gene therapy.

[0363] The nucleic acid sequences can be directly administered *in vivo*, where it is expressed to produce the encoded product. This can be accomplished by any of numerous methods known in the art, e.g., by constructing them as part of an appropriate nucleic acid expression vector and administering it so that they become intracellular, e.g., by infection using defective or attenuated retroviral or other viral vectors (see U.S. Patent No. 4,980,286), or by direct injection of naked DNA, or by use of microparticle bombardment (e.g., a gene gun; Biolistic, Dupont), or by coating with lipids or cell-surface receptors or transfecting agents, encapsulation in liposomes, microparticles, or microcapsules, or by administering them in linkage to a peptide which is known to enter the nucleus, by administering it in linkage to a ligand subject to receptor-mediated endocytosis (See, e.g., Wu and Wu, 1987, J. Biol. Chem. 262:4429-4432) (which can be used to target cell types specifically expressing the receptors), etc. Nucleic acid-ligand complexes can be formed in which the ligand comprises a fusogenic viral peptide to disrupt endosomes, allowing the nucleic acid to avoid lysosomal degradation. The nucleic acid can be targeted *in vivo* for cell specific uptake and

expression, by targeting a specific receptor (See, e.g., U.S. Patent Application Publication No. 2005/0002903; PCT Publications WO 92/06180; WO 92/22635; WO92/20316; WO93/14188; WO 93/20221). Alternatively, the nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination (Koller and Smithies, 1989, Proc. Natl. Acad. Sci. USA 86:8932-8935; and Zijlstra et al., 1989, Nature 342:435-438).

[0364] Viral vectors that contain nucleic acid sequences encoding an antibody or a fusion protein can be used. For example, a retroviral vector can be used (See Miller et al., 1993, *Meth. Enzymol.* 217:581-599). These retroviral vectors contain the components necessary for the correct packaging of the viral genome and integration into the host cell DNA. The nucleic acid sequences encoding the antibody or a fusion protein to be used in gene therapy are cloned into one or more vectors, which facilitates delivery of the nucleotide sequence into a subject. More detail about retroviral vectors can be found in Boesen et al., (1994, *Biotherapy* 6:291-302), which describes the use of a retroviral vector to deliver the mdr 1 gene to hematopoietic stem cells in order to make the stem cells more resistant to chemotherapy. Other references illustrating the use of retroviral vectors in gene therapy are: Clowes et al., 1994, *J. Clin. Invest.* 93:644-651; Klein et al., 1994, *Blood* 83:1467-1473; Salmons and Gunzberg, 1993, *Human Gene Therapy* 4:129-141; and Grossman and Wilson, 1993, *Curr. Opin. in Genetics and Devel.* 3:110-114.

[0365] Adenoviruses are other viral vectors that can be used in gene therapy. Adenoviruses are especially attractive vehicles for delivering genes to respiratory epithelia. Adenoviruses naturally infect respiratory epithelia where they cause a mild disease. Other targets for adenovirus-based delivery systems are liver, the central nervous system, endothelial cells, and muscle. Adenoviruses have the advantage of being capable of infecting non-dividing cells. Kozarsky and Wilson (Current Opinion in Genetics and Development 3:499-503, 1993, present a review of adenovirus-based gene therapy. Bout et al., (Human Gene Therapy, 5:3-10, 1994) demonstrated the use of adenovirus vectors to transfer genes to the respiratory epithelia of rhesus monkeys. Other instances of the use of adenoviruses in gene therapy can be found in Rosenfeld et al., 1991, *Science* 252:431-434; Rosenfeld et al., 1992, *Cell* 68:143-155; Mastrangeli et al., 1993, *J. Clin. Invest.* 91:225-234; PCT Publication WO94/12649; and Wang et al., 1995, *Gene Therapy* 2:775-783. It is preferred that adenovirus vectors are used.

[0366] Adeno-associated virus (AAV) has also been proposed for use in gene therapy (see, e.g., Walsh et al., 1993, *Proc. Soc. Exp. Biol. Med.* 204:289-300 and U.S. Patent No. 5,436,146).

[0367] Another approach to gene therapy involves transferring a gene to cells in tissue culture by such methods as electroporation, lipofection, calcium phosphate mediated transfection, or viral infection. Usually, the method of transfer includes the transfer of a selectable marker to the cells. The cells are then placed under selection to isolate those cells that have taken up and are expressing the transferred gene. Those cells are then delivered to a subject.

[0368] The nucleic acid can be introduced into a cell prior to administration *in vivo* of the resulting recombinant cell. Such introduction can be carried out by any method known in the art, including but not limited to, transfection, electroporation, microinjection, infection with a viral or bacteriophage vector, containing the nucleic acid sequences, cell fusion, chromosome-mediated gene transfer, microcellmediated gene transfer, spheroplast fusion, etc. Numerous techniques are known in the art for the introduction of foreign genes into cells (See, e.g., Loeffler and Behr, 1993, *Meth. Enzymol.* 217:599-618, Cohen et al., 1993, *Meth. Enzymol.* 217:618-644; and Clin. Pharma. Ther. 29:69-92, 1985) and may be used in accordance with the present specification, provided that the necessary developmental and physiological functions of the recipient cells are not disrupted. The technique should provide for the stable transfer of the nucleic acid to the cell, so that the nucleic acid is expressible by the cell and preferably heritable and expressible by its cell progeny.

[0369] The resulting recombinant cells can be delivered to a subject by various methods known in the art. Recombinant blood cells (e.g., hematopoietic stem or progenitor cells) are preferably administered intravenously. The amount of cells envisioned for use depends on the desired effect, patient state, etc., and can be determined by one skilled in the art.

[0370] Cells into which a nucleic acid can be introduced for purposes of gene therapy encompass any desired, available cell type, and include but are not limited to epithelial cells, endothelial cells, keratinocytes, fibroblasts, muscle cells, hepatocytes; blood cells such as T lymphocytes, B lymphocytes, monocytes, macrophages, neutrophils, eosinophils, megakaryocytes, granulocytes; various stem or progenitor cells, in particular hematopoietic stem or progenitor cells, e.g., as obtained from bone marrow, umbilical cord blood, peripheral blood, fetal liver, etc.

[0371] Preferably the cell used for gene therapy is autologous to the subject.

[0372] In an example in which recombinant cells are used in gene therapy, nucleic acid sequences encoding an antibody or a fusion protein are introduced into the cells such that they are expressible by the cells or their progeny, and the recombinant cells are then administered *in vivo* for therapeutic effect. In a specific example, stem or progenitor cells are used. Any stem and/or

progenitor cells which can be isolated and maintained *in vitro* can potentially be used as described herein (See e.g., PCT Publication WO 94/08598; Stemple and Anderson, 1992, Cell 7:1973-985; Rheinwald, 1980, Meth. Cell Bio. 21A:229; and Pittelkow and Scott, 1986, Mayo Clinic Proc. 61:771).

[0373] The nucleic acid can be introduced for purposes of gene therapy comprises an inducible promoter operably linked to the coding region, such that expression of the nucleic acid is controllable by controlling the presence or absence of the appropriate inducer of transcription.

5.5.3 KITS

[0374] Also described is a pharmaceutical pack or kit comprising one or more containers filled with antibodies of the invention. Additionally, one or more other prophylactic or therapeutic agents useful for the treatment of a disease can also be included in the pharmaceutical pack or kit. Also disclosed is a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.

[0375] Kits that can be used in the above methods are also disclosed. A kit can comprise one or more antibodies of the invention. A kit may further comprise one or more other prophylactic or therapeutic agents useful for the treatment of cancer, in one or more containers. A kit may further comprise one or more cytotoxic antibodies that bind one or more cancer antigens associated with cancer. The other prophylactic or therapeutic agent can be a chemotherapeutic. The prophylactic or therapeutic agent can be a biological or hormonal therapeutic.

5.6 CHARACTERIZATION AND DEMONSTRATION OF THERAPEUTIC UTILITY

[0376] Several aspects of the pharmaceutical compositions or prophylactic or therapeutic agents of the specification are preferably tested *in vitro*, e.g., in a cell culture system, and then *in vivo*, e.g., in an animal model organism, such as a rodent animal model system, for the desired therapeutic activity prior to use in humans. For example, assays which can be used to determine whether administration of a specific pharmaceutical composition is indicated, include cell culture assays in which a patient tissue sample is grown in culture, and exposed to or otherwise contacted with a pharmaceutical composition, and the effect of such composition upon the tissue sample is observed, e.g., inhibition of or decrease in growth and/or colony formation in soft agar or tubular network formation in three-dimensional basement membrane or extracellular matrix preparation. The tissue sample can be obtained by biopsy from the patient. This test allows the identification of the therapeutically most effective prophylactic or therapeutic molecule(s) for each individual patient. Alternatively, instead of culturing cells from a patient, therapeutic agents and methods may be screened using cells of a tumor or malignant cell line. In various specific instances, *in vitro* assays can be carried out with representative cells of cell types involved in an autoimmune or inflammatory disorder (e.g., T cells), to determine if a pharmaceutical composition of the invention has a desired effect upon such cell types. Many assays standard in the art can be used to assess such survival and/or growth; for example, cell proliferation can be assayed by measuring ^3H -thymidine incorporation, by direct cell count, by detecting changes in transcriptional activity of known genes such as proto-oncogenes (e.g., fos, myc) or cell cycle markers; cell viability can be assessed by trypan blue staining, differentiation can be assessed visually based on changes in morphology, decreased growth and/or colony formation in soft agar or tubular network formation in three-dimensional basement membrane or extracellular matrix preparation, etc. Additional assays include raft association, CDC, ADCC and apoptosis assays as known in the art and described in the Examples.

[0377] Combinations of prophylactic and/or therapeutic agents can be tested in suitable animal model systems prior to use in humans. Such animal model systems include, but are not limited to, rats, mice, chicken, cows, monkeys, pigs, dogs, rabbits, etc. Any animal system well-known in the art may be used. Combinations of prophylactic and/or therapeutic agents can be tested in a mouse model system. Such model systems are widely used and well-known to the skilled artisan. Prophylactic and/or therapeutic agents can be administered repeatedly. Several aspects of the procedure may vary such as the temporal regime of administering the prophylactic and/or therapeutic agents, and whether such agents are administered separately or as an admixture.

[0378] Preferred animal models for use in the methods described herein are for example, transgenic mice expressing Fc γ R on mouse effector cells, e.g., any mouse model described in U.S. Patent No. 5,877,396. Transgenic mice for use in the methods described herein include but are not limited to mice carrying human Fc γ RIIA, mice carrying human Fc γ RIIA, mice carrying human Fc γ RIIB and human Fc γ RIIA, mice carrying human Fc γ RIIB and human Fc γ RIIA.

[0379] Once the prophylactic and/or therapeutic agents described herein have been tested in an animal model they can be tested in clinical trials to establish their efficacy. Establishing clinical trials will be done in accordance with common methodologies known to one skilled in the art, and the optimal dosages and routes of administration as well as toxicity profiles of the compositions of the invention can be established using routine experimentation.

[0380] The anti-inflammatory activity of the combination therapies described herein can be determined by using various experimental animal models of inflammatory arthritis known in the art and described in Crofford L.J. and Wilder R.L., "Arthritis and Autoimmunity in Animals", in Arthritis and Allied Conditions: A Textbook of Rheumatology, McCarty et al.(eds.), Chapter 30 (Lee and Febiger, 1993). Experimental and spontaneous animal models of inflammatory arthritis and autoimmune rheumatic diseases can also be used to assess the anti-inflammatory activity of the combination therapies described. The following are some assays provided as examples, and not by limitation.

[0381] The principle animal models for arthritis or inflammatory disease known in the art and widely used include: adjuvant-induced arthritis rat models, collagen-induced arthritis rat and mouse models and antigen-induced arthritis rat, rabbit and hamster models, all described in Crofford L.J. and Wilder R.L., "Arthritis and Autoimmunity in Animals", in Arthritis and Allied Conditions: A Textbook of Rheumatology, McCarty et al.(eds.), Chapter 30 (Lee and Febiger, 1993).

[0382] The anti-inflammatory activity of the combination therapies described herein can be assessed using a carrageenan-induced arthritis rat model. Carrageenan-induced arthritis has also been used in rabbit, dog and pig in studies of chronic arthritis or inflammation. Quantitative histomorphometric assessment is used to determine therapeutic efficacy. The methods for using such a carrageenan-induced arthritis model is described in Hansra P. et al., "Carrageenan-Induced Arthritis in the Rat," Inflammation, 24(2): 141-155, (2000). Also commonly used are zymosan-induced inflammation animal models as known and described in the art.

[0383] The anti-inflammatory activity of the combination therapies described herein can also be assessed by measuring the inhibition of carrageenan-induced paw edema in the rat, using a modification of the method described in Winter C. A. et al., "Carrageenan-Induced Edema in Hind Paw of the Rat as an Assay for Anti-inflammatory Drugs" Proc. Soc. Exp. Biol Med. 111, 544-547, (1962). This assay has been used as a primary *in vivo* screen for the anti-inflammatory activity of most NSAIDs, and is considered predictive of human efficacy. The anti-inflammatory activity of the test prophylactic or therapeutic agents is expressed as the percent inhibition of the increase in hind paw weight of the test group relative to the vehicle dosed control group.

[0384] Additionally, animal models for inflammatory bowel disease can also be used to assess the efficacy of the combination therapies described herein (Kim et al., 1992, Scand. J. Gastroentrol. 27:529-537; Strober, 1985, Dig. Dis. Sci. 30(12 Suppl):3S-10S). Ulcerative colitis and Crohn's disease are human inflammatory bowel diseases that can be induced in animals. Sulfated polysaccharides including, but not limited to amylopectin, carrageen, amylopectin sulfate, and dextran sulfate or chemical irritants including but not limited to trinitrobenzenesulphonic acid (TNBS) and acetic acid can be administered to animals orally to induce inflammatory bowel diseases.

[0385] Animal models for asthma can also be used to assess the efficacy of the combination therapies described. An example of one such model is the murine adoptive transfer model in which aeroallergen provocation of TH1 or TH2 recipient mice results in TH effector cell migration to the airways and is associated with an intense neutrophilic (TH1) and eosinophilic (TH2) lung mucosal inflammatory response (Cohn et al., 1997, J. Exp. Med. 186:1737-1747).

[0386] Animal models for autoimmune disorders can also be used to assess the efficacy of the combination therapies described. Animal models for autoimmune disorders such as type 1 diabetes, thyroid autoimmunity, systemic lupus erythematosus, and glomerulonephritis have been developed (Flanders et al., 1999, Autoimmunity 29:235-246; Krogh et al., 1999, Biochimie 81:511-515; Foster, 1999, Semin. Nephrol. 19:12-24).

[0387] Further, any assays known to those skilled in the art can be used to evaluate the prophylactic and/or therapeutic utility of the combinatorial therapies disclosed herein for autoimmune and/or inflammatory diseases.

[0388] Toxicity and efficacy of the prophylactic and/or therapeutic protocols of the instant specification can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD₅₀ (the dose lethal to 50% of the population) and the ED₅₀ (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD₅₀/ED₅₀. Prophylactic and/or therapeutic agents that exhibit large therapeutic indices are preferred. While prophylactic and/or therapeutic agents that exhibit toxic side

effects may be used, care should be taken to design a delivery system that targets such agents to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.

[0389] The data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage of the prophylactic and/or therapeutic agents for use in humans. The dosage of such agents lies preferably within a range of circulating concentrations that include the ED₅₀ with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For any agent used in the method of the specification, the therapeutically effective dose can be estimated initially from cell culture assays. A dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC₅₀ (*i.e.*, the concentration of the test compound that achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma may be measured, for example, by high performance liquid chromatography.

[0390] The anti-cancer activity of the therapies used in accordance with the present specification also can be determined by using various experimental animal models for the study of cancer such as the SCID mouse model or transgenic mice or nude mice with human xenografts, animal models, such as hamsters, rabbits, etc. known in the art and described in Relevance of Tumor Models for Anticancer Drug Development (1999, eds. Fiebig and Burger); Contributions to Oncology (1999, Karger); The Nude Mouse in Oncology Research (1991, eds. Boven and Winograd); and Anticancer Drug Development Guide (1997 ed. Teicher).

[0391] The protocols and compositions described herein are preferably tested *in vitro*, and then *in vivo*, for the desired therapeutic or prophylactic activity, prior to use in humans. Therapeutic agents and methods may be screened using cells of a tumor or malignant cell line. Many assays standard in the art can be used to assess such survival and/or growth; for example, cell proliferation can be assayed by measuring ³H-thymidine incorporation, by direct cell count, by detecting changes in transcriptional activity of known genes such as proto-oncogenes (*e.g.*, fos, myc) or cell cycle markers; cell viability can be assessed by trypan blue staining, differentiation can be assessed visually based on changes in morphology, decreased growth and/or colony formation in soft agar or tubular network formation in three-dimensional basement membrane or extracellular matrix preparation, etc.

[0392] Compounds for use in therapy can be tested in suitable animal model systems prior to testing in humans, including but not limited to in rats, mice, chicken, cows, monkeys, rabbits, hamsters, etc., for example, the animal models described above. The compounds can then be used in the appropriate clinical trials.

[0393] Further, any assays known to those skilled in the art can be used to evaluate the prophylactic and/or therapeutic utility of the combinatorial therapies disclosed herein for treatment or prevention of cancer, inflammatory disorder, or Autoimmune disease.

5.7 DIAGNOSTIC METHODS

[0394] Labeled antibodies of the invention can be used for diagnostic purposes to detect, diagnose, or monitor diseases, disorders or infections. There is also discussed the detection or diagnosis of a disease, disorder or infection, particularly an Autoimmune disease comprising: (a) assaying the expression of Fc_YRIIB in cells or a tissue sample of a subject using one or more antibodies that immunospecifically bind to Fc_YRIIB; and (b) comparing the level of the antigen with a control level, *e.g.*, levels in normal tissue samples, whereby an increase in the assayed level of antigen compared to the control level of the antigen is indicative of the disease, disorder or infection.

[0395] Antibodies of the invention can be used to assay Fc_YRIIB levels in a biological sample using classical immunohistological methods as described herein or as known to those of skill in the art (*e.g.*, see Jalkanen et al., 1985, *J. Cell. Biol.* 101:976-985; Jalkanen et al., 1987, *J. Cell. Biol.* 105:3087-3096). Other antibody-based methods useful for detecting protein gene expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA). Suitable antibody assay labels are known in the art and include enzyme labels, such as, alkaline phosphatase, glucose oxidase; radioisotopes, such as iodine (¹²⁵I, ¹³¹I), carbon (¹⁴C), sulfur (³⁵S), tritium (³H), indium (¹¹³In), and technetium (^{99m}Tc); luminescent labels, such as luminol; and fluorescent labels, such as fluorescein and rhodamine.

[0396] Also described is the detection and diagnosis of a disease, disorder, or infection in a human. The diagnosis may comprise: a) administering (for example, parenterally, subcutaneously, or intraperitoneally) to a subject an effective amount of a labeled antibody that immunospecifically binds to Fc_YRIIB; b) waiting for a time interval following the administration for permitting the labeled antibody to preferentially concentrate at sites in the subject where Fc_YRIIB is expressed (and for unbound labeled

molecule to be cleared to background level); c) determining background level; and d) detecting the labeled antibody in the subject, such that detection of labeled antibody above the background level indicates that the subject has the disease, disorder, or infection. The antibody is labeled with an imaging moiety which is detectable using an imaging system known to one of skill in the art. Background level can be determined by various methods including, comparing the amount of labeled molecule detected to a standard value previously determined for a particular system.

[0397] It will be understood in the art that the size of the subject and the imaging system used will determine the quantity of imaging moiety needed to produce diagnostic images. In the case of a radioisotope moiety, for a human subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of ^{99m}Tc . The labeled antibody will then preferentially accumulate at the location of cells which contain the specific protein. *In vivo* tumor imaging is described in S.W. Burchiel et al., "Immunopharmacokinetics of Radiolabeled Antibodies and Their Fragments." (Chapter 13 in Tumor Imaging: The Radiochemical Detection of Cancer, S.W. Burchiel and B. A. Rhodes, eds., Masson Publishing Inc. (1982).

[0398] Depending on several variables, including the type of label used and the mode of administration, the time interval following the administration for permitting the labeled molecule to preferentially concentrate at sites in the subject and for unbound labeled molecule to be cleared to background level is 6 to 48 hours or 6 to 24 hours or 6 to 12 hours. In another example the time interval following administration is 5 to 20 days or 5 to 10 days.

[0399] The monitoring of a disease, disorder or infection can be carried out by repeating the method for diagnosing the disease, disorder or infection, for example, one month after initial diagnosis, six months after initial diagnosis, one year after initial diagnosis, etc.

[0400] Presence of the labeled molecule can be detected in the subject using methods known in the art for *in vivo* scanning. These methods depend upon the type of label used. Skilled artisans will be able to determine the appropriate method for detecting a particular label. Methods and devices that may be used in the diagnostic methods of the specification include, but are not limited to, computed tomography (CT), whole body scan such as position emission tomography (PET), magnetic resonance imaging (MRI), and sonography.

[0401] In a specific example, the molecule is labeled with a radioisotope and is detected in the patient using a radiation responsive surgical instrument (Thurston et al., U.S. Patent No. 5,441,050). In another example, the molecule is labeled with a fluorescent compound and is detected in the patient using a fluorescence responsive scanning instrument. In another example, the molecule is labeled with a positron emitting metal and is detected in the patient using positron emission-tomography. In yet another example, the molecule is labeled with a paramagnetic label and is detected in a patient using magnetic resonance imaging (MRI).

6. EXAMPLES

6.1 PREPARATION OF MONOCLONAL ANTIBODIES

[0402] A mouse monoclonal antibody was produced from clone 8B5.3.4 with ATCC accession number PTA-7610. A mouse monoclonal antibody that specifically binds Fc γ RIIB with greater affinity than said monoclonal antibody binds Fc γ RIIA, was generated. Transgenic Fc γ RIIA mice (generated in Dr. Ravetch Laboratory, Rockefeller University) were immunized with Fc γ RIIB purified from supernatant of 293 cells that had been transfected with cDNA encoding the extracellular domain of the human Fc γ RIIB receptor, residues 1-180. Hybridoma cell lines from spleen cells of these mice were produced and screened for antibodies that specifically bind Fc γ RIIB with greater affinity than the antibodies bind Fc γ RIIA.

6.2 ANTIBODY SCREENING AND CHARACTERIZATION

6.2.1 MATERIALS AND METHODS

[0403] Supernatants from hybridoma cultures are screened for immunoreactivity against Fc γ RIIA or Fc γ RIIB using ELISA assays. In each case, the plate is coated with 100 ng/well of Fc γ RIIA or Fc γ RIIB. The binding of the antibody to the specific receptor is

detected with goat anti-mouse HRP conjugated antibody by monitoring the absorbance at 650 nm.

[0404] In the blocking ELISA experiment, the ability of the antibody from the hybridoma supernatant to block binding of aggregated IgG to Fc γ RIIB is monitored. The plate is blocked with the appropriate "blocking agent", washed three times (200 μ l/well) with wash buffer (PBS plus 0.1 % Tween). The plate is pre-incubated with hybridoma supernatant for 1 hour at 37 °C. Subsequent to blocking, a fixed amount of aggregated biotinylated human IgG (1 μ g/well) is added to the wells to allow the aggregate to bind to the Fc γ RIIB receptor. This reaction is carried out for two hours at 37°C. Detection is then monitored, after additional washing, with streptavidin horseradish peroxidase conjugate, which detects the bound aggregated IgG. The absorbance at 650nm is proportional to the bound aggregated IgG.

[0405] In a β -hexoaminidase release assay the ability of an antibody from the hybridoma supernatant to inhibit Fc γ -induced release of β -hexoaminidase is monitored. RBL-2H3 cells are transfected with human Fc γ RIIB; cells are stimulated with various concentration of goat anti-mouse F(ab) $_2$ fragment ranging from 0.03 μ g/mL to 30 μ g/mL; sensitized with either mouse IgE alone (at 0.01 μ g/mL) or with an anti- Fc γ RIIB antibody. After 1 hour incubation at 37° temperature, the cells are spun down; the supernatant is collected; and the cells are lysed. The β -hexoaminidase activity released in the supernatant is determined in a colorometric assay using p-nitrophenyl N-acetyl- β D-glucoasminide. The release β -hexoaminidase activity is expressed as a percentage of the released activity relative to the total activity.

[0406] **BiAcore Analysis:** Antibody binding to CD32A-H¹³¹, CD32A-R¹³¹ or CD32B was analyzed by surface plasmon resonance in a BiAcore 3000 biosensor (Biacore AB, Uppsala, Sweden) by using soluble extracellular domains of the receptors expressed in 293H cells. The capturing antibody, a F(ab') $_2$ fragment of a goat anti-mouse Fc-specific antibody (Jackson Immunoresearch, West Grove, PA), was immobilized on the CM-5 sensor chip according to the procedure recommended by the manufacturer. Briefly, the carboxyl groups on the sensor chip surface were activated with an injection of a solution containing 0.2M N-ethyl-N-(3diethylamino-propyl) carbodiimide and 0.05M N-hydroxy-succinimide. The F(ab') $_2$ fragment was then injected over the activated CM-5 surface in 10mM sodium-acetate, pH 5.0, at flow rate 5 μ l/min for 420 sec, followed by 1 M ethanolamine for deactivation. Binding experiments were performed in HBS-P buffer containing 10mM Hepes, pH 7.4, 150mM NaCl, and 0.005% P20 surfactant. Each Monoclonal antibody was captured on the CM-5 chip by injecting a 300nM-antibody solution at flow rate 5 μ l/min for 240sec, followed by an injection of the monomeric soluble receptors at concentration of 100 nM and a flow rate 50 μ l/min for 120sec with dissociation time 180sec. Regeneration of the F(ab') $_2$ GAM surface was performed by pulse injection of 50mM glycine, pH 1.5 and 50mM NaOH. Reference curves were obtained by injection of each soluble receptor over the immobilized F(ab') $_2$ GAM surface with no captured antibody. Reference curves were subtracted and responses were normalized to the same level of captured antibody. To obtain kinetic parameters of binding of soluble receptors to captured antibodies, binding curves to corresponding IgG at corresponding concentrations were subtracted. Resulted curves were analyzed by separate ka/kd fit. K_D values were calculated as average of four curves at two different concentrations.

[0407] **FACS ANALYSIS:** CHO cells, expressing Fc γ RIIB are stained with various antibodies and analyzed by FACS. In one series of experiment, the cells are directly labeled to determine if the monoclonal antibodies recognize the receptor.

[0408] In the blocking FACS experiments, the ability of the antibody from the hybridoma supernatant to block the binding of aggregated IgG to Fc γ RIIB is monitored. About 1 million cells (CHO cells expressing Fc γ RIIB) for each sample are incubated on ice for 30 minutes with 2 μ g of the isotype control (mouse IgG1) or with the 8B5.3.4 antibody. Cells are washed once with PBS+1%BSA and incubated with 1 μ g of aggregated biotinylated human IgG for 30 minutes on ice. Cells are washed and the secondary antibodies are added, goat anti-mouse-FITC to detect the bound antibody and Streptavidin-PE conjugated to detect the bound aggregated biotinylated human IgG and incubated on ice for 30 minutes. Cells are washed and analyzed by FACS.

[0409] B Lymphocytes are stained to detect the presence of Fc γ RIIB and CD20. 200 μ l of "buffy coat" for each sample is incubated on ice with 2 μ g of isotype control or the monoclonal antibodies, 8B5.3.4. Cells are washed once with PBS+1%BSA and incubated with 1 μ l of goat anti mouse-PE antibody for 30 minutes on ice. Cells are washed once and CD20-FITC antibody (2 μ g) is added to the samples and incubated on ice for 30 minutes. All samples are washed with PBS+1%BSA once and the cells are analyzed by FACS.

[0410] Human PBMCs are stained with 8B5.3.4 and IV.3 antibodies, followed by a goat anti-mouse-Cyanine (Cy5) conjugated antibody (two color staining using anti-CD20-FITC conjugated for B lymphocytes, anti-CD14-PE conjugated for monocytes, anti-CD56-PE conjugated for NK cells and anti-CD16-PE conjugated for granulocytes).

[0411] **ADCC ASSAY:** 4-5x10 6 target cells expressing Her2/neu antigen (IGROV-1 or SKBR-3 cells) are labeled with

bis(acetoxymethyl) 2,2':6',2"-terpyridine-t-6"-dicarboxylate (DELFIA BATDA Reagent, Perkin Elmer/Wallac). BATDA reagent is added to the cells and the mixture is incubated at 37°C preferably under 5% CO₂, for at least 30 minutes. The cells are then washed with a physiological buffer, e.g., PBS with 0.125 mM sulfinpyrazole, and media containing 0.125 mM sulfinpyrazole. The labeled target cells are added to effector cells, e.g., PBMC, to produce effector:target ratios of approximately 50:1, 75:1, or 100:1. PBMC is isolated by layering whole blood onto Ficoll-Hypaque (Sigma) and spinning at room temperature for 30 mins at 500 g. The leukocyte layer is harvested as effectors for Europium-based ADCC assays. Frozen or freshly isolated elutriated monocytes (Advanced Biotechnologies, MD) is used as effectors with the tumor target cell lines at varying effector to target ratio of 100:1 to 10:1 and the concentration of the antibodies is titrated from 1-15 µg/ml. Monocytes obtained as frozen stocks stimulated with cytokines is used as effector cells in ADCC assays. If frozen monocytes perform optimally they will be routinely used otherwise fresh cells will be used. MDM will be prepared by treatment with cytokines GM-CSF or M-CSF that are known to enhance the viability and differentiation of monocytes in culture. MDM will be stimulated with cytokines and the expression of the various Fc_YRs (I, IIA, IIB, and IIIA) determined by FACS analysis.

[0412] The effector and target cells are incubated for at least two hours, and up to 16 hours, at 37°C, under 5% CO₂ in the presence of an anti-tumor antibody, specific for an antigen expressed on the target cells, Her2/neu, and in the presence or absence of an anti-Fc_YRIIB antibody. A chimeric 4D5 antibody that has been engineered to contain the N297A mutation which is used as a negative control since this antibody binds the tumor target cells via its variable region. Loss of glycosylation at this site abolishes binding of the Fc region of the antibody to Fc_YR. Commercially available human IgG1/k serves as an isotype control for the anti-Fc_YRIIB antibody. Cell supernatants are harvested and added to an acidic europium solution (e.g., DELFIA Europium Solution, Perkin Elmer/Wallac). The fluorescence of the Europium-TDA chelates formed is quantitated in a time-resolved fluorometer (e.g., Victor 1420, Perkin Elmer/Wallac). Maximal release (MR) and spontaneous release (SR) are determined by incubation of target cells with 1% TX-100 and media alone, respectively. Antibody independent cellular cytotoxicity (AICC) is measured by incubation of target and effector cells in the absence of antibody. Each assay is preferably performed in triplicate. The mean percentage specific lysis is calculated as: Experimental release (ADCC) - AICC)/(MR-SR) x 100.

6.2.2 CHARACTERIZATION OF THE MONOCLONAL ANTIBODY PRODUCED FROM THE 8B5.3.4 CLONE

[0413] ***Direct binding of the antibody produced from the 8B5.3.4 clone to Fc_YRIIA and Fc_YRIIB:*** The direct binding of the MAb 8B5.3.4 produced from the 8B5.3.4 clone to Fc_YRIIA and Fc_YRIIB was compared by ELISA assay with Fc_YRIIA and Fc_YRIIB-coated plates (Table 8 and FIG. 1). Culture supernatant from the 8B5.3.4 hybridoma clone containing the MAb 8B5.3.4 was tested (in duplicate) for specific binding to Fc_YRIIA and Fc_YRIIB. The supernatant from hybridoma clone 8B5.3.4 has significantly higher affinity for Fc_YRIIB than Fc_YRIIA, as indicated by the higher absorbance values relative to the positive and negative controls in Table 8 (FIG. 1).

TABLE 8: Results of ELISA assay to characterize the binding of MAb 8B5.3.4 produced by hybridoma clone 8B5.3.4 to Fc_YRIIA and Fc_YRIIB. The absorbance values (in duplicate) at 650 nm are reported for each sample.

	CD32A-coated wells	CD32B- coated wells
8B5.3.4	0.094	2.044
	0.092	2.028
Negative Control	0.071	0.074
	0.065	0.078
Positive Control	0.340	0.332
	0.352	0.308

[0414] ***Isotyping the MAb 8B5.3.4 produced from the 8B5.3.4 clone:*** The isotype of the MAb 8B5.3.4 was determined by ELISA assay (Table 9 and FIG. 2). Antibodies against various isotypes indicated were assayed. The absorbance values in Fig. 2 show that the anti-IgG, anti-IgG1, and anti-kappa antibodies have the highest reactivity with the MAb 8B5.3.4, which indicates that the MAb 8B5.3.4 has an IgG1/kappa isotype.

[0415] TABLE 9: Results of ELISA assay to characterize the isotype of MAb 8B5.3.4 produced by hybridoma clone 8B5.3.4. The absorbance values at 650 nm are reported for the indicated antibody isotype.

Antibody Isotype	Absorbance @ 650 nm
IgG	2.828

Antibody Isotype	Absorbance @ 650 nm
IgG3	0.165
IgM	0.105
IgG2a	0.246
IgG2b	0.213
IgG1	2.488
IgA	0.363
kappa	0.511

6.2.3 IN VIVO ADCC ASSAYS

6.2.3.1 ACTIVITY OF Fc_YRIIB ANTIBODIES IN XENOGRAFT MURINE MODELS USING HUMAN TUMOR CELL LINES

[0416] Six to eight week old female Balb/c nude mice (Jackson Laboratories, Bar Harbor, ME; Taconic) are utilized for establishing the xenograft ovarian and breast carcinoma models. Mice are housed in Biosafety Level-2 facilities for the xenograft model using the ascites-derived ovarian cells and pleural effusion-derived breast cancer cells as sources of tumors. Mice are placed in groups of 4 for these experiments and monitored three times weekly. The weight of the mice and survival time are recorded and criteria for growing tumors is abdominal distention and palpable tumors. Mice showing signs of visible discomfort or that reach 5 grams in tumor weight are euthanized with carbon dioxide and autopsied. The antibody-treated animals are placed under observation for an additional two months after the control group.

[0417] *Establishment of the xenograft tumor model with tumor cell lines.* In order to establish the xenograft tumor model, 5×10^6 viable IGROV-1 or SKBR-3 cells are injected s.c into three age and weight matched female nude athymic mice with Matrigel (Becton Dickinson). The estimated weight of the tumor is calculated by the formula: length x (width)²/2 not to exceed 3 grams. For *in vivo* passaging of cells for expansion, anchorage-dependent tumor is isolated and the cells dissociated by adding 1 μ g of collagenase (Sigma) per gram of tumor at 37 C overnight.

[0418] Injection of IGROV-1 cells subcutaneously gives rise to fast growing tumors while the intraperitoneal route induces a peritoneal carcinomatosis which kills the mice in 2 months. Since the IGROV-1 cells form tumors within 5 weeks, at day 1 after tumor cell injection, monocytes as effectors are co-injected i.p. along with therapeutic antibodies ch4D5 and ch8B5.3.4 at 4 μ g each per gm of mouse body weight (mbw) (Table 10). The initial injection is followed by weekly injections of antibodies for 4-6 weeks thereafter. Human effector cells are replenished once in two weeks. A group of mice will receive no therapeutic antibody but will be injected with ch4D5 N297A and human IgG1 as isotype control antibodies for the anti-tumor and ch8B5.3.4 antibody, respectively.

[0419] TABLE 10: Outline for tumor clearance studies with chimeric anti-Her2neu antibody ch4D5 and chimeric anti-Fc_YRIIB antibody ch8B5.3.4 (or humanized anti-Fc_YRIIB antibody (h8B5.3.4)) in xenograft tumor model in nude mice with adoptively transferred human monocytes as ADCC effectors. MBW (mouse body weight).

8 mice/group	Tumor cell s.c day 0	Monocytes i.p at day 1	ch4D5 at 4 μ g/gm of mbw day 1 i.p	ch4D5 N297A at 4 μ g/gm of mbw day 1 i.p	ch8B5.3.4 N297A at 4 μ g/gm of mbw day 1 i.p	Human IgG1 4 μ g/gm of mbw day 1 i.p
A	+	-	-	-	-	-
B	+	+	-	-	-	-
C	+	+	+	-	-	-
D	+	+	+	-	+	-
E	+	+	-	-	+	-
F	+	+	-	+	-	+

[0420] As shown in Table 10, 6 groups of 8 mice each are required for testing the role of an anti-Fc_YRIIB antibody in tumor clearance with one target and effector combination, with two different combinations of the antibody concentrations. These groups are A) tumor cells, B) tumor cells and monocytes, C) tumor cells, monocytes, anti-tumor antibody, ch4D5, D) tumor cells, monocytes, anti-tumor antibody ch4D5, and an anti-Fc_YRIIB antibody, e.g., ch8B5.3.4, E) tumor cells, monocytes, and an anti-Fc_YRIIB antibody, e.g., ch8B5.3.4, and F) tumor cells, monocytes, ch4D5 N297A, and human IgG1. Various combination of antibody concentration can be tested in similar schemes.

[0421] Studies using the breast cancer cell line, SKBR-3, are carried out in parallel with the IGROV-1 model as SKBR-3 cells over-express Her2/neu. This will increase the stringency of the evaluation of the role of anti-Fc_YRIIB antibody in tumor clearance. Based on the outcome of the tumor clearance studies with the IGROV-1 cells, modifications are made to experimental design of future experiments with other targets.

[0422] The endpoint of the xenograft tumor model is determined based on the size of the tumors (weight of mice), survival time, and histology report for each group in Table 10. Mice are monitored three times a week; criteria for growing tumors are abdominal distention and presence of palpable masses in the peritoneal cavity. Estimates of tumor weight versus days after inoculation is calculated. Based on these three criteria from group D mice in Table 10 versus the other groups of mice will define the role of anti-Fc_YRIIB antibodies in enhancement of tumor clearance. Mice that show signs of visible pain or reach 5 grams of tumor weight are euthanized with carbon dioxide and autopsied. The antibody-treated animals are followed for two months after this time-point.

6.2.3.2 IN VIVO ACTIVITY OF FCYRIIB ANTIBODIES IN XENOGRAFT MURINE MODEL WITH HUMAN PRIMARY OVARIAN AND BREAST CARCINOMA DERIVED CELLS

[0423] Primary tumors are established from primary ovarian and breast cancers by transferring tumors cells isolated from exudates from patients with carcinomatosis. In order to translate these studies into the clinic, the xenograft model are evaluated with ascites- and pleural effusion-derived tumor cells from two ovarian and two breast carcinoma patients, respectively. Pleural effusion, as a source of breast cancer cells, and implantation of malignant breast tissue have been used to establish xenograft murine models successfully, see, e.g., Sakakibara et al., 1996, Cancer J. Sci. Am. 2: 291. These studies will determine the broad range application of the anti-Fc_YRIIB antibody in tumor clearance of primary cells. Tumor clearance is tested using anti-tumor antibody, ch4D5 and anti-Fc_YRIIB antibody, e.g., ch8B5.3.4, in Balb/c nude mouse model with adoptively transferred human monocytes

[0424] ***Human ascites and pleural effusion-derived primary tumor cells.*** Ascites from patients with ovarian cancer and pleural effusions from breast cancer patients are used. The ascites and pleural effusion from patients may contain 40-50 % tumor cells and samples with a high expression of Her2neu+ tumor cells will be used to establish the xenograft models.

[0425] Ascites and pleural effusion samples are tested for expression of Her2/neu on neoplastic cells prior to establishment of the xenograft tumor model. The percentage of the neoplastic cells versus other cellular subsets that may influence the establishment of the tumor model will be determined. Ascites and pleural effusion from patients with ovarian and breast cancer, respectively are routinely analyzed to determine the level of expression of Her2/neu+ on the neoplastic cells. FACS analysis is used to determine the percentage of Her2/neu+ neoplastic cells in the clinical samples. Samples with high percentage of Her2/neu+ neoplastic cells are selected for initiation of tumors in Balb/c mice.

[0426] ***Histochemistry and Immunohistochemistry.*** Histochemistry and immunohistochemistry is performed on ascites and pleural effusion of patients with ovarian carcinoma to analyze structural characteristics of the neoplasia. The markers that are monitored are cytokeratin (to identify ovarian neoplastic and mesothelial cells from inflammatory and mesenchymal cells); calretinin (to separate mesothelial from Her2/neu positive neoplastic cells); and CD45 (to separate inflammatory cells from the rest of the cell population in the samples). Additional markers that will be followed will include CD3 (T cells), CD20 (B cells), CD56 (NK cells), and CD14 (monocytes).

[0427] For immunohistochemistry staining, frozen sections and paraffinized tissues are prepared by standard techniques. The frozen as well as the de-paraffinized sections are stained in a similar staining protocol. The endogenous peroxidase of the tissues is quenched by immersing the slides in 3% hydrogen peroxide and washed with PBS for 5 minutes. Sections are blocked and the primary antibody ch4D5 is added in blocking serum for 30 minutes followed by washing the samples with PBS three times. The secondary anti-human antibody conjugated with biotin is added for 30 minutes and the slides are washed in PBS for 5 minutes. Avidin-Biotin peroxidase complex (Vector Labs) is added for 30 minutes followed by washing. The color is developed by incubating the slides in fresh substrate DAB solution and the reaction is stopped by washing in tap water. For H& E staining, the

slides are deparaffinized and then hydrated in different alcohol concentrations. The slides are washed in tap water and placed in hematoxylin for 5 minutes. Excess stain is removed with acid-alcohol, followed by ammonia, and water. The slides are placed in Eosin and followed by 90 to 100 % alcohol washes for dehydration. Finally, the slides are placed in xylene and mounted with fixative for long-term storage. In all cases, the percentage of tumor cells is determined by Papanicolaou stain.

[0428] *Histochemical Staining.* Ascites from two different patients with ovarian carcinoma are stained by Hematoxylin and Eosin (H & E) and Giemsa to analyze the presence of tumor cells and other cellular types.

[0429] *Murine Models.* Samples from ovarian carcinoma patients are processed by spinning down the ascites at 6370 g for 20 minutes at 4 C, lysing the red blood cells followed by washing the cells with PBS. Based on the percentage of Her2/neu+ tumor cells in each sample, two samples, a median and high expressor are selected for s.c inoculation to establish the xenograft model to evaluate the role of anti-Fc_YR_{IIIB} antibody, in clearance of tumors. It has been reported that tumor cells make up 40-50% of the cellular subset of unprocessed ascites, and after purification ~ 10-50 x 10⁶ tumor cells were obtained from 2 liters of ascites (Barker et al., 2001, Gynecol. Oncol. 82: 57-63). The isolated ascites cells are injected i.p into mice to expand the cells. Approximately 10 mice will be injected i. p and each mouse ascites further passaged into two mice each to obtain ascites from a total of 20 mice, which is used to inject a group of 80 mice. Pleural effusion is handled in a manner similar to ascites and Her2neu+ tumor cells are injected into the upper right and left mammary pads in matrigel. After s.c inoculation of tumor cells, mice are followed for clinical and anatomical changes. As needed, mice may be necropsied to correlate total tumor burden with specific organ localization.

6.3 SCREENING OF CD32B-SPECIFIC MONOCLONAL ANTIBODIES

[0430] CD32B-specific antibodies will be screened for reactivity, raft association, CDC, and induction of apoptosis in B-cell lymphoma lines and cells from patients with B-cell malignancies. Isolation of cells from patients and reactivity screening is described above.

[0431] *Raft association.* A measure of the ability of the antibody to trigger redistribution of the antigen into specialized membrane microdomains, lipid raft association is conveniently performed by measuring the amount of antibody recovered into the detergent-insoluble cellular fraction after lysis with 0.5% TX-100 at 4C (Veri et al., 2001, Mol Cell Bio 21:6939-6950; Cragg et al., 2004, Blood 103:2738-43). In a typical experiment, cells will be coated on ice with the antibody of interest and washed. An aliquot will be subjected to additional cross-linking with an appropriate secondary antibody. Pelleted cells will be subjected to TX-100 detergent fractionation. Parallel samples will be solubilized with glucopyranoside, a detergent known to destroy lipid rafts, or directly with SDS-based Laemmli sample buffer to obtain the total amount of cell-associated antibody. The insoluble fractions will be analyzed by SDS-PAGE and western blot. Redistribution to lipid rafts with or without additional cross-linking will be recorded by densitometric comparisons.

[0432] *CDC.* CDC will be assessed by one of several methods known in the art, such as propidium iodide (PI) exclusion in FACS analysis (Cragg et al., 2004, Blood 103:2738-43) or traditional radiolabel release (e.g., ⁵¹Cr and ¹¹¹In release). In brief, cells will be incubated with titrating amounts of the antibodies of interest for 15 min at 37C followed by the addition of serum (20% final concentration) as a source of complement and the incubation continued for additional 5 min prior to analysis. Owing to the high variation of human serum, Pel-Freeze rabbit serum will be used as a standard source of complement. Pooled normal human AB serum will also be prepared. Each batch of serum will be tested in red blood cell lysis against rabbit serum for quality assurance.

[0433] *Apoptosis.* Apoptosis induced by soluble or plate immobilized anti-CD32B antibodies will be studied by standard FACS-based methodology by using annexin V membrane translocation and PI staining (Cragg et al., 2004, Blood 103:2738-43) in multicolor analysis to identify the population of interest (e.g. Cy5-CD 19). Briefly, cells will be treated for different intervals of time (2 to 18 hours) with titrating amounts of the antibody of interest in free solution or immobilized on 96-well plates. Cells will then be recovered by gentle scraping and/or centrifugation and stained with 1 ug/ml of FITC-annexin V plus 10 ug/ml of PI to distinguish between early apoptosis and secondary necrosis.

6.4 IN VIVO TUMOR CLEARANCE STUDIES IN MURINE TUMOR XENOGRAFT MODELS OF LYMPHOMAS

[0434] The ability to prevent tumors in a mouse model of lymphoma is an important criterion to determine the potential for an antibody to proceed into clinical studies.

[0435] A number of well characterized Burkitt's lymphoma cell lines are available for use as models of NHL (Epstein et al., 1966, J Natl Cancer Inst 37:547-559; Klein et al., 1968, Cancer Res 28:1300-1310; Klein et al., 1975, Intervirology 5:319-334; Nilsson et al., 1977, Intl J Cancer 19:337-344; Ohsugi et al., 1980, J Natl Cancer Inst 65:715-718). A xenograft model of lymphoma formation has been established in nude mice similar to previously reported models (Vallera et al., 2003, Cancer Biother Radiopharm 18:133-145; Vuist et al., 1989, Cancer Res 49:3783-3788).

[0436] In brief, the Burkitt's lymphoma cell line, Daudi (5-10x10⁶ cells), will be transplanted subcutaneously into an immunodeficient nu/nu mouse strain. The BALB/c nu/nu mouse strain will be used together with adoptively transferred human PBMC purified from a healthy donor as effector cells. A prevailing effector cell population in human PBMC is represented by NK cells, which exert ADCC via their CD16A (FcγRIIIa). A nu/nu mouse strain in which the murine CD16A gene has been knocked out and which has been genetically engineered to express human CD16A will also be used. This CD16A-/huCD16Atg, nu/nu mouse allows for the examination of anti-tumor activity in the context of a human Fc receptor without the need for the adoptive transfer of human cells.

[0437] Mice will be treated with the selected chimerized antibody injected i.p. on day 1, 4, 7, and 15. A starting dose of 4 ug/g of body weight will be used, but additional doses will be tested to establish the relative potency of the antibodies in this model. Rituxan and Campath will be used for comparison. Furthermore, potential synergism of combination therapy with Rituxan or Campath will also be studied. In these studies, tumor growth and morbidity will be monitored to compare antibody treated and control groups. Mice will be sacrificed immediately if moribund or at the completion of the studies. The tumors will then be excised and gross and microscopic necropsy performed. Cytopathology on paraffin-embedded sections and immunohistochemistry on frozen sections will be performed for a morphological and immunological evaluation of the tumor and cellular infiltrates.

SEQUENCE LISTING

[0438]

<110> MacroGenics, Inc.

<120> FCgammaRIIB-Specific Antibodies and Methods of Use Thereof

<130> 13783-105016

<140> PCT/US2007/072153

<141> 2007-06-26

<150> US 60/816,688

<151> 2006-06-26

<160> 12

<170> PatentIn version 3.4

<210> 1

<211> 321

<212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic

<220>

<221> misc_feature

<223> 8B5.3.4 VL nucleotide sequence

<400> 1

<220>
 <223> Synthetic <220>
 <221> MISC_FEATURE
 <223> 8B5.3.4 VH amino acid sequence

<400> 4
 Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15
 Ser Met Lys Leu Ser Cys Glu Ala Ser Gly Phe Thr Phe Ser Asp Ala
 20 25 30
 Trp Met Asp Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val
 35 40 45
 Ala Glu Ile Arg Asn Lys Ala Lys Asn His Ala Thr Tyr Tyr Ala Glu
 50 55 60
 Ser Val Ile Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser
 65 70 75 80
 Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr
 85 90 95
 Tyr Cys Gly Ala Leu Gly Leu Asp Tyr Trp Gly Gln Gly Thr Thr Leu
 100 105 110
 Thr Val Ser Ser
 115

<210> 5
 <211> 11
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic
 <220>
 <221> MISC_FEATURE
 <223> 8B5.3.4 VL amino acid sequence (CDR1)

<400> 5
 Arg Ala Ser Gln Glu Ile Ser Gly Tyr Leu Ser
 1 5 10

<210> 6
 <211> 7
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<220>
 <221> MISC_FEATURE
 <223> 8B5.3.4 VL amino acid sequence (CDR2)

<400> 6
 Ala Ala Ser Thr Leu Asp Ser
 1 5

<210> 7
 <211> 9
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<220>
 <221> MISC_FEATURE
 <223> 8B5.3.4 VL amino acid sequence (CDR3)

<400> 7
 Leu Gln Tyr Phe Ser Tyr Pro Leu Thr
 1 5

<210> 8
 <211> 5
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<220>
 <221> MISC_FEATURE
 <223> 8B5.3.4 VH amino acid sequence (CDR1)

<400> 8
 Asp Ala Trp Met Asp
 1 5

<210> 9
 <211> 19
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<220>
 <221> MISC_FEATURE
 <223> 8B5.3.4 VH amino acid sequence (CDR2)

<400> 9
 Glu Ile Arg Asn Lys Ala Lys Asn His Ala Thr Tyr Tyr Ala Glu Ser
 1 5 10 15

Val Ile Gly

<210> 10
 <211> 7
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<220>
 <221> MISC_FEATURE
 <223> 8B5.3.4 VH amino acid sequence (CDR3)

<400> 10
 Gly Ala Leu Gly Leu Asp Tyr
 1 5

<210> 11
 <211> 5
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<220>

<221> MISC_FEATURE
 <223> Fusion Protein - partial sequence

<400> 11
 Ala Pro Ser Ser Ser
 1 5

<210> 12
 <211> 8
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Synthetic

<220>
 <221> MISC_FEATURE
 <223> Fusion Protein - partial sequence

<400> 12
 Val Pro Ser Met Gly Ser Ser Ser
 1 5

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- [WO2005115452A \[0003\]](#)
- [WO2007021841A \[0004\]](#)
- [US5601621A \[0035\]](#)
- [US5653980A \[0035\]](#)
- [WO9731946A \[0036\]](#)
- [EP239400A \[0095\] \[0136\] \[0146\]](#)
- [EP592106A \[0095\] \[0136\] \[0146\]](#)
- [EP519596A \[0095\] \[0136\] \[0146\]](#)
- [WO9109967A \[0095\] \[0136\] \[0146\]](#)
- [WO9317105A \[0095\] \[0136\]](#)
- [US5225539A \[0095\] \[0136\] \[0146\]](#)
- [US5530101A \[0095\] \[0136\] \[0136\] \[0146\]](#)
- [US5565332A \[0095\] \[0136\] \[0146\]](#)
- [US5586089A \[0095\] \[0136\] \[0136\] \[0136\] \[0146\] \[0147\]](#)
- [US5766806A \[0095\] \[0136\]](#)
- [US6407213B \[0095\] \[0136\]](#)
- [US20040185045A \[0109\]](#)
- [US20060013810A \[0109\]](#)
- [US20040043401A \[0113\]](#)
- [US6534633B \[0113\]](#)
- [US6818418B \[0113\]](#)
- [WO9317715A \[0115\]](#)
- [WO9209802A \[0115\]](#)
- [WO9100360A \[0115\]](#)
- [WO9205793A \[0115\]](#)

- [US4474893A \[0115\]](#)
- [US4714681A \[0115\]](#)
- [US4925648A \[0115\]](#)
- [US5573920A \[0115\]](#)
- [US5601819A \[0115\]](#)
- [US6277375B1 \[0127\]](#)
- [US4179037A \[0129\]](#)
- [US4444887A \[0133\]](#)
- [US4716111A \[0133\]](#)
- [WO9846645A \[0133\]](#)
- [WO9850433A \[0133\]](#)
- [WO9824893A \[0133\] \[0145\]](#)
- [WO9816654A \[0133\]](#)
- [WO9634096A \[0133\] \[0145\]](#)
- [WO9633735A \[0133\] \[0145\]](#)
- [WO9110741A \[0133\]](#)
- [US56988204P \[0134\]](#)
- [US60582043B \[0134\]](#)
- [US12697805A \[0134\]](#)
- [US20040049014A \[0136\]](#)
- [US20030229208A \[0136\]](#)
- [US6350861B \[0136\]](#)
- [US6180370B \[0136\]](#)
- [US5693762A \[0136\]](#)
- [US5693761A \[0136\]](#)
- [US5413923A \[0145\]](#)
- [US5625126A \[0145\]](#)
- [US5633425A \[0145\]](#)
- [US5569825A \[0145\]](#)
- [US5661016A \[0145\]](#)
- [US5545806A \[0145\]](#)
- [US5814318A \[0145\]](#)
- [US5939598A \[0145\]](#)
- [US6311415B \[0146\]](#)
- [US5807715A \[0146\] \[0236\]](#)
- [US4816567A \[0146\]](#)
- [US4816397A \[0146\]](#)
- [US20050037000A \[0146\] \[0236\]](#)
- [US20050064514A \[0148\] \[0236\]](#)
- [US5624821A \[0148\]](#)
- [US5648260A \[0148\]](#)
- [EP0307434A \[0148\]](#)
- [WO04029207A \[0149\]](#)
- [WO04029092A \[0149\]](#)
- [WO04023564A \[0149\]](#)
- [WO9958572A \[0149\]](#)
- [WO9951642A \[0149\]](#)
- [WO9823289A \[0149\]](#)
- [WO8907142A \[0149\]](#)
- [WO8807089A \[0149\]](#)
- [US5843597A \[0149\]](#)
- [US5642821A \[0149\]](#)
- [US6194551B \[0149\] \[0149\]](#)
- [WO042072A \[0149\]](#)
- [US20050064514A1 \[0154\]](#)
- [WO03035835A \[0160\] \[0164\]](#)
- [US6218149B \[0164\] \[0164\]](#)
- [EP0359096B1 \[0164\]](#)

- [US20020028486A \[0164\]](#)
- [US20030115614A \[0164\]](#)
- [US6472511B \[0164\]](#)
- [WO9321232A \[0171\]](#)
- [EP439096A \[0171\]](#)
- [US5474991A \[0171\]](#)
- [WO9733899A \[0172\]](#)
- [WO9734911A \[0172\]](#)
- [WO9923105A \[0172\]](#)
- [US5336603A \[0174\]](#)
- [US5622929A \[0174\]](#)
- [US5359046A \[0174\]](#)
- [US5349053A \[0174\]](#)
- [US5447851A \[0174\]](#)
- [US5112946A \[0174\]](#)
- [EP307434A \[0174\]](#)
- [EP367166A \[0174\]](#)
- [WO9604388A \[0174\]](#)
- [WO9106570A \[0174\]](#)
- [US5605793A \[0175\]](#)
- [US5811238A \[0175\]](#)
- [US5830721A \[0175\]](#)
- [US5834252A \[0175\]](#)
- [US5837458A \[0175\]](#)
- [US4741900A \[0176\]](#)
- [US4676990A \[0181\]](#)
- [US5877396A \[0185\] \[0378\]](#)
- [US5824487A \[0185\]](#)
- [WO9201047A \[0187\] \[0187\]](#)
- [WO9002809A \[0187\]](#)
- [WO9110737A \[0187\]](#)
- [WO9218619A \[0187\]](#)
- [WO9311236A \[0187\]](#)
- [WO9515982A \[0187\]](#)
- [WO9520401A \[0187\]](#)
- [US5698426A \[0187\]](#)
- [US5223409A \[0187\]](#)
- [US5403484A \[0187\]](#)
- [US5580717A \[0187\]](#)
- [US5427908A \[0187\] \[0187\]](#)
- [US5750753A \[0187\]](#)
- [US5821047A \[0187\]](#)
- [US5571698A \[0187\]](#)
- [US5516637A \[0187\]](#)
- [US5780225A \[0187\]](#)
- [US5658727A \[0187\]](#)
- [US5733743A \[0187\]](#)
- [US5969108A \[0187\]](#)
- [WO9222324A \[0189\]](#)
- [US4946778A \[0189\]](#)
- [US5258498A \[0189\]](#)
- [US6373577B \[0194\]](#)
- [US6269288B \[0194\]](#)
- [US5322798A \[0194\]](#)
- [US5341215A \[0194\]](#)
- [US6268125B \[0194\]](#)
- [US6455677B \[0296\]](#)

- US6306393B [0301]
- US6426336B [0319]
- US20020035109A1 [0319]
- US20020010343A [0319]
- US6403080B [0327]
- US4485045A [0334]
- US4544545A [0334] [0335]
- US5013556A [0325]
- US20050074403A [0335]
- US6787153B [0336]
- US20030044407A [0336]
- WO9739731A [0338]
- US6019968A [0339]
- US598520A [0339]
- US5985309A [0339]
- US5934272A [0339]
- US5874064A [0339]
- US5865913A [0339]
- US5290540A [0339]
- US4880078A [0339]
- WO9219244A [0339]
- WO9732572A [0339]
- WO9744013A [0339]
- WO9831346A [0339]
- WO9966903A [0339]
- US4526938A [0346] [0347]
- WO9105548A [0346] [0347]
- WO9620698A [0346] [0347]
- US5679377A [0346]
- US5916597A [0346]
- US5912015A [0346]
- US5989463A [0346]
- US5128326A [0346]
- WO9915154A [0346]
- WO9920253A [0346]
- US5945155A [0346]
- US5888533A [0346]
- US4980286A [0348] [0363]
- US2005002903A [0363]
- WO9206180A [0363]
- WO9222635A [0363]
- WO9220316A [0363]
- WO9314188A [0363]
- WO9320221A [0363]
- WO9412649A [0365]
- US5436146A [0366]
- WO9408598A [0372]
- US5441050A [0401]
- US2007072153W [0438]
- US6081666B [0438]

Non-patent literature cited in the description

- **RAVETCH J.V. et al.** *Ann. Rev. Immunol.*, 1991, vol. 9, 457-92 [0003]

- **GERBER J.S.** Microbes and Infection, 2001, vol. 3, 131-139 [0003]
- **BILLADEAU D.D. et al.** The Journal of Clinical Investigation, 2002, vol. 2, 109161-1681 [0003]
- **RAVETCH J.V. et al.** Science, 2000, vol. 290, 84-89 [0003]
- **RAVETCH J.V. et al.** Annu. Rev. Immunol., 2001, vol. 19, 275-90 [0003]
- **RAVETCH J.V.** Cell, 1994, vol. 78, 4553-60 [0003]
- Immunobiology: The Immune System in Health and Disease Elsevier Science Ltd/Garland Publishing 19990000 [0003]
- **ROBBINSANGELL** Basic Pathology W.B. Saunders Co. 1976000068-122 [0011]
- **WILLIAMS et al.** Hematology McGraw Hill 20010000 [0013]
- **FOON et al.** Annals Int. Medicine, 1990, vol. 113, 525- [0014]
- **ALIZADEH et al.** Nature, 2000, vol. 403, 503-511 [0015]
- **ROSENWALD et al.** J. Exp. Med., 2001, vol. 184, 1639-1647 [0015]
- **DAMLE et al.** Blood, 2002, vol. 99, 4087-4093 [0015]
- Principles of Cancer Patient Management **STOCKDALE** Scientific American: Medicine 19980000 vol. 3, [0016]
- **GILMAN et al.** Goodman and Gilman's: The Pharmacological Basis of Therapeutics Pergamon Press 19900000 [0017]
- Principles Of Cancer Patient Management **STOCKDALE** Scientific American Medicine 19980000 vol. 3, [0018]
- **DEVESA et al.** J. Nat'l Cancer Inst., 1987, vol. 79, 701- [0019]
- **GREEN M.C. et al.** Cancer Treat Rev., 2000, vol. 26, 269-286 [0021]
- **WEINER LM** Semin Oncol., 1999, vol. 26, 1443-51 [0021]
- **SUZANNE A. ECCLES** Breast Cancer Res., 2001, vol. 3, 86-90 [0021]
- **CHANG, T.W.** Nature Biotechnology, 2000, vol. 18, 157-62 [0024]
- **STADLER et al.** Int. Arch. Allergy and Immunology, 1993, vol. 102, 121-126 [0035]
- **RUDOLF et al.** Journal of Immunology, 1998, vol. 160, 3315-3321 [0036]
- Fundamental Immunology Raven Press 19890000332-336 [0076]
- **KARLINALTSCHUL** Proc. Natl. Acad. Sci. U.S.A., 1990, vol. 87, 2264-2268 [0082]
- **KARLINALTSCHUL** Proc. Natl. Acad. Sci. U.S.A., 1993, vol. 90, 5873-5877 [0082]
- **ALTSCHUL et al.** J. Mol. Biol., 1990, vol. 215, 403- [0082]
- **ALTSCHUL et al.** Nucleic Acids Res., 1997, vol. 25, 3389-3402 [0082]
- **MYERSMILLER** CABIOS, 1988, vol. 4, 11-17 [0082]
- **KABAT et al.** SEQUENCES OF PROTEINS OF IMMUNOLOGICAL INTEREST National Institutes of Health 19870000 [0088]
- **PADLAN** Molecular Immunology, 1991, vol. 28, 4/5489-498 [0095] [0136] [0146]
- **STUDNICKA et al.** Protein Engineering, 1994, vol. 7, 6805-814 [0095] [0136]
- **ROGUSKA et al.** Proc Natl Acad Sci USA, 1994, vol. 91, 969-973 [0095]
- **TAN et al.** J. Immunol., 2002, vol. 169, 1119-25 [0095] [0136]
- **CALDAS et al.** Protein Eng., 2000, vol. 13, 353-60 [0095] [0136]
- **MOREA et al.** Methods, 2000, vol. 20, 267-79 [0095] [0136]
- **BACA et al.** J. Biol. Chem., 1997, vol. 272, 10678-84 [0095] [0136]
- **ROGUSKA et al.** Protein Eng., 1996, vol. 9, 895-904 [0095] [0136]
- **COUTO et al.** Cancer Res., 1995, vol. 55, 235973s-5977s [0095] [0136]
- **COUTO et al.** Cancer Res., 1995, vol. 55, 1717-22 [0095] [0136]
- **SANDHUGEN** Gene, 1994, vol. 150, 409-10 [0095] [0136]
- **PEDERSEN et al.** J. Mol. Biol., 1994, vol. 235, 959-73 [0095] [0136]
- **JONES et al.** Nature, 1986, vol. 321, 522-525 [0095] [0136]
- **REICHMANN et al.** Nature, 1988, vol. 332, 323-329 [0095]
- **PRESTA** Curr. Op. Struct. Biol., 1992, vol. 2, 593-596 [0095] [0136]
- **KABAT et al.** Sequences of Proteins of Immunological Interest National Institutes of Health 19910000 [0096]
- **CHOTHIALESKJ.** Mol. Biol., 1987, vol. 196, 901-917 [0096]
- Physicians' Desk Reference 20020000 [0102]
- **PLUCKTHUN** The Pharmacology of Monoclonal Antibodies Springer-Verlag 19940000 vol. 113, 269-315 [0103]
- **TUTT et al.** J. Immunol., 1991, vol. 147, 60-69 [0115]
- **KOSTELNY et al.** J. Immunol., 1992, vol. 148, 1547-1553 [0115]
- **TODOROVSKA et al.** Journal of Immunological Methods, 2001, vol. 248, 47-66 [0115]
- **WARD et al.** Nature, 1989, vol. 341, 544-546 [0119]
- **DUMOULIN et al.** Protein Sci., 2002, vol. 11, 500-515 [0119] [0120]
- **DAVIES et al.** Bio/Technol., 1995, vol. 13, 475-479 [0119] [0120]
- **VAN DEN BEUCKEN et al.** J. Mol. Biol., 2001, vol. 310, 591-601 [0119] [0120]
- **PEREIRA et al.** Biochem., 1998, vol. 37, 1430-1437 [0119]
- **MARKS et al.** Bio/Technol., 1992, vol. 10, 779-783 [0119]
- **KLIMKA et al.** Brit. J. Cancer, 2000, vol. 83, 2252-260 [0119]

- **RADER et al.** Proc. Natl. Acad. Sci. USA, 1998, vol. 95, 8910-8915 [0119]
- **PEREIRA et al.** Biochemistry, 1998, vol. 37, 1430-1437 [0120]
- **TSUMOTO et al.** FEBS Letters, 2002, vol. 525, 77-82 [0120]
- **WARD** Nature, 1989, vol. 341, 544-546 [0120]
- Current Protocols in Molecular Biology Green Publishing Associates, Inc. and John Wiley and Sons, Inc. 19890000 vol. 1, 6.3.1-6.3.62.10.3- [0123]
- **GREENSPAN BONAFASE** B. J., 1989, vol. 7, 437-444 [0126]
- **NISSINOFF** J. Immunol., 1991, vol. 147, 2429-2438 [0126]
- **ROGUSKA et al.** Proc Natl Acad Sci USA, 1994, vol. 91, 969-973 [0136]
- **RIECHMANN et al.** Nature, 1988, vol. 332, 323- [0136] [0136] [0147]
- **MATSUDA et al.** J. Exp. Med., 1998, vol. 188, 2151062- [0143]
- **RAVETCH et al.** Cell, 1981, vol. 27, 3583-91 [0143]
- **LAUTNER-RIESKE et al.** Eur. J. Immunol., 1992, vol. 22, 1023-1029 [0143]
- **HIERER et al.** J. Biol. Chem., 1982, vol. 257, 1516-22 [0143]
- **LONBERGHUSZAR** Int. Rev. Immunol., 1995, vol. 13, 65-93 [0145]
- **MORRISON** Science, 1985, vol. 229, 1202- [0146]
- **OL et al.** BioTechniques, 1986, vol. 4, 214- [0146]
- **GILLIES et al.** J. Immunol. Methods, 1989, vol. 125, 191-202 [0146]
- **STUDNICKA et al.** Protein Engineering, 1994, vol. 7, 805- [0146]
- **ROGUSKA et al.** PNAS, 1994, vol. 91, 969- [0146]
- **HUBBARD et al.** Ann. Rev. Biochem., 1981, vol. 50, 555-583 [0157]
- **JEFFERIS et al.** Immunol. Rev., 1998, vol. 163, 59-76 [0156]
- **WRIGHT et al.** Trends Biotech, 1997, vol. 15, 26-32 [0158]
- **JASSAL et al.** Biochem. Biophys. Res. Commun., 2001, vol. 288, 243-9 [0158]
- **GROENINK et al.** J. Immunol., 1996, vol. 26, 1404-7 [0158]
- **BOYD et al.** Mol. Immunol., 1995, vol. 32, 1311-8 [0158]
- **KUMPEL et al.** Human Antibody Hybridomas, 1994, vol. 5, 143-51 [0158]
- **RIBKASTANLEY** Somatic Cell & Molec. Gen., 1986, vol. 12, 151-62 [0160]
- **RIPKA et al.** Arch. Biochem. Biophys., 1986, vol. 249, 2533-45 [0160]
- **SHIELDS et al.** J. Biol. Chem., 2002, vol. 277, 3026733-40 [0160]
- **SHIELDS R.L. et al.** J. Biol. Chem., 2001, vol. 277, 3026733-40 [0161]
- **DAVIES J. et al.** Biotechnology & Bioengineering, 2001, vol. 74, 4288-294 [0161]
- **WALLICK et al.** Journal of Exp. Med., 1988, vol. 168, 31099-1109 [0161]
- **TAO et al.** Journal of Immunology, 1989, vol. 143, 82595-2601 [0161]
- **ROUTLEDGE et al.** Transplantation, 1995, vol. 60, 8847-53 [0161]
- **ELLIOTT et al.** Nature Biotechnology, 2003, vol. 21, 414-21 [0161]
- **SHIELDS et al.** Journal of Biological Chemistry, 2002, vol. 277, 3026733-40 [0161]
- **JEFFERIS et al.** Immunology Letters, 1995, vol. 44, 111-7 [0162]
- In vitro Mutagenesis **J. D. WATSON et al.** Recombinant DNA: A Short Course W.H. Freeman and Company 19830000106-116 [0162]
- **NARAMURA et al.** Immunol. Lett., 1994, vol. 39, 91-99 [0171]
- **GILLIES et al.** Proc Natl Acad Sci, 1992, vol. 89, 1428-1432 [0171]
- **FELL et al.** J. Immunol., 1991, vol. 146, 2446-2452 [0171]
- **TAKAHASHI et al.** J. Immunol., 1994, vol. 6, 1567-1574 [0172]
- **GENTZ et al.** Proc. Natl. Acad. Sci. USA, 1989, vol. 86, 821-824 [0173]
- **WILSON et al.** Cell, 1984, vol. 37, 767- [0173]
- **KNAPPIK et al.** Biotechniques, 1994, vol. 17, 4754-761 [0173]
- **ASHKENAZI et al.** Proc. Natl. Acad. Sci. USA, 1991, vol. 88, 10535-10539 [0174]
- **ZHENG et al.** J. Immunol., 1995, vol. 154, 5590-5600 [0174]
- **VIL et al.** Proc. Natl. Acad. Sci. USA, 1992, vol. 89, 11337-11341 [0174]
- **PATTEN et al.** Curr. Opinion Biotechnol., 1997, vol. 8, 724-33 [0175]
- **HARAYAMA** Trends Biotechnol., 1998, vol. 16, 76- [0175]
- **HANSSON et al.** J. Mol. Biol., 1999, vol. 287, 265- [0175]
- **LORENZO BLASCO** BioTechniques, 1998, vol. 24, 308- [0175]
- **DENARDO et al.** Clin Cancer Res., 1998, vol. 4, 2483-90 [0176]
- **PETERSON et al.** Bioconjug. Chem., 1999, vol. 10, 553- [0178]
- **ZIMMERMAN et al.** Nucl. Med. Biol., 1999, vol. 26, 943-50 [0178]

- Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy **ARNON et al.** Monoclonal Antibodies And Cancer Therapy Alan R. Liss, Inc. 19850000243-56 [0179]
- Antibodies For Drug Delivery **HELLSTROM et al.** Controlled Drug Delivery Marcel Dekker, Inc. 19870000623-53 [0179]
- Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review **THORPE et al.** Monoclonal Antibodies '84: Biological And Clinical Applications 19850000475-506 [0179]
- Analysis, Results, And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy Monoclonal Antibodies For Cancer Detection And Therapy Academic Press 19850000303-16 [0179]
- **THORPE et al.** Immunol. Rev., 1982, vol. 62, 119-58 [0179]
- **HARLOW et al.** Antibodies: A Laboratory Manual Cold Spring Harbor Laboratory Press 19880000 [0183]
- **HAMMERLING et al.** Monoclonal Antibodies and T-Cell Hybridomas Elsevier 19810000563-681 [0183]
- **BIEG et al.** Autoimmunity, 1999, vol. 31, 115-24 [0185]
- **LODMELL D.I. et al.** Vaccine, 2000, vol. 18, 1059-1066 [0185]
- **ULRICH et al.** Methods in Molecular Medicine, 2000, 273-282 [0185]
- **JOHNSON et al.** Journal of Medicinal Chemistry, 1999, vol. 42, 4640-4649 [0185]
- **BALDRIDGE et al.** Methods, 1999, vol. 19, 103-107 [0185]
- **ETON et al.** Clin. Cancer Res, 1998, vol. 4, 3619-27 [0185]
- **GUBTA R. et al.** Vaccine, 1995, vol. 13, 141263-76 [0185]
- **BRINKMAN et al.** J. Immunol. Methods, 1995, vol. 182, 41-50 [0187]
- **AMES et al.** J. Immunol. Methods, 1995, vol. 184, 177-186 [0187]
- **KETTLEBOROUGH et al.** Eur. J. Immunol., 1994, vol. 24, 952-958 [0187]
- **PERSIC et al.** Gene, 1997, vol. 187, 9-18 [0187]
- **BURTON et al.** Advances in Immunology, 1994, vol. 57, 191-280 [0187]
- **MULLINAX et al.** BioTechniques, 1992, vol. 12, 6864-869 [0186]
- **SAWAI et al.** AJRI, 1995, vol. 34, 26-34 [0186]
- **BETTER et al.** Science, 1988, vol. 240, 1041-1043 [0186]
- **HUSTON et al.** Methods in Enzymology, 1991, vol. 203, 46-88 [0188]
- **SHU et al.** Proc Natl Acad Sci USA, 1993, vol. 90, 7995-7999 [0188]
- **SKERRA et al.** Science, 1988, vol. 240, 1038-1040 [0188]
- **GLASER et al.** J. Immunology, 1992, vol. 149, 3903- [0189]
- **WU et al.** Proc Natl. Acad Sci. USA, 1998, vol. 95, 6037- [0189]
- **YELTON et al.** J. Immunology, 1995, vol. 155, 1994- [0189]
- **SCHIER et al.** J. Mol. Bio., 1996, vol. 263, 551- [0189]
- Current Protocols in Molecular Biology John Wiley & Sons, Inc. 19940000 vol. 1, [0193]
- **MULLET et al.** Methods, 2000, vol. 22, 77-91 [0194]
- **DONG et al.** Review in Mol. Biotech., 2002, vol. 82, 303-23 [0194]
- **FIVASH et al.** Current Opinion in Biotechnology, 1998, vol. 9, 97-101 [0194]
- **RICH et al.** Current Opinion in Biotechnology, 2000, vol. 11, 54-61 [0194]
- **METCALFE D.D. et al.** Physiol. Rev., 1997, vol. 77, 1033- [0201]
- **LONG E.O.** Annu Rev. Immunol., 1999, vol. 17, 875- [0201]
- **OTT V. L.J.** Immunol., 2002, vol. 162, 94430-9 [0201]
- **CARPINO et al.** Cell, 1997, vol. 88, 197- [0201]
- **YAMANSHI et al.** Cell, 1997, vol. 88, 205- [0201]
- **BARSUMIAN E.L. et al.** Eur. J. Immunol., 1981, vol. 11, 317- [0202] [0203]
- **MALBEC et al.** J. Immunol., 1998, vol. 160, 1647- [0202]
- **DAERON et al.** J. Clin. Invest., 1995, vol. 95, 577- [0202]
- **OTT et al.** J. of Immunol., 2002, vol. 168, 4430-4439 [0202]
- **AKETANI et al.** Immunol. Lett., 2001, vol. 75, 185-9 [0207]
- **AKETANI et al.** Anal. Chem., 2000, vol. 72, 2653-8 [0207]
- Immunology Letters, 2001, vol. 75, 185-9 [0209]
- British J. of Pharm, 2002, vol. 136, 837-45 [0209]
- J. of Immunology, vol. 168, 4430-9 [0209]
- J. of Cell Biol., vol. 153, 2339-49 [0209]
- **KIRSHENBAUM et al.** Leukemia research, 2003, vol. 27, 677-82 [0211]
- **KIRSHENBAUM et al.** Leukemia research, 2003, vol. 27, 677-682 [0211]
- **TRIDANDAPANI et al.** J. Biol. Chem., 2002, vol. 277, 75082-5089 [0212]
- **PRICOP et al.** J. of Immunol., 2001, vol. 166, 531-537 [0212]
- **CAMERON et al.** Immunology Letters, 2002, vol. 83, 171-179 [0212]
- **BRAUWEILER A. et al.** Journal of Immunology, 2001, vol. 167, 1204-211 [0215]

- **TRIDANDAPANI et al.** *J. Biol. Chem.*, 2002, vol. 277, 75082-9 [0216]
- **TRIDANDAPANI et al.** *J. Biol. Chem.*, 2000, vol. 275, 20480-7 [0222]
- **PERUSSIA et al.** *Methods Mol. Biol.*, 2000, vol. 121, 179-92 [0224] [0225]
- **BAGGIOLINI et al.** *Experientia*, 1998, vol. 44, 10841-8 [0224]
- **LEHMANN et al.** *J. Immunol. Methods*, 2000, vol. 243, 1-2229-42 [0224]
- **BROWS EJ.** *Methods Cell Biol.*, 1994, vol. 45, 147-64 [0224]
- **MUNN et al.** *J. Exp. Med.*, 1990, vol. 172, 231-237 [0224]
- **ABDUL-MAJID et al.** *Scand. J. Immunol.*, 2002, vol. 55, 70-81 [0224]
- **DING et al.** *Immunity*, 1998, vol. 8, 403-411 [0224]
- **RAVETCH et al.** *Annu. Rev. Immunol.*, 1991, vol. 9, 457-92 [0225]
- **TREMP et al.** *Cancer Res.*, 1976, 33-41 [0227] [0250]
- **EPSTEIN et al.** *J. Natl. Cancer Inst.*, 1965, vol. 34, 231-240 [0227] [0250]
- **KLEIN et al.** *Cancer Res.*, 1968, vol. 28, 1300-10 [0227] [0250]
- **BENARD et al.** *Cancer Research*, 1985, vol. 45, 4970-9 [0227] [0250]
- **HAMILTON et al.** *Cancer Res.*, 1983, vol. 43, 5379-89 [0227]
- **DING et al.** *Immunity*, 1998, vol. 8, 403-11 [0229]
- **MURRAY et al.** *Cancer*, 1994, vol. 73, 351057-66 [0234]
- **YAMAMOTO et al.** *Nature*, 1986, vol. 319, 230-4 [0234]
- **LOTTICH et al.** *Breast Cancer Res. Treat.*, 1985, vol. 6, 149-56 [0234]
- **MANSI et al.** *Int. J. Rad. Appl. Instrum. B*, 1989, vol. 16, 2127-35 [0234]
- **COLCHER et al.** *Int. J. Rad. Appl. Instrum. B*, 1991, vol. 18, 395-41 [0234]
- **CARTER et al.** *Proc. Natl. Acad. Sci. USA*, 1992, vol. 89, 4285-9 [0234]
- **SHEILDS et al.** *J. Biol. Chem.*, 2001, vol. 276, 96591-604 [0236]
- **JEFFERIES et al.** *Immunol. lett.*, 1995, vol. 44, 111-7 [0236]
- **LUND et al.** *J. Immunol.*, 1996, vol. 157, 4963-69 [0236]
- **WRIGHT et al.** *J. Exp. Med.*, 1994, vol. 180, 1087-96 [0236]
- **WHITE et al.** *J. Immunol.*, 1997, vol. 158, 426-35 [0236]
- **BENARD et al.** *Cancer Res.*, 1985, vol. 45, 4970-9 [0241]
- **BARKER et al.** *Gynecol. Oncol.*, 2001, vol. 82, 57-63- [0246]
- **AL HAJJ et al.** *Proc. Natl. Acad. Sci. USA*, 2003, vol. 100, 3983-8- [0247]
- **SHILOWEINBERG** *Proc. Natl. Acad. Sci. U.S.A.*, 1981, vol. 78, 6789-6792 [0255]
- **SAMBROOK et al.** *Molecular Cloning, A Laboratory Manual* Cold Spring Harbor Laboratory Press 19890000 [0255]
- Current Protocols in Molecular Biology series of laboratory technique manual Current Protocols John Wiley and Sons, Inc. 19870000 [0255]
- Immobilization of nucleic acids and hybridization analysis **DYSON** In: *Essential Molecular Biology: A Practical Approach* IRL Press at Oxford University Press 19910000 vol. 2, 111-156 [0255]
- **SAMBROOK et al.** *Molecular Cloning, A Laboratory Manual* Cold Spring Harbor Laboratory 19900000 [0256] [0261]
- Current Protocols in Molecular Biology John Wiley & Sons 19980000 [0258] [0261]
- **CHOTHIA et al.** *J. Mol. Biol.*, 1998, vol. 278, 457-479 [0259]
- **FOECKING et al.** *Gene*, 1998, vol. 45, 101- [0263]
- **COCKETT et al.** *Bio/Technology*, 1990, vol. 8, 2- [0263]
- **RUTHER et al.** *EMBO J.*, 1983, vol. 2, 1791- [0265]
- **INOUE** *Nucleic Acids Res.*, 1985, vol. 13, 3101-3109 [0265]
- **VAN HEEKESCHUSTER** *J. Biol. Chem.*, 1989, vol. 24, 5503-5509 [0266]
- **LOGANSHENK** *Proc. Natl. Acad. Sci. USA*, 1984, vol. 81, 355-359 [0267]
- **BITTNER et al.** *Methods in Enzymol.*, 1987, vol. 153, 51-544 [0267]
- **WIGLER et al.** *Cell*, 1977, vol. 11, 223- [0270]
- **SZYBALSKA** *Proc. Natl. Acad. Sci. USA*, 1992, vol. 89, 202- [0270]
- **LOWY et al.** *Cell*, 1980, vol. 22, 817- [0270]
- **WIGLER et al.** *Proc. Natl. Acad. Sci. USA*, 1980, vol. 77, 357- [0270]
- **O'HARE et al.** *Proc. Natl. Acad. Sci. USA*, 1981, vol. 78, 1527- [0270]
- **MULLIGANBERG** *Proc. Natl. Acad. Sci. USA*, 1981, vol. 78, 2072- [0270]
- *Clinical Pharmacy*, vol. 12, 488-505 [0270]
- **TOLSTOSHEV** *Ann. Rev. Pharmacol. Toxicol.*, 1993, vol. 32, 573-596 [0270] [0359]
- **MULLIGAN** *Science*, 1993, vol. 260, 926-932 [0270] [0359]
- **MORGANANDERSON** *Ann. Rev. Biochem.*, 1993, vol. 62, 191-217 [0270] [0359]
- **TIB TECH**, 1993, vol. 11, 5155-215 [0270]

- Current Protocols in Molecular Biology John Wiley & Sons 19930000 [0270] [0359]
- KRIEGLER Gene Transfer and Expression, A Laboratory Manual Stockton Press 19900000 [0270] [0359]
- Current Protocols in Human Genetics John Wiley & Sons 19940000 [0270]
- COLBERRE-GARAPIN et al. J. Mol. Biol., 1981, vol. 150, 1- [0270]
- SANTERRE et al. Gene, 1984, vol. 30, 147- [0270]
- DNA cloning Academic Press 19870000 vol. 3, [0271]
- CROUSE et al. Mol. Cell. Biol., 1983, vol. 3, 257- [0271]
- PROUDFOOT Nature, 1986, vol. 322, 52- [0272]
- KOHLER Proc. Natl. Acad. Sci. USA, 1980, vol. 77, 2197- [0272]
- LYDEN et al. J. Immunol., 2001, vol. 166, 3882-3889 [0276]
- Physician's Desk Reference 20020000 [0290] [0298]
- LIN et al. J. Exp. Med., 2001, vol. 193, 6727-739 [0284]
- LIN et al. Journal of Mammary Gland Biology and Neoplasam, 2002, vol. 7, 2147-162 [0284]
- SCHOLL et al. Molecular Carcinogenesis, 1993, vol. 7, 207-11 [0284]
- CLYNES et al. Nature Medicine, 2000, vol. 6, 4443-446 [0284]
- FIDLER et al. Cancer Research, 1985, vol. 45, 4714-26 [0284]
- FISHMAN et al. Medicine J. B. Lippincott Co. 19850000 [0287]
- MURPHY et al. Informed Decisions: The Complete Book of Cancer Diagnosis, Treatment, and Recovery, Viking Penguin Penguin Books U.S.A., Inc. 19970000 [0287]
- PEREZWALKER J. Immunol., 1990, vol. 142, 32-37 [0289]
- BUMAL Hybridoma, 1988, vol. 7, 4407-415 [0289]
- YU et al. Cancer Res., 1991, vol. 51, 248-475 [0289]
- TAILOR et al. Nucl. Acids Res., 1990, vol. 18, 14928- [0289]
- HENTTUVIHKO Biochem. Biophys. Res. Comm., 1989, vol. 10, 2903-910 [0289]
- ISRAELI et al. Cancer Res., 1993, vol. 53, 227-230 [0289]
- ESTIN et al. J. Natl. Cancer Inst., 1989, vol. 81, 6445-44 [0289]
- VIJAYASARDAHAL et al. J. Exp. Med., 1990, vol. 171, 41375-1380 [0289]
- NATALI et al. Cancer, 1987, vol. 59, 55-3 [0289]
- MITTELMAN et al. J. Clin. Invest., 1990, vol. 86, 2136-2144 [0289]
- FOON et al. Proc. Am. Soc. Clin. Oncol., 1994, vol. 13, 294- [0289]
- YOKATA et al. Cancer Res., 1992, vol. 52, 3402-3408 [0289]
- RAGNHAMMAR et al. Int. J. Cancer, 1993, vol. 53, 751-758 [0289]
- HERLYN et al. J. Clin. Immunol., 1982, vol. 2, 135- [0289]
- GHETIE et al. Blood, 1994, vol. 83, 1329-1336 [0289]
- REFF et al. Blood, 1994, vol. 83, 435-445 [0289]
- SGOUROS et al. J. Nucl. Med., 1993, vol. 34, 422-430 [0289]
- SALEH et al. J. Immunol., 1993, vol. 151, 3390-3398 [0289]
- SHITARA et al. Cancer Immunol. Immunother., 1993, vol. 36, 373-380 [0289]
- LIVINGSTON et al. J. Clin. Oncol., 1994, vol. 12, 1036-1044 [0289]
- HOON et al. Cancer Res., 1993, vol. 53, 5244-5250 [0289]
- HELLSTROM et al. Cancer. Res., 1985, vol. 45, 2210-2188 [0289]
- HELLSTROM et al. Cancer Res., 1986, vol. 46, 3917-3923 [0289]
- BHATTACHARYA-CHATTERJEE et al. J. of Immun., 1988, vol. 141, 1398-1403 [0289]
- HILKENS et al. Trends in Bio. Chem. Sci., 1992, vol. 17, 359- [0289]
- BERNHARD et al. Science, 1989, vol. 245, 301-304 [0289]
- FEIZI Nature, 1985, vol. 314, 53-57 [0289]
- EDELSON The Cancer Journal, 1998, vol. 4, 62- [0289]
- WARREN et al. Semin Oncol., 2002, vol. 29, 293-7 [0291]
- WARREN et al. Clin Lymphoma, 2000, vol. 1, 157-61 [0291]
- OGASAWARA et al. Nature, 1993, vol. 364, 806- [0292]
- ICHIKAWA et al. Int. Immunol., 2000, vol. 12, 555- [0292]
- XU et al. Journal of Immunology, 2003, vol. 171, 562-568 [0292]
- CASSARD et al. Journal of Clinical Investigation, 2002, vol. 110, 101549-1557 [0293]
- SCANLAN et al. Proc. Natl. Acad. USA, 1994, vol. 91, 5657-61 [0296]
- PARK et al. J. Biol. Chem., 1999, vol. 274, 36505-12 [0296]
- RETTIG et al. Proc. Natl. Acad. Sci. USA, 1988, vol. 85, 3110-3114 [0296]
- GARIN-CHESEA et al. Proc. Natl. Acad. Sci. USA, 1990, vol. 87, 7235-7239 [0296]
- WUEST et al. Journal of Biotechnology, 2001, 159-168 [0296]

- **MERSMANN et al.** Int. J. Cancer, 2001, vol. 92, 240-248 [0296]
- **MILLS et al.** Am. Journal of Epidemiol., 1992, vol. 122, 66-74 [0297]
- **ERIKSSON et al.** Allergy, 1995, vol. 50, 718-722 [0297]
- **REALI et al.** Cancer Res., 2001, vol. 61, 5516-22 [0297]
- **CALLANAN M.B. et al.** Proc. Natl. Acad. Sci. U.S.A., 2000, vol. 97, 1309-314 [0301]
- **FREEDMAN** Hematol. Oncol. Clin. North Am., 1990, vol. 4, 405- [0301]
- **WEERATNA et al.** FEMS Immunol Med Microbiol., 2001, vol. 32, 165-71 [0306] [0317]
- **ESTIENNE et al.** FASEB J., 2002, vol. 16, 1087-1092 [0308]
- **METCALFE D. et al.** Physiol. Rev., 1997, vol. 77, 1033- [0310]
- **CAO Y.** Bioconj. Chem, 1998, vol. 9, 635-644 [0315]
- **KOELMIJ et al.** J. Immunother., 1999, vol. 22, 514-524 [0315]
- **SEGAL et al.** Curr. Opin. Immunol., vol. 11, 558-562 [0315]
- **CARTER et al.** J. of Immunol. Methods, 2001, vol. 248, 7-15 [0315]
- **SEGAL et al.** J. of Immunol. Methods, 2001, vol. 248, 7-15 [0315]
- **GLENNIE et al.** Tumor Immunobiology Oxford University press19950000225- [0315]
- BioWorld Today, 1998, 1- [0318]
- **LINHART et al.** FASEB Journal, 2000, vol. 16, 101301-3 [0328]
- **HORNER et al.** Allergy, 2002, vol. 57, 7224-9 [0328]
- **CHOI et al.** Ann. Allergy Asthma Immunology, 2002, vol. 88, 6584-91 [0328]
- **BARLAN et al.** Journal Asthma, 2002, vol. 39, 3239-46 [0328]
- **HOURIHANE et al.** Curr. Opin. Allergy Clin. Immunol., 2002, vol. 2, 3227-31 [0328]
- **WUJ.** Biol. Chem., 1987, vol. 262, 4429-4432 [0333] [0363]
- **EPSTEIN et al.** Proc. Natl. Acad. Sci. USA, 1985, vol. 82, 3688- [0334]
- **HWANG et al.** Proc. Natl. Acad. Sci. USA, 1980, vol. 77, 4030-4 [0334]
- **BENDAS et al.** BioDrugs, 2001, vol. 15, 4215-224 [0335]
- **ALLEN et al.** FEBS Lett., 1987, vol. 223, 42-6 [0335]
- **KLIBANOV et al.** FEBS Lett., 1990, vol. 268, 235-7 [0335]
- **BLUM et al.** Biochim. Biophys. Acta., 1990, vol. 1029, 91-7 [0335]
- **TORCHILIN** J. Liposome Res., 1996, vol. 6, 99-116 [0335]
- **LITZINGER et al.** Biochim. Biophys. Acta, 1994, vol. 1190, 99-107 [0335]
- **MARUYAMA et al.** Chem. Pharm. Bull., 1991, vol. 39, 1620-2 [0335]
- **KLIBANOV et al.** Biochim Biophys Acta, 1991, vol. 1062, 142-8 [0335]
- **ALLEN et al.** Adv. Drug Deliv., 1994, vol. 13, 285-309 [0335]
- **MARTIN et al.** J. Biol. Chem., 1982, vol. 257, 286-288 [0335] [0336]
- **ALLEN et al.** Stealth Liposomes CRC Press1995000233-44 [0336]
- **HANSEN et al.** Biochim. Biophys. Acta, 1995, vol. 1239, 133-44 [0336]
- Gene Therapy: Advances in Pharmacology Academic Press19970000vol. 40, 399-435 [0336] [0336]
- **DIETRICH et al.** Biochemistry, 1996, vol. 35, 1100-1105 [0336]
- **LOUGHREY et al.** Biochim. Biophys. Acta, 1987, vol. 901, 157-160 [0336]
- **MARTIN et al.** Biochemistry, 1981, vol. 20, 4429-38 [0336]
- **VINGERHOEDS et al.** Immunomethods, 1994, vol. 4, 259-72 [0338]
- **MARUYAMA** Biol. Pharm. Bull., 2000, vol. 23, 7791-799 [0338]
- **ABRA et al.** Journal of Liposome Research, 2002, vol. 12, 1821-3 [0338]
- **PARK** Bioscience Reports, 2002, vol. 22, 2267-281 [0339]
- **BENDAS et al.** BioDrugs, 2001, vol. 14, 4215-224 [0339]
- **LANGER** Science, 1990, vol. 249, 1527-1533 [0345] [0347]
- **TREAT et al.** Liposomes in the Therapy of Infectious Disease and Cancer Liss19890000353-365 [0345]
- **LOPEZ-BERESTEIN** LIPOSOMES IN THE THERAPY OF INFECTIOUS DISEASE AND CANCER vol. 3, 17-327 [0345]
- **NING et al.** Intratumoral Radioimmunotherapy of a Human Colon Cancer Xenograft Using a Sustained-Release Gel Radiotherapy & Oncology, 1996, vol. 39, 179-189 [0346]
- **SONG et al.** Antibody Mediated Lung Targeting of Long-Circulating Emulsions PDA Journal of Pharmaceutical Science & Technology, 1995, vol. 50, 372-397 [0346]
- **CLEEK et al.** Biodegradable Polymeric Carriers for a bFGF Antibody for Cardiovascular Application Pro. Int'l. Symp. Control. Rel. Bioact. Mater., 1997, vol. 24, 853-854 [0346]
- **LAM et al.** Microencapsulation of Recombinant Humanized Monoclonal Antibody for Local Delivery Proc. Int'l. Symp. Control. Rel. Bioact. Mater., 1997, vol. 24, 759-760 [0346]
- **SEFTON** CRC Crit. Ref. Biomed. Eng., 1987, vol. 14, 20- [0346]

- **BUCHWALD et al.** *Surgery*, 1980, vol. 88, 507- [0348]
- **SAUDEK et al.** *N. Engl. J. Med.*, 1989, vol. 321, 574- [0346]
- Medical Applications of Controlled ReleaseCRC Pres.19740000 [0346]
- Controlled Drug Bioavailability, Drug Product Design and PerformanceWiley19840000 [0346]
- **RANGERPEPPASJ.**, *Macromol. Sci. Rev. Macromol. Chem.*, 1983, vol. 23, 61- [0346]
- **LEVY et al.** *Science*, 1985, vol. 228, 190- [0346]
- **DURING et al.** *Ann. Neurol.*, 1989, vol. 25, 351- [0346]
- **HOWARD et al.** *J. Neurosurg.*, 1989, vol. 71, 105- [0346]
- **GOODSON** *Medical Applications of Controlled Release*, 1984, vol. 2, 115-138 [0346]
- **NING et al.** *Radiotherapy & Oncology*, 1996, vol. 39, 179-189 [0347]
- **SONG et al.** *PDA Journal of Pharmaceutical Science & Technology*, 1995, vol. 50, 372-397 [0347]
- **CLEEK et al.** *Pro. Int'l. Symp. Control. Rel. Bioact. Mater.*, 1997, vol. 24, 853-854 [0347]
- **LAM et al.** *Proc. Int'l. Symp. Control Rel. Bioact. Mater.*, 1997, vol. 24, 759-760 [0347]
- **JOLIOT et al.** *Proc. Natl. Acad. Sci. USA*, 1991, vol. 88, 1864-1868 [0348]
- **GOLDSPIEL et al.** *Clinical Pharmacy*, 1993, vol. 12, 488-505 [0359]
- **WUBiotherapy**, 1991, vol. 3, 87-95 [0359]
- **TIBTECH**, 1993, vol. 11, 5155-215 [0359]
- **SCHOLLJ.** *Biomed Biotechnol*, 2003, vol. 2003, 35-47 [0359]
- **KOLLERSMITHIES** *Proc. Natl. Acad. Sci. USA*, 1989, vol. 86, 8932-8935 [0360] [0363]
- **ZIJLSTRA et al.** *Nature*, 1989, vol. 342, 435-438 [0360] [0363]
- **MILLER et al.** *Meth. Enzymol.*, 1993, vol. 217, 581-599 [0364]
- **BOESEN et al.** *Biotherapy*, 1994, vol. 6, 291-302 [0364]
- **CLOWES et al.** *J. Clin. Invest.*, 1994, vol. 93, 644-651 [0364]
- **KLEIN et al.** *Blood*, 1994, vol. 83, 1467-1473 [0364]
- **SALMONSGUNZBERG** *Human Gene Therapy*, 1993, vol. 4, 129-141 [0364]
- **GROSSMANWILSON** *Curr. Opin. in Genetics and Devel.*, 1993, vol. 3, 110-114 [0364]
- **KOZARSKYWILSON** *Current Opinion in Genetics and Development*, 1993, vol. 3, 499-503 [0365]
- **BOUT et al.** *Human Gene Therapy*, 1994, vol. 5, 3-10 [0365]
- **ROSENFELD et al.** *Science*, 1991, vol. 252, 431-434 [0365]
- **ROSENFELD et al.** *Cell*, 1992, vol. 68, 143-155 [0365]
- **MASTRANGELI et al.** *J. Clin. Invest.*, 1993, vol. 91, 225-234 [0365]
- **WANG et al.** *Gene Therapy*, 1995, vol. 2, 775-783 [0366]
- **WALSH et al.** *Proc. Soc. Exp. Biol. Med.*, 1993, vol. 204, 289-300 [0366]
- **LOEFFLERBEHR** *Meth. Enzymol.*, 1993, vol. 217, 599-618 [0366]
- **COHEN et al.** *Meth. Enzymol.*, 1993, vol. 217, 618-644 [0368]
- *Clin. Pharma. Ther.*, 1985, vol. 29, 69-92 [0368]
- **STEMPLEANDERSON** *Cell*, 1992, vol. 7, 1973-985 [0372]
- **RHEINWALD** *Meth. Cell Bio.*, 1980, vol. 21A, 229- [0372]
- **PITTELKOWSCOTT** *Mayo Clinic Proc.*, 1986, vol. 61, 771- [0372]
- Arthritis and Autoimmunity in Animals **CROFFORD L.J.WILDER R.L. et al.** *Arthritis and Allied Conditions: A Textbook of Rheumatology* Lee and Febiger19930000 [0380] [0381]
- **HANSRA P. et al.** *Carrageenan-Induced Arthritis in the Rat* *Inflammation*, 2000, vol. 24, 2141-155 [0382]
- **WINTER C. A. et al.** *Carrageenan-Induced Edema in Hind Paw of the Rat as an Assay for Anti-inflammatory Drugs* *Proc. Soc. Exp. Biol. Med.*, 1962, vol. 111, 544-547 [0383]
- **KIM et al.** *Scand. J. Gastroentrol.*, 1992, vol. 27, 529-537 [0384]
- **STROBER** *Dig. Dis. Sci.*, 1985, vol. 30, 123S-10S [0384]
- **COHN et al.** *J. Exp. Med.*, 1997, 1861737-1747 [0385]
- **FLANDERS et al.** *Autoimmunity*, 1999, vol. 29, 235-246 [0386]
- **KROGH et al.** *Biochimie*, 1999, vol. 81, 511-515 [0386]
- **FOSTER** *Semin. Nephrol.*, 1999, vol. 19, 12-24 [0386]
- Relevance of Tumor Models for Anticancer Drug Development19990000 [0390]
- **KARGER** *Contributions to Oncology*, 1999, [0390]
- The Nude Mouse in Oncology Research19910000 [0390]
- Anticancer Drug Development Guide19970000 [0390]
- **JALKANEN et al.** *J. Cell. Biol.*, 1985, vol. 101, 976-985 [0395]
- **JALKANEN et al.** *J. Cell. Biol.*, 1987, vol. 105, 3087-3096 [0395]
- Immunopharmacokinetics of Radiolabeled Antibodies and Their Fragments **S.W. BURCHIEL et al.** *Tumor Imaging: The Radiochemical Detection of Cancer* Masson Publishing Inc.19820000 [0397]

- **SAKAKIBARA et al.** Cancer J. Sci. Am., 1996, vol. 2, 291- [0423]
- **BARKER et al.** Gynecol. Oncol., 2001, vol. 82, 57-63 [0429]
- **VERI et al.** Mol Cell Bio, 2001, vol. 21, 6939-6950 [0431]
- **CRAGG et al.** Blood, 2004, vol. 103, 2738-43 [0431] [0432] [0433]
- **EPSTEIN et al.** J Natl Cancer Inst, 1966, vol. 37, 547-559 [0435]
- **KLEIN et al.** Cancer Res, 1968, vol. 28, 1300-1310 [0435]
- **KLEIN et al.** Intervirology, 1975, vol. 5, 319-334 [0435]
- **NILSSON et al.** Intl J Cancer, 1977, vol. 19, 337-344 [0435]
- **OHSUGI et al.** J Natl Cancer Inst, 1980, vol. 65, 715-718 [0435]
- **VALLERA et al.** Cancer Biother Radiopharm, 2003, vol. 18, 133-145 [0435]
- **VUIST et al.** Cancer Res, 1989, vol. 49, 3783-3788 [0435]

Patentkrav

1. Isoleret antistof, eller antigenbindende fragment deraf, hvor det isolerede antistof, eller det antigenbindende fragment, specifikt binder til det ekstracellularære domæne af nativ human Fc γ RIIB med større affinitet, end antistoffet, eller det antigenbindende fragment, binder til nativ human Fc γ RIIA, og hvor:

i) antistoffet er 8B5.3.4-antistof fremstillet af hybridom-cellelinjen med ATCC-accessionsnummer PTA-7610; eller

ii) antistoffet, eller det antigenbindende fragment, omfatter et variabelt domæne af en tung kæde, som har aminosyresekvensen ifølge SEQ ID NO: 4, og et variabelt domæne af en let kæde, som har aminosyresekvensen ifølge SEQ ID NO: 3; eller

iii) antistoffet, eller det antigenbindende fragment, omfatter de seks CDR'er fra antistoffet fremstillet af hybridom-klonen 8B5.3.4 med ATCC-accessionsnummer PTA-7610, hvilke seks CDR'er henholdsvis har aminosyresekvenserne ifølge SEQ ID NO: 5 til SEQ ID NO: 10, hvor antistoffet, eller det antigenbindende fragment, binder til samme epitop på Fc γ RIIB, som den epitop, der genkendes af det antistof, der fremstilles af hybridom-klonen 8B5.3.4 med ATCC-accessionsnummer PTA-7610, og konkurrerer med antistoffet 8B5.3.4 om binding til nativ human Fc γ RIIB, og hvor antistoffet, eller det antigenbindende fragment, har en dissociations-konstant K_d (K_{off}/K_{on}) på mindre end 5×10^{-9} M bestemt ved overfladeplasmon-resonans.

2. Antistof, eller antigenbindende fragment deraf, ifølge krav 1, hvor antistoffet, eller det antigenbindende fragment, omfatter de seks CDR'er fra antistoffet fremstillet af hybridom-klonen 8B5.3.4 med ATCC-accessionsnummer PTA-7610, hvilke seks CDR'er henholdsvis har aminosyresekvenserne ifølge SEQ

ID NO: 5 til SEQ ID NO: 10, hvor antistoffet, eller det antigenbindende fragment, binder til samme epitop på Fc γ RIIB, som den epitop, der genkendes af det antistof, der fremstilles af hybridomklonen 8B5.3.4 med ATCC-accessions-nummer PTA-7610, og konkurrerer med antistoffet 8B5.3.4 om binding til nativ 5 human Fc γ RIIB, og hvor antistoffet, eller det antigenbindende fragment, har en dissociations-konstant K_d (K_{off}/K_{on}) på mindre end 5×10^{-9} M bestemt ved overfladeplasmon-resonans.

10 **3.** Antistof, eller antigenbindende fragment deraf, ifølge krav 1, hvor antistoffet er 8B5.3.4-antistoffet fremstillet af hybridom-cellelinjen med ATCC-accessions-nummer PTA-7610.

15 **4.** Antistof, eller antigenbindende fragment deraf, ifølge krav 1 eller krav 2, hvor antistoffet er et humant antistof, et monoklonalt antistof, et enkeltkædet antistof, et bi-specifikt antistof, eller en humaniseret form af 8B5.3.4-antistoffet.

20 **5.** Antistof, eller antigenbindende fragment deraf, ifølge krav 1, som omfatter et variabelt domæne af en tung kæde, som har aminosyrekvensen ifølge SEQ ID NO: 4, og et variabelt domæne af en let kæde, som har aminosyrekvensen ifølge SEQ ID NO: 3.

25 **6.** Antistof, eller antigenbindende fragment deraf, ifølge krav 1 eller krav 2, som har et Fc-domæne, der omfatter mindst én modifikation i Fc-domænet af den tunge kæde.

30 **7.** Antistof, eller antigenbindende fragment deraf, ifølge krav 6, hvor Fc-domænet af den tunge kæde i antistoffet omfatter mindst én aminosyresubstitution i position 240, 243, 247, 255, 270, 292, 300, 305, 316, 370, 392, 396, 416, 419 eller 421 med en anden aminosyre i den position.

8. Antistof ifølge krav 7, hvor Fc-domænet af den tunge kæde i antistoffet har en leucin i position 243, en prolin i position 292, en leucin i position 300, en isoleucin i position 305 og en leucin i position 396.

5 9. Antistoffragment ifølge krav 1 eller krav 2, som er et F(ab')₂-fragment eller et F(ab)-fragment.

10 10. Antistof, eller antigenbindende fragment deraf, ifølge et hvilket som helst af kravene 1 til 9, hvor antistoffet eller det antigenbindende fragment er operativt forbundet til et heterologt polypeptid eller er konjugeret til et terapeutisk middel.

15 11. Antistof, eller antigenbindende fragment deraf, ifølge krav 10, hvor det terapeutiske middel er:

15 (A) et antistof, som binder immunspecifikt til en anden celleoverfladereceptor end Fc γ RIIB; eller

15 (B) et antistof, som binder immunspecifikt til et tumorassocieret antigen.

20 12. Antistof, eller antigenbindende fragment deraf, ifølge krav 1, som reducerer binding af et Ig-Fc til Fc γ RIIB.

25 13. Farmaceutisk sammensætning, som omfatter (i) en terapeutisk effektiv mængde af det isolerede antistof, eller det antigenbindende fragment deraf, ifølge et hvilket som helst af kravene 1 til 12, og (ii) en farmaceutisk acceptabel bærer.

30 14. Farmaceutisk sammensætning ifølge krav 13, som yderligere omfatter et yderligere middel valgt fra gruppen bestående af et kemoterapeutisk middel, et stråleterapeutisk middel, et hormonterapeutisk middel, et immunterapeutisk middel, et antiinflammatorisk middel, og et immunmodulerende middel.

DRAWINGS

Figure 1




Figure 2




Figure 3

8B5.3.4 VL Nucleotide/Amino Acid Sequence

gac att cag atg aca cag tct cca tcc tcc cta ctt gcg gcg ctg gga 48
 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Leu Ala Ala Leu Gly

1 5 10 15

CDR1

gaa aga gtc agt ctc act tgt cgg gca agt cag gaa att agt ggt tac 96
 Glu Arg Val Ser Leu Thr Cys Arg Ala Ser Gln Glu Ile Ser Gly Tyr
 20 25 30

tta agc tgg ctt cag cag aaa cca gat gga act att aaa cgc ctg atc 144
 Leu Ser Trp Leu Gln Gln Lys Pro Asp Gly Thr Ile Lys Arg Leu Ile

35 40 45

CDR2

tac gcc gca tcc act tta gat tct ggt gtc cca aaa agg ttc agt ggc 192
 Tyr Ala Ala Ser Thr Leu Asp Ser Gly Val Pro Lys Arg Phe Ser Gly
 50 55 60

agt gag tct ggg tca gat tat tct ctc acc atc agc agt ctt gag tct 240
 Ser Glu Ser Gly Ser Asp Tyr Ser Leu Thr Ile Ser Ser Leu Glu Ser

65 70 75 80

CDR3

gaa gat ttt gca gac tat tac tgt cta caa tat ttt agt tat ccg ctc 288
 Glu Asp Phe Ala Asp Tyr Tyr Cys Leu Gln Tyr Phe Ser Tyr Pro Leu

85 90 95

acg ttc ggt gct ggg acc aag ctg gag ctg aaa 321
 Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys

100 105

8B5.3.4 VH Nucleotide/Amino Acid Sequence Figure 4

gaa gtg aag ctt gag gag tct gga gga ggc ttg gtg caa cct gga gga	48
Glu Val Lys Leu Glu Glu Ser Gly Gly Leu Val Gln Pro Gly Gly	
1 5 10 15	
tcc atg aaa ctc tct tgt gaa gcc tct gga ttc act ttt agt gac gcc	96
Ser Met Lys Leu Ser Cys Glu Ala Ser Gly Phe Thr Phe Ser Asp Ala	
20 25 30	
—CDR1—	
tgg atg gac tgg gtc cgt cag tct cca gag aag ggg ctt gag tgg gtt	144
Trp Met Asp Trp Val arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val	
35 40 45	
—CDR2—	
gct gaa att aga aac aaa gct aaa aat cat gca aca tac tat gct gag	192
Ala Glu Ile Arg Asn Lys Ala Lys Asn His Ala Thr Tyr Tyr Ala Glu	
50 55 60	
tct gtg ata ggg agg ttc acc atc tca aga gat gat tcc aaa agt agt	240
Ser Val Ile Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ser	
65 70 75 80	
gtc tac ctg caa atg aac agc tta aga gct gaa gac act ggc att tat	288
Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Gly Ile Tyr	
85 90 95	
—CDR3—	
tac tgt ggg gct ctg ggc ctt gac tac tgg ggc caa ggc acc act ctc	336
Tyr Cys Gly Ala Leu Gly Leu Asp Tyr Trp Gly Gln Gly Thr Thr Leu	
100 105 110	
aca gtc tcc tcg	348
Thr Val Ser Ser	
115	